



5th Schizophrenia International Research Society Conference

*Deconstructing Schizophrenia
Towards Targeted Treatment*



FLORENCE, ITALY
2 – 6 APRIL 2016

VANDERBILT UNIVERSITY



School of Medicine



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

Opening Letter

Dear Attendees,

It is our great pleasure to welcome you to the 5th Biennial Schizophrenia International Research Society (SIRS) Conference. SIRS is a non-profit organization dedicated to promoting research and communication about schizophrenia among research scientists, clinicians, drug developers, and policy makers internationally. We sincerely appreciate your interest in the Society and in our conference. The fourth congress in 2014 was a major success for the field attracting more than 1700 attendees from 53 countries. We anticipate an even higher attendance at this congress with most of the best investigators in the world in attendance.

SIRS was founded in 2005 with the goal of bringing together scientists from around the world to exchange the latest advances in biological and psychosocial research in schizophrenia. The Society is dedicated to facilitating international collaboration to discover the causes of, and better treatments for, schizophrenia and related disorders. Part of the mission of the Society is to promote educational programs in order to effectively disseminate new research findings and to expedite the publication of new research on schizophrenia.

The focus of the 5th Biennial Conference is 'Deconstructing Schizophrenia Towards Targeted Treatment.' Under the outstanding leadership of Program Committee Chairs Akira Sawa and Neeltje van Haren, we have an exciting scientific program planned for this year. The Program Committee selected thirty-five outstanding symposia sessions out of 108 submissions. The number of submissions for symposia increased by 18% over 2014 while poster submissions saw an increase of 21%. They also put together a Pharmaceutical Pipeline session for Monday and selected ninety-six superior oral presentations to be presented on Tuesday from more than 650 abstracts submitted. Plan to visit the poster sessions during lunch on Sunday, Monday and Tuesday to see the over 1,000 posters.

Please remember to complete an evaluation at the end of the conference so the Society can continue to improve its educational offerings. If you are not already a member, please stop by the registration desk and inquire about member benefits and how to join. We hope you enjoy this conference and in addition to learning about the latest, cutting edge research in the field, you will enjoy the beautiful city of Florence and its rich history.

Sincerely,

The Organizers

René Kahn, M.D. Ph.D., President

Patrick McGorry, FRCP, M.D., Ph.D., President-Elect

John Kane, M.D., Past-President

Cynthia Shannon Weickert, Ph.D., Secretary

Til Wykes, Ph.D., Treasurer

Akira Sawa, M.D., Ph.D., Program Committee Chair

Neeltje van Haren, Ph.D., Program Committee Co-Chair

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



Table of Contents

General Information	Page 2	
Saturday, 2 April	Page 22	
Sunday, 3 April	Page 24	
Monday, 4 April	Page 34	
Tuesday, 5 April	Page 44	
Wednesday, 6 April	Page 62	
Sunday Posters	Page 68	
Monday Posters	Page 97	
Tuesday Posters	Page 127	
Index of Presenters and Authors	Page 157	
Notes	Page 167	



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

Disclosures

Disclosures for 2016 speakers, plenary, symposia, oral presentations and poster presenters may be found online at www.SchizophreniaConference.org. A copy of the disclosures will be available at the registration desk.

Acknowledgements

The Schizophrenia International Research Society appreciates the generous support of the Society from our 2015-2016 Supporting Corporations.

Gold



Silver



SUNOVION



Boehringer
Ingelheim



Intra-Cellular Therapies



GEDEON RICHTER

Other Sponsorships



PHARMACEUTICAL COMPANIES
OF Johnson & Johnson

Educational Grants:

The Society expresses appreciation to the following companies for their support of this educational activity by providing unrestricted educational grants:

- Otsuka America Pharmaceuticals, Inc.
- Eli Lilly and Company

The Junior Travel Award Fellowship Program is partially sponsored by a grant from the U.S. National Institute Drug Abuse to Harvard Medical School (Lynn DeLisi, PI).

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



General Information

General Information

OFFICERS:



René Kahn
M.D., Ph.D.
President



Patrick McGorry
FRCP, M.D., Ph.D.
President-Elect



Cynthia Shannon Weickert
Ph.D.
Secretary



Til Wykes
Ph.D.
Treasurer

BOARD OF DIRECTORS (2014-2016):

Anissa Abi-Dargham	USA
Celso Arango	Spain
Geraldo Busatto	Brazil
Tyrone Cannon	USA
Eric Chen	China
Paolo Dazzan	United Kingdom
Michael Green	USA
Stephan Heckers	USA
Patrick McGorry	Australia
Herbert Meltzer	USA
Sophia Vinogradov	USA
Cynthia Shannon-Weickert	Australia

INCOMING OFFICERS:

Patrick McGorry	Australia, <i>President</i>
Lynn DeLisi	USA, <i>President-Elect</i>
Til Wykes	United Kingdom, <i>Secretary</i>
Shitij Kapur	United Kingdom, <i>Treasurer</i>
René Kahn	The Netherlands, <i>Past-President</i>



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

General Information

INTERNATIONAL ADVISORY COUNCIL

Jean Addington	Canada	Matti Huttunen	Finland
Deanna Barch	USA	James Kennedy	Canada
Alessandro Bertolino	Italy	Shon Lewis	United Kingdom
Robert Buchanan	USA	Mario Maj	Italy
Mary Cannon	Ireland	John McGrath	Australia
David Castle	Australia	Paulo Menezes	Brazil
Eric Chen	China	Preben Mortensen	Denmark
Siow Ann Chong	Singapore	Patricio O'Donnell	USA
Christoph Correll	USA	Emmanuelle Peters	United Kingdom
Christina Dalman	Sweden	Anita Riecher-Rössler	Switzerland
Anthony David	United Kingdom	Sibylle Schwab	Germany
F.W. Deakin	United Kingdom	Iris Sommer	Netherlands
Lynn DeLisi	USA	Dawn Velligan	USA
Wolfgang Fleishhacker	Austria	Mark Weiser	USA
Kyung Sue Hong	Republic of Korea		

2016 Meetings Committees

TRAVEL AWARD SELECTION COMMITTEE

Robin Emsley	South Africa, Chair
Paola Dazzan	United Kingdom
Wagner Gattaz	Brazil
Lorna Lopez	Ireland
Douglas Noordsy	USA
Joseph McEvoy	USA
Si Tianmei	China

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



2016 PROGRAM COMMITTEE



Akira Sawa
 USA
Chair



Neeltje van Haren
 Netherlands
Co-Chair

General Information

Larry Alphas	USA
Robert Buchanan	USA
Raymond Chan	China
Barbara Cornblatt	USA
Paola Dazzan	United Kingdom
J.F.W. Deakin	United Kingdom
Sophia Dollfus	France
Robin Emsley	South Africa
Peter Falkai	Germany
Wolfgang Fleischhacker	Austria
Phil Harvey	USA
Oliver Howes	United Kingdom
Hilleke Hulshoff Pol	Netherlands
Shitij Kapur	United Kingdom

James Kennedy	Canada
Steve Marder	USA
Patrick McGorry	Australia
John McGrath	Australia
Phillip McGuire	United Kingdom
Igor Nenadic	Germany
Christos Pantelis	Australia
Maxine Patel	United Kingdom
Charles Schulz	USA
Michael Spedding	France
Rajiv Tandon	United States
Jari Tiihonen	Finland
Aristotle Voineskos	Canada
Thomas Weickert	Australia



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

Continuing Medical Education

ACCME:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Vanderbilt University School of Medicine and the Schizophrenia International Research Society. Vanderbilt University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Vanderbilt University School of Medicine designates this live activity for a maximum of 24 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

To obtain credit, registered participants must complete an online evaluation. The evaluation may be completed at www.SchizophreniaConference.org. There will be a \$50.00 USD charge for scientific registrants to obtain CME credits.

COURSE OBJECTIVES:

After participating in the CME Activity, Clinicians should be able to describe and discuss:

- Strategies for determining an approach to manage patients with schizophrenia
- The status of genetic findings and how they can be incorporated into strategies for managing patients with schizophrenia
- The use of brain imaging data about pathophysiology and disease progression to revise or continue a strategy for managing patients with schizophrenia
- The implications of basic neuroscience findings for managing patients with schizophrenia

After participating in the CME Activity, Researchers should be able to describe and discuss:

- Approaches to develop novel treatments for schizophrenia
- Strategies for translating basic neuroscience into knowledge that can be used in clinical practice
- Differences in schizophrenia research across diverse cultures and geographic areas
- Novel intervention studies that will promote the development of advanced knowledge about schizophrenia
- Methods to advance the clinical application of genetic research in schizophrenia

DISCLOSURES:

It is the policy of Vanderbilt University School of Medicine and Schizophrenia International Research Society to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations. Disclosures for 2016 speakers, plenary, symposia, oral presentations and poster presenters may be found online at www.SchizophreniaConference.org. A copy of the disclosures will be available at the registration desk.

FINAL PROGRAM

FLORENCE, ITALY

2 – 6 APRIL 2016



EACCME:

The 5th Biennial Schizophrenia International Research Society Conference has been granted 24 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME). Physicians should claim on the credits commensurate with the extent of their participation in the activity. To obtain credit, registered participants must complete an online evaluation. The evaluation may be completed at www.SchizophreniaConference.org. There will be a \$50.00 USD charge to obtain credits.

CONFERENCE EVALUATION:

All conference attendees are urged to complete an evaluation of the meeting. Attendees who are requesting CME (ACCME, EACCME) credit for the meeting **are required** to complete the evaluation. This form is available online only. You may complete the evaluation in the Computer Center or on-line at www.SchizophreniaConference.org. All evaluations must be completed by Friday, 6 May 2016.

VIDEOTAPING SESSIONS:

Attendees may **not** videotape, audiotape, or photograph (camera or camera phone) presentations at the conference without prior permission from the session chair.

General Information

REGISTRATION

Registration for the 5th Biennial Schizophrenia International Research Society Conference is located at the Main Entrance of Firenze Fiera Congress Center, Piazza Adua.

DATE

Saturday, 2 April
Sunday, 3 April
Monday, 4 April
Tuesday, 5 April
Wednesday, 6 April

TIME

1:00 PM – 8:00 PM
8:00 AM – 6:30 PM
8:00 AM – 7:00 PM
8:00 AM – 8:00 PM
8:00 AM – 12:00 PM

REGISTRATION TYPES:

Delegate: Scientific Attendee

Student: Full-time graduate students, medical students, or students in the first two years of a post-doctoral fellowship program at a university in a field relevant to schizophrenia research. A letter from the student's immediate supervisor verifying his/her student status and relevant field will be required for registration.



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

General Information

REGISTRATION FEES:

Category	Up to 1 March 2016	2 March or later
SIRS 2015 and 2016 Member	450.00€	500.00€
SIRS 2016 New Member	490.00€	540.00€
SIRS 2015 and 2016 Student Member	170.00€	220.00€
SIRS 2016 New Student Member	210.00€	260.00€
Non-Member Delegate	700.00€	750.00€
Non-Member Student	250.00€	300.00€
Welcome Reception Ticket	60.00€	60.00€

WELCOME RECEPTION TICKET:

The welcome reception ticket is included in the registration fee. If a guest would like to attend, the cost is €60 per ticket.

REGISTRATION TIME FRAMES:

Regular: Register August 2015 – 1 March 2016

Late: Register 2 March 2016 – onsite

COMPUTER ACCESS

Complimentary wireless internet is available in the conference center. To access the wireless internet, choose the SIRS2016 network. "SIRS2016" is the password. Conference attendees may also use the Computer Center located in Limonaia.

The Computer Center is provided this year for the convenience of meeting attendees. The Computer Center will be open the following hours:

Saturday, 2 April	1:00 PM – 7:00 PM
Sunday, 3 April	8:00 AM – 6:30 PM
Monday, 4 April	8:00 AM – 6:30 PM
Tuesday, 5 April	8:00 AM – 6:30 PM
Wednesday, 6 April	8:00 AM – 1:00 PM

FINAL PROGRAM

FLORENCE, ITALY

2 – 6 APRIL 2016



SPEAKER READY ROOM:

The speaker ready room is available in Sala 103 in the Palazzo Congressi. All presenters are required to come to the speaker ready room to upload their presentation, preferably 24-hours prior to the presentation. Presentations from individual computers are not permitted. Below are the hours for the Speaker Ready Room:

Speaker Ready Room Sala 103

Saturday, 2 April	1:00 PM – 7:00 PM
Sunday, 3 April	8:00 AM – 7:00 PM
Monday, 4 April	8:00 AM – 7:00 PM
Tuesday, 5 April	8:00 AM – 7:00 PM
Wednesday, 6 April	8:00 AM – 12:00 PM

ABSTRACTS:

Abstracts for all presentations will be published electronically by *npj Schizophrenia* and will be available as an electronic flipbook and as a PDF document at www.SchizophreniaConference.org.

Awards

The Awards Committee and Board of Directors of the Schizophrenia International Research Society are pleased to announce the Society's Honoric Award Winners.

SIRS LIFETIME ACHIEVEMENT AWARD



Herbert Meltzer, M.D.

Herbert Y. Meltzer, M.D., is Professor of Psychiatry and Behavioral Sciences and Professor of Pharmacology and Physiology at the Feinberg School of Medicine Chicago, IL. Prior to that, he was Professor of Psychiatry at the University of Chicago, held endowed Professorships at Case Western Reserve and Vanderbilt University Schools of Medicine. He has been President of ACNP and CINP, and is a founder of the Brain Behavior Research Foundation (formerly NARSAD). He has over 900 peer reviewed publications and 150 book chapters. Among numerous awards he has received are the Efron and Paul Hoch awards of the ACNP, the Noyes Prize of the Commonwealth of Pennsylvania, the Lieber Prize for Schizophrenia Research from NARSAD, the Stanley Dean Award for Research in Schizophrenia of the American College of Psychiatry, the Gold Medal Award of the Society of Biological Psychiatry, the Earl Sutherland Prize for Lifetime Research Achievement of Vanderbilt University, the Research Prize of the American Psychiatric Association, the Lifetime Achievement Award of the Winter Conference on Psychosis Research. He chaired the International Psychopharmacology Algorithm Project, a WHO-recognized web-based algorithm to guide the treatment of schizophrenia (www.IPAP.org). His Hirsch index is 111. The total number of citations of his research (Web of Science:2/23/2016) is 54,167.

continued on next page



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

Herbert Meltzer, M.D. *(continued)*

The highlights of his research achievements include: 1) establishing the superior efficacy of clozapine and other atypical antipsychotic drugs for positive symptoms for treatment resistant schizophrenia; 2) discovery of the 5-HT_{2A}/D₂ ratio as the general pharmacologic principle of atypical antipsychotic drugs and the contribution of 5-HT_{1A} partial agonism to antipsychotic drug action, leading to the development of most such clinically used drugs; 3) discovery of the antisuicidal properties of clozapine and leading the InterSePT Trial to obtain FDA approval for this indication; 4) discovery of the ability of clozapine and other atypical APDs to improve some domains of cognition in schizophrenia, and preclinical studies to demonstrate the basis for this mechanism of action using the NMDAR rodent model; 5) discovery of the ability of pimavanserin (ACP-103), a selective 5-HT_{2A} inverse agonist, now the first approved non-dopamine based antipsychotic drug, with applications to schizophrenia and other psychotic disorders forthcoming; and 6) pharmacogenomic studies identifying biomarkers for treatment resistant schizophrenia and prediction of the efficacy and side effects of atypical antipsychotic drugs based upon candidate genes and GWAS.

OUTSTANDING BASIC RESEARCH



Anthony Grace, Ph.D.


Dr. Anthony A. Grace is a Distinguished Professor of Neuroscience and a Professor of Psychiatry and Psychology at the University of Pittsburgh in Pittsburgh, PA. He received his Ph.D. from Yale University School of Medicine with Dr. Benjamin S. Bunney and had postdoctoral training with Dr. Rodolfo Llinas in the Department of Physiology and Biophysics at New York University School of Medicine. Dr. Grace has been involved in translational research related to the dopamine system for over 30 years. His early work pioneered the mode of action of antipsychotic drugs, and the identification and characterization of dopamine-containing neurons, and was the first to provide a means to quantify

their activity state and pattern in a way that is the standard in the literature. His current work involves novel treatments for schizophrenia and its prevention, the role of dopamine in anhedonia and affective disorders, and the mode of action of ketamine and novel antidepressant drugs. Dr. Grace has received several awards for his research, including the William K. Warren Award for Excellence in Schizophrenia Research, the Paul Janssen Schizophrenia Research Award and the Lilly Basic Scientist Award from the International College of Neuropsychopharmacology, the Efron Award and the Axelrod Award from the American College of Neuropsychopharmacology, the Gold Medal award from the Society of Biological Psychiatry, as well as a NIMH MERIT award, a Distinguished Investigator award from the National Alliance for Research in Schizophrenia and Depression, the Judith Silver Memorial Investigator Award from the National Alliance for the Mentally Ill, a Fellow of the American Association for the Advancement of Science, and appointment as a Distinguished Professor of Neuroscience at the University of Pittsburgh. He is also a past member of the governing council of the American College of Neuropsychopharmacology and the Schizophrenia International Research Society and is on the editorial board for numerous leading journals in the field. Dr. Grace has made a substantial impact on the field, publishing more than 280 articles



(H index 88) spanning basic and clinical research, and has been cited more than 29,000 times. Tony is one of a handful of individuals that not only performs important basic research, but can to integrate this work into testable models relevant to the human condition.

OUTSTANDING CLINICAL/COMMUNITY RESEARCH



Larry Siedman, Ph.D.

Dr. Seidman is Professor of Psychology in the Harvard Medical School Department of Psychiatry at Beth Israel Deaconess Medical Center (BIDMC) and Massachusetts General Hospital. He has been Director of the Massachusetts Department of Mental Health funded Center of Excellence in Clinical Neuroscience and Psychopharmacological Research since 2002 and Vice Chair (Research), Massachusetts Mental Health Center Public Psychiatry Division, BIDMC since 2005. Dr. Seidman obtained his B.A. in Psychology at the City College of New York in 1971 and his doctorate in Clinical-Community Psychology at Boston University in 1980. He has been an associate editor for *Neuropsychology*, and for *the Journal of the International Neuropsychological Society (JINS)*, and on the editorial boards of the *American Psychologist*, *Schizophrenia Bulletin*, *Journal of Abnormal Psychology*, *Asian Journal of Psychiatry*, and several others. He has authored over 400 journal articles. In 2014 and 2016, he was recognized by Thompson Reuters Science Watch as one of the “The World’s Most Influential Scientific Minds” based on his highly cited papers. He has received 31 grants, mainly from NIMH, and has collaborated with many investigators around the world. He has been involved extensively in mentoring young investigators with more than 50 mentees in academic positions, at least 23 of whom have received independent funding. This has been recognized by a number of mentorship and teaching awards at Harvard Medical School. His laboratory has focused on prefrontal cortex, hippocampus, executive and memory functions, largely in schizophrenia and other psychotic disorders, but also in ADHD. His studies have utilized neurocognitive and brain imaging measures, and have been applied to relatives, children and adolescents at risk for psychosis as well as patients. He has long-standing interests in treatment and prevention of schizophrenia and has helped facilitate prodromal and first episode intervention programs at BIDMC and in the Commonwealth of Massachusetts.



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

RISING STAR



Alan Anticevic, Ph.D

Dr. Anticevic trained in Clinical Psychology and Cognitive Neuroscience at Washington University in St. Louis where he worked with Drs. Deanna Barch and David Van Essen. Following his graduate training, Dr. Anticevic completed his internship in Clinical Neuropsychology at Yale University. After internship, he joined the Yale University Department of Psychiatry as research faculty while concurrently serving as the Administrative Director for the Center for the Translational Neuroscience of Alcoholism. Subsequently, he was appointed as an Assistant Professor of Psychiatry and Psychology at the Yale University

School of Medicine, where he directs a clinical neuroimaging laboratory focused on severe psychiatric illness such as schizophrenia. Dr. Anticevic is a recipient of the NARSAD Young Investigator Award, the International Congress of Schizophrenia Research Young Investigator Award, the NIH Director's Early Independence Award, the NARSAD Independent Investigator Award and the Klerman Prize for Exceptional Clinical Research. He currently serves as the Co-Director of the Division of Neurocognition, Neurocomputation, and Neurogenetics (N3) at Yale School of Medicine.

Broadly, his research interests are centered on cognitive neuroscience of psychiatric illness, functional connectivity, as well as functional neuroimaging analysis methodology. Specifically, Dr. Anticevic is interested in characterizing brain circuits involved in cognitive operations such as working memory as well as their interaction with neural systems involved in affective processes, with the focus of understanding how these interactions may go awry in the context of severe neuropsychiatric illness (e.g. schizophrenia, bipolar disorder and substance abuse). Methodologically, his research harnesses the combination of task-based, resting-state, pharmacological functional neuroimaging, as well as computational modeling approaches to mechanistically understand neural circuit dysfunction in disorders such as schizophrenia.

FINAL PROGRAM

FLORENCE, ITALY

2 – 6 APRIL 2016



RIISING STAR



Aristotle Voineskos, M.D., Ph.D.

Dr. Voineskos is Director of the Slaight Family Centre for Youth in Transition, and Head of the Kimel Family Translational Imaging-Genetics Laboratory at the Centre for Addiction and Mental Health in Toronto, Canada. He is also Canada Research Chair in Neuroimaging of Schizophrenia and Associate Professor of Psychiatry at the University of Toronto.

Dr. Voineskos's work combines multi-modal neuroimaging and genetics approaches to map gene effects on brain circuitry with a view to discovering vulnerability pathways for severe mental illness using a lifespan approach. A related area of Dr. Voineskos's work includes using structural and functional neuroimaging in medication-based, brain stimulation, and behavioural treatment studies in schizophrenia and related disorders. He is currently leading several multi-site neuroimaging studies spanning a number of sites in North America. He also holds a special interest in early identification and intervention for young people with emerging mental illness. Dr. Voineskos presently holds operating funding as Principal Investigator from the National Institute of Mental Health, Canadian Institutes of Health Research, Canada Foundation for Innovation, Ontario Ministry of Research and Innovation, and as a NARSAD Independent Investigator.

AWARD COMMITTEE MEMBERS

Shitij Kapur	United Kingdom, <i>Chair</i>
Anthony David	United Kingdom
Paola Dazzan	United Kingdom
John McGrath	Australia
Akira Sawa	USA

POSTER AWARDS

Cognitive Neuropsychiatry, *npj Schizophrenia*, and *Schizophrenia Bulletin* will award poster prizes during the Closing Session on Wednesday, 6 April at 9:30 AM. The Schizophrenia International Research Society Awards Committee will collaborate with journal editors to select the awards recipients. All three journals require that researchers be less than 40 years of age at the time of the conference for consideration.

The winners of the **Schizophrenia Research Founding Editors Award** are as follows:

Rajiv Tandon: Best Paper by a Senior Investigator

Hans-Gert Bernstein: Best Paper by a Junior Investigator



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

General Information

CONGRATULATIONS TO THE 2016 TRAVEL FELLOWS:

Myrto Samara	Germany	Marie Labouesse	Switzerland
Johanna Seitz	United States	Gabriëlla Blokland	United States
Emily Kline	United States	Laila Asmal	South Africa
Marta Rapado-Castro	Spain	Sonja de Zwart	Netherlands
Godefridus Koevoets	Netherlands	Aoife O'Gorman	Ireland
Donna Cosgrove	Ireland	Jessica Hartmann	Australia
Simone Ciufolini	Italy	Meenakshi Dauwan	Netherlands
Paulo Lizano	United States	Hannah Jongsma	United Kingdom
Jennifer Donegan	United States	Daniel Shapiro	United States
Martine Van Nierop	Netherlands	Andrea Jones	Canada
Patricia Di Prinzio	Australia	Kyle Minor	United States
Rashmi Patel	United Kingdom	André Schmidt	United Kingdom
Shinichiro Nakajima	Canada	Sarah McEwen	United States
Sze Chun Lee	Australia	Ran Barzilay	Israel
Jose Cortes-Briones	United States	Hugh Ramsay	Ireland
Michael Benros	Denmark	Joanne Newbury	United Kingdom
Babatunde Fadipe	Nigeria	Hideaki Tani	Japan
Giovanni Mansueto	Italy	Nicolas Crossley	Chile
Anne-Kathrin Fett	United Kingdom	Oleg Papsuev	Russia
Marc Bohlken	Netherlands	Onur Kucukcoban	Turkey
Emma Neilson	United Kingdom	Sanja Andric	Serbia
Leslie Horton	United States	TianHong Zhang	China
Agnieszka Potasiewicz	Poland	Sri Mahavir Agarwal	India
Marcos Leite Santoro	Brazil	Ahmed Mhalla	Tunisia
Linda Scoriels	Brazil		

KEYNOTE LECTURE



Saturday, 5 April, 6:00 PM – 7:00 PM

Auditorium

Susannah Cahalan began her investigative reporting career at the *New York Post* when she took an internship in her senior year of high school. She has now been there for ten years. Her work has also been featured in the *New York Times* and the *Czech Business Weekly*, where she worked when she studied abroad during her junior year of college. She was the recipient of the Silurian Award of Excellence in Journalism for Feature Writing for the article “My Mysterious Lost Month of Madness,” on which this book is based. She lives in Jersey City, New Jersey.

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



PLENARY SESSIONS

Sunday, 3 April

Auditorium

8:30 AM – 9:30 AM

Positive Allosteric Modulators Acetylcholine Receptors as a Novel Approach for Treatment for Schizophrenia

Jeff Conn

10:00 AM – 11:00 AM

The Recovery Project: The Who, What, Where, and When of Psychological Treatments

Til Wykes

Monday, 4 April

Auditorium

8:30 AM – 9:30 AM

Toward Predictive Psychiatry – Prognostic and Diagnostic Applications of Pattern Recognition Methods

Nikolaos Koutsouleris

10:00 AM – 11:00 AM

Precision Medicine for Psychosis: Challenges and Promise

Raquel Gur

Tuesday, 5 April

Auditorium

8:30 AM – 9:30 AM

Convergent Evidence Linking Neonatal Vitamin D Status and Risk of Schizophrenia

John McGrath

10:00 AM – 11:00 AM

Balancing Plasticity/Stability Across Brain Development

Takao Hensch

Wednesday, 6 April

Auditorium

8:30 AM – 9:30 AM

Feeding From Bedside Into Bench, and Back to Bedside: Towards Better Understanding of Schizophrenia

Koko Ishizuka



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

SYMPOSIA SESSIONS

The title and location of each symposium is indicated in the program. The presentations in each session are scheduled at approximately 20 – 25 minute intervals. A general discussion period is scheduled after the last presenter in each session. Symposia are scheduled:

Sunday, 3 April	1:00 PM – 3:00 PM 3:30 PM – 5:30 PM
Monday, 4 April	1:00 PM – 3:00 PM 3:30 PM – 5:30 PM
Tuesday, 5 April	1:00 PM – 3:00 PM
Wednesday, 6 April	10:30 AM – 12:30 PM

ORAL PRESENTATIONS

Two oral presentation sessions are scheduled on Tuesday, 5 April from 3:15 PM – 5:15 PM and again from 5:30 PM – 7:30 PM. Within the concurrent sessions, there are 8 individual presentations. Oral presentation sessions scheduled:

Cognition: Multifaceted Approach

Chair: Philip Harvey

Epidemiology: Roles for Environmental Factors

Chair: James MacCabe

Neurodevelopment: Childhood, Adolescence and Adulthood

Chair: Aristotle Voineskos

Brain Imaging-I: Molecules, Structures and Functions

Chair: Igor Nenadic

Genetics: Multifaceted Approach

Chair: James Kennedy

Phenomenology and Dimensional Discussion

Chair: Celso Arango

Neurobiology

Chair: John F. Deakin

Clinical Trials

Chair: Hilleke Hulshoff Pol

FINAL PROGRAM

FLORENCE, ITALY

2 – 6 APRIL 2016



Psychosocial Functioning

Chair: Merete Nordentoft

Treatment and Clinical Service

Chair: Patrick McGorry

Brain Imaging-II: Molecules, Structures and Functions

Chair: Paola Dazzan

Biomarkers

Chair: Christos Pantelis

POSTERS

Three poster sessions are scheduled. Presenters should put their poster up by 9:30 AM and remove the poster by 5:00 PM on the day it is scheduled. Poster presentations are grouped by general topic when possible. All three poster sessions are located in the Cavaniglia. Lunch will be served each day with the poster session. Poster viewing will be open until 5:00 PM; E-Posters are available for viewing online at www.SchizophreniaConference.org.

Sunday, 3 April	Poster Session I 11:00 AM – 1:00 PM
Monday, 4 April	Poster Session II 11:00 AM – 1:00 PM
Tuesday, 5 April	Poster Session III 11:00 AM – 1:00 PM

REFRESHMENT BREAKS:

All registered individuals are invited. Coffee and light pastries are available Sunday through Wednesday beginning at 8:00 AM. The morning break will be located in the Passi Perduti, located outside the Auditorium.

Afternoon coffee/tea will be available beginning at 12:45 PM Sunday – Wednesday outside the Palazzo Affari meeting rooms, the Auditorium and the Sala Verde.

LUNCHEONS:

Buffet lunch will be served Sunday through Tuesday from 11:00 AM – 1:00 PM in the Cavaniglia during the poster sessions. Boxed lunches will be served on Wednesday from 12:30 PM – 1:00 PM in the Passi Perduti, located outside the Auditorium.




5th Schizophrenia International Research Society Conference


Deconstructing Schizophrenia Towards Targeted Treatment

General Information


Floor Plan



Poster Sessions and lunches will be held at the Fortezza da Basso in the Cavaniglia. This is a short 3 to 5 minute walk from the Palazzo de Congressi.



Concurrent Symposia and Oral Presentations will be held on the Lower Level, Ground Level, First Level, Second Level of the Palazzo degli Affari.



The Computer Center will be located in the Limonaia building just between the Palazzo Degli Affari and the Villa Vittoria.




5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

General Information

Palazzo Congressi - Villa Vittoria AUDITORIUM




Keynote, Plenary Sessions and some Symposia and Oral Presentations will be held in the Auditorium.




Palazzo Congressi - Villa Vittoria

General Information

First Floor



Second Floor



The Speaker Ready Room (Sala 103) and other small meeting rooms and committee meetings will be in the Villa Vittoria Building on the 1st Floor and 2nd Floor. The Villa Vittoria building is connected to the Auditorium.

The Sala Verde room is on the 2nd floor of the Villa Vittoria building.

	7 AM 8 AM	8 AM 9 AM	9 AM 10 AM	10 AM 11 AM	11 AM 12 PM	12 PM 1 PM	1 PM 2 PM	2 PM 3 PM	3 PM 4 PM	4 PM 5 PM	5 PM 6 PM	6 PM 7 PM	7 PM 8 PM 8 PM 9 PM
Auditorium	<div>6:00 PM 7:15 PM</div> <div>Keynote: Susannah Cahalan</div>												
Passi Perduti	<div>5:30 PM 6:00 PM</div> Coffee Break <div>7:15 PM 9:00 PM</div> Opening Night Reception												
Palazzo Affari Entrance	<div>1:00 PM 8:00 PM</div> Registration												
Sala 103	<div>1:00 PM 7:00 PM</div> Speaker Ready Room												
Limonaia	<div>1:00 PM 7:00 PM</div> Computer Center												

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



Saturday, 2 April 2016

SIRS EXECUTIVE BOARD MEETING (INVITATION ONLY)

11:00 AM - 1:00 PM

Location: Congressi 101

REGISTRATION

1:00 PM - 8:00 PM

Location: Palazzo Entrance

COFFEE BREAK

5:30 PM - 6:00 PM

Location: Congressi, Passi Perduti

CONFERENCE OPENING AND KEYNOTE SESSION

6:00 PM - 7:15 PM

KEYNOTE LECTURE: An Evening with Susannah Cahalan, author of *Brain on Fire*

Location: Congressi Auditorium

OPENING NIGHT RECEPTION

7:15 PM - 9:00 PM

Location: Congressi, Passi Perduti

Saturday 2 April

Schizophrenia Bulletin

remains at the forefront of the quickly evolving field of psychosis.

VISIT
our booth in
the Salone
Club of the
Palazzo Dei
Congressi



READ our Related Disorders collection
now at oxford.ly/relateddisorders

OXFORD
UNIVERSITY PRESS

	7 AM 8 AM	8 AM 9 AM	9 AM 10 AM	10 AM 11 AM	11 AM 12 PM	12 PM 1 PM	1 PM 2 PM	2 PM 3 PM	3 PM 4 PM	4 PM 5 PM	5 PM 6 PM	6 PM 7 PM	7 PM 8 PM	8 PM 9 PM
Auditorium		8:30 AM - 9:30 AM Positive Allosteric Modulators...	9:30 AM - 10:00 AM Coffee Break	10:00 AM - 11:00 AM The Recovery Project			1:00 PM - 3:00 PM Alterations in Hippocampal Activity, Glutamate and GABA Before the Onset of Psychosis	3:00 PM - 3:30 PM Coffee Break	3:30 PM - 5:00 PM Exciting New Findings About Dopamine		5:45 PM - 6:45 PM SIRS Business Meeting			
Sala Verde							1:00 PM - 3:00 PM How Can Sex Hormones Influence Psychosis and Cognitive Abilities in Men and Women With Schizophrenia?	3:00 PM - 3:30 PM Coffee Break	3:30 PM - 5:00 PM The Pivotal Role of Glia in Schizophrenia: Providing Molecular Insights for Developing New Therapies					
Palazzo Affari Ground Level							1:00 PM - 3:00 PM Childhood Trauma and Psychosis: Mechanisms, Symptom Profiles, Outcome, and Treatment	3:00 PM - 3:30 PM Coffee Break	3:30 PM - 5:00 PM Cognitive Remediation: Effects on Social Cognition and New Insights on Mediators and Moderators of Treatment Outcomes					
Palazzo Affari Lower Level							1:00 PM - 3:00 PM I Did It! The Experience of Self-Agency in Schizophrenia	3:00 PM - 3:30 PM Coffee Break	3:30 PM - 5:00 PM The WHO International Classification of Functioning Core Sets: A Consensus Process for Key Components of Functioning for Schizophrenia					
Palazzo Affari 1st Level							1:00 PM - 3:00 PM Improving Identification and Treatment of Early Phase Psychosis	3:00 PM - 3:30 PM Coffee Break	3:30 PM - 5:00 PM Schizophrenia and Mortality - Different Aspects, Different Solutions					
Palazzo Affari 2nd Level							1:00 PM - 3:00 PM Cannabis and Psychosis: What Now for Dopamine?	3:00 PM - 3:30 PM Coffee Break	3:30 PM - 5:00 PM Psychotic Experiences in the E-Generation: Measuring Symptoms, Functioning and Long Term Course in Young People					
Cavaniglia					11:00 AM - 1:00 PM Poster Session 1 and Lunch									
Palazzo Affari Entrance						8:00 AM - 6:30 PM Registration								
Sala 103						8:00 AM - 7:00 PM Speaker Ready Room								
Limonaia						8:00 AM - 6:30 PM Computer Center								
Passi Perduti			8:00 AM - 10:30 AM Coffee Available			12:45 PM - 3:45 PM Coffee Available								

Legend: [Keynote](#) [Special Session](#) [Speaker Ready](#) [Registration](#) [Computer Center](#) [Symposia](#) [Poster Session](#) [Plenary](#) [Oral Presentation](#) [Coffee Break](#)

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



Sunday, 3 April 2016

REGISTRATION

8:00 AM - 6:30 PM

Location: Palazzo Entrance

MORNING COFFEE

8:00 AM - 8:30 AM

Location: Congressi, Passi Perduti

**PLENARY SESSION: POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC
ACETYLCHOLINE RECEPTORS AS A NOVEL APPROACH FOR TREATMENT
OF SCHIZOPHRENIA**

8:30 AM - 9:30 AM

Location: Congressi Auditorium

P. Jeffrey Conn

Vanderbilt University Medical Center, United States

Sunday 3 April

Abstract: Previous clinical studies as well as a large number of cellular and animal behavioral studies suggest that selective activators of M1 and/or M4 subtypes of muscarinic acetylcholine receptors (mAChRs) could provide a novel approach to treatment of schizophrenia. Especially exciting is the possibility that such agents could have efficacy in treatment of positive, negative, and cognitive symptoms in schizophrenia patients. Unfortunately, previous efforts to develop selective agonists of individual mAChR subtypes have not been successful and previous compounds have failed in development because of adverse effects due to activation of multiple mAChR subtypes. Furthermore, the relative roles of M1 and M4 in mediating the overall therapeutic effects of less selective mACh agonists are not understood. We have been highly successful in developing highly selective positive allosteric modulators (PAMs) of both M1 and M4 that have excellent properties for in vivo studies and potential development as drug candidates. Interestingly, selective M1 PAMs have robust efficacy in improving specific domains of cognitive function in animal models but do not have antipsychotic-like effects. In contrast, selective M4 PAMs have robust antipsychotic-like effects in animal models. Electrophysiology and genetic studies are providing important new insights into the mechanisms by which M1 and M4 PAMs act in specific cortical and midbrain circuits. These studies provide an exciting new approach to that has potential for treatment of multiple symptom clusters in schizophrenia patients.

COFFEE BREAK

9:30 AM - 10:00 AM

Location: Congressi, Passi Perduti



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

PLENARY SESSION: THE RECOVERY PROJECT: THE WHO, WHAT, WHERE AND WHEN OF PSYCHOLOGICAL TREATMENTS

10:00 AM - 11:00 AM

Location: Congressi Auditorium

Til Wykes

Institute of Psychiatry, Psychology & Neuroscience, United Kingdom

Abstract: Psychological treatments aimed at symptoms or behaviours that impede recovery now have a relatively strong database but it is not clear which treatments are more effective and when. Tailoring treatment, considering adherence and personal goals will tax the current evidence base but clinicians still need to make decisions. Data to help them will be discussed in this plenary lecture.

POSTER SESSION I AND LUNCH

11:00 AM – 1:00 PM

Location: Cavaniglia

Buffet Lunch will be served daily in the poster session

Please see page 68 for a complete listing of posters

CONCURRENT SYMPOSIA

1:00 PM - 3:00 PM

ALTERATIONS IN HIPPOCAMPAL ACTIVITY, GLUTAMATE AND GABA BEFORE THE ONSET OF PSYCHOSIS

Location: Congressi Auditorium

Chair: Philip McGuire

1:00 PM *Elevated Hippocampal Glutamate Levels Predict the Later Onset of Psychosis*
Matthijs Bossong

1:25 PM *Resting Hyperperfusion of the Hippocampus, Midbrain and Basal Ganglia in People at High Risk for Psychosis*
Paul Allen

1:50 PM *GABAergic Dysregulation in Individuals at Ultra-High Risk for Psychosis Investigated With Proton Magnetic Resonance Spectroscopy*
Gemma Modinos

2:15 PM *Altered Relationship Between Hippocampal Activation and Subcortical Dopamine Function in People at Ultra High Risk of Psychosis*
Toby Winton-Brown

Discussant: Anthony Grace

Sunday 3 April

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



HOW CAN SEX HORMONES INFLUENCE PSYCHOSIS AND COGNITIVE ABILITIES IN MEN AND WOMEN WITH SCHIZOPHRENIA?

Location: Congressi, Sala Verde

Chair: Thomas Weickert

1:00 PM *Sex Differences and Effects of Sex Steroid Hormones in Animal Models of Schizophrenia*
Maarten van den Buuse

1:25 PM *Sex Hormones to Improve Symptoms and Cognition in Schizophrenia*
Iris Sommer

1:50 PM *Molecular Explanation for Estrogens Role in Schizophrenia Lays the Foundation of Novel Treatment for Men and Women*
Cynthia Shannon Weickert

2:15 PM *Hormonal Influences on Cognition and Brain Activity in Schizophrenia*
Thomas Weickert

Discussant: Raquel Gur

CHILDHOOD TRAUMA AND PSYCHOSIS: MECHANISMS, SYMPTOM PROFILES, OUTCOME, AND TREATMENT

Location: Affari, Ground Level

Chair: Ruud Van Winkel

1:00 PM *Trauma, Attachment and Dissociation: Moving Towards Process-Focused Psychological Interventions for Psychosis*
Filippo Varese

1:25 PM *Using a Stratified Approach in Psychiatry – Implications for Treatment and the Search for Underlying Mechanisms of Mental Illness*
Martine Van Nierop

1:50 PM *The Role of Childhood Abuse in the Course and Outcome of Psychotic Disorders Over 10 Years*
Helen Fisher

2:15 PM *Treating PTSD in Psychosis With Prolonged Exposure of Eye Movement Desensitization and Reprocessing: A Randomised Controlled Trial*
Mark Van der Gaag

Discussant: Robin Murray

Sunday 3 April



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

I DID IT! THE EXPERIENCE OF SELF-AGENCY IN SCHIZOPHRENIA

Location: Affari, Lower Level

Chair: Neeltje Van Haren

- 1:00 PM** *Self Disturbance: A Construct to Integrate Phenomenology and Neurocognition in Early Psychosis?*
Barnaby Nelson
- 1:25 PM** *Premotor Signals Affecting the Subjective Experience of Agency - An fMRI Study in Schizophrenia Patients and Healthy Volunteers*
Martin Voss
- 1:50 PM** *Schizotypy and the Awareness of Intention: Variability in the Timing of Intention Awareness Predicts Schizotypy Scores*
James Moore
- 2:15 PM** *Neural and Clinical Consequences of Self-Agency Processing in Schizophrenia*
Neeltje Van Haren

Discussant: Tilo Kircher

IMPROVING IDENTIFICATION AND TREATMENT OF EARLY PHASE PSYCHOSIS

Location: Affari, First Level

Chair: John Kane

- 1:00 PM** *Pathways to Care in Early Psychosis: The Role of the Internet and Social Media*
John Kane
- 1:25 PM** *The Step-Ed Project: A Population Based Approach to Early Intervention for Psychosis*
Vinod Srihari
- 1:50 PM** *Effectiveness of Early Intervention Services for Patients With Early Psychosis: Systematic Review and Meta-Analysis of Specialized Care Versus Usual or Modular Care*
Christoph Correll
- 2:15 PM** *Mobile Behavioral Sensing in Outpatients and Inpatients With Schizophrenia*
Dror Ben-Zeev

Discussant: Robert Zipursky

Sunday 3 April

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



CANNABIS AND PSYCHOSIS: WHAT NOW FOR DOPAMINE?

Location: Affari, Second Level

Chair: Michael Bloomfield

- 1:00 PM** *Psychosis and the Psychopharmacology of Cannabinoids*
Amir Englund
- 1:25 PM** *The Effects of Delta-9-Tetrahydrocannabinol (THC) on Dopamine Synthesis and Release: Evidence From Pre-Clinical and Clinical Studies*
Michael Bloomfield
- 1:50 PM** *Clinical Neuroimaging Studies of the Effects of Cannabis in Psychosis*
Romina Mizrahi
- 2:15 PM** *Non-Dopaminergic Pathways From THC to Psychosis: GABA Deficits Enhance the Psychotomimetic Effects of Δ^9 -THC*
Deepak D'Souza

Discussant: Marta Di Forti

COFFEE BREAK

3:00 PM - 3:30 PM

Location: Passi Perducci, Affari Foyers, and the Sala Verde Foyer

CONCURRENT SYMPOSIA

3:30 PM - 5:30 PM

EXCITING NEW FINDINGS ABOUT DOPAMINE

Location: Congressi Auditorium

Chair: Bitá Moghaddam

- 3:30 PM** *Dopamine Neurotransmission in Schizophrenia: New Findings From Combined PET and fMRI Studies*
Anissa Abi-Dargham
- 3:55 PM** *Adolescent Dopamine Development, Netrin-1, and Vulnerability to Schizophrenia*
Cecillia Flores
- 4:20 PM** *A Novel Role for Dopamine Regulation of Striatal and Cortical Information Processing*
Bitá Moghaddam
- 4:45 PM** *A Molecular Signature of Dopamine Dysregulation Exists in the Substantia Nigra in Schizophrenia*
Tertia Purves-Tyson

Discussant: Marco Bortolato

Sunday 3 April



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

THE PIVOTAL ROLE OF GLIA IN SCHIZOPHRENIA: PROVIDING MOLECULAR INSIGHTS FOR DEVELOPING NEW THERAPIES

Location: Congressi, Sala Verde

Chair: Johann Steiner

3:30 PM *Histology and Biochemistry of White Matter in Psychiatric Disease*
Andrew Dwork

3:55 PM *Connecting the Energy Dysfunction Observed in Schizophrenia Brains to Glia Cells in Vitro*
Daniel Martins-De-Souza

4:20 PM *Clozapine Promotes Glycolysis and Myelin Lipid Synthesis in Cultured Oligodendrocytes*
Johann Steiner

4:45 PM *DISC1 Induced Expansion of the Hindbrain Oligodendrocytes Progenitors in Forebrain During Development – Relevance to Schizophrenia*
Pavel Katsel

Discussant: Kolja Schiltz

COGNITIVE REMEDIATION: EFFECTS ON SOCIAL COGNITION AND NEW INSIGHTS ON MEDIATORS AND MODERATORS OF TREATMENT OUTCOMES

Location: Affari, Ground Level

Chair: Marieke (Gerdina) Pijnenborg

3:30 PM *Improvement of Social Cognition Deficits in Chronic Schizophrenia After CRT*
Natalia Ojeda

3:55 PM *Exploring the Role of Metacognition in Cognitive and Functional Change Following a New Generation Metacognitive Cognitive Remediation Programme for People With Schizophrenia*
Clare Reeder

4:20 PM *Reading the Mind of the Avatar: Demonstration of a New Virtual Reality Social Cognition Training for People With Psychotic Disorders*
Saskia Nijman

4:45 PM *Training of Social Cognition in Psychotic Disorders: A Meta-Analysis*
Marieke (Gerdina) Pijnenborg

Discussant: Torill Ueland

Sunday 3 April

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



THE WHO INTERNATIONAL CLASSIFICATION OF FUNCTIONING CORE SETS: A CONSENSUS PROCESS FOR KEY COMPONENTS OF FUNCTIONING FOR SCHIZOPHRENIA

Location: Affari, Lower Level

Chair: Oscar Pino

- 3:30 PM** *Social Disconnectedness in Schizophrenia and in the General Community: Do They Look the Same?*
Junghee Lee
- 3:55 PM** *A Closer Look at Functioning – What Are International Classification of Functioning, Disability and Health Core Sets and How They Can Be Used*
Michaela Coenen
- 4:20 PM** *Preliminary Studies for the Development of the International Classification of Functioning, Disability and Health Core Sets (ICF-CS) for Schizophrenia*
Georgina Guilera
- 4:45 PM** *The Comprehensive and Brief International Classification of Functioning, Disability and Health Core Sets (ICF-CS) for Schizophrenia*
Oscar Pino

Discussant: William Carpenter

SCHIZOPHRENIA AND MORTALITY - DIFFERENT ASPECTS, DIFFERENT SOLUTIONS

Location: Affari, First Level

Chair: Carsten Hjorthøj

- 3:30 PM** *Substance Use and Mortality in Schizophrenia, Bipolar Disorder, and Unipolar Depression*
Carsten Hjorthøj
- 3:55 PM** *Mortality in Schizophrenia and Bipolar Disorder: Clinical and Serological Predictors*
Faith Dickerson
- 4:45 PM** *Epidemiological and Biological Correlates of Premature Mortality in People With Psychosis*
Cherrie Galletly
- 5:10 PM** *Homelessness as a Risk Factor for Mortality: A Danish Nationwide Register-Based Cohort Study*
Sandra Feodor Nilsson

Discussant: John McGrath

Sunday 3 April



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

PSYCHOTIC EXPERIENCES IN THE E-GENERATION: MEASURING SYMPTOMS, FUNCTIONING AND LONG TERM COURSE IN YOUNG PEOPLE

Location: Affari, Second Level

Chair: Annegien Bartels-Velthuis

3:30 PM *Psychotic Experiences in a Community Sample of Youths: Relationship With Mental Distress and Global Functioning*

Ian Kelleher

3:55 PM *Introducing the White Noise Task in Childhood: Associations Between Speech Illusions and Psychosis Vulnerability*

Martin Rimvall

4:20 PM *Course of Auditory Vocal Hallucinations in Childhood: 11-Year Follow-Up Study*

Annegien Bartels-Velthuis

4:45 PM *The MHASC Application Assessing Early-Onset Hallucinations in the Touch-Screen Generation*

Renaud Jardri

Discussant: Pia Jeppesen

SIRS BUSINESS MEETING (SIRS MEMBERS ONLY)

5:45 PM - 6:45 PM

Location: Congressi Auditorium

Sunday 3 April

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



NOTES

Sunday 3 April

	7 AM 8 AM	8 AM 9 AM	9 AM 10 AM	10 AM 11 AM	11 AM 12 PM	12 PM 1 PM	1 PM 2 PM	2 PM 3 PM	3 PM 4 PM	4 PM 5 PM	5 PM 6 PM	6 PM 7 PM	7 PM 8 PM	8 PM 9 PM
Auditorium		8:30 AM - 9:30 AM Toward Predictive Psychiatry...	9:30 AM - 10:00 AM Coffee Break	10:00 AM - 11:00 AM Precision Medicine for Psychosis: Challenges and Promise			1:00 PM - 3:00 PM Pharmaceutical Pipeline	3:00 PM - 3:30 PM Coffee Break	3:30 PM - 5:00 PM The Role of Development and Stage of Psychotic Illness on Characteristics of Longitudinal Neurocognitive Functioning					
Sala Verde							1:00 PM - 3:00 PM Neuroimaging Biomarkers for Psychiatric Disorders in Adolescence and Young Adulthood: Prediction of Risk, Transition and Illness Course	3:00 PM - 3:30 PM Coffee Break	3:30 PM - 5:00 PM Duration of Early Intervention and the Critical Period					
Palazzo Affari Ground Level							1:00 PM - 3:00 PM Psychosis in Children and Adolescents: From the Prodrome to Schizophrenia	3:00 PM - 3:30 PM Coffee Break	3:30 PM - 5:00 PM Elephant in the Room: Gila Contribution to Mental Disorders					
Palazzo Affari Lower Level							1:00 PM - 3:00 PM Neuroimaging Approaches to Treatment Outcome in Schizophrenia	3:00 PM - 3:30 PM Coffee Break	3:30 PM - 5:00 PM Negative Symptoms - Integrating Clinical and Neuroimaging Perspectives					
Palazzo Affari 1st Level							1:00 PM - 3:00 PM Characterizing a Putative "Traumagenic" Subtype of Psychosis	3:00 PM - 3:30 PM Coffee Break	3:30 PM - 5:00 PM Non-Traditional Methods of Classification in Psychosis: Applying a Precision Medicine Model					
Palazzo Affari 2nd Level							1:00 PM - 3:00 PM NMDAR Antibodies and Their Relevance for Schizophrenia	3:00 PM - 3:30 PM Coffee Break	3:30 PM - 5:00 PM Movement Disorders: A Non-Mental Core Symptom of Psychotic Disorders and the Importance of Instrumental Screening					
Cavaniglia					11:00 AM - 1:00 PM Poster Session II and Lunch									
Palazzo Affari Entrance							8:00 AM - 7:00 PM Registration							
Sala 103							8:00 AM - 7:00 PM Speaker Ready Room							
Limonaia							8:00 AM - 6:30 PM Computer Center							
Passi Perduti			8:00 AM - 10:30 AM Coffee Available				12:45 PM - 3:45 PM Coffee Available							

Legend: [Keynote](#) [Special Session](#) [Speaker Ready](#) [Registration](#) [Computer Center](#) [Symposia](#) [Poster Session](#) [Plenary](#) [Oral Presentation](#) [Coffee Break](#)

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



Monday, 4 April 2016

REGISTRATION

8:00 AM - 7:00 PM

Location: Palazzo Entrance

MORNING COFFEE

8:00 AM - 8:30 AM

Location: Congressi, Passi Perduti

**PLENARY SESSION: TOWARD PREDICTIVE PSYCHIATRY – PROGNOSTIC AND
DIAGNOSTIC APPLICATIONS OF PATTERN RECOGNITION METHODS**

8:30 AM - 9:30 AM

Location: Congressi Auditorium

Nikolaos Koutsouleris
Ludwig-Maximilian-University, Germany

Abstract: Recently, both high-dimensional ‘omics’ data and powerful multivariate pattern analysis tools have become available for psychiatric research. These developments have stirred the hope that predictive signatures could be extracted from these multi-modal databases with far-reaching potential for individualized prognosis and (differential) diagnosis of schizophrenic, affective and neurodegenerative disorders. Yet, given the crisis of the current neuropsychiatric taxonomy and the inefficiencies of univariate statistics, it remains unclear (1) if robust mappings between neurobiological patterns and the traditional clinical diagnostic entities actually exist, and (2) whether these patterns generalize enough to be encapsulated into clinically useful ‘biomarkers’.

The lecture will first review concepts and the state-of-the-art of multivariate pattern analysis (MVPA) in psychiatric research, putting the focus on candidate markers for individualized risk stratification and differential diagnosis of schizophrenia-spectrum and mood disorders. Strengths and pitfalls of MVPA will be discussed in terms of sensitivity to overfitting, to center and data acquisition effects as well as to population biases. Preliminary data from the PRONIA study (www.pronia.eu) will be presented in order to exemplify the current status and the challenges to be addressed by predictive psychiatry.

Candidate neuroimaging, neurocognitive and clinical prediction models developed by means MVPA technology will be described by (1) reporting sensitivity, specificity and accuracy of prognostic and (differential) diagnostic predictions in patients with schizophrenia-spectrum and affective psychoses, (2) visualizing underlying patterns, and (3) discussing the moderating influence of diagnostic boundaries psychopathological features, disease courses, brain maturation and environmental variables on prediction performance.

MVPA may provide a powerful and adaptive set of statistical tools to decompose the complexity of psychiatric phenotypes into their most predictive components. The designs of the next-generation translational studies have to take into account the strengths and pitfalls of these methods in order to assess which of these components have the highest bench-to-bedside potential.

Monday 4 April



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

COFFEE BREAK

9:30 AM - 10:00 AM

Location: Congressi, Passi Perduti

PLENARY SESSION: PRECISION MEDICINE FOR PSYCHOSIS: CHALLENGES AND PROMISE

10:00 AM - 11:00 AM

Location: Congressi Auditorium

Raquel Gur

University of Pennsylvania, United States

Abstract: Consistent with the goals of precision medicine to re-define illness mechanistically through elucidating the pathophysiology from gene action to symptoms, large scale genomic studies have been linking genomic variation to continuous quantitative phenotypes. Such an approach can lead to early detection and pathological processes enabling early intervention. This paradigm shift is now applied in psychiatry with an increased focus in schizophrenia research on early identification of psychosis as the process emerges. Convergent approaches integrate phenotypic features with neurocognitive and neuroimaging measures in large -scale studies. Most studies have examined help seeking youths.

This presentation highlights complementary strategies to probe the underlying neurobiology of psychosis risk. The first, most widely applied is the study of help-seeking individuals who present with subthreshold psychotic symptoms and are at high risk for psychotic illness. The second, community-based samples of youths with no known neurogenetic syndrome. The Philadelphia Neurodevelopment Cohort illustrates such an approach. The third, the study of youths with a known genetic syndrome, the 22q11.2 Deletion Syndrome (22q11DS) that confers significant increased risk for psychosis (~25%), emerging in adolescence and early adulthood.

Methodological considerations and emerging finding across strategies will be discussed and the implication for early identification and intervention emphasized.

POSTER SESSION II AND LUNCH

11:00 AM – 1:00 PM

Location: Cavaniglia

Buffet Lunch will be served daily in the poster session

Please see page 97 for a complete listing of posters

Monday 4 April

FINAL PROGRAM

FLORENCE, ITALY

2 – 6 APRIL 2016



CONCURRENT SYMPOSIA

1:00 PM - 3:00 PM

PHARMACEUTICAL PIPELINE

1:00 PM - 3:00 PM

Location: Congressi Auditorium

Chair: Akira Sawa

- 1:00 PM** *Drug Development Strategies for Schizophrenia Using a Novel PDE10A Inhibitor: TAK-063*
Tom Macek
- 1:20 PM** *Can Pharmacogenetics Improve Drug Discovery? : Insights From a Naturalistic Study and a Randomized Controlled Trial for Schizophrenia Treatment Outcomes*
Eric Huang
- 1:40 PM** *Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Encenicline as Pro-Cognitive Treatment in Patients With Schizophrenia on Chronic Stable Atypical Antipsychotic Therapy*
Stephen Brannan
- 2:00 PM** *A Phase 2 Study of PF-02545920 (PDE10A Inhibitor) in Adjunctive Treatment of Outpatients With Sub-Optimally Controlled Symptoms of Schizophrenia*
Nicholas Demartinis
- 2:20 PM** *The Open Translational Science in Schizophrenia Project: Janssen Clinical Trial and NIH Data Together in an Open-Science Collaboration*
Marsha Wilcox
- 2:40 PM** *Evenamide (NW-3509), a Putative Antipsychotic, Targets Abnormal Electrical Activity and Glutamatergic Abnormalities in Improving Psychotic Symptoms in Patients With Schizophrenia in a Phase II, Placebo-Controlled Trial*
Ravi Anand

Monday 4 April

NEUROIMAGING BIOMARKERS FOR PSYCHIATRIC DISORDERS IN ADOLESCENCE AND YOUNG ADULTHOOD: PREDICTION OF RISK, TRANSITION AND ILLNESS COURSE

Location: Congressi, Sala Verde

Chair: Hugo Schnack

- 1:00 PM** *Machine Learning in Psychiatric Neuroimaging: Introduction and Applications in Adolescent Offspring of Patients With Schizophrenia or Bipolar Disorder*
Hugo Schnack
- 1:25 PM** *Neuroanatomical Features as Transdiagnostic Biomarkers of Psychosis and Autism Spectrum Disorders*
Joost Janssen
- 1:50 PM** *MRI-Based Risk Stratification in Clinical High-Risk Individuals: State-of-the-Art and Challenges Ahead*
Nikolaos Koutsouleris



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

2:15 PM *Stratifying Psychosis Outcome at Illness Onset Using MRI-Based Univariate Approaches and Pattern Classification Methods*

Paola Dazzan

Discussant: Stephen Lawrie

PSYCHOSIS IN CHILDREN AND ADOLESCENTS: FROM THE PRODROME TO SCHIZOPHRENIA

Location: Affari, Ground Level

Chair: Anne Katrine Pagsberg

1:00 PM *Age-Related Characteristics of Attenuated Positive Symptoms Syndrome*

Miriam Gerstenberg

1:25 PM *Differentiation Between the Prodrome to Schizophrenia-Spectrum and Bipolar-Spectrum Disorders: Can We Separate Clinical High-Risk States?*

Christoph Correll

1:50 PM *Illness Course and Outcome in Early Onset Schizophrenia: A Nationwide Danish Register Case-Control Study*

Ditte Lammers Vernal

2:15 PM *Antipsychotic Treatment for Children and Adolescents With Schizophrenia Spectrum Disorders: A Systematic Review and Network Meta-Analysis*

Anne Katrine Pagsberg

Discussant: Celso Arango

NEUROIMAGING APPROACHES TO TREATMENT OUTCOME IN SCHIZOPHRENIA

Location: Affari, Lower Level

Chair: Robert Buchanan

1:00 PM *Advantages and Challenges of Multi-Site Neuroimaging Data in Schizophrenia*

Jessica Turner

1:25 PM *Neuroimaging and Machine Learning Algorithms to Identify Biological Subtypes of Schizophrenia*

Aristotle Voineskos

1:50 PM *The Role of PET in Optimizing Treatment Outcome*

Anissa Abi-Dargham

2:15 PM *From the Genome to the Connectome: Detecting Biomarkers of Antipsychotic Drug Response*

Anil Malhotra

Discussant: Shitij Kapur

Monday 4 April

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



CHARACTERIZING A PUTATIVE “TRAUMAGENIC” SUBTYPE OF PSYCHOSIS

Location: Affari, First Level

Chair: Mary Cannon

- 1:00 PM** *Trauma and Transition to Psychosis in the Ultra High Risk Population: Results From a Long Term Follow Up Study*
Andrew Thompson
- 1:25 PM** *Childhood Events and Psychosis in Bipolar Affective Disorder*
Rachel Upthegrove
- 1:50 PM** *Trauma, Stress Reactivity and Prediction of Outcome in the Ultra High Risk Population: Data From the Neurapro-E Study*
Barnaby Nelson
- 2:15 PM** *Interplay Between Childhood Victimization and Familial Liability in the Persistence of Psychotic Symptoms During Adolescence*
Helen Fisher

Discussant: Ian Kelleher

NMDAR ANTIBODIES AND THEIR RELEVANCE FOR SCHIZOPHRENIA

Location: Affari, Second Level

Chair: Belinda Lennox

- 1:00 PM** *Antibodies to Neuronal Cell Surface Antigens in Psychiatric Disease*
Angela Vincent
- 1:25 PM** *Impact of Anti-NMDA Receptor Autoantibody From Schizophrenic Patients on Membrane Receptors Using Single Molecule Imaging*
Laurent Groc
- 1:50 PM** *Neurocognitive Phenotype and Imaging Abnormalities of Patients With NMDAR Antibodies*
Carsten Finke
- 2:15 PM** *Clinical Phenotype of Patients With NMDAR Antibodies*
Belinda Lennox

Discussant: Joseph Masdeu

COFFEE BREAK

Location: Passi Perdutti, Affari Foyers, and the Sala Verde Foyer

3:00 PM - 3:30 PM

Monday 4 April



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

CONCURRENT SYMPOSIA

3:30 PM - 5:30 PM

THE ROLE OF DEVELOPMENT AND STAGE OF PSYCHOTIC ILLNESS ON CHARACTERISTICS OF LONGITUDINAL NEUROCOGNITIVE FUNCTIONING

Location: Congressi Auditorium

Chair: Larry Seidman

3:30 PM *Cognitive and Functional Outcome in Early-Onset Schizophrenia: 13- and 20-Year Follow-Up*
Merete Øie

3:55 PM *Cognitive Profile and Cognitive Recovery After a First Episode of Adult-Onset Schizophrenia:
One-Year Longitudinal Study*
Keith Nuechterlein

4:20 PM *Neurocognition and Duration of Psychosis Before and After Start of Treatment: What
Predicts the Course of Schizophrenia?*
Bjorn Rund

4:45 PM *Neurocognitive Functioning in the Second Phase of the North American Prodrome
Longitudinal Study*
Larry Seidman

Discussant: Abraham Reichenberg

DURATION OF EARLY INTERVENTION AND THE CRITICAL PERIOD

Location: Congressi, Sala Verde

Chair: Merete Nordentoft

3:30 PM *Duration of Early Intervention and the Critical Period: Insights From Cohort and Controlled
Studies From Hong Kong*
Eric Chen

3:55 PM *A Randomized Controlled Study of Five vs. Two Years of Specialized Early Intervention
Service*
Ashok Malla

4:20 PM *How Long Should Early Intervention Last? Results From a Randomized Clinical Trial of the
Effect of Five-Years Versus Two-Years Specialized Assertive Intervention for First Episode
Psychosis – The OPUS-II Trial*
Nikolai Albert

4:45 PM *Neurobiological Changes During the Early Phase of Psychosis and Clinical Response*
Oliver Howes

Discussant: Max Birchwood

Monday 4 April

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



ELEPHANT IN THE ROOM: GLIA CONTRIBUTION TO MENTAL DISORDERS

Location: Affari, Ground Level

Chair: Mikhail Pletnikov

3:30 PM *Cell-Specific Vulnerability to Adolescent Cannabis Exposure: The Expanding Role of Astrocytes*
Mikhail Pletnikov

3:55 PM *Interactions Between Glia and Extracellular Matrix in Schizophrenia*
Sabina Berretta

4:20 PM *Glial Dopamine Controls Neuronal Network Activity and Functions in the Prefrontal Cortex*
Jean-Pierre Mothet

4:45 PM *Glioproteomics to Define the Role of Glia in Neuroinflammatory Diseases*
Kyounggho Suk

Discussant: Akira Sawa

NEGATIVE SYMPTOMS - INTEGRATING CLINICAL AND NEUROIMAGING PERSPECTIVES

Location: Affari, Lower Level

Chair: Silvana Galderisi

3:30 PM *Progressive Brain Changes Associated With Persistent Negative Symptoms Following a First Episode of Psychosis*
Martin Lepage

3:55 PM *The Impact of Negative Symptom Domains on Real-Life Functioning of People With Schizophrenia and First-Degree Relatives*
Armida Mucci

4:20 PM *The Neural Basis of Distinct Negative Symptom Dimensions in Schizophrenia*
Stefan Kaiser

4:45 PM *New Clinical and Neuroimaging Investigations of Real-World Motivation Deficits in Schizophrenia in the Context of Virtual Reality Assessments*
George Foussias

Discussant: Celso Arango

Monday 4 April



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

NON-TRADITIONAL METHODS OF CLASSIFICATION IN PSYCHOSIS: APPLYING A PRECISION MEDICINE MODEL

Location: Affari, First Level

Chair: Katherine Burdick

3:30 PM *Empirical Classification of Psychotic Patients Using Neurocognitive Profiles*
Katherine Burdick

3:55 PM *Polygenic Risk Scores Among Cognitive Subtypes of Psychosis*
Melissa Green

4:20 PM *Prospects for Genetic Subtyping in Polygenic Disease*
Shaun Purcell

4:45 PM *Parsing Neurobiological Variance in Psychosis via Brain Based Biomarkers*
Brett Clementz

Discussant: John McGrath

MOVEMENT DISORDERS: A NON-MENTAL CORE SYMPTOM OF PSYCHOTIC DISORDERS AND THE IMPORTANCE OF INSTRUMENTAL SCREENING

Location: Affari, Second Level

Chair: Peter Van Harten

3:30 PM *Instrumental Measurement of Bradykinesia and Dyskinesia in Psychosis and Individuals at Risk*
Peter Van Harten

3:55 PM *Decreased Right-Handedness and Somatosensory Asymmetry in Youth at Ultrahigh Risk for Psychosis*
Vijay Mittal

4:20 PM *Resting State Functional Connectivity in the Motor Loop Correlates With Hypokinesia in Schizophrenia*
Sebastian Walther

4:45 PM *Instrument-Based Assessment of Dyskinesia Across Dimensions of Genetic Liability for Psychosis and Severity of Psychopathology*
Jerilyn Kent

Discussant: Jim Van Os

TRAVEL AWARD RECEPTION (Invitation Only)

Location: Affari, 4th Floor

5:45 PM - 6:45 PM

Monday 4 April

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



NOTES

Monday 4 April

	7 AM 8 AM	8 AM 9 AM	9 AM 10 AM	10 AM 11 AM	11 AM 12 PM	12 PM 1 PM	1 PM 2 PM	2 PM 3 PM	3 PM 4 PM	4 PM 5 PM	5 PM 6 PM	6 PM 7 PM	7 PM 8 PM	8 PM 9 PM
Auditorium	8:30 AM - 9:30 AM Convergent Evidence Linking Neonatal Vitamin D Status and Risk of Schizophrenia		9:30 AM - 10:00 AM Coffee Break	10:00 AM - 11:00 AM Balancing Plasticity / Stability Across Brain Development			1:00 PM - 3:00 PM Excitation/Inhibition Balance Disturbances in Schizophrenia: From Circuits to Large-Scale Networks	3:00 PM - 3:15 PM Coffee Break	3:15 PM - 5:15 PM Brain Imaging - I: Molecules, Structures, and Functions	5:15 PM - 5:30 PM Coffee Break	5:30 PM - 7:30 PM Brain Imaging - II: Molecules, Structures, and Functions			
Sala Verde							1:00 PM - 3:00 PM Trajectories of Children-Adolescents at Risk of Major Affective and Non-Affective Disorders: Exploring the Period Preceding the "CHR Risk Phase" ...	3:00 PM - 3:15 PM Coffee Break	3:15 PM - 5:15 PM Cognition: Multifaceted Approach	5:15 PM - 5:30 PM Coffee Break	5:30 PM - 7:30 PM Biomarkers			
Palazzo Affari Ground Level							1:00 PM - 3:00 PM Negative Symptoms: Why They Are so Important and yet so Difficult to Treat?	3:00 PM - 3:15 PM Coffee Break	3:15 PM - 5:15 PM Genetics: Multifaceted Approach	5:15 PM - 5:30 PM Coffee Break	5:30 PM - 7:30 PM Neurobiology			
Palazzo Affari Lower Level							1:00 PM - 3:00 PM Symptom Dimensions in Schizophrenia – Brain Correlates and Personalised Treatment Options	3:00 PM - 3:15 PM Coffee Break	3:15 PM - 5:15 PM Neurodevelopment: Childhood, Adolescence, and Adulthood	5:15 PM - 5:30 PM Coffee Break	5:30 PM - 7:30 PM Clinical Trials			
Palazzo Affari 1st Level							1:00 PM - 3:00 PM Lifespan Development of Schizophrenia and How the Treatments Improve the Outcomes	3:00 PM - 3:15 PM Coffee Break	3:15 PM - 5:15 PM Epidemiology: Roles for Environmental Risk Factors	5:15 PM - 5:30 PM Coffee Break	5:30 PM - 7:30 PM Treatment and Clinical Service			
Palazzo Affari 2nd Level							1:00 PM - 3:00 PM Social (Cognitive) Functioning in Schizophrenia: Mechanisms, Course and Treatment	3:00 PM - 3:15 PM Coffee Break	3:15 PM - 5:15 PM Phenomenology and Dimensional Discussion	5:15 PM - 5:30 PM Coffee Break	5:30 PM - 7:30 PM Psychosocial Functioning			
Cavaniglia					11:00 AM - 1:00 PM Poster Session III and Lunch									
Palazzo Affari Entrance	8:00 AM - 8:00 PM Registration													
Sala 103	8:00 AM - 7:00 PM Speaker Ready Room													
Limonaia	8:00 AM - 6:30 PM Computer Center													
Passi Perduti	8:00 AM - 10:30 AM Coffee Available				12:45 PM - 3:45 PM Coffee Available									

Legend: [Keynote](#) [Special Session](#) [Speaker Ready](#) [Registration](#) [Computer Center](#) [Symposia](#) [Poster Session](#) [Plenary](#) [Oral Presentation](#) [Coffee Break](#)

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



Tuesday, 5 April 2016

REGISTRATION

8:00 AM - 7:00 PM

Location: Palazzo Entrance

MORNING COFFEE

8:00 AM - 8:30 AM

Location: Congressi, Passi Perduti

PLENARY SESSION: CONVERGENT EVIDENCE LINKING NEONATAL VITAMIN D STATUS AND RISK OF SCHIZOPHRENIA

8:30 AM - 9:30 AM

Location: Congressi Auditorium

John McGrath

University of Queensland, Queensland Brain Institute

Abstract: Unravelling the aetiology and pathogenesis of brain disorders is a task that requires multidisciplinary skills, integration of data from different domains and tenacity. This lecture will present convergent evidence from epidemiology, genetics, and neuroscience aimed at finding modifiable risk factors for schizophrenia. In this lecture, Dr. McGrath will outline the results of a large replication study that confirms the association between low neonatal vitamin D concentration and an increased risk of schizophrenia. In addition, based on slice electrophysiology and wide-field calcium imaging, Dr. McGrath will present new evidence that links vitamin D with neurobiological mechanisms identified in recent GWAS studies for schizophrenia. Most importantly, if future studies confirm the association between developmental vitamin D deficiency and risk of schizophrenia, then it raises the tantalizing prospect of the primary prevention of mental disorders, in a manner comparable to folate supplementation and the prevention of spina bifida.

Tuesday 5 April

COFFEE BREAK

9:30 AM - 10:00 AM

Location: Congressi, Passi Perduti



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

PLENARY SESSION: BALANCING PLASTICITY / STABILITY ACROSS BRAIN DEVELOPMENT

10:00 AM - 11:00 AM

Location: Congressi Auditorium

Takao Hensch
Harvard University

Abstract: Maturing neural circuits are dramatically shaped by their environment, creating sequential windows of opportunity and vulnerability to early experience across brain regions. This lecture examines the biological bases of such 'critical periods' in development. Targeting specific GABA circuits by genetic or pharmacological manipulation can robustly accelerate or delay onset. Conversely, lifting a variety of brake-like factors which normally emerge to stabilize adult networks can reactivate plasticity. Notably, the mechanisms which open (excitatory-inhibitory circuit balance) or close (molecular brakes) these windows of circuit rewiring are increasingly implicated in cognitive disorders, such as autism and schizophrenia. This suggests mis-timed maturational processes may contribute, which in turn could be strategically leveraged to rescue circuit function. In particular, the interplay of most of these cell-autonomous and extrinsic factors converge upon fast-spiking, parvalbumin-positive cells, whose high metabolic demands render them sensitive to oxidative stress. Focusing on the cellular/molecular biology of these pivotal cells underlying trajectories of cortical processing and plasticity offers new insights into disease etiology and potential therapeutic approaches.

POSTER SESSION III AND LUNCH

11:00 AM – 1:00 PM

Location: Cavaniglia

Buffet Lunch will be served daily in the poster session

Please see page 127 for a complete listing of posters

Tuesday 5 April

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



CONCURRENT SYMPOSIA

1:00 PM - 3:00 PM

EXCITATION/INHIBITION BALANCE DISTURBANCES IN SCHIZOPHRENIA: FROM CIRCUITS TO LARGE-SCALE NETWORKS

Location: Congressi Auditorium

Chair: Peter Uhlhaas

1:00 PM *Neural Oscillations and E/I-Balance Parameters Across the Schizophrenia Spectrum: Insights from Magnetoencephalography (MEG)*
Peter Uhlhaas

1:25 PM *Schizophrenia and NMDA Receptor Deficiency: Rebalancing Excitation/Inhibition Disturbances*
Lawrence Kegeles

1:50 PM *Genetic Evidence for the Disruption of Excitatory and Inhibitory Signalling in Schizophrenia*
Andrew Pocklington

2:15 PM *Inhibitory and Disinhibitory GABAergic Interactions in the Hippocampus of Schizophrenics*
Francine Benes

Discussant: Patricio O'Donnell

TRAJECTORIES OF CHILDREN-ADOLESCENTS AT RISK OF MAJOR AFFECTIVE AND NON-AFFECTIVE DISORDERS: EXPLORING THE PERIOD PRECEDING THE “CHR RISK PHASE” FOR PRECLINICAL STAGING OF RISK AND IMPLICATIONS IN CLINICAL PRACTICE

Location: Congressi, Sala Verde

Chair: Michel Maziade

1:00 PM *Aggregation of Risk Indicators in Offspring of Patients Affected by Affective or Non-Affective Psychoses: Teachings From Québec Longitudinal High-Risk Families for the Staging of the Childhood-Adolescence Risk Trajectory*
Michel Maziade

1:25 PM *Transdiagnostic Antecedent-Based Strategy for Early Detection of Individuals at Risk of Severe Mental Illness: A FORBOW Study Report*
Rudolf Uher

1:50 PM *The Determinants of the Onset and Course of Early Mood Disorders: A Controlled 10-Year Follow-Up Study of Offspring of Parents With Bipolar and Unipolar Mood Disorders*
Martin Preisig

2:15 PM *Early Signs of Bipolar Disorder. A Study on Symptomatology Among Prospectively Followed Bipolar Offspring*
Manon Hillegers

Discussant: Patrick McGorry

Tuesday 5 April



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

NEGATIVE SYMPTOMS: WHY THEY ARE SO IMPORTANT AND YET SO DIFFICULT TO TREAT?

Location: Affari, Ground Level

Chair: Matteo Cella

1:00 PM *Reduction of Negative Symptoms With the Rehacop in Chronic Patients With Schizophrenia*
Natalia Ojeda

1:25 PM *Changes in Dimensions of Negative Symptoms Differentially Predict Self-Rated and Observer-Rated Functional Outcomes Following Cognitive Remediation*
Christopher Bowie

1:50 PM *Cognitive Remediation Can Improve Social Functioning and Symptoms in First Episode Schizophrenia*
Joseph Ventura

2:15 PM *Cognitive Remediation for Negative Symptoms of Schizophrenia: A Network Meta-Analysis*
Matteo Cella

Discussant: Til Wykes

SYMPTOM DIMENSIONS IN SCHIZOPHRENIA – BRAIN CORRELATES AND PERSONALISED TREATMENT OPTIONS

Location: Affari, Lower Level

Chair: Werner Strik

1:00 PM *The Neurobiology of Formal Thought Disorder: Specific for Schizophrenia?*
Tilo Kircher

1:25 PM *Formal Thought Disorder in Non-Clinical Individuals With Auditory Verbal Hallucinations*
Iris Sommer

1:50 PM *Causes of the Variable Efficacy of rTMS in the Treatment of Auditory Hallucinations in Schizophrenia: From Placebo Effect to Brain Morphology Modifications*
Sonia Dollfus

2:15 PM *A Three Dimensional Symptom Structure of Schizophrenia is Linked to Specific Structural and Functional Brain Changes*
Werner Strik

Discussant: Stephan Heckers

Tuesday 5 April

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



LIFESPAN DEVELOPMENT OF SCHIZOPHRENIA AND HOW THE TREATMENTS IMPROVE THE OUTCOMES

Location: Affari, First Level

Chair: Matti Isohanni

- 1:00 PM** *MRI-Based Risk Stratification in Clinical High-Risk Individuals: State-of-the-Art and Challenges Ahead*
Nikolaos Koutsouleris
- 1:25 PM** *Somatic Comorbidity and Its Outcomes in Schizophrenia During Lifespan*
Jussi Seppälä
- 1:50 PM** *Long-Term Outcome of Psychosis: Modulation by Environmental Factors Like Exercise*
Peter Falkai
- 2:15 PM** *Antipsychotic Medication and Outcomes in Schizophrenia From a Lifespan Perspective*
Hannu Koponen

Discussant: Silvana Galderisi

SOCIAL (COGNITIVE) FUNCTIONING IN SCHIZOPHRENIA: MECHANISMS, COURSE AND TREATMENT

Location: Affari, Second Level

Chair: Avi Reichenberg

- 1:00 PM** *The 20-Year Longitudinal Trajectories of Social Functioning in Psychotic Disorders*
Eva Velthorst
- 1:25 PM** *Origins of Social Deficits in the Psychosis Phenotype*
Avi Reichenberg
- 1:50 PM** *Oxytocin for Schizophrenia: A Randomized Controlled Trial*
Mark Weiser
- 2:15 PM** *Trust vs. Paranoia: The Dynamics of Social Interaction in Early and Chronic Psychosis*
Anne-Kathrin Fett

Discussant: Junghee Lee

COFFEE BREAK

Location: Passi Perdutti, Affari Foyers, and the Sala Verde Foyer

3:00 PM - 3:30 PM

Tuesday 5 April



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

ORAL PRESENTATIONS

3:15 PM – 5:15 PM

BRAIN IMAGING-I: MOLECULES, STRUCTURES, AND FUNCTIONS

3:15 PM – 5:15 PM

Location: Congressi Auditorium

Chair: Igor Nenadic

3:15 PM *Accelerated Gray and White Matter Aging in Schizophrenia*
Vanessa Cropley

3:30 PM *Structural Connectivity Correlates of Planning and Executing Goal-Directed Behaviour in Schizophrenia*
Ishraq Siddiqui

3:45 PM *Differences in Global Brain Abnormalities Between Offspring, Siblings, Cotwins and Parents of Patients With Schizophrenia*
★ Sonja de Zwarte

4:00 PM *Increase in Extracellular Free Water in First-Episode Schizophrenia Patients is Related to Improved Cognitive Outcomes*
Amanda Lyall

4:15 PM *Cortical Thickness Changes With Age in a Subset of First Episode Psychosis Patients Presenting With Persistent Negative Symptoms: A Longitudinal MRI Study*
Carolina Makowski

4:30 PM *A Sensitized Prefrontal Dopamine Response to Psychosocial Stress in the Early Stage of Psychosis*
Huai-Hsuan Tseng

4:45 PM *Cellular and Extracellular Abnormalities in Healthy Subjects With Auditory Verbal Hallucinations*
Ofer Pasternak

5:00 PM *Glutamate in Psychosis: A Meta-Analysis of Proton Magnetic Resonance Spectroscopy (1H-MRS) Studies*
Kate Merritt

★ – Travel Awardee

Tuesday 5 April

FINAL PROGRAM

FLORENCE, ITALY

2 – 6 APRIL 2016



COGNITION: MULTIFACETED APPROACH

3:15 PM - 5:15 PM

Location: Congressi, Sala Verde

Chair: Philip Harvey

3:15 PM *Polygenic MiR-137 Pathway Scores Explain Variability in Cognitive Performance in Patients With Schizophrenia and Controls*

★ Donna Cosgrove

3:30 PM *Neuropsychological Functioning Over Time in the North American Prodrome Longitudinal Study (NAPLS)-2 Clinical High Risk Cohort*

Kristen Woodberry

3:45 PM *Educational Achievement in Psychiatric Patients and Their Siblings; A Register-Based Study in 30,000 Individuals in the Netherlands*

Fabian Termorshuizen

4:00 PM *Source Memory Distortions May Be Related to Attenuated Psychotic Experiences in Young Offspring of Parents Affected by Major Psychoses*

Elsa Gilbert

4:15 PM *Relational and Item Specific Memory Markers of Psychosis Risk*

J. Daniel Ragland

4:30 PM *Schizophrenia Patients With Delusions Show a Specific Deficit in Updating Beliefs From Positive But Not Negative New Evidence*

James Gilleen

4:45 PM *Self Assessment of Social Cognition in Schizophrenia: Impairments in Evaluating Task Difficulty and Adjusting Effort Accordingly*

Philip Harvey

5:00 PM *Long-Term Cariprazine Treatment for the Prevention of Relapse in Patients With Schizophrenia: Additional Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial*

Wolfgang Fleischhacker

Tuesday 5 April

★ – Travel Awardee



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

GENETICS: MULTIFACETED APPROACH

Location: Affari, Ground Level

Chair: James Kennedy

3:15 PM *Association of Schizophrenia GWAS Risk Variants With Cognitive Deficits in the Genus Consortium Schizophrenia Sample Collection*

★ Gabriëlla Blokland

3:30 PM *Gene Expression Analysis in Peripheral Bloodmononuclear Cells of First Episode Psychosispatients From the Genetic and Psychotic Disorders (GAP) Study*
Daniel Leirer

3:45 PM *Phenotypic Manifestation of Genetic Risk for Schizophrenia During Adolescence in the General Population*
Stanley Zammit

4:00 PM *Genetic Variation in Schizophrenia Liability Explained Through Intellectual Ability and Brain Structure*

★ Marc Bohlken

4:15 PM *Genetic Overlap Between Schizophrenia and the Big Five Personality Traits*
Olav Smeland

4:30 PM *Unique Dual Cortico-Striatal Action of Dopamine D2 Receptor Functionally Selective Ligands Modulate Schizophrenia-Like Phenotypes*
Marc Caron

4:45 PM *Association of the Polygenic Risk Score for Schizophrenia With Mortality and Suicidal Behavior - A Danish Population-Based Study*
Thomas Laursen

5:00 PM *Exploiting Epidemiological Links Between Rheumatoid Arthritis and Schizophrenia Refines GWAS in the HLA Region*
Tulsi Malavia

Tuesday 5 April

★ – Travel Awardee

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



NEURODEVELOPMENT: CHILDHOOD, ADOLESCENCE AND ADULTHOOD

3:15 PM - 5:15 PM

Location: Affari, Lower Level

Chair: Aristotle Voineskos

- 3:15 PM** *Adult Neurogenesis in the Striatum: Effect of Psychiatric Treatment*
Dragos Inta
- 3:30 PM** *Maternal Symptoms and Neonatal Behaviour in Postpartum Psychosis*
Katie Hazelgrove
- 3:45 PM** *Accumulation of Risk Endophenotypes in Children and Adolescents at Genetic Risk of Major Psychoses: Longitudinal Findings From the Eastern Quebec Densely Affected Families*
Thomas Paccalet
- 4:00 PM** *Offspring With Familial Risk for Severe Mental Illness and Incidences for Having a Child and Adolescent Psychiatric Diagnosis at Age 0-17 Years – a Danish Register Study*
Anne Thorup
- 4:15 PM** *Mood Disorders and Schizophrenia in the Offspring of Antenatally Depressed Mothers in the Northern Finland 1966 Birth Cohort: Relationship to Parental History of Severe Mental Disorder*
Pirjo Mäki
- 4:30 PM** *Cognitive Developmental Trajectories in the Extended Psychosis Phenotype*
Josephine Mollon
- 4:45 PM** *The Impact of Cannabis Use on Emerging Psychotic Experiences Explained by the Presence of Affective Symptoms*
Josiane Bourque
- 5:00 PM** *Childhood and Adolescence Physical Activity Patterns – Effects on Psychosis Risk*
Elina Sormunen

Tuesday 5 April



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

EPIDEMIOLOGY: ROLES FOR ENVIRONMENTAL RISK FACTORS

3:15 PM - 5:15 PM

Location: Affari, First Level

Chair: James MacCabe

- 3:15 PM** *Artistic Creativity, IQ and Risk for Schizophrenia and Bipolar Disorder: A Swedish Population-Based Case-Control Study and Sib Pair Analysis in 4.5 Million Individuals*
James MacCabe
- 3:30 PM** *Children of Parents With Severe Psychiatric Disorders: With Whom Do They Grow up? - A Prospective, Population-Based Study*
Anne Ranning
- 3:45 PM** *Age-At-Migration and Risk of First Episode Psychosis in England: Epidemiological Evidence From the Sepea Study*
James Kirkbride
- 4:00 PM** *Toxic Social Environments and Psychosis: The Role of Violence and Multiple Adversities in Childhood*
Craig Morgan
- 4:15 PM** *Exposure to Anti-Infective Agents and the Risk of Severe Mental Disorders – A Nationwide Study*
Ole Köhler
- 4:30 PM** *Incidence of Psychotic Disorders in England, France, Italy, the Netherlands, Spain and Brazil: Data From the EU-GEI Study*
★ Hannah Jongsma
- 4:45 PM** *Is There a Cumulative Effect of Social Disadvantage on Risk of Psychosis?*
Simona Stilo
- 5:00 PM** *Mortality and Deliberate Self-Harm During Clozapine Use in Treatment-Resistant Schizophrenia: Results From the Crestar Collaboration*
Maria Theresa Wimberley

★ – Travel Awardee

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



PHENOMENOLOGY AND DIMENSIONAL DISCUSSION

3:15 PM - 5:15 PM

Location: Affari, Second Level

Chair: Celso Arango

- 3:15 PM** *Exploring the Applicability of a Network Approach to Psychosis*
Johanna Wigman
- 3:30 PM** *Childhood Trauma and Social Stress Reactivity in Psychosis: A Virtual Reality Study*
Wim Veling
- 3:45 PM** *Premorbid and Social Determinants of Formal Thought Disorder in Early Psychosis*
Eric Roche
- 4:00 PM** *A Dimensional Approach to Elucidating the Neural Basis of Psychotic Spectrum Traits*
Samantha Abram
- 4:15 PM** *Conversion from Psychosis Like Experiences in the Community to Not Only Psychotic Disorders; But Also to Depression and Anxiety Disorders: Six Years Follow-Up Study in a Community Based Population*
Umut Kirli
- 4:30 PM** *Auditory Hallucinations in Adults With Hearing Impairment*
Mascha Linszen
- 4:45 PM** *Cognitive Heterogeneity on the Schizophrenia – Bipolar Spectrum*
Tamsyn Van Rheenen
- 5:00 PM** *Outcomes of Non-Transitioned Cases in a Sample at Ultra-High Risk for Psychosis*
Ashleigh Lin

Tuesday 5 April

COFFEE BREAK

5:00 PM - 5:30 PM

Location: Passi Perdutti, Affari Foyers, and the Sala Verde Foyer



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

ORAL PRESENTATIONS

5:30 PM – 7:30 PM

BRAIN IMAGING-II: MOLECULES, STRUCTURES, AND FUNCTIONS

5:30 PM – 7:30 PM

Location: Congressi Auditorium

Chair: Paola Dazzan

- 5:30 PM** *Aberrant Salience and Dysfunctional Neural Processing of Self-Reference in Unmedicated Schizophrenia Patients*
Teresa Katthagen
- 5:45 PM** *Single Dose of Cannabidiol Attenuates Neurofunctional Abnormalities Present in Individuals at High Risk of Psychosis*
Sagnik Bhattacharyya
- 6:00 PM** *Hippocampal Perfusion and Novelty-Dependent Learning in Individuals at Ultra High Risk for Psychosis*
Mathilde Antoniades
- 6:15 PM** *Does Dopaminergic Function Underlie Clinical Response in First Episode Psychosis: An 18F-DOPA PET Study*
Sameer Jauhar
- 6:30 PM** *Altered Glutamine, Glutamate and GABA Levels in Schizophrenia Patients and Their Healthy First-Degree Relatives: A 1H-MRS Study at 7T*
Lara Rösler
- 6:45 PM** *Environmental Influences on White Matter Integrity in Psychotic Disorder: A Longitudinal Family-Based DTI Study*
Patrick Domen
- 7:00 PM** *Heterogeneity- A Novel Way to Study Microstructural Gray Matter Organization in Schizophrenia?*
★ Johanna Seitz
- 7:15 PM** *Frontal White Matter Tract Profiles Underpin Continuous Individual Differences in Positive Schizotypy: Evidence From a Large Nonclinical Sample*
Rachael Grazioplene

★ – Travel Awardee

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



BIOMARKERS

5:30 PM – 7:30 PM

Location: Congressi, Sala Verde

Chair: Christos Pantelis

- 5:30 PM** *Anti-Inflammatory and Antioxidant Effects of Risperidone on Drug Naïve First Episode Psychosis*
Cristiano Noto
- 5:45 PM** *Dose-Related Target Occupancy and Engagement of the Glycine Transporter-1 Inhibitor PF-03463275, in Healthy Humans Subjects and Schizophrenia Subjects*
Deepak D'Souza
- 6:00 PM** *Maternal Markers of Inflammation During Pregnancy and Schizophrenia in the Offspring*
Håkan Karlsson
- 6:15 PM** *Event-Related Potentials Changes Associated With Violence in Violent Patients With Schizophrenia*
Menahem Krakowski
- 6:30 PM** *Clinical Staging and Profiling in Psychiatry*
Dorien Nieman
- 6:45 PM** *Glutamatergic Dysfunction is Associated With Feedback Learning Dysfunction and Myelination Deficiency in Schizophrenia: Multi-Modal Imaging Evidence From 1H-MRS, mcDESPOT and Functional MRI*
Elias Mouchlianitis
- 7:00 PM** *Cannabis-Induced Attenuated Psychotic Symptoms: Implications for Prognosis in Young People at Ultra-High Risk for Psychosis*
Barnaby Nelson

Tuesday 5 April



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

NEUROBIOLOGY

5:30 PM - 7:30 PM

Location: Affari, Ground Level

Chair: John F. Deakin

5:30 PM *Pathogenic Neuronal Autoantibodies in Patients With a Psychotic Disorder: Results of Screening Three Large Cohorts*
Hans van Mierlo

5:45 PM *Exposure to Childhood Physical and Sexual Abuse is Associated With Divergent Cortical Abnormalities in First Episode Psychosis Patients and Controls and With Diurnal Cortisol Concentration Only in Controls*
★ Simone Ciufolini

6:00 PM *Protein Pathology in Chronic Mental Illnesses - Towards a Biological Definition*
Carsten Korth

6:15 PM *TAK-063, a Phosphodiesterase 10A Inhibitor With Balanced Activation of Direct and Indirect Pathways, Provides Potent and Dose-Dependent Antipsychotic-Like Effects in Multiple Paradigms*
Haruhide Kimura

6:30 PM *Hyperprolactinaemia in First Episode Psychosis- A Longitudinal Assessment*
John Lally

6:45 PM *Early Treatment Non-Response as a Predictor of Lack of Clinically Significant Antipsychotic Effect in Youth With a First Episode of Psychosis: 12-Week Results From a Randomized Controlled Trial*
Pia Jeppesen

7:00 PM *Thalamic Reticular Nucleus Dysfunction as a Driver of Thalamo-Prefrontal Dysconnectivity in NMDA Receptor Antagonist and Disc1 Schizophrenia Models*
Judith Pratt

7:15 PM *The DSM-5-Defined Attenuated Psychosis Syndrome and Conversion to Full Scale Schizophrenia Spectrum Disorders, an Institution-Wide Retrospective Review*
Zachary Zuschlag

Tuesday 5 April

★ – Travel Awardee

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



CLINICAL TRIALS

5:30 PM – 7:30 PM

Location: Affari, Lower Level

Chair: Hilleke Hulshoff Pol

- 5:30 PM** *Cariprazine as Monotherapy for the Treatment of Predominant Negative Symptoms of Patients With Schizophrenia: A Double-Blind, Active Comparator-Controlled Phase-3 Trial*
Wolfgang Fleischhacker
- 5:45 PM** *The Neurapro-E Study: A Multicentre RCT of Omega-3 Fatty Acids and Cognitive-Behavioural Case Management for Patients at Ultra-High Risk of Psychosis*
Patrick McGorry
- 6:00 PM** *The Randomized, Double-Blind Switch Study: Do Non-Improvers Benefit From a Change of the Antipsychotic After 2 Weeks of Treatment?*
Stephen Heres
- 6:15 PM** *Positive Phase 3 Clinical Trial of ITI-007 for the Treatment of Schizophrenia: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Trial*
Kimberly Vanover
- 6:30 PM** *Effects of Estrogen and SERM Augmentation on Symptom Severity and Cognition in Schizophrenia: A Meta-Analysis*
Sophie Heringa
- 6:45 PM** *rTMS for the Treatment of Schizophrenia Negative Symptoms - Clinical, Neurocognitive and Imaging Results From a Large-Scale Multi-Centric Trial*
Alkomiet Hasan
- 7:00 PM** *Antipsychotic Medication Continuity Following Housing First: Results of a Randomized Trial*
Julian Somers
- 7:15 PM** *A Double-Blind, Randomised, Placebo-Controlled, Parallel Group Trial of Cannabidiol as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder*
Philip McGuire

Tuesday 5 April



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

TREATMENT AND CLINICAL SERVICE

5:30 PM – 7:30 PM

Location: Affari, First Level

Chair: Patrick McGorry

- 5:30 PM** *Can Non-Invasive Brain Stimulation Improve Working Memory in Schizophrenia?*
Kate Hoy
- 5:45 PM** *Smartphone-Enhanced Symptom Management and Relapse Prevention: A Randomised Controlled Trial*
Shon Lewis
- 6:00 PM** *Adding Aerobic Exercise to Cognitive Training Enhances the Impact on Cognition and Work Functioning: A UCLA Pilot RCT in First Episode Schizophrenia*
Keith Nuechterlein
- 6:15 PM** *Antipsychotic Treatment Algorithm for First Episode Schizophrenia – A Guide for Clinicians*
Ofer Agid
- 6:30 PM** *Ultra High Risk for Psychosis is Not Associated With Greater Rates of Transition to Psychosis Compared to Those Not at Such Risk*
Vaughan Carr
- 6:45 PM** *How Many Psychiatric Beds per Capita Do We Need?*
Richard O'Reilly
- 7:00 PM** *An Investigation of the Potential Specificity of Childhood Maltreatment Trauma in Patients With Non-Affective Psychosis as Compared to Other Mental Health Disorders*
Nina Morkved
- 7:15 PM** *12-Year Follow-Up Study of Mortality Due to Suicide Among First Episode Psychosis COHORT: Is the Early Intervention Program More Effective in Reducing Excess Mortality Due to Suicide in Psychosis*
Kit Wa Sherry Chan

Tuesday 5 April

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



PSYCHOSOCIAL FUNCTIONING

5:30 PM – 7:30 PM

Location: Affari, Second Level

Chair: Merete Nordentoft

- 5:30 PM** *Persistent or Recurrent Course of Co-Morbid Disorders is Associated With Functional Impairment at 6-YEAR Follow-Up in Patients at Clinical High Risk for Psychosis*
 Grazia Rutigliano
- 5:45 PM** *Personalised Predictions of Global Functioning in Chronic Patients Across 17 European Sites*
 Dominic Dwyer
- 6:00 PM** *Mechanisms of Formal Thought Disorder in First Episode Psychosis and Psychometric Schizotypy: The Role of Affective and Cognitive Systems*
 ★ Kyle Minor
- 6:15 PM** *Using Ehealth Technology to Detect Barriers to Social Functioning in People With Schizophrenia*
 Matteo Cella
- 6:30 PM** *Persistent Negative Symptoms in First Episode Psychosis: Prevalence, Predictors and Long Term Prognosis*
 Stephen Austin
- 6:45 PM** *The Core Role of Metacognition in Mediating Between Cognition, Functional Capacity and Real-Life Function in First-Episode Psychosis*
 Geoff Davies
- 7:00 PM** *The Daily Activity Report to Assess Productive Activity*
 Dawn Velligan
- 7:15 PM** *Prediction of Longer-Term Functional Outcome in the Vienna Omega-3 Study*
 G. Paul Amminger

Tuesday 5 April

★ – Travel Awardee

	7 AM 8 AM	8 AM 9 AM	9 AM 10 AM	10 AM 11 AM	11 AM 12 PM	12 PM 1 PM	1 PM 2 PM	2 PM 3 PM	3 PM 4 PM	4 PM 5 PM	5 PM 6 PM	6 PM 7 PM	7 PM 8 PM	8 PM 9 PM
Auditorium	8:30 AM - 9:30 AM Feeding From Bedside into Bench, and Back to Bedside...		9:30 AM 10:00 AM Awards Ceremony	10:00 AM 10:30 AM Coffee Break	10:30 AM - 12:30 PM Microglia in Schizophrenia									
Sala Verde				10:30 AM - 12:30 PM Zooming in on the Synapse in Schizophrenia										
Palazzo Affari Ground Level				10:30 AM - 12:30 PM Global Perspectives on Stigma in the Clinical High Risk State for Psychosis: New Empirical Advances										
Palazzo Affari Lower Level				10:30 AM - 12:30 PM Second Chance: What Would Senior Schizophrenia Researchers Do if They Could Start Over Again?										
Palazzo Affari 1st Level				10:30 AM - 12:30 PM Clinical and Neurobiological Impact of Physical Exercise Interventions in Schizophrenia										
Palazzo Affari 2nd Level				10:30 AM - 12:30 PM Back to the Hippocampus: Investigating Hippocampal Abnormalities in Early Psychosis										
Cavaniglia														
Palazzo Affari Entrance	8:00 AM - 12:00 PM Registration													
Sala 103	8:00 AM - 12:00 PM Speaker Ready Room													
Limonaia	8:00 AM - 1:00 PM Computer Center													
Passi Perduti	8:00 AM - 10:30 AM Coffee Available			12:30 PM 1:00 PM Lunch										

Legend: [Keynote](#) [Special Session](#) [Speaker Ready](#) [Registration](#) [Computer Center](#) [Symposia](#) [Poster Session](#) [Plenary](#) [Oral Presentation](#) [Coffee Break](#)

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



Wednesday, 6 April 2016

REGISTRATION

8:00 AM - 12:00 PM

Location: Palazzo Entrance

MORNING COFFEE

8:00 AM - 8:30 AM

Location: Congressi, Passi Perduti

PLENARY SESSION: FEEDING FROM BEDSIDE INTO BENCH, AND BACK TO BEDSIDE: TOWARDS BETTER UNDERSTANDING OF SCHIZOPHRENIA

8:30 AM - 9:30 AM

Location: Congressi Auditorium

Koko Ishizuka
Johns Hopkins School of Medicine

Abstract: The diagnostic boundaries defined by current diagnostic systems are being challenged by recent advances in the genetic architecture of psychiatric disorders. The field of psychiatry is now moving towards a “dimensional” approach to understanding mental disorders, based on specific phenotypes with defined biological etiology and pathophysiology.

We have built an infrastructure to conduct preclinical and clinical studies seamlessly to seek the goal of early diagnosis and intervention for psychotic and mood disorders.

Study participants are characterized at the levels of clinical psychiatry and psychology. Then, we study the patients, according to molecular and/or cellular phenotypes obtained from their cells via biopsies, in combination with brain imaging and other physiological studies that provide the information at the circuitry level. In the clinical study domain, we explore correlations among molecular, cellular, circuitry, and behavioral characteristics. Mechanistic link among these characteristics at the different levels is addressed by using animal models in which we use cutting-edge methodologies of molecular and circuitry interventions in pathological trajectories. In summary, we aim to clarify common pathophysiological pathways for the mental conditions downstream of a wide variety of etiopathogenesis.

This talk will include the following topics:

- 1) Utility of nasal biopsy: genome-wide epigenetic study and a novel, non-invasive brush swab approach.
- 2) Combination of stem cells, brain imaging, neuropsychology, and animal models: elucidating the role for specific phosphorylation of DISC1 protein in neurodevelopment and cognitive function.
- 3) Perspectives: how are preclinical and clinical studies integrated to address clinical and scientific questions?

AWARDS CEREMONY

9:30 AM - 10:00 AM

Location: Congressi Auditorium

Wednesday 6 April



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

COFFEE BREAK

10:00 AM - 10:30 AM

Location: Congressi, Passi Perduti

CONCURRENT SYMPOSIA

10:30 AM - 12:30 PM

MICROGLIA IN SCHIZOPHRENIA

Location: Congressi Auditorium

Chair: René Kahn

10:30 AM *Microglial Activity in Schizophrenia: PET Data in the Prodrome and the Effects of Antipsychotic Treatment*
Oliver Howes

10:55 AM *Maternal Immune Activation Increases Inflammatory Cytokine Expression in the Offspring's Brain Without Overt Signs of Microglia Anomalies*
Urs Meyer

11:20 AM *Increased Inflammatory Markers Associated With Astrogliosis in the Midbrain in Schizophrenia*
Cynthia Shannon Weickert

11:45 AM *Neuroinflammation at Different Stages of Schizophrenia: A PET Study of Microglial Activation*
Christos Pantelis

Discussant: Darryl Eyles

ZOOMING IN ON THE SYNAPSE IN SCHIZOPHRENIA

Location: Congressi, Sala Verde

Chair: David Cotter

10:30 AM *Role of Lifespan Expression Trajectories in Psychiatric Disease Onset*
Nathan Skene

10:55 AM *Proteomic Analysis of the Postsynaptic Density in the Major Psychoses Schizophrenia and Bipolar Disorder*
Melanie Foecking

11:20 AM *Dysregulated Intracellular Targeting and Synaptic Abnormalities of Receptor Proteins in Schizophrenia*
James Meador-Woodruff

11:45 AM *Focusing on Synaptosomal and Mitochondrial Proteomes From Schizophrenia Postmortem Brains*
Daniel Martins-De-Souza

Discussant: Chang-Gyu Hahn

Wednesday 6 April

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



GLOBAL PERSPECTIVES ON STIGMA IN THE CLINICAL HIGH RISK STATE FOR PSYCHOSIS: NEW EMPIRICAL ADVANCES

Location: Affari, Ground Level

Chair: Lawrence Yang

- 10:30 AM** *Risk of Psychosis, Mental Illness Stigma and Suicidality*
Nicolas Rüsch
- 10:55 AM** *Self-Perceptions of Having a Mental Illness and Relationship With Help - Seeking From Brazilian and UK Community Samples of Young People At-Risk of Psychosis*
Sara Evans-Lacko
- 11:20 AM** *Stigma of People at Clinical High Risk State for Psychosis in a Chinese Population*
Lin Jingxia
- 11:45 AM** *Stigma Related to Initial Self-Identification of Being 'at High Risk for Psychosis' vs. a 'Non-psychotic Disorder' in Individuals at Clinical High-Risk for Psychosis*
Lawrence Yang

Discussant: Antonio Lasalvia

SECOND CHANCE: WHAT WOULD SENIOR SCHIZOPHRENIA RESEARCHERS DO IF THEY COULD START OVER AGAIN?

Location: Affari, Lower Level

Chair: E. Fuller Torrey

- 10:30 AM** *A Schizophrenia Research Plan as Psychiatry Merges With Neurology*
E. Fuller Torrey
- 10:55 AM** *On Recovering From a Delusion*
Robin Murray
- 11:20 AM** *Possibilities and Pitfalls - Reflections on 42 Years in Academic Psychiatry and Lessons for a Suggested Repeat Performance*
Eve Johnstone
- 11:45 AM** *A Personal Retreat and Advance*
William Carpenter

Discussant: Mark Weiser

Wednesday 6 April



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

CLINICAL AND NEUROBIOLOGICAL IMPACT OF PHYSICAL EXERCISE INTERVENTIONS IN SCHIZOPHRENIA

Location: Affari, First Level

Chair: Hilleke Hulshoff Pol

10:30 AM *Changes in Brain Connectivity After Endurance Training in Schizophrenia*
Hilleke Hulshoff Pol

10:55 AM *The Impact of Endurance Training on Brain Structure and Function in Schizophrenia Patients*
Berend Malchow

11:20 AM *An Exercise Intervention for Patients With Antipsychotic-Resistant Schizophrenia*
William Honer

11:45 AM *Translational Evidence of the Impact of Exercise on Brain Structure and Function in Animal Models and Healthy Humans*
Andreas Meyer-Lindenberg

Discussant: Peter Falkai

BACK TO THE HIPPOCAMPUS: INVESTIGATING HIPPOCAMPAL ABNORMALITIES IN EARLY PSYCHOSIS

Location: Affari, Second Level

Chair: Mary Cannon

10:30 AM *Evidence of Hippocampal Change in Adolescents Reporting Psychotic Experiences: A Population-Based MRI Study*
Erik O'Hanlon

10:55 AM *Age-Dependent Patterns of Aberrant Brain Structure in Youth With Psychosis Spectrum Symptoms*
Daniel Wolf

11:20 AM *Hippocampal Shape Analysis Yields New Clues About Symptom Progression in Youth at Ultrahigh Risk for Psychosis*
Vijay Mittal

11:45 AM *Longitudinal Changes in Hippocampal Volume in Adolescents With Psychotic Symptoms – Relationship to Functioning, Co-Morbid Disorder and Stressful Life Events*
Ana Calvo

Discussant: Anthony David

LUNCH

Take away box lunches available in the Passi Perduti.

12:30 PM - 1:00 PM

NOTES

Wednesday 6 April



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

POSTERS, SUNDAY 3 APRIL

11:00 AM - 1:00 PM

Location: Cavaniglia

Travel Awardee Posters are Circled

S1. REACTIVITY TO SOCIAL STRESS IN SECOND-GENERATION MOROCCAN-DUTCH MEN, A PROXY FOR SOCIAL DEFEAT

Martin Gevonden*, Inez Myin-Germeys, Marieke Wichers, Jan Booij, Wim van den Brink, Ruud van Winkel, Jean-Paul Selten

S2. ASSESSMENT OF CARDIAC AUTONOMIC MODULATION IN ANTIPSYCHOTIC-INDUCED AKATHISIA

Jae Seung Chang, Sang Hoon Yi, Yeni Kim, Hee-Yeon Jung, Yong Sik Kim*

S3. INTERMEDIATE RESULTS OF A STUDY ABOUT SEXUAL DYSFUNCTION IN PATIENTS WITH SCHIZOPHRENIC DISORDERS TREATED WITH ATYPICAL ANTIPSYCHOTICS

Joaquín Carlos Martín*, María José Acuña, Matilde Blanco, Victor García de la Borbolla, Vanesa Hervás, Reyes Navarro, Olalla Santamaría, Beatriz Torres

S4 NEUROCOGNITIVE PROFILE OF CHILDHOOD TRAUMA-RELATED MIXED PSYCHOPATHOLOGY PHENOTYPE IN PSYCHOSIS

Giovanni Mansueto*, Martine van Nierop, Koen Schruers, Fiammetta Cosci, GROUP investigators, Ruud van Winkel

S5. IMPACT OF DIFFERENT CHILDHOOD ADVERSITIES ON 1-YEAR OUTCOMES OF PSYCHOTIC DISORDER IN THE GENETICS AND PSYCHOSIS STUDY

Antonella Trotta*, Robin Murray, Anthony David, Anna Kolliakou, Jennifer O'Connor, Marta Di Forti, Paola Dazzan, Valeria Mondelli, Craig Morgan, Helen Fisher

S6. EXTRAPYRAMIDAL SYMPTOMS DURING TREATMENT WITH QUETIAPINE VERSUS ARIPIRAZOLE IN CHILDREN AND ADOLESCENTS WITH PSYCHOSIS, THE TEA TRIAL.

Ditte Rudå*, Karsten Gjessing Jensen, Dea Gowers KLauber, Marie Stentebjerg-Olesen, Jens Richardt Jepsen, Pia Jeppesen, Birgitte Fagerlund, Christoph U Correll, Anne Katrine Pagsberg, Anders Fink-Jensen

S7. VIOLENCE RISK PREDICTION IN SCHIZOPHRENIA - A FRAMINGHAM APPROACH?

Seena Fazel*, Achim Wolf, Susan Mallett, Paul Lichtenstein, Henrik Larsson, Thomas Fanshawe

S8. VARIANTS IN DOPAMINE-RELATED GENES ARE ASSOCIATED TO ABDOMINAL OBESITY AND METABOLIC ABNORMALITIES CAUSED BY ANTIPSYCHOTIC TREATMENT.

Mercedes Zumárraga*, Nieves Basterreche, Ainara Arnaiz, M^a Isabel Zamalloa, Olga Olivas, Estibaliz Gordo, Ihintza Angoitia, Leire Erkoreka, Aurora Arrúe

S9. ARE ANTIPSYCHOTIC DRUGS ASSOCIATED WITH INCREASED OR REDUCED MORTALITY AND SERIOUS ADVERSE EVENTS? A META-ANALYSIS

Johannes Schneider, Maximilian Huhn*, Philipp Rothe, Myrto Samara, Yikang Zhu, Susanne Bächer, Matteo Rabaioli-Fischer, Stefan Leucht

FINAL PROGRAM

FLORENCE, ITALY

2 – 6 APRIL 2016



S10. COMPARISON OF 3-MONTHLY VERSUS 1-MONTHLY PALIPERIDONE PALMITATE FOR TIME TO ONSET AND TIME TO RESOLUTION OF EXTRAPYRAMIDAL SYMPTOMS IN PATIENTS WITH EXACERBATED SCHIZOPHRENIA

Maju Mathews*, Isaac Nuamah, David Hough, Dean Najarian, Edward Kim, Srihari Gopal

S11. PREVIOUS ATTEMPTS OF SUICIDE IN FIRST EPISODE OF PSYCHOSIS AND PREMORBID ADJUSTMENT

Manuel Canal-Rivero*, Alba Yañez Castro, Gloria Benitez, Jorge Garcia Egea, Jordi E. Obiols Llandrich, Miguel Ruiz Veguilla

S12. BENZODIAZEPINES LONG-TERM CONSUMPTION IS ASSOCIATED WITH HIGHER AGGRESSIVENESS IN SCHIZOPHRENIA. RESULTS FROM THE FACE-SZ DATASET.

Guillaume Fond*, Maurine Favez, Franck Schurhoff, Laurent Boyer, Pierre-Michel Llorca

S13. TREATMENT WITH ANTI-TOXOPLASMIC ACTIVITY (TATA) FOR TOXOPLASMA POSITIVE PATIENTS WITH BIPOLAR DISORDERS OR SCHIZOPHRENIA: A CROSS-SECTIONAL STUDY.

Guillaume Fond*, Nora Hamdani, Laurent Boyer, Marion Leboyer

S14. LIPIDOMIC STUDY OF THE ANTIPSYCHOTIC-INDUCED METABOLIC SYNDROME IN SCHIZOPHRENIA PATIENTS. TOWARDS A LIPIDIC BIOMARKER OF METABOLIC SYNDROME?

Cedric Tessier, Julien Thomas, Antonin Lamaziere, Philippe Seksik, Philippe Nuss*

S15. MOLECULAR PREDICTION OF METABOLIC SYNDROME IN PSYCHOSIS

Conrad Iyegbe*, Olesya Ajnakina, Lauren Allen, John Lally, Daniel Leirer, Hamel Patel, Poonam Sood, Stephen Newhouse, Marta Di Forti, richard dobson, Robin Murray, Fiona Gaughran

S16. EXPRESSION PROFILES AND SOCIAL FUNCTION AS A PREDICTIVE BIOMARKER OF SCHIZOPHRENIA: A PILOT STUDY

Yuko Okahisa*, Shinji Sakamoto, Manabu Takaki, Norihito Yamada

S17. CHILDHOOD INFLAMMATORY CYTOKINES AS PREDICTORS OF ADULT PSYCHOSIS

Lorna Lopez*, Melanie Foecking, Mary Clarke, Patrick Dicker, Mary Cannon, Stanley Zammit, David Cotter

S18. A COMPREHENSIVE ANALYSIS OF CORTISOL SECRETION IN EARLY PSYCHOSIS

Boris Chaumette*, Oussama Kebir, Yannick Morvan, Célia Mam-Lam-Fook, Julie Bourgin, Bill P. Godsil, Marion Plaze, Raphaël Gaillard, Thérèse M. Jay, Marie-Odile Krebs

S19. NEONATAL LEVELS OF GROWTH FACTORS IN NON-AFFECTIVE PSYCHOSIS

Renee Gardner*, Christina Dalman, Carmen Fourier, Håkan Karlsson

S20. NEUROANATOMICAL CORRELATES OF STRESS AND INFLAMMATORY BIOMARKERS AMONG CHILDREN AT ELEVATED RISK FOR SCHIZOPHRENIA

Alexis Cullen*, Sajani Sagar, Maria Calem, Ruth Roberts, Carmine Pariante, Helen Fisher, Patricia Zunszain, Kristin Laurens



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

(S21) INCREASED NEURAL NOISE IS ASSOCIATED WITH THE PSYCHOSIS-LIKE EFFECTS OF THC
Jose Cortes-Briones*, John Cahill, Patrick Skosnik, Mohini Ranganathan, Deepak D'Souza

S22. DEFICIENT MYELINATION IN TREATMENT RESISTANT SCHIZOPHRENIA: EVIDENCE USING
MCDESPOT IMAGING

Lucy Vanes*, Elias Mouchilianitis, Sukhi Shergill

S23. COMBINATORIAL NEUROANATOMICAL AND COGNITIVE SIGNATURES OF REMISSION AND
RELAPSE IN SCHIZOPHRENIA

Newfei Ho*, Lawrence JK Wee, Mingyuan Wang, Min Yi Sum, Kang Sim

(S24) USING METABOLOMICS TO IDENTIFY BIOMARKERS OF PSYCHOTIC EXPERIENCES AT AGE
17 IN THE AVON LONGITUDINAL STUDY OF PARENTS AND CHILDREN (ALSPAC) COHORT
Aoife O'Gorman*, Lorraine Brennan, Matej Oresic, Tommi Suvitaival, Tuulia Hyotylainen, Stanley
Zammit, Mary Cannon, David Cotter

S25. STUDYING THE INFLUENCE OF CLINICAL AND DEMOGRAPHIC MODERATORS IN
MULTIVARIATE MODELING OF BRAIN FUNCTION IN SCHIZOPHRENIA

Carlos Cabral*, Lana Kambeitz-Ilankovic, Joseph Kambeitz, Sebastian Von Saldern, Dominic Dwyer,
Vince Calhoun, Maria Urquijo, Peter Falkai, Nikolaos Koutsouleris

S26. A COMPARISON OF B CELL REPERTOIRE IN CEREBROSPINAL FLUID OF HEALTHY
INDIVIDUALS AND PATIENTS WITH SCHIZOPHRENIA

Sehba Husain-Krautter*, Anil Malhotra, Thomas Rothstein

S27. IMPROVING TREATMENT OF PATIENTS WITH SCHIZOPHRENIA – GLUTAMATE AS A
MARKER FOR CHOICE OF TREATMENT

Kirsten Borup Bojesen*, Brian V. Broberg, Kasper Jessen, Anne Sigvard, Egill Rostrup, Birte Glenthøj

S28. QUANTIFICATION OF THE SERUM LEVELS OF NR1 AND NR2 NMDA RECEPTOR IN PATIENTS
IN THE FIRST EPISODE PSYCHOSIS

Camila Loureiro*, Rosana Shuhama, Paulo Menezes, Cristina Del-Ben, Paulo Louzada-Junior

S29. HUMAN PROTEIN ATLAS ENABLED NEUROPROTEOMIC PROFILING OF BODY FLUIDS

David Just, Peter Nilsson*

S30. EFFECTS OF OMEGA-3 PUFA ON THE VITAMIN E AND GLUTATHIONE ANTIOXIDANT
DEFENSE SYSTEM IN INDIVIDUALS AT ULTRA-HIGH RISK OF PSYCHOSIS

Stefan Smesny*, Berko Milleit, Miriam Schaefer, Uta-Christina Hipler, Jana Hesse, Heinrich Sauer, G
Paul Amminger

S31. LOW LEVELS OF VITAMIN D POORLY RESPONSIVE TO DAYLIGHT EXPOSURE IN PATIENTS
WITH THERAPY-RESISTANT SCHIZOPHRENIA

Jan Bogers*, Tijmen Bostoen, Broekman Theo

S32. EEG COHERENCE AS A TRAIT MARKER OF SCHIZOPHRENIA

Yu Sang Lee*, Eunsoo An

FINAL PROGRAM

FLORENCE, ITALY

2 – 6 APRIL 2016



S33. COGNITIVE AND PSYCHOSOCIAL CORRELATES OF SUSPICIOUS YOUNG MINDS: A UK-HONG KONG FOLLOW-UP STUDY OF 9- TO 16-YEAR-OLDS

Keri Wong*

S34. TWELVE-MONTH PSYCHOSIS-PREDICTIVE VALUE OF THE ULTRA-HIGH RISK CRITERIA IN CHILDREN AND ADOLESCENTS

Marco Armando*, Maria Pontillo, Franco De Crescenzo, Luigi Mazzone, Elena Monducci, Nella Lo Cascio, Stefano Vicari, Benno G. Schimmelmann, Frauke Schultze-Lutter

S35. HIGH-RISK SYMPTOMS FOR PSYCHOSIS THROUGH ADOLESCENCE: ARE THERE AGE-RELATED PECULIARITIES IN THE PROFILE OF NEGATIVE SYMPTOMS?

Olga Puig-Navarro*, Inmaculada Baeza, Elena De la Serna, Ana Sintes, Clara Espelt, Jordina Tor, Gisela Sugranyes, Vanessa Sanchez-Gistau, Mireia Rosa, Marta Pardo, Montserrat Dolz

S36. RELATIONSHIP BETWEEN EMOTIONAL AND REASONING SCHEMATA ABOUT SELF AND OTHERS AND TYPE OF DELUSIONAL SYMPTOMS IN A SAMPLE OF CHILD AND ADOLESCENTS AT CLINICAL RISK FOR PSYCHOSIS

Ana Sintes, Jordina Tor, Marta Pardo, Olga Puig-Navarro, Clara Espelt, Daniel Muñoz, Elena De la Serna, Inmaculada Baeza, Montserrat Dolz*

S37. ABNORMAL INVOLUNTARY MOVEMENTS ARE LINKED TO PSYCHOSIS-RISK IN CHILDREN AND ADOLESCENTS: RESULTS OF A POPULATION-BASED STUDY

Jochen Kindler*, Frauke Schultze-Lutter, Chantal Michel, Alexandra Martz-Irngartinger, Caroline Linder, Stefanie Schmidt, Benno G. Schimmelmann, Sebastian Walther

S38. INTERACTION BETWEEN DISC1 MUTATION AND CANNABIS EXPOSURE IN ADOLESCENCE RESULTS IN ABERRANT BEHAVIORAL AND NEUROBIOLOGICAL PHENOTYPES IN A TRANSLATIONAL MOUSE MODEL OF SCHIZOPHRENIA

Hadar Segal-Gavish, Neta Gazit, Yael Barhum, Tali Ben-Zur, Michal Taler, Nissim Peretz, Irit Gil-Ad, Abreham Weizman, Inna Slutzki, Raphael Mechoulam, Atsushi Kamiya, Akira Sawa, Daniel Offen, Ran Barzilay*

S39. THE DANISH HIGH RISK AND RESILIENCE STUDY – VIA 7 - A COHORT STUDY OF 520 7 YEAR OLD CHILDREN BORN OF PARENTS DIAGNOSED WITH EITHER SCHIZOPHRENIA, BIPOLAR DISORDER OR NEITHER OF THESE TWO MENTAL DISORDERS

Anne Thorup*, Jens R. Jepsen, Ditte V. Ellersgaard, Birgitte K. Burton, Camilla J. Christiani, Noline Hemager, Katrine S. Spang, Ditte L. Gantriis, Aja Greve, Ole Mors, Kerstin J. Plessen, Merete Nordentoft

S40. ABERRANT LINGUISTIC SALIENCE ATTRIBUTION AS A RISK FACTOR FOR PSYCHOSIS-PRONENESS: INSIGHTS FROM THE TWINSSCAN CHINA STUDY

Winifred Mark*, Francesca Cotier, Pearl Chen, Jim van Os, Timothea Touloupoulou

S41. THE ROLE OF AUTOIMMUNITY ON NEURODEVELOPMENT: STUDY ON OFFSPRING OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS

Maria Gariup*, Azucena Gonzalez, Ricard Cervera, Roger Borrás, Carles Serra-Pagés, Astrid Morer



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

S42. IS IT STILL CORRECT TO DIFFERENTIATE BETWEEN EARLY AND VERY EARLY ONSET PSYCHOSIS?

Ashleigh Lin*, Klaas Wardenaar, Maria Pontillo, Franco De Crescenzo, Luigi Mazzone, Stefano Vicari, Stephen Wood, Amanda Beavan, Marco Armando

S43. CLINICAL PROFILE AND PREDICTORS OF OUTCOMES IN OUTPATIENTS WITH PRODROMAL PSYCHOSIS IN SHANGHAI, CHINA

Huijun Li, TianHong Zhang, LiHua Xu, Kristen Woodberry, Daniel Shapiro, Larry Seidman*, Jijun Wang

S44. MECHANISMS OF TRANSMISSION OF HEALTH AND RISK IN PARENTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER AND THEIR OFFSPRING (THE WARM STUDY)

Angus MacBeth*, Kirstine Davidsen, Jenna-Marie Lundy, Katrine Røhder, Christopher Trier-Lind, Maja Nyström-Hansen, Emilie Nayberg, Andrew Gumley, Susanne Harder

S45. GENOME-WIDE METHYLATION CHANGES FOLLOWING EARLY AND LATE PRENATAL IMMUNE ACTIVATION: FOCUS ON THE PREFRONTAL CORTEX

Juliet Richetto*, Renaud Massart, Moshe Szyf, Marco A. Riva, Urs Meyer

S46. NEUROCHEMICAL CHANGES UNDERLYING ANTIPSYCHOTIC PHENOTYPE IN MGLU4 KNOCKOUT MICE.

Paulina Cieslik*, Marcin Marciniak, Piotr Branski, Andrzej Pilc, Joanna M. Wieronska

S47. DIFFERENTIAL REGULATION OF VENTRAL TEGMENTAL AREA DOPAMINE NEURONS BY INFRALIMBIC PREFRONTAL CORTEX AND LATERAL HABENULA: IMPLICATIONS FOR SCHIZOPHRENIA

Jared Moreines*, Zoe Owruksy, Anthony Grace

S48. A RANDOMISED CONTROLLED TRIAL OF COGNITIVE BEHAVIOURAL THERAPY VERSUS NON-DIRECTIVE REFLECTIVE LISTENING FOR YOUNG PEOPLE AT RISK OF DEVELOPING PSYCHOSIS: THE DETECTION AND EVALUATION OF PSYCHOLOGICAL THERAPY (DEPTH) TRIAL.

Helen Stain*, Sandra Bucci, Amanda Baker, Vaughan Carr, Richard Emsley, Sean Halpin, Terry Lewin, Ulrich Schall, Vanessa Clark, Kylie Crittenden, Mike Startup

S49. SELECTIVE ESTROGEN RECEPTOR MODULATION INCREASES DORSOLATERAL PREFRONTAL CORTEX ACTIVITY DURING EMOTIONAL INHIBITION IN SCHIZOPHRENIA

Thomas Weickert*, Jochen Kindler, Rhoshel Lenroot, Peter Schofield, Cynthia Shannon Weickert

S50. AGGRESSIVITY MANAGEMENT IN SCHIZOPHRENIA DIAGNOSED PATIENTS USING CALCIUM CHANNEL ALPHA-2-DELTA LIGANDS

Daniel Vasile*, Octavian Vasiliu, Diana Gabriella Vasiliu, Florin Vasile

S51. WEIGHT REDUCTION WITH REBOXETINE TREATMENT: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REBOXETINE AND CITALOPRAM AS ADJUNCTS TO ATYPICAL ANTIPSYCHOTICS

Cristina V. Oliveira, Raquel López-Carrilero, Miquel Bernardo*, Roberto Rodriguez-Jimenez, Iluminada Corripio, Jose Carlos Gonzalez-Piqueras, Ana Espliego, Blanca Fernandez, Angela Ibáñez, Judith Usall



S52. EFFECTS OF COMMUNITY MENTAL HEALTH SERVICE IN SUBJECTS WITH EARLY PSYCHOSIS

Young Chul Chung*, Yin Cui, Eunjin Na

S53. RESULTS OF AN EXPLORATORY PHASE II STUDY WITH MIN-101, A 5-HT_{2A}/SIGMA₂ ANTAGONIST, FOR THE TREATMENT OF SCHIZOPHRENIA.

Corrine Staner, Michael Davidson*, Nadine Noel, Jay Saoud, Michael Detke, Remy Luthringer

S54. SEX AND GENDER DIFFERENCES IN EMERGING PSYCHOSIS – RESULTS FROM THE BASEL FEPSY PROJECT

Anita Riecher-Rössler*

S55. INCREASING SIGNAL DETECTION IN CLINICAL TRIALS: IMPROVING FIDELITY OF INSTRUMENTS

Jonathan Rabinowitz*, Nina Schooler

S56. COMBINING AEROBIC EXERCISE AND COGNITIVE TRAINING DECREASES NEGATIVE SYMPTOMS AND IMPROVES SOCIAL FUNCTIONING IN FIRST EPISODE SCHIZOPHRENIA: A UCLA PILOT RCT

Joseph Ventura*, Sarah McEwan, Kenneth Subotnik, Luana Turner, Yurika Sturdevant, Gerhard Helleman, Keith Nuechterlein

S57. WHY DO CLINICAL TRIALS FAIL SO OFTEN IN SCHIZOPHRENIA? A QUANTITATIVE SYSTEMS PHARMACOLOGY APPROACH TO ACCOUNT FOR THE EFFECT OF COMEDICATIONS AND GENOTYPES

Hugo Geerts*, Athan Spiros

S59. INITIAL DEVELOPMENT OF A PATIENT REPORTED OUTCOME MEASURE OF EXPERIENCES WITH COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA

Raymond Rosen, Lisa C. Welch, Jeremiah Trudeau, Steven Silverstein, Michael Sand*

S60. EFFICACY AND SAFETY OF PALIPERIDONE PALMITATE 3-MONTH VERSUS 1-MONTH FORMULATION IN SCHIZOPHRENIA: GLOBAL AND ASIAN SUBGROUP ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, NON-INFERIORITY STUDY

Adam Savitz*, Srihari Gopal, Yu Feng, Haiyan Xu, Jianmin Zhuo, Lu Yu, Isaac Nuamah, Paulien Ravenstijn, Cathy Wu, David Hough

S61. TOWARD A NEGATIVE SYMPTOM SYSTEM OF SCHIZOPHRENIA: A NETWORK APPROACH

Stephen Levine*, Stefan Leucht

S62. OUTCOMES OF MAINTENANCE ANTIPSYCHOTIC TREATMENT VERSUS DISCONTINUATION STRATEGIES FOLLOWING REMISSION FROM FIRST EPISODE PSYCHOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Andrew Thompson*, Catherine Winsper, Steven Marwaha, Mario Alvarez-Jimenez, Alba Realpe, Laura Vail, Jon Haynes, Sarah Hetrick, Sarah Sullivan



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

S63. PREDICTION OF TRANSITION TO PSYCHOSIS IN PATIENTS WITH A CLINICAL HIGH RISK FOR PSYCHOSIS: A SYSTEMATIC REVIEW OF METHODOLOGY AND REPORTING

Erich Studerus*, Avinash Ramyeed, Anita Riecher-Rössler

S64. THE PRACTICAL IMPLICATIONS OF METACOGNITIVE PSYCHOTHERAPY IN PSYCHOSIS: FINDINGS FROM A PILOT STUDY

Steven De Jong*, Rozanne van Donkersgoed, Andre Aleman, Mark van der Gaag, Lex Wunderink, Johan Arends, Paul Lysaker, Marieke Pijnenborg

S65. LONG-TERM EFFECTIVENESS OF ARIPIPRAZOLE ONCE-MONTHLY IS MAINTAINED IN THE QUALIFY EXTENSION STUDY

Dieter Naber*, Ross A. Baker, Anna Eramo, Carlos Forray, Karina Hansen, Christophe Sapin, Timothy Peters-Strickland, Anna-Greta Nylander, Peter Hertel, Simon Nitschky Schmidt, Jean-Yves Loze, Steven G. Potkin

S66. ITI-007 EXHIBITS UNIQUE PHARMACOLOGY: COMBINED RESULTS FROM POSITRON EMISSION TOMOGRAPHY (PET) STUDIES IN HEALTHY VOLUNTEERS AND PATIENTS WITH SCHIZOPHRENIA

Robert Davis, Kimberly Vanover*, Cedric O'Gorman, Jelena Saillard, Michal Weingart, Sharon Mates

S67. PSYCHIATRIC STABILITY MAINTAINED IN TARDIVE DYSKINESIA SUBJECTS TREATED WITH VALBENZAZINE

Jean-Pierre Lindenmayer*, Richard Josiassen, Joshua Burke, Scott Siegert, Bill Aurora

S68. SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TAK-063, A PDE10A INHIBITOR, AFTER A SINGLE DOSE IN HEALTHY JAPANESE AND NON-JAPANESE SUBJECTS

Max Tsai, Tom Macek*, Lambros Chrones, Jinhui Xie, Hakop Gevorkyan

S69. FIVE-YEAR FOLLOW-UP OF A RANDOMIZED-CONTROLLED TRIAL ON 2-YEAR VS. 3-YEAR SPECIALIZED EARLY INTERVENTION FOR YOUNG PATIENTS PRESENTING WITH FIRST-EPISODE PSYCHOSIS

WY Kwong, Wing Chung Chang*, LM Hui, SK Lau, KW Chan, HM Lee, EYH Chen

S70. PROBABILISTIC REINFORCEMENT LEARNING IN PATIENTS WITH FIRST-EPISODE SCHIZOPHRENIA-SPECTRUM DISORDER: PRELIMINARY RESULTS OF A 1-YEAR FOLLOW-UP STUDY

SI Chan, Wing Chung Chang*, TCW Chan, J Waltz, J Gold, EYH Chen

S71. TESTING DIFFERENTS DOMAINS OF SOCIAL COGNITION IN THE PREDICTION OF SOCIAL FUNCTIONING IN PATIENTS WITH SCHIZOPHRENIA

Rafael Penades*, Alexandre González-Rodríguez, Clemente García-Rizo, Rosa Catalán, Miquel Bernardo



S72. VALIDATION OF THE TABLET-BASED BRIEF ASSESSMENT OF COGNITION (BAC APP) FOR ASSESSMENT OF COGNITION IN SCHIZOPHRENIA

Richard Keefe*, Alexandra Atkins, Vicki Davis, Tina Tseng, Adam Vaughn, Philip Harvey, Thomas Patterson, Meera Narasimhan

S73. TO ACT AS ONE WHILE REMAINING TWO -- SELF-OTHER DISTINCTION IN CHILDREN AT RISK FOR PSYCHOSIS

Neeltje Van Haren*, Merel Prikken, Manon Hillegers, Anouk Van Der Weiden

S74. ANALYSIS OF AKT1 AND CANNABIS MODERATION EFFECTS ON PSYCHOTIC EXPERIENCES AND COGNITIVE PERFORMANCE IN HEALTHY SUBJECTS

Barbara Arias*, Manuel Ignacio Ibañez, Jorge Moya, Generós Ortet, Lourdes Fañanás, Mar Fatjó-Vilas

S75. ARE COGNITIVE FUNCTIONS DETERIORATING DURING THE FIRST 5 YEARS AFTER AN EARLY-ONSET PSYCHOSIS?

Elena De la Serna*, Inmaculada Baeza, Gisela Sugranyes, Covadonga Martinez-Caneja, Jéssica Merchan-Naranjo, Celso Arango, Josefina Castro-Fornieles

S76. A COMPARISON OF NEUROCOGNITIVE BATTERIES AFTER SINGLE DOSE MODAFINIL IN EARLY SCHIZOPHRENIA AND HEALTH

Richard Drake*, Jane Lees, Panagiota Michalopoulou, Gahan Pandina, Shon Lewis

(S77). THEORY OF MIND FUNCTIONING IS NO LONGER A NATURAL PROCESS IN PRODROMAL PSYCHOSIS: A MODEL OF SOCIAL COGNITION COMPENSATED BY NEUROCOGNITION

TianHong Zhang*, HuiJun Li, William S. Stone, HuiRu Cui, Daniel I. Shapiro, YingYing Tang, LiHua Xu, Larry J. Seidman, JiJun Wang

S78. IMPROVEMENT IN DEPRESSIVE SYMPTOMS AND FUNCTIONING IN SCHIZOPHRENIA: A TREATMENT STUDY

Philip Harvey*, Masaaki Ogasa, Cynthia Siu, Antony Loebel

S79. SOCIAL COGNITION OVER TIME IN INDIVIDUALS AT CLINICAL HIGH RISK FOR PSYCHOSIS: FINDINGS FROM THE NAPLS-2 COHORT

Danijela Piskulic*, Lu Liu, Kristin Cadenhead, Tyrone Cannon, Barbara Cornblatt, Mcglashan Thomas, Diana Perkins, Larry Seidman, Ming Tsuang, Elaine Walker, Scott Woods, Carrie Bearden, Daniel Mathalon, Jean Addington

S80. DYSEXECUTIVE IMPAIRMENT IN FIRST-EPISODE OF SCHIZOPHRENIA

Gricel Orellana Vidal*, Andrea Slachevsky

S81. META-ANALYSIS OF COGNITIVE PERFORMANCE IN DRUG-NAÏVE PATIENTS WITH SCHIZOPHRENIA

Helena Fatouros-Bergman, Simon Cervenka, Lena Flyckt*, Gunnar Edman, Lars Farde

S82. COMPREHENSIVE ASSESSMENT OF AUDITORY PERCEPTION AND ITS RELATION TO IMPAIRED EMOTION RECOGNITION IN SCHIZOPHRENIA

Michael Kraus*, Trina Walker, L. Fredrik Jarskog, Robert Millet, Richard Keefe



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

S83. COGNITIVE REMEDIATION AND OCCUPATIONAL OUTCOME IN SCHIZOPHRENIA SPECTRUM DISORDERS: A 2 YEAR FOLLOW-UP STUDY

June lystad*, Erik Falkum, Helen Bull, Stig Evensen, Torill Ueland

S84. IMPROVEMENT OF EXECUTIVE FUNCTIONS USING THE OCCUPATIONAL GOAL INTERVENTION METHOD IN PATIENTS WITH TREATMENT -RESISTANT SCHIZOPHRENIA: RESULTS OF THE FOLLOW-UP PHASE

Adriana Vizzotto, Diego Celestino, Patricia Buchain, Alexandra Oliveira, Graça Oliveira, Elaine Di Sarno, Isabel Napolitano, Helio Elks*

S85. COGNITIVE IMPAIRMENT AS A VULNERABILITY MARKER FOR PSYCHOSIS: THE ROLE OF CHILDHOOD TRAUMA

Marieke Begemann*, Kirstin Daalman, Sophie Heringa, Maya Schutte, Iris Sommer

S86. EMOTIONAL INTELLIGENCE AND NON-SOCIAL COGNITION IN SCHIZOPHRENIA AND BIPOLAR-I-DISORDER

Beatrice Frajo-Apor*, Georg Kemmler, Silvia Pardeller, Tamara Plass, Moritz Muehlbacher, Anna-Sophia Welte, Wolfgang Fleischhacker, Alex Hofer

S87. THE COGNITIVE UNDERPINNINGS OF MULTITASKING OF DAILY LIFE ACTIVITIES IN PERSONS DIAGNOSED WITH SCHIZOPHRENIA: VALIDATION OF A NEW MODEL.

Julien Laloyaux*, Martial Van der Linden, Keith H. Nuechterlein, Frank Larøi

S88. COGNITIVE ARCHITECTURE OF INDIVIDUALS AT RISK TO PSYCHOSIS: FINDINGS FROM LYRIKS

Max Lam*, Jimmy Lee, Attilio Rapisarda, Michael Kraus, Richard Keefe

S89. FAMILIALITY OF COGNITIVE PERFORMANCE AND ITS RELATIONSHIP WITH THE NEUROCOGNITIVE EVOLUTION PROFILE IN PSYCHOTIC PATIENTS

Claudia Prats Balado*, Panagiotis Ferentinos, Jordi Soler Garcia, Salvador Miret, Silvia Campanera, Maria Giralt, Maria José Muñoz, Lourdes Fañanás, Mar Fatjó-Vilas

S90. EEG MU-RHYTHM SUPPRESSION IN PATIENTS WITH SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER AND ITS RELATION TO PSYCHOPATHOLOGY

Yulia Zaytseva*, Zhanna Garakh

(S91) THE RELATIONSHIP BETWEEN CORTISOL AND COGNITIVE FUNCTIONS IN THE PSYCHOSIS PRODROME AND THOSE AT CLINICAL HIGH-RISK IN NAPLS2

Daniel Shapiro*, Elaine Walker, NAPLS PIs, Larry Seidman

S92. NEUROANATOMICAL CORRELATES OF SOCIOECONOMIC STATUS IN SCHIZOPHRENIA AND ITS IMPLICATIONS FOR COGNITION

Leire Zubiaurre-Elorza, Ainara Gómez-Gastiasoro, Naroa Ibarretxe-Bilbao, Javier Peña, Natalia Ojeda*, David Schretlen

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



S93. CLINICAL USEFULNESS OF THE SCREEN FOR COGNITIVE IMPAIRMENT IN PSYCHIATRY (SCIP) IN PATIENTS WITH SCHIZOPHRENIA BEFORE AND AFTER COGNITIVE REMEDIATION

Gabriele Sachs*, Eva Maihofer, Manuela Neuwirth, Hemma Swoboda, Andreas Erfurth

S94. AN INVESTIGATION OF SEMANTIC MEMORY IN FIRST-EPISODE PSYCHOSIS

Susan Rossell*

(S95). LEARNING TO TRUST: TRUST AND ATTACHMENT IN EARLY PSYCHOSIS

Anne-Kathrin Fett*, Sukhi Shergill, Nikie Korver-Nieberg, Paula Gromann, Lydia Krabbendam

S96. IMPLICIT MENTALIZING IN SCHIZOPHRENIA: A MULTIVARIATE FMRI STUDY AND ASSOCIATION WITH GENETIC RISK VARIANTS

Andrew Martin*, Ilvana Dzafic, Gail Robinson, David Reutens, Bryan Mowry

(S97). COGNITIVE INSIGHT IN SCHIZOPHRENIA: STUDY ABOUT 30 TUNISIAN PATIENTS.

Ahmed Mhalla*, Bochra Ben Mohamed, Ahmed Hadj Mohamed, Soumaya Chatti, Ferid Zaafrane, Lotfi Gaha

S98. EXECUTIVE DYSFUNCTION IN PSYCHOSIS FOLLOWING TRAUMATIC BRAIN INJURY

Rachel Batty*, Andrew Francis, Neil Thomas, Malcolm Hopwood, Jennie Ponsford, Susan Rossell

S99. NEUROLOGICAL SOFT SIGNS IN CHRONIC SCHIZOPHRENIA

Christina J. Herold, Marc Montgomery Lässer*, Ulrich Seidl, Philipp Arthur Thomann, Johannes Schröder

S100. DOES COGNITIVE PERFORMANCE MAP TO CATEGORICAL DIAGNOSES OF SCHIZOPHRENIA, SCHIZOAFFECTIVE DISORDER AND BIPOLAR DISORDER? A DISCRIMINANT FUNCTIONS ANALYSIS.

Tamsyn Van Rheenen*, Shayden Bryce, Eric Tan, Erica Neill, Caroline Gurvich, Stephanie Louise, Susan Rossell

S101. CHANGE IN VERBAL MEMORY PERFORMANCE IN SCHIZOPHRENIA PATIENTS AND THEIR SIBLINGS

Rosa Ayesa-Arriola*, Neeltje Van Haren, Jessica De Nijs, Wiepke Cahn, René S. Kahn

S102. UNDERSTANDING THE PROGRESSION OF SEMANTIC DYSFUNCTION IN SCHIZOPHRENIA: INSIGHTS USING THE SCHIZOTYPY ANALOGUE

Eric Tan*, Giorgia Wagner, Susan Rossell

S103. BUILDING A NEUROCOGNITIVE PROFILE OF AUDITORY VERBAL HALLUCINATIONS IN SCHIZOPHRENIA

Eric Tan*, Caroline Gurvich, Matthew Hughes, Neil Thomas, Erica Neill, Tamsyn Van Rheenen, Stephanie Louise, William Woods, Patricia Michie, Susan Rossell

S104. MUSIC & EMOTIONS IN SCHIZOPHRENIA PATIENTS

Christian Mikutta*, Andreas Altorfer, Werner Strik, Daniel Mathalon



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

S105. CIGARETTE SMOKING AND COGNITIVE FUNCTIONING IN SCHIZOPHRENIA

Faith Dickerson*

S106. HIGH PREVALENCE OF OBSTRUCTIVE SLEEP APNOEA IN PATIENTS TAKING CLOZAPINE COMPARED TO AGE MATCHED CONTROLS

Cherrie Galletly*, Hannah Myles, Robert Adams, Nick Antic, Madhu Chandratilleke, Dennis Liu, Jeremy Mercer, Andrew Vakulin, Andrew Vincent, Nicholas Myles, Gary Wittert

S107. HIGH METABOLIC RISK FACTORS DO NOT SUBSIDE BY ROUTINE OUTCOME MONITORING; DATA FROM THE PHAMOUS PROJECT.

Richard Bruggeman*, Joanneke Bruins, Marieke Pijnenborg, Edwin van den Heuvel, Ellen Visser, Eva Corpeleijn, Agna Bartels-Velthuis, Frederike Jorg

S108. THE EFFECTIVENESS OF SHORT-TERM GROUP SCHEMA COGNITIVE BEHAVIORAL THERAPY (SCBT-G) FOR PEOPLE WITH PSYCHOTIC DISORDERS AND CO-MORBID PERSONALITY PROBLEMS

Ellen Horselsenberg*, Hugo Wolters, Johans Brink, Esther Sportel

S109. THE BIAS EFFECT OF CNVS CONFERRING RISK FOR BOTH AUTISM AND SCHIZOPHRENIA

Ahmad Abu-Akel*, Stephen Wood, Peter Hansen, Ian Apperly

S110. DEPRESSION AND CLINICAL HIGH-RISK STATES: CLINICAL PRESENTATION OF DEPRESSED VS. NON-DEPRESSED PARTICIPANTS IN THE NAPLS-2 COHORT

Emily Kline*, Jean Addington, Kristen Woodberry, Carrie Bearden, Kristin Cadenhead, Tyrone Cannon, Barbara Cornblatt, Thomas McGlashan, Diana Perkins, Ming Tsuang, Elaine Walker, Scott Woods, Larry Seidman

S111. HALLUCINATIONS AND TRAUMA: A COMPLEX RELATION

Jack J.A. Jenner, B.J. Kollen, H. Burger, Bert L.B. Luteijn*

S112. UNIQUE AND OVERLAPPING SYMPTOMS IN SCHIZOPHRENIA SPECTRUM AND DISSOCIATIVE DISORDERS IN RELATION TO MODELS OF PSYCHOPATHOLOGY: A SYSTEMATIC REVIEW

Selwyn Renard*, Rafaele Huntjens, Paul Lysaker, Andrew Moskowitz, Andre Aleman, Marieke (Gerdina) Pijnenborg

S113. DOES AGE OF FIRST CANNABIS USE AND FREQUENCY OF USE INFLUENCE AGE OF FIRST-EPIISODE PSYCHOSIS (FEP)? A COMPARISON BETWEEN NORTH AND SOUTH OF EUROPE

Caterina La Cascia, Fabio Seminero*, Lucia Sideli, Laura Ferraro, Alice Mulè, Crocettarachele Sartorio, Giada Tripoli, Marta Di Forti, Daniele La Barbera, Robin Murray

S114. LONG-TERM EFFECTS OF ADOLESCENT THC ON THE ADULT BRAIN: AN VIVO MRI / 1H-MRS STUDY WITH EX VIVO AND POST-MORTEM CONFIRMATION

Anthony Vernon*, Sotiris Kakanos, William Crum, David Lythgoe, Marie-Caroline Cotel, Po-Wah So, Sagnik Bhattacharyya, Kapur Shitij



S115. NICOTINE DEPENDENCE IN PATIENTS WITH SCHIZOPHRENIA: RELATIONSHIPS TO PSYCHOPATHOLOGY, INSIGHT AND SEVERITY OF ILLNESS

Zeynep Baran Tatar*, Erhan Kurt

S116. THE IMPACT OF CANNABIS USE IN PSYCHOSIS: REFLECTIONS AND ANALYSIS OF MOTIVATIONAL INTERVIEWING/COGNITIVE BEHAVIOUR THERAPY TRIALS IN ESTABLISHED PSYCHOSIS

Sandra Bucci*, Christine Barrowclough, Amanda Baker, Lynsey Gregg, Richard Emsley

S117. YOUTH OFFENDING, THE NARROW LINE BETWEEN SUBSTANCE ABUSE AND PSYCHOSIS.

Yolanda Rendal*, Teresa Jimeno, Carolina Roset, Patricia Herbera, Joana M. Andrés, Jaume Morey

S118. STRONG ASSOCIATION BETWEEN SEVERE NICOTINE DEPENDENCE AND DEPRESSION IN SMOKERS WITH SCHIZOPHRENIA. RESULTS FROM THE FACE-SZ DATASET.

Romain Rey*, Thierry D'Amato, Pierre-Michel Llorca, Guillaume Fond

S119. THE NATURE OF THE RELATIONSHIP OF PSYCHOMOTOR SLOWING WITH NEGATIVE SYMPTOMATOLOGY IN SCHIZOPHRENIA

Chris Bervoets*, Lise Docx, Bernard Sabbe, Manuel Morrens

S120. TACKLING MENTAL HEALTH STIGMA AND DISCRIMINATION BY CHANGING THE NAME: THE CASE AGAINST SCHIZOPHRENIA

Antonio Lasalvia*

S121. CONVERSION INTO OVERT PSYCHOSIS IN INDIVIDUALS AT ULTRA-HIGH RISK FOR PSYCHOSIS: POSSIBLE ROLES OF SCHIZOTYPY AND BASIC SYMPTOMS

Minji Bang*, Eun Lee, Suk Kyoan An

S122. IS DISORGANIZED SCHIZOPHRENIA A RISK FACTOR FOR TREATMENT RESISTANCE IN SCHIZOPHRENIA? NEW EVIDENCE FOR A TRADITIONAL SUBTYPE.

Bruno Ortiz*, Cinthia Higuchi, Cristiano Noto, Daiane Medeiros, Deyvis Rocha, Rodrigo Bressan, Ary Gadelha

S123. CLINICAL NETWORK ANALYSIS: INSIGHT IN VARIATION IN SYMPTOM SEVERITY AND CLUSTERING TO IMPROVE SCHIZOPHRENIA CARE; A CASE REPORT

Maarten Bak*, Marjan Drukker, Jim Van Os

S124. AFFECTIVE FEATURES AND GENDER IN PSYCHOSIS: DURATION OF ILLNESS MAKES A DIFFERENCE

Santiago Latorre, Jesús Cobo, Lourdes Nieto, Susana Ochoa, Esther Pousa, Judith Usall, Iris Baños, Isabel Ruiz, Carles Garcia-Ribera, Ada Ruiz*

S125. SELF-EVALUATION OF NEGATIVE SYMPTOMS (SNS): A NOVEL TOOL TO ASSESS NEGATIVE SYMPTOMS

Sonia Dollfus*, Cyril Mach, Rémy Morello



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

S126. CULTURAL INFLUENCES ON SCHIZOTYPY AMONG BRITISH AND TRINIDADIAN ADULTS: A LATENT MEAN COMPARISON AND EVENT-RELATED POTENTIAL STUDY

David Barron*, Kevin Morgan, Viren Swami, Gerard Hutchinson, Tony Towell

S127. PSYCHOTIC SYMPTOMS IN PATIENTS WITH ANXIETY AND DEPRESSION – CLINICAL CORRELATES AND IMPLICATIONS FOR PSYCHIATRIC SERVICE UTILIZATION

Nomi Werbeloff*

S128. SCHIZOTYPAL PERSONALITY QUESTIONNAIRE-BRIEF: FACTOR STRUCTURE ANALYSIS IN GENERAL POPULATION IN FRANCE

Louise Todorov*, Aziz Ferchou, Grégoire Baudin, Mohamed Lajnef, Baptiste Pignon, Andrei Szöke, Marion Leboyer, Franck Schürhoff

S129. THE RELATION BETWEEN CHILDHOOD TRAUMA HISTORY AND PSYCHOTIC SYMPTOMS IN PATIENTS WITH FIRST EPISODE PSYCHOSIS

Ahmet Ayer*, Esra Aydinli, Koksai Alptekin

S130. TRAJECTORIES OF DEPRESSION IN A PRAGMATIC, RANDOMIZED TRIAL

Eirik Kjelby*, Rolf Gjestad, Igne Sinkeviciute, Rune A Kroken, Else-Marie Løberg, Hugo A Jørgensen, Erik Johnsen

S131. INTRODUCTION AND VALIDATION OF THE QUESTIONNAIRE FOR PSYCHOTIC EXPERIENCES: A CLINICAL TOOL TO ASSESS PSYCHOTIC SYMPTOMS ACROSS DIAGNOSES

Maya Schutte*, Dominic ffychte, Mascha Linszen, Sanne Koops, Edwin van Dellen, Sophie Heringa, Arjen Slooter, Rob Teunisse, Odile van den Heuvel, Evelien Lemstra, Elizabeth Foncke, Ralph Hoffman, Clara Strauss, Neil Thomas, Susan Rossell, Iris Sommer

S132. SEARCHING ACROSS THE DIAGNOSTIC DIVIDE: TOWARDS A MECHANISTIC UNDERSTANDING OF DISEASE PROGRESSION THROUGH SYMPTOM AND COGNITIVE TRAJECTORIES

Rico Sze Chun Lee*, Daniel Hermens, Jan Scott, Nick Glozier, Bridianne O'Dea, Ian Hickie

S133. BAYESIAN CONFIRMATORY FACTOR ANALYSIS FAILS TO CONFIRM FIVE-FACTOR MODEL OF THE POSITIVE AND NEGATIVE SYNDROME SCALE FOR SCHIZOPHRENIA (PANSS) IN A REPRESENTATIVE BRAZILIAN SAMPLE.

Cinthia Higuchi*, Hugo Cogo-Moreira, Bruno Ortiz, Rosana de Freitas, Cristiano Noto, Quirino Cordeiro, Sintia Belangero, Bernardo dos Santos, Rodrigo Bressan, Helio Elkis, Ary Gadelha

S134. RISK FACTORS FOR AGGRESSION IN FIRST EPISODE PSYCHOSIS – A NATURALISTIC DATABASE STUDY IN SINGAPORE

Sutapa Basu*, Edimansyah Abidin, Swapna Verma

S135. SOCIAL MEDIA IN FIRST EPISODE PSYCHOSIS: A LINGUISTIC ANALYSIS

Asra Rizvi*, Michael Birnbaum, Leonardo Lopez, Ryan Boyd, John Kane

FINAL PROGRAM

FLORENCE, ITALY

2 – 6 APRIL 2016



S136. THE FACTOR STRUCTURE OF PSYCHOTIC SYMPTOMS IN EARLY PSYCHOSIS

Eric Roche*, Ricardo Segurado, Brian O'Donoghue, Laoise Renwick, Caragh Behan, Kevin Madigan, John Lyne, Mary Clarke

S137. THE ASSOCIATIONS BETWEEN PATERNAL AGE, AGE AT ONSET OF PSYCHOSIS IN PATIENTS AND SCHIZOTYPAL TRAITS IN GENERAL POPULATION

Sanja Andric*, Marina Mihaljevic, Tijana Mirjanic, Nadja Maric

S138. DELUSIONS IN FIRST-EPISODE PSYCHOSIS: FACTOR ANALYSIS OF TWELVE TYPES OF DELUSIONS AND THEIR DEMOGRAPHIC AND CLINICAL CORRELATES

Enrico Paolini*, Patrizia Moretti, Michael Compton

S139. IS A NARROW DEFINITION OF SCHIZOPHRENIA MORE HERITABLE THAN WHEN WE EMBRACE THE FULL SPECTRUM OF THE ILLNESS? HERITABILITY OF SCHIZOPHRENIA AND SCHIZOPHRENIA SPECTRUM IN THE NATIONWIDE DANISH TWIN AND HEALTH REGISTERS

Rikke Hilker*, Dorte Helenius, Birgitte Fagerlund, Axel Skytthe, Kaare Christensen, Thomas Werge, Merete Nordentoft, Birte Glenthøj

S140. EMPIRICALLY BASED QUALITATIVE AND QUANTITATIVE VARIATIONS ON THE PSYCHOSIS CONTINUUM IN THE 'HOWNUTSARETHEDUTCH' POPULATION SAMPLE

Johanna Wigman*, Klaas Wardenaar, Rob Wanders, Sanne Booij, Bertus Jeronimus, Lian van der Krieke, Marieke Wichers, Peter de Jonge

S141. MORTALITY IN FIRST EPISODE PSYCHOSIS: A 20-YEAR FOLLOW-UP OF THE DUBLIN FIRST EPISODE PSYCHOSIS COHORT

Roisin Doyle*, Donal O'Keefe, Anthony Kinsella, Ailish Hannigan, Kevin Madigan, Elizabeth Lawlor, Aine Kelly, Ann Sheridan, Mary Clarke

S142. HAS DEINSTITUTIONALIZATION AFFECTED INPATIENT SUICIDE? PSYCHIATRIC INPATIENT SUICIDE RATES BETWEEN 1990 AND 2013 IN ISRAEL

Linda Levi*, Nomi Werbeloff, Inna Pugachova, Rinat Yoffe, Matthew Large, Michael Davidson, Mark Weiser

S143. PREVALENCE AND PERSISTENCE OF PSYCHOTIC-LIKE EXPERIENCES IN HONG KONG

Kit Wai Lee*, Kit Wa Chan, Wing Chung Chang, Edwin Ho Ming Lee, Christy Lai Ming Hui, Jingxia Lin, Eric Yu Hai Chen

S144. PHYSICAL ACTIVITY IN PEOPLE LIVING WITH PSYCHOTIC ILLNESS: FINDINGS FROM THE SURVEY OF HIGH IMPACT PSYCHOSIS

Shuichi Suetani*, Anna Waterreus, Vera Morgan, Debra Foley, Cherrie Galletly, Johanna Badcock, Gerald Watts, Andrew McKinnon, David Castle, Sukanta Saha, James Scott, John McGrath

S145. SYSTEMATIC REVIEW AND META-ANALYSIS OF THE PREVALENCE OF PSYCHOTIC EXPERIENCES IN COUNTRIES OUTSIDE OF NORTH AMERICA, EUROPE, AND AUSTRALASIA.

Suttha Supanya*, Craig Morgan, Ulrich Reininghaus



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

S146. PATHWAYS TO CARE AND PATTERNS OF CARE IN FIRST EPISODE PSYCHOSIS PATIENTS TREATED IN COMMUNITY BASED-MENTAL HEALTH SERVICES OVER 5 YEARS. FINDINGS FROM THE PICOS-VENETO PROJECT

Elisabetta Miglietta*, Antonio Lasalvia, Doriana Cristofalo, Sarah Tosato, Chiara Bonetto, Gioia Zanatta, Silvia Zoppei, Sara Petterlini, Carla Comacchio, Giorgia Dimitri, Carla Cremonese, Luana Ramon, Mirella Ruggeri

(S147). INVESTIGATING THE ASSOCIATION OF MATERNAL SEVERE MENTAL ILLNESS AND EXPOSURE TO OBSTETRIC COMPLICATIONS WITH RATES OF INTELLECTUAL DISABILITY.

Patricia Di Prinzio*, Vera Morgan, Jonas Jonas Björk, Maxine Croft, Assen Jablensky, Thomas McNeil

(S148). WHY ARE CHILDREN LIVING IN URBAN NEIGHBOURHOODS AT INCREASED RISK FOR CHILDHOOD PSYCHOTIC SYMPTOMS? FINDINGS FROM A UK LONGITUDINAL COHORT STUDY

Joanne Newbury*, Louise Arseneault, Avshalom Caspi, Terrie Moffitt, Candice Odgers, Helen Fisher

S149. LOWER GLOBAL ASSESSMENT OF FUNCTIONING (GAF-F) SCORES PREDICT THE RISK OF HOSPITALIZATION IN MALE PATIENTS WITH A FIRST-TIME SCHIZOPHRENIA DIAGNOSIS

Ole Köhler*, Henriette Thisted Horsdal, Lone Baandrup, Ole Mors, Christiane Gasse

S150. PREVALENCE AND INCIDENCE OF SCHIZOPHRENIA IN TAIWAN: 10-YEAR POPULATION-BASED APPROACH

Szu-Nian Yang*, Yu-Hsiang Kao

(S151). PSYCHOSIS SYMPTOM PROFILES AND VARIABILITY OVER TIME IN A COHORT OF MARGINALLY HOUSED ADULTS IN VANCOUVER, CANADA

Andrea Jones*, Kristina Gicas, Fidel Vila-Rodriguez, Olga Leonova, Verena Langheimer, Donna Lang, Alasdair Barr, Ric Procyshyn, Geoffrey Smith, Tari Buchanan, Michael Krausz, William MacEwan, William Panenka, Allen Thornton, William Honer

S152. A NEW APPROACH TO INVESTIGATING THE ASSOCIATION BETWEEN DURATION OF UNTREATED PSYCHOSIS AND OUTCOMES IN PSYCHOSIS USING INSTRUMENTAL VARIABLES.

Sarah Sullivan*, Robert Carroll, Tim Peters, Tim Amos, Peter Jones, Helen Fisher, Sonia Johnson, Max Marshall, Max Birchwood, David Fowler, Kate Tilling

S153. UNHELPLEFUL METACOGNITIVE BELIEFS IN EARLY PSYCHOSIS ARE ASSOCIATED WITH AFFECTIVE SYMPTOMS AND CHILDHOOD SOCIAL ADJUSTMENT

Tiril Østefjells*, Ingrid Melle, Roger Hagen, Kristin L. Romm, Nasrettin Sönmez, Ole A. Andreassen, Jan Ivar Røssberg

S154. DEMOGRAPHIC AND SOCIO-ENVIRONMENTAL PREDICTORS OF PREMORBID CANNABIS USE AMONG PATIENTS WITH FIRST-EPISODE PSYCHOSIS

Luca Pauselli*, Michael Birnbaum, Beatriz Paulina Vázquez Jaime, Enrico Paolini, Mary E. Kelly, Beth Broussard, Michael Compton



S155. IDENTIFYING PATIENTS WITH AN INDICATION FOR CLOZAPINE IN DUTCH OUTPATIENT SETTINGS.

Yvonne van der Zalm*, Raphael Schulte, Iris Sommer, Jean-Paul Selten

S156. PREVALENCE OF CHILDHOOD TRAUMA IN RECENT ONSET PSYCHOSIS AND ARMS SUBJECTS: A CONTROLLED STUDY

Alba Valiente*, Rosa Marine, Eduard Izquierdo, Montse Sole, Angel Cabezas, Sara Arranz, Alfonso Gutierrez-Zotes, Javier Labad, Vanessa Sanchez-Gistau

S157. THE EPIDEMIOLOGY OF FIRST EPISODE PSYCHOSIS IN EARLY INTERVENTION IN PSYCHOSIS SERVICES: FINDINGS FROM THE SOCIAL EPIDEMIOLOGY OF PSYCHOSES IN EAST ANGLIA [SEPEA] NATURALISTIC COHORT STUDY

James Kirkbride*, Yasir Hameed, Gayatri Ankireddipalli, Nikolett Kabacs, Carolyn Crane, Antonio Metastasio, Ashkan Espandian, Stella Styliani, Suneetha Siddabattuni, Konstantinos Ioannidis, Ben Walden, Rebecca Webster, Jesus Perez, Peter Jones

S158. SCHIZOTYPY AND MIGRATION IN A GENERAL POPULATION SAMPLE IN FRANCE

Andrea Tortelli*, Andrei Szoke, Gregoire Baudin

S159. CLOSING THE GAP: SENSITIVITY AND SPECIFICITY OF NEUROLOGICAL SIGNS ACROSS THE LIFESPAN PROFILING IN SCHIZOPHRENIA SPECTRUM DISORDERS

Raymond Chan*, Weizhen Xie, Fu-lei Geng, Ya Wang, Simon S.Y. Lui, Chuan-Yue Wang, Xin Yu, Eric F.C. Cheung, Robert Rosenthal

S160. NEUROBIOLOGICAL SUBTYPING OF SCHIZOPHRENIC AND AFFECTIVE PSYCHOSES IN CROSS-DISORDER COHORTS

Oliver Gruber*

S161. EARLY PARENTAL LOSS AND NRG1 HAPICE GENOTYPES ARE DIFFERENTIALLY ASSOCIATED WITH COGNITIVE FUNCTION IN SCHIZOPHRENIA

Vaidy Swaminathan*, Ruth Wells, Avril Pereira, Leonid Churilov, Chad Bousman, Vanessa Cropley, Christos Pantelis, Andrew Zalesky, Rhoshel Lenroot, Jason Bruggemann, Cyndi Shannon Weickert, Thomas Weickert, Suresh Sundram

S162. CORRELATION OF BDNF MRNA EXPRESSION WITH VAL66MET POLYMORPHISM IN BRAIN

Sern Yih Cheah, Leesa Wockner, Robert McLeay, Bruce Lawford, Ross Young, Charles Morris, Joanne Voisey*

S163. AUDITORY PROCESSING IN AUTISM SPECTRUM DISORDER: MISMATCH NEGATIVITY DEFICITS

Niels Bilenberg*, Chantal Vlaskamp, Gitte Falcher Madsen, Jens Richardt Jepsen, Sarah Durston, Cathriona Cantio, Birte Glenthøj, Bob Oranje

S164. PRIMARY AND SECONDARY ALTERATIONS OF WHITE MATTER CONNECTIVITY IN SCHIZOPHRENIA: A WHOLE-BRAIN TRACTOGRAPHY-BASED ANALYSIS

Tzung-Jeng Hwang*, Chen-Hao Wu, Chih-Min Liu, Yu-Jen Chen, Wen-Yih Isaac Tseng



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

S165. THE BENEFIT OF MACRO-ANATOMICAL ALIGNMENT FOR FMRI-BASED IMAGING GENETICS OF COMMON SCHIZOPHRENIA RISK VARIANTS

Robert Bittner*, Peter Hahn, Christina Novak, Tom Lancaster, Astrid Rehner, Anna Seitz, Danko Nikolic, Andreas Reif, David Linden

S166. PREFRONTAL-STRIATAL FUNCTIONING OF EFFORT-BASED REINFORCEMENT IN SCHIZOPHRENIA

Il Ho Park*, Byong-Chul Lee, Joong Il Kim, Min-Seung Koo

S167. BRAIN ACTIVATION DURING FACIAL AFFECT PERCEPTION DIFFERENTIATES HIGH VS. LOW FUNCTIONING INDIVIDUALS WITH SCHIZOPHRENIA

Tatiana Karpouzian, Matthew Schroeder, Eva Alden, Samantha Abram, James Reilly, Matthew Smith*

S168. TASK-RELATED NETWORK ANALYSIS IN SCHIZOPHRENIA PATIENTS WITH AUDITORY VERBAL HALLUCINATIONS

Leonie Bais*, Ans Vercammen, Edith Liemburg, Henderikus Knegtering, André Aleman

S169. FUNCTIONAL CONNECTIVITY OF THE DEFAULT MODE NETWORK IN FIRST EPISODE PSYCHOSIS: PRELIMINARY FINDINGS

Eleni Ganella, Vanessa Copley, James Olver, Bernhard Baune, Patrick D McGorry, Ian Everall, G Paul Amming, Christos Pantelis, Andrew Zalesky, Cali Bartholomeusz*

S170. NEURAL MECHANISMS OF HOW MOOD MODULATES REALITY-MONITORING IN SCHIZOPHRENIA

Karuna Subramaniam*, Ryan LoPilato, Jenny Marino, Daniel Mathalon, Srikantan Nagarajan, Sophia Vinogradov

S171. FRONTAL HYPER-ACTIVATION DURING CAUSAL WORD GENERATION IN SOCIAL CONTEXTS IN SCHIZOPHRENIA

Kim Wende*, Carolin Wagener, Andreas Jansen, Benjamin Straube, Mirjam Stratmann, Tilo Kircher, Arne Nagels

S172. FUNCTIONAL CONNECTIVITY AND DELUSIONAL COGNITIVE BIAS: A RESTING STATE FUNCTIONAL MAGNETIC RESONANCE IMAGING STUDY ON SCHIZOPHRENIA

Jun Miyata*, Akihiko Sasamoto, Nobukatsu Sawamoto, Yasuo Mori, Masanori Isobe, Shinichi Urayama, Toshihiko Aso, Hidenao Fukuyama, Toshiya Murai, Hidehiko Takahashi

S173. FUNCTIONAL NEUROIMAGING OF WORKING MEMORY ENCODING IN A ORIENTATION CHANGE DETECTION TASK IN SCHIZOPHRENIA AND FIRST-DEGREE RELATIVES

Michael Stäblein*, Dominik Kraft, Helena Storchak, Denisa Ghinea, Christian Knöchel, Robert Bittner, Andreas Reif, Viola Oertel-Knöchel

S174. NEURAL, COGNITIVE, AND CLINICAL CORRELATES OF CEREBELLAR-DEPENDENT ASSOCIATIVE LEARNING IN INDIVIDUALS WITH SCHIZOPHRENIA

Jerilyn Kent*, Dae-Jin Kim, Josselyn Howell, Patty Krempely, Sharlene Newman, Hu Cheng, Amanda Bolbecker, Brian O'Donnell, William Hetrick

FINAL PROGRAM

FLORENCE, ITALY

2 – 6 APRIL 2016



S175. FUNCTIONAL CONNECTIVITY BETWEEN MIDLINE STRUCTURES OF THE DEFAULT MODE NETWORK IS INCREASED IN FIRST-EPISODE PSYCHOSIS DURING A MOVIE STIMULUS (ALICE IN WONDERLAND)

Eva Rikandi*, Teemu Mäntylä, Jaana Suvisaari, Tuukka Raij

S176. WIDESPREAD REDUCTIONS IN RESTING-STATE FUNCTIONAL CONNECTIVITY IN A TREATMENT-RESISTANT SCHIZOPHRENIA GROUP

Eleni Ganella*, Calí Bartholomeusz, Christos Pantelis, Ian Everall, Christina Phassouliotis, Andrew Zalesky

S177. HYPOFUNCTION OF BASAL GANGLIA INDIRECT PATHWAY IN SCHIZOPHRENIA

Jong Yoon*

S178. THE PREDICTIVE VALUE OF DIFFERENT NEUROCHEMICAL PROFILES FOR TREATMENT OUTCOME IN ANTIPSYCHOTIC-NAÏVE SCHIZOPHRENIA PATIENTS

Anne Sigvard*, Kirsten Borup Bojesen, Kasper Jessen, Egill Rostrup, Lars Thorbjørn Jensen, Albert Gjedde, Birte Glenthøj

S179. THALAMIC AND HIPPOCAMPUS DRIVEN ALTERATIONS IN LARGE-SCALE NEURAL OSCILLATIONS DIFFER ACROSS THE DIFFERENT ILLNESS STAGES OF SCHIZOPHRENIA: AN MEG RESTING-STATE STUDY.

Tineke Grent-[†]t-Jong*, Tobias Navarro Schroeder, Limin Sun, Christine Grützner, F. Markus Leweke, Davide Rivolta, Andreas Sauer, Michael Wibral, Wolf Singer, Peter Uhlhaas

S180. PROLACTIN LEVELS IN PATIENTS WITH A FIRST PSYCHOTIC EPISODE WITH NO PREVIOUS ANTIPSYCHOTIC TREATMENT. RELATIONSHIP WITH SEXUAL SIDE EFFECTS. PRELIMINARY RESULTS.

Marta Coromina*, Núria Del Cacho, Anna Butjosa, Regina Vila-Badia, Christian Núñez, Elena Rubio-Abadal, Marta Pardo, Sheila López-Romero, GRUP PEP-PROLACTINA, Judith Usall

S181. ORAL HEALTH IN FIRST EPISODE PSYCHOSIS: QUANTITATIVE AND QUALITATIVE STUDY ON PREVALENCE OF ORAL HEALTH PROBLEMS, RISK FACTORS AND NEED FOR INTERVENTION

Aaltsje Malda*, Annemieke Zwart, Sonja Kuipers, Nynke Boonstra

S182. CONNECTOMIC CORRELATES OF RESPONSE TO TREATMENT IN FIRST-EPISODE PSYCHOSIS

Nicolas Crossley*, Tiago Reis Marques, Heather Taylor, Christopher Chaddock, Flavio Dell'Acqua, AAT Simone Reinders, Valeria Mondelli, Marta Di Forti, Andrew Simmons, Anthony David, Shitij Kapur, Carmine Pariante, Robin Murray, Paola Dazzan

S183. STRUCTURAL BRAIN ABNORMALITIES IN MEDICATION NAIVE OFFSPRING OF SCHIZOPHRENIA AND BIPOLAR PATIENTS

Godefridus Koevoets*, Neeltje Van Haren, Matthijs Vink, Rene Kahn, Manon Hillegers



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

S184. ALTERATIONS OF STRUCTURAL CONNECTIVITY IN PATIENTS WITH SCHIZOPHRENIA: A SYSTEMATIC REVIEW

Hyerim Oh*, Tae Young Lee, Jun Soo Kwon

S185. HERITABILITY OF VOLUMETRIC BRAIN CHANGES IN ADOLESCENCE

Rachel Brouwer*, Marinka Koenis, Suzanne Swagerman, Dorret Boomsma, Hilleke Hulshoff Pol

S186. BRAIN METABOLITES IN ULTRA HIGH RISK PATIENTS FOR PSYCHOSIS

Therese van Amelsvoort, Mariken de Koning, Tobias Gleich, Matthan Caan, Oswald Bloemen*

S187. ARCUATE FASCICULUS SIZE IS ASSOCIATED WITH AUDITORY HALLUCINATIONS

Liv E. Falkenberg*, René Westerhausen, Kenneth Hugdahl

S188. INFLUENCE OF ENVIRONMENTAL RISK FACTORS ON WHITE MATTER MICROSTRUCTURE: A DIFFUSION TENSOR IMAGING STUDY

Elena Fischer*, Bruno Dietsche, Felicitas Meier, Jennifer Engelen, Henrike Bröhl, Udo Dannlowski, Axel Krug, Tilo Kircher

S189. RELATIONSHIPS BETWEEN CORPUS CALLOSUM VOLUME AND FUNCTIONAL ASYMMETRY IN THE LANGUAGE NETWORK IN SCHIZOPHRENIA AND BIPOLAR DISORDER

Maxime Tréhout*, Leroux Elise, Delcroix Nicolas, Sonia Dollfus

S190. RESTING STATE DEFICITS IN THETA BAND CONNECTIVITY IN SCHIZOPHRENIA USING MAGNETOENCEPHALOGRAPHY

Sarah Lancaster*, Susan Rossell, William Woods, Matthew Hughes

S191. STRUCTURAL BRAIN NETWORK DISTURBANCES IN THE PSYCHOSIS SPECTRUM

Edwin van Dellen*, Marc Bohlken, Laurijn Draaisma, Prejaas Tewarie, Remko Van Lutterveld, Rene Mandl, Cornelis Stam, Iris Sommer

S192. INSIGHT AND WHITE MATTER CHANGES IN FIRST-EPISODE SCHIZOPHRENIA

Laila Asmal*, Stefan du Plessis, Matthijs Vink, Bonginkosi Chiliza, Robin Emsley

S193. BRAIN MORPHOMETRY CORRELATES OF SOCIAL COGNITION IN SCHIZOPHRENIA: A SYSTEMATIC REVIEW

Abhinav Nahar*, Ramajayam Govindaraj, Urvakhsh Meherwan Mehta

S194. FUNCTIONAL DYSCONNECTIVITY IN MEDICATION-NAÏVE SCHIZOPHRENIA PATIENTS WITH AUDITORY VERBAL HALLUCINATIONS

Xiao Chang*, Guusje Collin, Yibin Xi, Longbiao Cui, Huaning Wang, Hong Yin, René S. Kahn, Martijn Van Den Heuvel

S195. MUSICAL DEFICITS AND CORTICAL THICKNESS IN PATIENTS WITH SCHIZOPHRENIA

Ryoshuke Fujito, Ken Sawada*, Masayoshi Mineo, Sanae Hatada, Shigeru Morinobu, William Honer

S196. PHENOTYPIC CHARACTERIZATION OF SCHIZOPHRENIA PATIENTS WITH LINKAGE TO CHROMOSOME 13Q, 1P AND 13Q + 1P

Johannes Roos*, Pierre Malherbe, René Ehlers, Maria Karayiorgou

FINAL PROGRAM

FLORENCE, ITALY

2 – 6 APRIL 2016



S197. RESULTS FROM A GENOME-WIDE ASSOCIATION STUDY WITH CLINICAL RESPONSE TO DULOXETINE AND PLACEBO

Daniel Müller*, Malgorzata Maciukiewicz, Victoria Marshe, Arun Tiwari, Trehani Fonseka, Natalie Freeman, James Kennedy, Susan Rotzinger, Jane Foster, Sidney Kennedy

S198. INVESTIGATION OF THE GENETIC BASIS OF SPECIFIC PSYCHOTIC EXPERIENCES IN ADOLESCENCE

Oliver Pain*, Frank Dudbridge, Alastair Cardno, Daniel Freeman, Paul Lichtenstein, Stanley Zammit, Robert Plomin, Angelica Ronald

S199. ASSOCIATION OF POLYGENIC RISK SCORE OF DOPAMINERGIC PATHWAY WITH SCHIZOPHRENIA AND ITS GREY MATTER VOLUME ALTERATION OF PUTAMEN

Jian Zhang*, Hongyan Ren, Qiang Wang, Tao Li

S200. FURTHER EVIDENCE FOR VULNERABILITY-STRESS MODEL OF SCHIZOPHRENIA: POSSIBLE ROLE OF FKBP5 GENE HAPLOTYPES IN A SERBIAN POPULATION

Marina Mihaljevic*, Katarina Zeljic, Sanja Andric, Tijana Mirjanic, Ivana Novakovic, Nadja Maric

S201. THE ROLE OF A CATHECHOL-O-METHYLTRANSFERASE (COMT) VAL158/MET GENETIC POLYMORPHISM IN SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND UPDATED META-ANALYSIS OF 32 816 SUBJECTS

Tania Gómez Peralta*

S202. METHYLOMIC CHANGES IN INDIVIDUALS EXPOSED IN UTERO TO DIETHYLSTILBESTROL

Fabrice Rivollier*, Oussama Kebir, Boris Chaumette, Marie-Odile Krebs

S203. GENETIC OVERLAP BETWEEN AMYOTROPHIC LATERAL SCLEROSIS AND SCHIZOPHRENIA

Dick Schijven*, Russell McLaughlin, Jurjen Luykx, Wouter van Rheenen, Ammar Al-Chalabi, René Kahn, Leonard van den Berg, Orla Hardiman, Jan Veldink

S204. MATERNAL IMMUNE ACTIVATION REDUCES TRANSLOCATOR PROTEIN (TSPO) EXPRESSION IN THE OFFSPRING PREFRONTAL CORTEX

Tina Notter*, Urs Meyer

S205. THE ACUTE AND CHRONIC EFFECTS OF ANTIPSYCHOTIC TREATMENT ON SYNAPTIC DOPAMINE LEVELS: PRELIMINARY RESULTS FROM A META-ANALYSIS OF MICRODIALYSIS STUDIES

Joseph Kambeitz*

S206. ASSESSING FACTORS OF TREATMENT RESISTANCE TO ANTIPSYCHOTICS: NICOTINE AND CAFFEINE AFFECT HALOPERIDOL-INDUCED EFFECTS ON BEHAVIORS AND ON MOLECULES OF THE POST-SYNAPTIC DENSITY.

Elisabetta F Buonaguro*, Carmine Tomasetti, Federica Marmo, Gianmarco Latte, Rodolfo Rossi, Camilla Avagliano, Felice Iasevoli, Andrea de Bartolomeis



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

(S207). INFLUENCE OF VAL158MET POLYMORPHISM IN COMT GENE ON EXECUTIVE FUNCTION AND GREY MATTER IN EARLY ONSET-FIRST EPISODE PATIENTS

Elisa Rodríguez-Toscano, David Fraguas, Miquel Bioque, Ana Gonzalez-Pinto, Antonio Lobo, Miguel Bernardo Arroyo, Mara Parellada, Marta Rapado-Castro*

S208. PHENOTYPE AND FUNCTION OF MYELOID CELLS IN SCHIZOPHRENIA PATIENTS

Paul R. Ormel*, Manja Litjens, Hans C. van Mierlo, Elly M. Hol, René Kahn, Lot D. Witte

S209. ABNORMALITIES IN THE UNFOLDED PROTEIN RESPONSE IN SCHIZOPHRENIA

Pitna Kim*, Vahram Haroutunian, James Meador-Woodruff

S210. THE ROLE OF ATP SIGNALING IN CANNABIS-INDUCED PSYCHOTIC EXPERIENCES

Yujie He*

S211. PROTEASOME ABUNDANCE AND ACTIVITY IN THE SUPERIOR TEMPORAL GYRUS OF PATIENTS WITH SCHIZOPHRENIA

Madeline Scott*, Maria Rubio, Vahram Haroutunian, James Meador-Woodruff

S212. MATERNAL IMMUNE ACTIVATION INDUCES EARLY CHANGES IN NEURODEVELOPMENT OF MALE AND FEMALE RATS

Michelle Edye*, Katie Murray, Joanna Dennison, Herve Boutin, Michael Harte, Irene Knuesel, Eric Prinssen, Joanna Neill

S213. RETICULAR THALAMIC CONTRIBUTION IN THE CONTROL OF THALAMOCORTICAL PATHWAYS: INVOLVEMENT IN SCHIZOPHRENIA RELATED BEHAVIORS

Hasna Elboukhari*, Zakaria Ouhaz, Saadia Ba M'Hamed, Mohamed Bennis

S214. PUPILLARY CHANGES AS SIGNS OF AUTONOMIC DYSBALANCE IN A RAT MODEL OF NEUROPSYCHIATRIC DISORDERS

Alexandra Büki*, Gabriella Kekesi, Gyongyi Horvath

S215. FAMILIAL AGGREGATION OF SCHIZOTYPAL TRAITS AND ITS CORRELATION WITH THE PRESENCE OF DERMATOGLYPHIC ANOMALIES: A STUDY BASED ON HEALTHY RELATIVES OF PATIENTS WITH SCHIZOPHRENIA-SPECTRUM DISORDERS

Jordi Soler Garcia*, Panagiotis Ferentinos, Claudia Prats Balado, Salvador Miret, Maria Giralt, Lourdes Fananas, Mar Fatjó-Vilas

S216. A ROLE FOR BDNF IN MEDIATING ADOLESCENT GABAERGIC INTERNEURON EXPRESSION

Xin Du*, Kelsey Serena, Candace Wu, Wu Jeong Hwang, Schroeder Anna, Adrienne Grech, Rachel Hill

S217. SALIENCE PROCESSING AND PSYCHOPATHOLOGY FOLLOWING VERY PRETERM BIRTH

Jasmin Kroll*, Philip Brittain, Sean Froudish-Walsh, Slava Karolis, Jane Tseng, Chiara Nosarti

S218. M-RESIST, AN INTEGRATIVE M-HEALTH SOLUTION FOR TREATMENT-RESISTANT SCHIZOPHRENIA ACCORDING TO USER' NEEDS: FOCUS GROUPS FINDINGS

Huerta-Ramos Elena*, Maria Soledad Escobar, Katya Rubinstein, Elena Rubio-Abadal, Kata Fazekas, Unoka Zsolt, Susana Ochoa, Jussi Seppälä, Margarita Hospedales Salomó, Jesús Berdún Peñato, Asaf Caspi, Erika Jääskeläinen, Eva Grasa, Iluminada Corripio, Judith Usall



S219. CHANGE - A RANDOMIZED CLINICAL TRIAL TO INVESTIGATE THE EFFECT OF AN INDIVIDUALIZED LIFESTYLE INTERVENTION COMPARED TO CARE COORDINATION COMPARED TO TREATMENT AS USUAL

Ane Jakobsen*

S220. EFFECT OF BRIEF INDIVIDUAL COGNITIVE BEHAVIORAL THERAPY FOR AUDITORY HALLUCINATIONS ON NEGATIVE SYMPTOMS IN A SAMPLE OF EGYPTIAN PATIENTS WITH SCHIZOPHRENIA

Dalia Nagui Rizk*, Hoda Salama, Tarek Molokhiya, Layla Kassem

S221. THE IBEEP STUDY: EXPLORING THE FEASIBILITY AND EFFECTS OF EXERCISE IN EARLY PSYCHOSIS

Joseph Firth*, Rebekah Carney, Rebecca Elliott, Paul French, Alison Yung

S222. THE EFFICACY OF NON-PHARMACOLOGICAL INTERVENTIONS (NPIS) ON BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) IN PATIENTS WITH SCHIZOPHRENIA: A SYSTEMATIC REVIEW.

Kenji Sanada*, Iñaki Zorrilla, Mónica Martinez-Cengotitabengoa, Ana Gonzalez-Pinto

S223. THE ROLE OF COMPREHENSIVE PSYCHOSOCIAL OUTPATIENT PROGRAMMING IN THE TREATMENT OF FIRST EPISODE PSYCHOSIS PATIENTS.

Laura Pientka*, S. Charles Schulz, Kelvin Lim, Suzanne Geier Jasberg

S224. MODEN: A THERAPEUTIC INTEGRATIVE EDUCATIONAL PROGRAM FOR PEOPLE WITH SCHIZOPHRENIA FOCUSING ON NEGATIVE AND COGNITIVE SYMPTOMS: PRELIMINARY RESULTS IN 22 PATIENTS

Marie-Cécile Bralet*, Sarah-Lise Farhat, Christophe Hochard, Sandrine Orens, Thierry Lambert, Corine Gautier, Corine Bismuth, Adrian Melac, Audrey Tanguy

S225. A NEW RECOVERY FOCUSED INTERVENTION COMBINING PEER SUPPORT AND SKILL TRAINING FOR PEOPLE WITH SCHIZOPHRENIA: RESULTS OF A PILOT STUDY

Jelle Sjoerd Vogel*, Mark Van der Gaag, Stynke Castelein, Marte Swart, Edith Liemburg, Petrie Roobol

S226. INTERVENTIONS FOR CARERS OF PEOPLE WITH PSYCHOSIS: IS IT TIME TO CONSIDER A ROLE FOR MASSIVE OPEN ONLINE COURSES (MOOCS)?

Juliana Onwumere*, Shitij Kapur, Elizabeth Kuipers

S227. THE PRACTICE AND EFFECTIVENESS OF ELECTROCONVULSIVE THERAPY

Sung Woo Joo*, Chang Yoon Kim, Jung Sun Lee, Yeon Ho Joo

S228. PREDICTIVE VALUE OF THE PREMORBID ADJUSTMENT SCALE AND THE STRAUSS AND CARPENTER PROGNOSTIC SCALE FOR GLOBAL FUNCTIONING AT 2 YEARS AFTER THE FIRST PRESENTATION OF PSYCHOTIC SYMPTOMS IN ADOLESCENTS WITH EARLY ONSET PSYCHOSIS
 Raquel Vicente, Pilar Baos, Celso Arango, Beatriz Paya, Angel del Rey-Mejias, Josefina Castro-Fornieles, Ana Gonzalez-Pinto, Montse Graell, Dolores Moreno, Marta Rapado-Castro*



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

S229. COULD EVENTS OF WONDERLAND HAPPEN IN REAL LIFE—GENERALIZATION OF REALITY DISTORTION IN FIRST EPISODE PSYCHOSIS.

Tuukka Raij*, Teemu Mäntylä, Eva Rikandi, Tuula Kieseppä, Jaana Suvisaari

S230. DEFICIT SYNDROME IN SCHIZOPHRENIA IS NOT RELATED TO DURATION OF ILLNESS, AGE OF ONSET, OR GENDER, IN A SPANISH SAMPLE OF PATIENTS.

Álvaro López-Díaz*, José Luis Fernández-González, Pablo Lorenzo-Herrero

S231. A LINGUISTIC COMPARISON BETWEEN AUDITORY VERBAL HALLUCINATIONS IN PATIENTS WITH A PSYCHOTIC DISORDER AND IN NONPSYCHOTIC INDIVIDUALS: NOT JUST WHAT THE VOICES SAY, BUT HOW THEY SAY IT

Janna de Boer*, Sophie Heringa, Edwin van Dellen, Frank Wijnen, Iris Sommer

S232. SYMPTOM CONTENT STUDY OF PERCEPTUAL ABNORMALITIES IN THOSE AT CLINICAL HIGH RISK FOR PSYCHOSIS

Yun Lu*, Catherine Marshall, Kristin Cadenhead, Tyrone Cannon, Barbara Cornblatt, Diana Perkins, Larry Seidman, Ming Tsuang, Elaine Walker, Scott Woods, Carrie Bearden, Daniel Mathalon, Thomas McGlashan, Jean Addington

S233. INSIGHT EVOLUTION: IS THERE A DIFFERENCE BETWEEN SELF AND HETERO ASSESSMENT ?

Delphine Capdevielle*, Joanna Norton, Aurélie Schandrin, Guillaume FOND, Pierre-Michel LLORCA

S234. TARDIVE DYSKINESIA AND TARDIVE DYSTONIA WITH SECOND-GENERATION ANTIPSYCHOTICS IN SCHIZOPHRENIA AND BIPOLAR DISORDER PATIENTS UNEXPOSED TO FIRST-GENERATION ANTIPSYCHOTICS

So Yung Yang, Seunghyong Ryu, Jae Hyun Yoo, Ahram Lee, Ji Hyun Baek, Ji Sun Kim, Mi Ji Choi, Kyooseob Ha, Kyung Sue Hong*

S235. PAM-2, A POSITIVE ALLOSTERIC MODULATOR OF THE $\alpha 7$ NACHRS, REVERSES SCHIZOPHRENIA-LIKE COGNITIVE DEFICITS IN RATS.

Agnieszka Nikiforuk*, Agnieszka Potasiewicz, Tomasz Kos, Małgorzata Hołuj, Piotr Popik, Hugo R Arias

S236. GABAERGIC DYSFUNCTION FOLLOWING PRENATAL INFECTION IN MICE: MODULATORY ACTIVITY OF CHRONIC LURASIDONE ADMINISTRATION.

Juliet Richetto, Alessia Luoni, Linda Longo, Teresa Calzoni, Urs Meyer, Marco Andrea Riva*

S237. A POLYGENIC SCORE REFLECTING PREFRONTAL DOPAMINE D2 RECEPTOR CO-EXPRESSION AND ADMINISTRATION OF BROMOCRIPTINE INTERACT NON-LINEARLY ON PREFRONTAL ACTIVITY DURING WORKING MEMORY

Pierluigi Selvaggi*, Giulio Pergola, Barbara Gelao, Maria Antonietta Nettis, Pasquale Di Carlo, Valentina Felici, Leonardo Fazio, Giuseppe Blasi, Alessandro Bertolino

FINAL PROGRAM

FLORENCE, ITALY

2 – 6 APRIL 2016



S238. HOW WELL DO PATIENTS WITH A FIRST EPISODE OF SCHIZOPHRENIA RESPOND TO ANTIPSYCHOTICS: A META-ANALYSIS

Yikang Zhu*, Chunbo Li, Maximilian Huhn, Philipp Rothe, Susanne Bächer, Johannes Schneider, Matteo Rabaioli, Stefan Leucht

S239. TRAJECTORIES OF TREATMENT RESPONSE IN HALLUCINATIONS

Igné Sinkeviciute*, Kenneth Hugdahl, Rolf Gjestad, Eirik Kjelby, Rune A. Kroken, Else-Marie Løberg, Hugo A. Jørgensen, Erik Johnsen

S240. PRIOR D2 ANTAGONIST ANTIPSYCHOTIC DRUG TREATMENT PREVENTS RESPONSE TO NOVEL TARGET COMPOUNDS IN MAM MODEL OF SCHIZOPHRENIA: POTENTIAL CIRCUMVENTION USING ARIPIRAZOLE

Susan Sonnenschein*, Kathryn Gill, Sarah Miller, Anthony Grace

S241. MAINTENANCE ANTIPSYCHOTIC DOSE CAN BE DECREASED IN LATE-LIFE SCHIZOPHRENIA: A PROSPECTIVE DOPAMINE D_{2/3} RECEPTOR OCCUPANCY STUDY WITH [11C]-RACLOPRIDE

Shinichiro Nakajima*, David Mamo, Fernando Caravaggio, Takefumi Suzuki, Hiroyuki Uchida, Philip Gerretsen, Wanna Mar, Tarek Rajji, Benoit Mulsant, Bruce Pollock, Ariel Graff-Guerrero

S242. THE PHOSPHODIESTERASE 10A SELECTIVE INHIBITOR TAK-063 IMPROVES COGNITIVE FUNCTIONS ASSOCIATED WITH SCHIZOPHRENIA IN RODENT MODELS

Kazunori Suzuki*, Eri Shiraishi, Akina Harada, Noriko Suzuki, Haruhide Kimura

S243. LONG-TERM ANTIPSYCHOTIC USE AND BRAIN VOLUME CHANGES IN SCHIZOPHRENIA: THE NORTHERN FINLAND BIRTH COHORT 1966 STUDY

Sanna Huhtaniska*, Tuomas Heikka, Erika Jääskeläinen, Jani Moilanen, Tanja Nordström, Jussi Tohka, Jose V. Manjon, Pierrick Coupe, Lassi Björnholm, Juha Veijola, Matti Isohanni, Vesa Kiviniemi, Graham Murray, Jouko Miettunen

S244. THE DOPAMINE D₂ RECEPTOR PARTIAL AGONIST 2-BROMOTERGURIDE AMELIORATES PCP-INDUCED DEFICITS IN PREPULSE INHIBITION AND NOVEL OBJECT RECOGNITION IN RATS

Emilia Tarland*, Heinz Pertz, Heidrun Fink, Jan Brosda

S245. PRESCRIBING PATTERNS OF ANTIDEPRESSANTS AND OTHER DRUGS IN KOREAN BIPOLAR AFFECTIVE DISORDER PATIENTS

Dayae Baek*, Woon Yoon, Yeon Ho Joo, JungSun Lee, Chang Yoon Kim

S246. PATTERNS OF USE OF ARIPIRAZOLE LONG-ACTING INJECTABLE IN STANDARD CLINICAL PRACTICE

Sergio Sánchez Alonso*, Laura Mata, Elsa Arrúa, Constanza Vera, Miren Iza, Raquel Álvarez, Santiago Ovejero

S247. USE OF ARIPIRAZOLE LONG-ACTING INJECTABLE IN TWO INPATIENT UNITS

Santiago Ovejero*, Raquel Alvarez, Miren Iza, Nore Palomar, Marta Migoya, Fanny Cegla, Laura Mata, Sergio Sanchez



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

S248. THE MODULATION OF CYCLIC NUCLEOTIDE DEPENDENT PATHWAYS IN THE RAT STRIATUM BY CPL-500-036-02 - A PHOSPHODIESTERASE 10A INHIBITOR.

Sylwia Janowska*, Piotr Pankiewicz, Maciej Swiatkiewicz, Marlena Welniak-Kaminska, Malgorzata Borkowska, Jakub Majer, Rafal Moszczynski-Petkowski, Krzysztof Dubiel, Maciej Wieczorek, Mikolaj Matloka

S249. RELATIVE EFFICACY AND SAFETY OF INDIVIDUAL SECOND-GENERATION ANTIPSYCHOTICS IN TREATING FIRST EPISODE PSYCHOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Jianping Zhang*, Juan Gallego, Tianxu Xia, Delbert Robinson, Anil Malhotra, John Kane, Christoph Correll

S250. ELECTROCONVULSIVE THERAPY AUGMENTATION IN CLOZAPINE-RESISTANT SCHIZOPHRENIA : A FRENCH SAMPLE.

Maud Rotharmel*, Pierre Quesada, Vincent Compere, Olivier Guillin

S251. ERRONEOUS INTERVIEWING AND RATING PATTERNS DETECTED DURING SCREENING PREDICT SUBSEQUENT QUALITY ISSUES

David Daniel*, Alan Kott

S252. RELATIONSHIP BETWEEN PSYCHIATRIC PRESCRIPTION PATTERN AND ADHERENCE IN PATIENTS WITH SCHIZOPHRENIA

Soohyun Joe*, Yeonho Joo, Changyoon Kim, Joonho Ahn, Joong Sun Lee

S253. 1 YEAR MIRROR STUDY USING PALIPERIDONE PALMITATE FOR RELAPSE PREVENTION OF SCHIZOPHRENIA IN 4 UNIVERSITY HOSPITALS IN CANADA.

Philippe Vincent*, Marie-France Demers, Josée Duchesneau, Violaine Masson

S254. AUGMENTING NMDA RECEPTOR SIGNALING IN SCHIZOPHRENIA ENHANCES NEURAL RESPONSIVITY AND WORKING MEMORY WITHOUT AFFECTING EXPERIENCE-DEPENDENT PLASTICITY.

Jen Forsyth*, Peter Bachman, Daniel Mathalon, Brian Roach, Elissa Ye, Robert Asarnow

S255. THE RELATION OF THOUGHT DISORDERS IN SCHIZOPHRENIA WITH REMISSION OF SYMPTOMS AND PSYCHOSOCIAL IMPROVEMENT

Berna Yalinçetin, Koksai Alptekin*, Levent Var, Halis Ulaş, İ. Tolga Binbay, Berna Binnur Akdede

S256. EFFECT OF BREXPIPIRAZOLE ON LONG-TERM FUNCTIONING IN ADULTS WITH SCHIZOPHRENIA: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MAINTENANCE STUDY

Wolfgang Fleischhacker*, Mary Hobart, John Ouyang, Andy Forbes, Catherine Weiss, Emmanuelle Weiller

S257. PSYCHOSIS IN INTRA-FAMILIAL HOMICIDE

Dominique Bourget*, Pierre Gagné, Alain Labelle



S258. RESEARCHER KNOW THY AUDIENCE: GETTING TRANSLATION RIGHT

Eoin Killackey*

(S259). PREVALENCE AND CORRELATES OF SELF-STIGMA AMONG A SAMPLE OF NIGERIAN PATIENTS WITH SCHIZOPHRENIA

Babatunde Fadipe*, Timothy Adebowale, Adegboyega Ogunwale, Andrew Olagunju, Yetunde Fadipe

S260. SOCIAL SKILLS EVALUATION OF PATIENTS WITH SCHIZOPHRENIA: COMPARISON BETWEEN TREATMENT RESISTANT, NON TREATMENT RESISTANT AND NORMAL CONTROLS

Silvia Scemes, Mariangela Gentil Savoia, Zilda Del Prette, Paulo Mestriner, Aline Roberta da Silva, Helio Elkis*

S261. RELATIONSHIP OF INSIGHT WITH COGNITIVE FUNCTION, PSYCHOPATHOLOGY AND PSYCHOSOCIAL FACTORS IN PATIENTS WITH SCHIZOPHRENIA

Seung Hyun Kim*, Jung-Seo Yi, Jung Jin Kim

S262. PREDICTORS AND OUTCOMES FOR PATIENTS WHO REDUCE OR DISCONTINUE THEIR ANTI-PSYCHOTIC TREATMENT AFTER FIRST EPISODE PSYCHOSIS.

Nikolai Albert*, Carsten Hjorthøj, Heidi Jensen, Kelly Allott, Marianne Melau, Merete Nordentoft

S263. COGNITIVE ADAPTATION TRAINING HELPS YOU LIVE AT HOME: INTERIM RESULTS OF THE FINNISH CAT-STUDY

Eila Sailas*, Tuukka Mehtälä, Satu Viertiö

S264. DOES BASELINE APATHY PREDICT SOCIAL AND VOCATIONAL OUTCOME AT TWO YEARS FOLLOW UP IN A VOCATIONAL REHABILITATION STUDY?

Helen Bull*, Torill Ueland, June Ilystad, Stig Evensen, Erik Falkum

S265. COGNITIVE ADAPTATION AS A NURSING INTERVENTION FOR LONG-TERM HOSPITALIZED PATIENTS

Annemarie Stiekema*, Jeroen Redmeijer, Marian Dethmers, Kees Rietberg, Jaap van Weeghel, André Aleman, Dawn Velligan, Richard Bruggeman, Lisette van der Meer

S266. THE EFFICACY OF 12 WEEKS PHYSICAL HEALTH PROMOTION PROGRAM IN PATIENTS WITH MAJOR PSYCHIATRIC DISORDER

Kyuyoung Lee*, Minjung Kang

S267. ASSOCIATION BETWEEN FAMILY HISTORY OF PSYCHIATRIC DISORDERS AND LONG-TERM OUTCOME IN SCHIZOPHRENIA – THE NORTHERN FINLAND BIRTH COHORT 1966 STUDY

Juha Kakela*, Riikka Marttila, Juha Veijola, Matti Isohanni, Heli Koivumaa-Honkanen, Erika Jääskeläinen, Jouko Miettunen

S268. NEGATIVE SYMPTOMS MEDIATE THE RELATIONSHIP BETWEEN SOCIAL COGNITION AND FUNCTIONING IN SCHIZOPHRENIA: A PILOT STUDY

Miguel Bajouco*, Nuno Madeira, Salomé Caldeira, Carolina Roque, Ana Telma Pereira, Maria João Martins, David Mota, Vitor Santos, Sofia Morais, Joana Ribeiro, Ana Sofia Cabral, António Macedo



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

S269. INVESTIGATION OF THE CORRELATES OF HAPPINESS, LIFE SATISFACTION AND SUCCESS IN SCHIZOPHRENIA

Sarah Saperia*, Ishraq Siddiqui, Krysta McDonald, Gagan Fervaha, Ofer Agid, Gary Remington, George Foussias

S270. SELF-CLARITY AND DIFFERENT CLUSTERS OF INSIGHT AND SELF-STIGMA IN SERIOUS MENTAL ILLNESS

Ilanit Hasson-Ohayon*, Michal Mashiach-Eizenberg, David Roe, Paul Lysaker

S271. HEALTH RELATED QUALITY OF LIFE IN ANTIPSYCHOTIC-TREATED CHILDREN AND ADOLESCENTS WITH PSYCHOSIS

Dea Gowers Klauber*, Ditte Rudå, Karsten Gjessing Jensen, Marie Stentebjerg-Olesen, Birgitte Fagerlund, Jens R. Jepsen, Anders Fink-Jensen, Christoph U Correll, Anne Katrine Pagsberg

S272. A 24-MONTH FOLLOW-UP EVALUATION OF QUALITY OF LIFE (QOL) AS AN OUTCOME MEASURE FOR COMMUNITY TREATMENT ORDERS (CTOS) IN CENTRAL ALBERTA, CANADA
Cornelius Ehlers*

S273. THE SOCIAL FUNCTIONALITY OF SCHIZOPHRENIC PATIENTS AND THE BURDEN EXPERIENCED BY THEIR CAREGIVERS: A SAMPLE OF TURKEY

Yunus Kaya*, Fatma Öz

S274. CAREGIVER BURDEN IN SCHIZOPHRENIA: POOLED ANALYSIS OF THE INVOLVEMENT EVALUATION QUESTIONNAIRE DATA FOR PALIPERIDONE PALMITATE 3-MONTH FORMULATION
Srihari Gopal*, Haiyan Xu, Kelly McQuarrie, Adam Savitz, Isaac Nuamah, Kimberly Woodruff, Maju Mathews

S275. HEALTH-RELATED QUALITY OF LIFE AND BURDEN CAREGIVER'S OF PEOPLE WITH SEVERE MENTAL HEALTH DISORDERS.

Gemma Prat*, Jordi Giménez-Salinas, Crespo Maria de la Cruz, Gonzalez Jennifer, Monreal Rebeca, Fernández-Capo Maria

S276. QUALITY OF LIFE AND RESILIENCE IN OUTPATIENTS WITH SCHIZOPHRENIA

Fabienne Wartelsteiner*, Beatrice Frajo-Apor, Georg Kemmler, Anna-Sophia Welte, Yuya Mizuno, Hiroyuki Uchida, Wolfgang Fleischhacker, Alex Hofer

S277. BELIEF AND DISTRESS IN PSYCHOTIC COMPARED TO NON-PSYCHOTIC HALLUCINATORS
Megan Kelley*, Philip Corlett

S278. TREATMENT DECISIONMAKING AMONG YOUTH WITH EARLY PSYCHOSIS IN THE US: PRELIMINARY FINDINGS

Neely Myers*

S279. YOUTH MENTAL HEALTH SERVICES IN ITALY. AN ACHIEVABLE DREAM?

Martina Brandizzi*, Alice Masillo, Barnaby Nelson, Nella Lo Cascio, Riccardo Saba, Juliana Fortes Lindau, Ludovica Telesforo, Paola Venturini, Dori Montanaro, Marco D'Alema, Paolo Girardi, Paolo Fiori Nastro, Patrick McGorry



S280. RELATIONSHIP BETWEEN DIRECTOR LEADERSHIP OF COMMUNITY MENTAL HEALTH CENTER AND ORGANIZATIONAL EFFECTIVENESS

Myungsun Cho, Jung-Seo Yi, Myung Hun Jung*

S281. DO ROUTINE OUTCOME MONITORING RESULTS TRANSLATE TO CLINICAL PRACTICE? A CROSS-SECTIONAL STUDY IN PATIENTS WITH A PSYCHOTIC DISORDER

Magda Tasma*, Marte Swart, Gert Wolters, Edith Liemburg, Richard Bruggeman, Henderikus Knegtering, Stynke Castelein

S282. BIAS BLASTER, A GAME TO BEAT INTERPRETATION BIAS IN PATIENTS WITH PSYCHOSIS
 Nynke Boonstra*, Annemieke Zwart, Aaltsje Malda, Mechteld Radermacher, Job van 't Veer, Lian van der Krieke

S283. PERSON CENTERED PSYCHOSIS CARE (PCPC) IN AN INPATIENT SETTING: THE IMPLEMENTATION PROCESS AND STAFF EXPERIENCES

Anneli Goulding*, Lilas Ali, Katarina Allerby, Margda Waern

S284. WHAT DRIVES THE HIGHER INCIDENCE OF PSYCHOSIS IN LONDON COMPARED TO PALERMO?

Alice Mulè, Lucia Sideli, Marta Di Forti, Laura Ferraro, Caterina La Cascia, Crocettarachele Sartorio, Fabio Seminerio*, Giada Tripoli, Daniele La Barbera, Robin Murray

S285. DECIDE STUDY: EFFECTIVENESS OF SHARED DECISION MAKING IN TREATMENT PLANNING AT DISCHARGE OF INPATIENT WITH SCHIZOPHRENIA: DESIGN, TOOLS, CLINICAL AND SUBJECTIVE EXPERIENCES.

José Pérez Revuelta*, Ignacio Lara Ruiz-Granados, Juan Manuel Pascual Paño, Jesús Mestre Morales, José María Villagrán Moreno

S286. DECIDE STUDY: EFFECTIVENESS OF SHARED DECISION MAKING IN TREATMENT PLANNING AT DISCHARGE OF INPATIENT WITH SCHIZOPHRENIA. PRELIMINARY DATA CONCLUSIONS AFTER 20 MONTHS OF THE STUDY

José Pérez Revuelta*, Francisco González Sáiz, José María Mongil San Juan, Carmen Rodríguez Gómez, José María Villagrán Moreno

S287. NEURAL CORRELATES OF FAUX PAS-DETECTION: THE ROLE OF SCHIZOTYPAL PERSONALITY TRAITS

Amelie Schreier, Alexander Rapp*

S288. WHITE MATTER CONNECTIVITY AND PREFRONTAL CORTICAL FOLDING ALTERATIONS IN SCHIZOPHRENIA

C. Christoph Schultz*, Kathrin Koch, Gerd Wagner, Heinrich Sauer

S289. IMPACT OF ASSERTIVE COMMUNITY TREATMENT IN THE OPTIMIZATION OF PHARMACOLOGICAL TREATMENT IN PATIENTS WITH SEVERE MENTAL ILLNESS.

María-José Álvarez*, Pere Roura-Poch, Núria Riera, Clara Blanch, Ana-Cristina Martin, Judit Pons, Josep-Manuel Santos, Francesc Arrufat



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

S290. INCREASED PERFUSION OF HIGHER ORDER MOTOR CONTROL AREAS IS RELEVANT FOR CATATONIA IN SCHIZOPHRENIA

Lea Schächli*, Katharina Stegmayer, Nadja Razavi, Andrea Federspiel, Jeanne Moor, Roland Wiest, Werner Strik, Sebastian Walther

S291. USING ARTIFICIAL INTELLIGENCE (AI) TO MONITOR MEDICATION ADHERENCE ON MOBILE DEVICES

Adam Hanina*, Laura Shafner

S292. THE RELATIONSHIP BETWEEN THEORY OF MIND AND THOUGHT- LANGUAGE DISORDER IN SCHIZOPHRENIA

Damlacan Güneyer, Onur Küçük çoban, Halis Ulaş, Tolga Binbay, Koksall Alptekin, Berna Akdede*

S293. BRAIN GREY MATTER ABNORMALITIES RELATED TO LACK OF INSIGHT IN PSYCHOSIS: A VOXEL-BASED MORPHOMETRY INVESTIGATION.

Diana Tordesillas-Gutiérrez, Rosa Ayesa-Arriola, Javier-David Lopez-Morinigo, Anthony David, Benedicto Crespo-Facorro*

S294. CHILDHOOD RESIDENTIAL MOBILITY AND PSYCHOSIS WITHIN A UK SAMPLE

Kathryn Hubbard, Charlotte Gayer-Anderson, Stephanie Beards, Tjasa Velikonja, Valeria Mondelli, Paola Dazzan, Robin Murray, Carmine Pariante, Craig Morgan*

S295. VALIDITY AND BIAS IN ASSESSMENTS OF ABUSE AMONG CASES WITH PSYCHOSIS.

Kathryn Hubbard, Charlotte Gayer-Anderson, Stephanie Beards, Valeria Mondelli, Carmine Pariante, Paola Dazzan, Robin Murray, Ulrich Reininghaus, Craig Morgan*

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



POSTERS, MONDAY 4 APRIL

11:00 AM - 1:00 PM

Location: Cavaniglia

Travel Awardee Posters are Circled

M1. CHILDHOOD ADVERSITIES IN FIRST EPISODE PSYCHOSIS

Maija Lindgren*, Teemu Mäntylä, Minna Torniainen, Tuula Kiesepää, Outi Mantere, Jaana Suvisaari

M2. CLOZAPINE AS A TREATMENT FOR TARDIVE DYSKINESIA: A META ANALYSIS

Thierry Mentzel*, Rene Snoek, van der, Margreet Oorschot, Wolfgang Viechtbauer, Oswald Bloemen, Ritsaert Lieveer, Peter Van Harten

M3. IMPACT OF ADVERSE CHILDHOOD EXPERIENCES ON PSYCHOTIC-LIKE SYMPTOMS AND STRESS REACTIVITY IN DAILY LIFE IN NONCLINICAL YOUNG ADULTS

Tamara Sheinbaum*, Paula Cristóbal-Narváez, Sergi Ballespí, Mercè Mitjavila, Inez Myin-Germeys, Thomas R. Kwapił, Neus Barrantes-Vidal

M4. SEXUAL DYSFUNCTION IN PATIENTS WITH SCHIZOPHRENIA: IS ANTIPSYCHOTIC MEDICATION TO BLAME?

Mette Nielsen*, Birte Glenthoj, Bjorn Ebdrup, Signe During, Henrik Nørbak-Emig

M5. THE EFFECT OF CHILDHOOD ABUSE ON OUTCOME IN INDIVIDUALS AT ULTRA HIGH RISK FOR PSYCHOSIS

Tamar Kraan*, Eva Velthorst, Lieuwe De Haan, Mark Van der Gaag

M6. IS IT WORTH TO GIVE CLOZAPINE A SECOND CHANCE? A SERIES OF 12 SUBJECTS RECHALLENGED WITH CLOZAPINE FOLLOWING A NEUTROPENIA

Esthel Malenfant*, Mireille Nadeau, Guillaume Chalifour, Marc-André Roy, Jocelyne Moisan, Marie-France Demers

M7. RISK FACTORS FOR TREMOR IN A POPULATION OF PATIENTS WITH SEVERE MENTAL ILLNESS: AN 18-YEAR PROSPECTIVE STUDY IN A GEOGRAPHICALLY REPRESENTATIVE SAMPLE

Charlotte Mentzel*, P. Roberto Bakker, Jim Van Os, Marjan Drukker, Michiel van den Oever, Glen Matroos, Hans Hoek, Marina Tijssen, Peter Van Harten

M8. THE EFFECT OF CHILDHOOD TRAUMA AND FIVE-FACTOR MODEL PERSONALITY TRAITS ON EXPOSURE TO ADULT LIFE EVENTS IN PATIENTS WITH PSYCHOTIC DISORDERS

Karin Pos*, Lindy-lou Boyette, Carin Meijer, Maarten Koeter, Lydia Krabbendam, Lieuwe De Haan

M9. CABERGOLINE USE TO COUNTERACT ANTIPSYCHOTIC SYMPTOMATIC RELATED HYPERPROLACTINEMIA: A RETROSPECTIVE LONGITUDINAL CASE-SERIES.

Marie-France Demers*, Vanessa Simard, Nathalie Dion, Esthel Malenfant, Marc-André Roy, Sophie Lauzier

M10. DIFFERENTIAL EFFECTS OF CHILDHOOD TRAUMA AND CANNABIS USE DISORDERS IN PATIENTS SUFFERING FROM NON-AFFECTIVE PSYCHOSIS

Grégoire Baudin*, Ophelia Godin, Mohamed Lajnef, Pierre-Michel Llorca, Franck Schürhoff



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

M11. CHILDHOOD MALTREATMENT, ANTENATAL ATTACHMENT AND SYMPTOM SEVERITY IN WOMEN AT RISK OF POSTPARTUM PSYCHOSIS

Alessandra Biaggi*, Katie Hazelgrove, Susan Conroy, Susan Pawlby, Montserrat Fuste-Boadella, Carmine M. Pariante, Paola Dazzan

M12. ADJUNCTIVE ARIPIRAZOLE FOR RISPERIDONE/PALIPERIDONE INDUCED HYPERPROLACTINEMIA. EFFECT OF FUNCTIONAL POLYMORPHISMS IN DOPAMINE-RELATED GENES.

Ainara Arnaiz, Nieves Basterreche, Aurora Arrúe, Olga Olivas, Estibaliz Gordo, Leire Erkoreka, Ihintza Angoitia, Mercedes Zumárraga*

M13. SECOND-GENERATION ANTIPSYCHOTIC COMBINATION IS A MAJOR RISK FACTOR FOR AKATHISIA AND LONG-TERM BENZODIAZEPINES DON'T HELP. RESULTS FROM THE FACE-SZ COHORT

Fabrice Berna, Guillaume Fond*, David Misdrahi, Laurent Boyer, Pierre-Michel Llorca

M14. BIRTH BY CESAREAN SECTION AND SCHIZOPHRENIA. RESULTS FROM THE MULTI-CENTER FACE-SZ DATA-SET.

Guillaume Fond*, Ewa Bulzacka, Laurent Boyer, Pierre-Michel Llorca, Marion Leboyer

M15. PERIPHERAL SUB-INFLAMMATION IS ASSOCIATED WITH ANTIDEPRESSANT CONSUMPTION IN SCHIZOPHRENIA. RESULTS FROM THE MULTI-CENTER FACE-SZ DATA SET.

Guillaume Fond*, Ophelia Godin, Franck Schurhoff, Pierre-Michel Llorca, Marion Leboyer

M16. EARLY COGNITIVE INFLAMMAGING IN SCHIZOPHRENIA

Guillaume Fond*, Ewa Bulzacka, Laurent Boyer, Pierre-Michel Llorca, Franck Schurhoff, Marion Leboyer

M17. CAN LESSONS LEARNT FROM CARDIAC STRESS TESTING BE APPLIED TO THE EARLY IDENTIFICATION OF PSYCHOSIS?

Deepak D'Souza*, Swapnil Gupta, Mohini Ranganathan

M18. PREDICTING TRANSITION TO PSYCHOSIS ON THE BASIS OF ELECTROPHYSIOLOGICAL SELF-SUPPRESSION ABNORMALITIES IN ULTRA-HIGH RISK INDIVIDUALS

Thomas Whitford*, Lavoie Suzie, Barnaby Nelson, Judith Ford, Daniel Mathalon, Brian Roach, Patrick McGorry

M19. CYTOKINE DYSREGULATION IN CEREBROSPINAL FLUID OF PATIENTS WITH SCHIZOPHRENIA

Juan Gallego*, Juan Del Ojo-Jimenez, Paula Moreno-Merino, Sehba Husain-Krautter, Christopher Morell, Anil Malhotra

M20. ANTIOXIDATIVE FUNCTION OF ALBUMIN MAY STRATIFYING TWO DIFFERENT GROUPS IN FIRST-EPIISODE, DRUG-NAÏVE SCHIZOPHRENIC PATIENTS.

Varvara Kalinina, Marat Uzbekov*, Natalia Smolina, Alexandr Shmukler, Eduard Misionzhnii, Sergei Shikhov, Gennadi Dobretsov



M21. THE STATE OF ANTIOXIDANT ENZYME ACTIVITIES IN PATIENTS WITH CHRONIC SCHIZOPHRENIA UNDER ANTIPSYCHOTIC TREATMENT.

Marat Uzbekov*, Svetlana Ivanova, Ludmila Smirnova, Nikolai Bokhan, Arkadi Semke

M22. DIFFERENTIAL PERIPHERICAL BIOMARKERS OF NEGATIVE DIMENSION IN SCHIZOPHRENIA

Leticia Garcia-Alvarez, M Paz Garcia-Portilla, Leticia Gonzalez-Blanco*, Lorena De La Fuente-Tomas, Celso Iglesias, Pilar Saiz-Martin, Julio Bobes

M23. AUTOANTIBODY PROFILING IN PATIENTS WITH SCHIZOPHRENIA

David Just*, Anna Häggmark, Eva Lindholm Carlström, Erik Jönsson, Janet Cunningham, Peter Nilsson

M24. ASSOCIATION OF SERUM SFLT-1 WITH PROGRESSIVE REDUCTION IN CORTICAL THICKNESS: A PRELIMINARY LONGITUDINAL STUDY OF FAMILIAL HIGH RISK FOR PSYCHOSIS SUBJECTS.

Paulo Lizano*, Jeffrey Yao, Neeraj Tandon, Matcheri Keshavan

M25. COMBINED EFFECT OF GENETIC VARIANTS IN GLUN2B CODING GENE (GRIN2B) ON PREFRONTAL FUNCTION DURING WORKING MEMORY PERFORMANCE

Dalila Albergó*, Giulio Pergola, Pasquale Di Carlo, Ileana Andriola, Barbara Gelao, Silvia Torretta, Leonardo Fazio, Antonio Rampino, Giuseppe Blasi, Alessandro Bertolino

M26. ODOR DEFICITS IN CHRONIC SCHIZOPHRENIA –RELATIONSHIP TO COGNITION, SYMPTOMS, AND EPIGENETIC MARKERS

Robert C. Smith*, Henry Sershen, Mohammed Sharifi, Mary Youssef, Abel Lajtha, Hua Jin, Alessandro Guidotti, John M. Davis

M27. ASSOCIATION BETWEEN ERYTHROCYTE MEMBRANE FATTY ACIDS AND PSYCHOPATHOLOGY IN INDIVIDUALS AT ULTRA-HIGH RISK FOR PSYCHOSIS

Min Jhon*, Sung-Wan Kim, Jae-Min Kim, Stefan Smesny, Simon Rice, Michael Berk, Miriam R Schäfer, Claudia M Klier, G. Paul Amminger

M28. PREDICTION OF FUNCTIONAL OUTCOME IN THE EARLY ONSET PSYCHOSIS AND PSYCHOSIS PRODROME USING NEUROANATOMICAL AND RESTING STATE PATTERN CLASSIFICATION

Lana Kambeitz-Ilanovic*, Carlos Cabral, Eva Meisenzahl, Joseph Kambeitz, Peter Falkai, Nikolaos Koutsouleris

M29. PRO- AND ANTI-INFLAMMATORY CYTOKINES IN YOUNG PEOPLE IN ULTRA-HIGH RISK OF DEVELOPING SCHIZOPHRENIA AND BIPOLAR DISORDER

Maiara Zeni Graiff Gama*, Lucas Rizzo, Pawan Kumar Maurya, Cinthia Higuchi, Ary Gadelha, Pedro Pan, Graciele Rodrigues da Cunha, Rodrigo Bressan, Elisa Brietzke



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

M30. EFFECTS OF OMEGA-3 PUFA ON MARKERS OF IMMUNE FUNCTION IN INDIVIDUALS AT ULTRA-HIGH RISK OF PSYCHOSIS

Stefan Smesny*, Berko Milleit, Miriam Schaefer, Uta-Christina Hipler, Heinrich Sauer, G Paul Amminger

M31. RETINAL ANOMALIES IN SCHIZOPHRENIA PATIENTS AND REGULAR CANNABIS USERS: A POTENTIAL WAY TO A BIOLOGICAL MARKER?

Thomas Schwitzer, Raymund Schwan, Anne Giersch, Vincent Laprevote*

M32. MARKERS OF THE GLUTATHIONE ANTIOXIDATIVE DEFENSE SYSTEM ARE ASSOCIATED WITH STRUCTURAL BRAIN CHANGES IN UNTREATED FIRST-EPISODE SCHIZOPHRENIA

Kerstin Langbein*, Jana Hesse, Alexander Gussew, Uta-Christina Hipler, Berko Milleit, Heinrich Sauer, Stefan Smesny

M33. NIACIN SKIN SENSITIVITY DECREASED IN CLOSE TO PSYCHOSIS ULTRA-HIGH RISK GROUPS AND ASSOCIATED WITH PREPSYCHOTIC SYMPTOMATOLOGY – AN OPTICAL REFLECTION SPECTROSCOPY STUDY

Kerstin Langbein*, Ulrike Schmidt, Stephan Schack, Natalie J. Biesel, Maria Rudzok, G. Paul Amminger, Heinrich Sauer, Stefan Smesny

M34. THE DUTCH BIPOLAR AND SCHIZOPHRENIA OFFSPRING STUDY; PSYCHOPATHOLOGY OUTCOME DURING EARLY ADOLESCENCE.

Manon Hillegers*, Matthijs Vink, Neeltje Van Haren, René Kahn

M35. AGE DIFFERENCES IN THE DIAGNOSTIC STABILITY OF PATIENTS WITH PSYCHOSIS NOS: A META-ANALYSIS

Daniel Ilzarbe*, Ditte Lammers Vernal, Alberto Ramos-Caneda, Christoph U Correll

M36. ADVERSE CHILDHOOD EVENTS AND ADULT PSYCHOSIS

Geoffrey Smith*, Tari Buchanan, Andrea Jones, Allen Thornton, William Panenka, Olga Leonova, Fidel Vila-Rodriguez, William MacEwan, William Honer

M37. THE LINK BETWEEN BULLYING VICTIMIZATION AND PSYCHOTIC-LIKE EXPERIENCES: AN EXPLORATORY VIEW IN THE YOUNG ADOLESCENT POPULATION.

Roberta Marotta*, Simone Pisano, Annarita Montesanto, Margherita Siciliano, Filomena Salerno, Antonella Gritti, Matthew R. Broome, Gennaro Catone

M38. EMOTION RECOGNITION AND SOCIAL SKILLS IN CHILD AND ADOLESCENT OFFSPRING OF PARENTS WITH SCHIZOPHRENIA

Leslie Horton*, Miranda Bridgwater, Gretchen Haas

M39. COGNITIVE DEVELOPMENT AND THE EMERGENCE OF PSYCHOTIC EXPERIENCES IN CHILDREN AT HIGH RISK OF SCHIZOPHRENIA: A LONGITUDINAL STUDY OF 22Q11.2 DELETION SYNDROME

Samuel Chawner*, Michael Owen, Marianne van den Bree



M40. NEUROTOXIC AUTOANTIBODIES AND FAMILIAR HISTORY OF AUTOIMMUNE DISEASE IN ACUTE CHILD AND ADOLESCENT PSYCHOPATHOLOGY

Maria Gariup*, Azucena Gonzalez, Carles Serra-Pagés, Roger Borrás, Ricard Cervera, Astrid Morer

M41. SIGNIFICANT DIFFERENCES IN SUBTEST RALVT BETWEEN A PEP'S GROUP AND CONTROLS.

Maria Isabel Calvo-Rubiales*, Manuel Canal-Rivero, Andrea Morina, Miguel Ruiz Veguilla

M42. ADOLESCENT TRAJECTORIES OF MOTOR FUNCTION AND RISK FOR PSYCHOSIS

Hannah Dickson*, Ruth Roberts, Melody To, Max Loh, Sheilagh Hodgins, Kristin Laurens

M43. NEGATIVE SYMPTOMS AT FIRST EPISODE AND THEIR IMPACT ON TREATMENT OUTCOMES IN EARLY-ONSET PSYCHOSIS

Johnny Downs*, Harry Dean, Suzannah Lechler, Nicola Sears, Rashmi Patel, Hitesh Shetty, Matthew Hotopf, Tamsin Ford, Celso Arango, James MacCabe, Richard Hayes, Laura Pina-Camacho

M44. FROM NEUROLOGICAL SOFT SIGNS TO FUNCTIONAL OUTCOME IN YOUNG INDIVIDUALS IN TREATMENT WITH SECONDARY SERVICES FOR NON-PSYCHOTIC DISORDERS.

Amedeo Minichino*, Marta Francesconi, Kristin Cadenhead, Ricardo Carrion, Maurizio Parisi, Santo Rullo, Francesco Saverio Bersani, Massimo Biondi, Arturo Bevilacqua, Roberto Delle Chiaie

M45. THEORY OF MIND AS A MEDIATOR VARIABLE BETWEEN NEUROCOGNITION AND FUNCTIONING IN YOUNG INDIVIDUALS IN TREATMENT WITH SECONDARY SERVICES FOR NON-PSYCHOTIC DISORDERS.

Marta Francesconi*, Amedeo Minichino, Kristin Cadenhead, Ricardo Carrion, Maurizio Parisi, Santo Rullo, Arturo Bevilacqua, Francesco Saverio Bersani, Massimo Biondi, Roberto Delle Chiaie

M46. NUCLEUS REUNIENS REGULATION OF VENTRAL TEGMENTAL AREA DOPAMINE NEURON ACTIVITY: RELEVANCE TO PSYCHOSIS

Eric Zimmerman*, Nicole Jakobowski, Anthony Grace

M47. BEHAVIORAL EFFECTS OF D-AMPHETAMINE APPLIED TO THE ASSOCIATE STRIATUM OF THE RAT AS A CIRCUITRY PARADIGM OF PSYCHOSIS

Severine Bandinelli, Daniela Alberati, Bart Ellenbroek, Eric Prinssen*

M48. A NEW INSIGHTS AT THE INTERACTION BETWEEN MGLU4 AND 5-HT1A RECEPTORS IN ANIMAL MODELS OF SCHIZOPHRENIA DISORDERS.

Monika Wozniak*, Karolina Noworyta-Sokolowska, Krystyna Golembiowska, Krzysztof Tokarski, Magdalena Kusek, Piotr Branski, Grzegorz Burnat, Andrzej Pilc, Joanna Wieronska

M49. $\alpha 5$ NACHR MODULATION OF CORTICO-MESOLIMBIC CIRCUITRY AND FUNCTION

William Howe*, Patrick Tierney, Julie Brooks, Edward Guilmette, Damon Young, Rouba Kozak

M50. THE RELIABILITY OF THE REMISSION AND EXACERBATION CRITERIA (REC) OF SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDERS USING THE STANDARD FOR CLINICIANS' INTERVIEW IN PSYCHIATRY (SCIP)

Ahmed Aboraya*, Ahmed Elshazly



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

M51. INVESTIGATION OF “CRITICAL PERIOD” IN THE TREATMENT FOR FIRST-EPISODE SCHIZOPHRENIA: ANALYSIS OF THE ASSOCIATION BETWEEN DURATION OF UNTREATED PSYCHOSIS AND CLINICAL OUTCOME.

Naohisa Tsujino*, Takahiro Nemoto, Tomoyuki Funatogawa, Yoko Baba, Yo Wada, Yuko Yorozuya, Taiju Yamaguchi, Naoyuki Katagiri, Masafumi Mizuno

M52. PANSS-6 MEASURES THE SEVERITY OF SCHIZOPHRENIA USING ONLY SIX ITEMS
Soren Dinesen Ostergaard*, Ole Lemming, Ole Mors, Christoph Correll, Per Bech

M53. ELECTRONIC CIGARETTES AS A HARM-REDUCTION STRATEGY IN PEOPLE WITH SERIOUS MENTAL ILLNESS: A PILOT CLINICAL TRIAL

Lauren Hickling*, Rocio Perez-Iglesias, Ann McNeill, Lynne Dawkins, John Moxham, Tamatha Ruffell, Kyra-Verena Sendt, Philip McGuire

M54. AN ASSESSMENT OF INJECTION SITE REACTIONS AND INJECTION SITE PAIN OF ONCE-EVERY ONE MONTH AND THREE-MONTH LONG-ACTING INJECTABLE FORMULATIONS OF PALIPERIDONE PALMITATE (PP1M VS PP3M)

Erica Elephant, Jennifer Kern Sliwa, Adam Savitz, Isaac Nuamah, Maju Mathews*, Srihari Gopal, Dean Najarian, Larry Alphs

M55. VALIDATION OF THE KOREAN VERSION OF THE CLINICAL ASSESSMENT INTERVIEW FOR NEGATIVE SYMPTOMS (CAINS)

Seon-Kyeong Jang*, Seung-Hwan Lee, Seon-Cheol Park, Jung-Seo Yi, Joong-Kyu Park, Jung Suk Lee, Kee-Hong Choi

M56. OPEN BOARD

M57. JOINT MODELING OF DROPOUT AND OUTCOME IN THREE PIVOTAL CLINICAL TRIALS OF SCHIZOPHRENIA

Stephen Levine*, Yair Goldberg, Myrto Samara, John Davis, Stefan Leucht

M58. A POSSIBLE ROLE FOR PROLACTIN IN EMERGING PSYCHOSIS

Sarah Ittig, Erich Studerus*, Anita Riecher-Rössler

M59. ENHANCING COMPUTER-ASSISTED COGNITIVE REMEDIATION FOR SCHIZOPHRENIA: AN OPEN-LABEL STUDY WITH ANODAL TDCS ON LEFT LATERAL PREFRONTAL CORTEX

Giorgio Di Lorenzo*, Emiliano Santarnecchi, Dario Serrone, Cherubino Di Lorenzo, Fabiola Ferrentino, Valerio De Lorenzo, Andrea Daverio, Cinzia Niolu, Stefano Seri, Simone Rossi, Alberto Siracusano

M60. SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF A NOVEL PDE10A INHIBITOR, TAK-063, FOLLOWING MULTIPLE DOSING IN SUBJECTS WITH STABLE SCHIZOPHRENIA AND HEALTHY JAPANESE SUBJECTS

Paul Goldsmith*, John Affinito, Tom Macek, Max Tsai, Jinhui Xie, Lev Gertsik

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



M61. STABILITY IN A 52-WEEK SCHIZOPHRENIA EXTENSION STUDY OF TREATMENT WITH LONG-ACTING INJECTABLE ARIPIPRAZOLE LAUROXIL

Arielle Stanford, Robert Risinger*, Yangchun Du, Jacqueline Zummo, Hassan Jamal, Chih-Chin Liu, Amy Claxton

M62. SPECIFICITY AND PROGNOSTIC ACCURACY OF THE BASEL SCREENING INSTRUMENT FOR PSYCHOSIS (BSIP) AND THE SO FAR OFTEN NEGLECTED PROBLEM OF FALSE NEGATIVES

Martina Papmeyer*, Jacqueline Aston, Judith Everts-Graber, Ulrike Heitz, Erich Studerus, Stefan Borgwardt, Rolf-Dieter Stieglitz, Anita Riecher-Rössler

M63. A PHASE 3 STUDY TO DETERMINE THE ANTIPSYCHOTIC EFFICACY AND SAFETY OF ALKS 3831 IN ADULT SUBJECTS WITH ACUTE EXACERBATION OF SCHIZOPHRENIA

Bernard Silverman*, Sanjeev Pathak, Lauren DiPetrillo, Adam Simmons, Ying Jiang, Jacqueline Zummo, Hassan Jamal, David McDonnell

M64. A PHASE 2, EFFICACY, SAFETY, AND TOLERABILITY STUDY OF ALKS 3831 IN SCHIZOPHRENIA WITH ALCOHOL USE DISORDER

Sanjeev Pathak, David McDonnell*, Lauren DiPetrillo, Adam Simmons, Ying Jiang, Jacqueline Zummo, Hassan Jamal, Bernard Silverman

M65. SAFETY, TOLERABILITY, & PK OF MULTIPLE RISING DOSES OF BI 425809 TABLETS GIVEN ORALLY ONCE DAILY FOR 12 DAYS TO YOUNG HEALTHY MALE & FEMALE VOLUNTEERS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, WITHIN-DOSE GROUPS, PHASE I STUDY

Holger Schmitt, Michael Desch, Sophia Goetz, Armin Schultz, Karl-Heinz Liesenfeld, Sven Wind, Glen Wunderlich, Sun-Young A. Yum*

M66. METABOLIC SYNDROME IN PATIENTS WITH SCHIZOPHRENIA RECEIVING LONG-TERM TREATMENT WITH LURASIDONE, QUETIAPINE XR, OR RISPERIDONE

John W. Newcomer, Michael Tocco*, Andrei Pikalov, Hanzhe Zheng, Josephine Cucchiaro, Antony Loebel

M67. POSITIVE PHASE 3 CLINICAL TRIAL OF ITI-007 FOR THE TREATMENT OF SCHIZOPHRENIA: SECONDARY ENDPOINTS AND SUBGROUP ANALYSES FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Michal Weingart, Kimberly Vanover*, Robert Davis, Cedric O'Gorman, Jelena Saillard, Sharon Mates

M68. USING AN MHEALTH APPROACH TO DELIVER A PSYCHOSOCIAL INTERVENTION IN EARLY PSYCHOSIS: PRELIMINARY RESULTS FROM THE ACTISSIST TRIAL

Sandra Bucci*

M69. WHICH ARE THE MOST IMPORTANT FIRST-GENERATION ANTIPSYCHOTIC DRUGS? SURVEY OF INTERNATIONAL SCHIZOPHRENIA EXPERTS

Stefan Leucht, Maximilian Huhn*, Philipp Rothe, Johannes Schneider, Yikang Zhu



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

M70. REDUCE - A RANDOMIZED CLINICAL TRIAL TO EVALUATE GRADUAL NEUROLEPTIC DISCONTINUATION IN CHRONIC STABLE SCHIZOPHRENIC PATIENTS

Maximilian Huhn*, Claudia Leucht, Markus Dold, Philipp Rothe, Stefan Heres, Stefan Leucht

M71. MORE PRONOUNCED COGNITIVE DEFICITS IN ADOLESCENT SUBJECTS AT CLINICAL HIGH RISK OF PSYCHOSIS

HuiRu Cui, HuiJun Li, William S. Stone, TianHong Zhang, YingYing Tang, ChunBo Li, Min Zhao Zhao, Larry J. Seidman, JiJun Wang, Larry Seidman*

M72. EFFECTS OF COGNITIVE TRAINING USING BRAIN TRAINING GAMES ON BRAIN STRUCTURE IN PATIENTS WITH SCHIZOPHRENIA

Kunio Iizuka*, Kazunori Matsumoto, Rui Nouchi, Yasuyuki Taki, Takayuki Nozawa, Hiroshi Hashizume, Ryoichi Yokoyama, Yukako Sasaki, Ikki Ueda, Chika Obara, Tatsuo Kikuchi, Hiroo Matsuoka, Ryuta Kawashima

M73. USE OF PRIOR KNOWLEDGE IN PERCEPTUAL INFERENCE DISSOCIATES COMPUTATIONAL MECHANISMS OF ANOMALOUS PERCEPTIONS AND DELUSIONS

Daniel Davies*, Christoph Teufel, Paul Fletcher

M74. DOES CHANGE IN COGNITION AFFECT PSYCHOSOCIAL FUNCTIONING AFTER COGNITIVE REMEDIATION FOR SCHIZOPHRENIA?

Jean-Pierre Lindenmayer*, Samantha Fregenti, Veronica Ozog, Isidora Ljuri, Abraham Goldring, Guoxin Kang, Anzalee Khan

M75. EMOTIONAL INTELLIGENCE DEFICITS IN SCHIZOPHRENIA: THE IMPACT OF NON-SOCIAL COGNITION

Silvia Pardeller*, Beatrice Frajo-Apor, Georg Kemmler, Anna-Sophia Welte, Alex Hofer

M76. WORKING MEMORY DEFICITS IN YOUNG ADULTS BORN SMALL FOR GESTATIONAL AGE

Annamaria Porcelli*, Annabella Di Giorgio, Leonardo Fazio, Barbara Gelao, Linda Antonella Antonucci, Daniela Marvulli, Giancarlo Maddalena, Aurora Bonvino, Raffaella Romano, Marina Mancini, Gianluca Ursini, Fabio Sambataro, Giuseppe Blasi, Alessandro Bertolino

M77. JUMPING TO CONCLUSIONS PREDICTS 4 YEAR-CLINICAL OUTCOME IN FIRST EPISODE PSYCHOSIS

Victoria Rodriguez*, Olesya Ajnakina, Aurora Falcone, Simona Stilo, Anthony David, Marta Di Forti, Robin Murray

M78. RELATIONSHIP BETWEEN COGNITIVE INSIGHT AND DIFFERENT DIMENSIONS OF SOCIAL COGNITION IN RECENT ONSET PSYCHOSIS

Esther Pousa*, Susana Ochoa, Raquel Lopez Carrilero, Maria Luisa Barrigon, Ana Barajas, Esther Lorente Rovira, Fermin Gonzalez Higuera, Eva Grasa, Jordi Cid, Spanish Metacognition Study Group Study Group



M79. FORMAL THOUGHT DISORDER IN ADOLESCENTS WITH AUTISM SPECTRUM DISORDER: RELATIONS WITH EXECUTIVE FUNCTIONING

Tim Ziermans*, Sophie van Rijn, Esther de Bruin, Hanna Swaab

M80. SCHIZOPHRENIA AND SHORT LIFETIME EXPECTANCY - THE IMPORTANCE OF IDENTIFYING RISK FACTORS EARLY IN THE ILLNESS.

Lars Helldin*, Fredrik Hjärthag, Anna-Karin Olsson

M81. DEFECTIVE TRANSLATION OF EMOTIONAL SALIENCE INTO MOTIVATED BEHAVIOUR: A ONE YEAR FOLLOW-UP STUDY IN FIRST-EPISODE SCHIZOPHRENIA

Simon S. Y. Lui*, William W H Chui, Amy C Y Liu, Hai-song Shi, Dong-jie Xie, Zhi Li, Eric F. C. Cheung, Raymond C. K. Chan

M82. PERSPECTIVE MEMORY PERFORMANCE AND ITS CLINICAL CORRELATES DURING THE FIRST YEAR OF TREATMENT IN FIRST-EPISODE SCHIZOPHRENIA: A FOLLOW-UP STUDY

Fu-Chun Zhou*, Yu-Tao Xiang, Chuan-Yue Wang

M83. CORRELATIONS OF NEUROCOGNITIVE FUNCTIONING WITH NEGATIVE SYMPTOMS AND DAILY FUNCTIONING IN A FIRST EPISODE PSYCHOSIS SAMPLE

Emily Revell*, Richard Drake, Michael Harte, Joanna Neill

M84. SCHIZOTYPY AND NEUROCOGNITIVE PERFORMANCE IN PSYCHOSIS: AN ANALYSIS FROM THE FIRST PRONIA SAMPLE

Maria F. Urquijo*, Dominic Dwyer, Johanna Weiske, Sebastian Von Saldern, Joseph Kambeitz, Lana Kambeitz-Ilanckovic, Carlos Cabral, Nikolaos Koutsouleris

M85. FUNCTIONAL STATUS AND FINANCIAL CAPACITY IN INDIVIDUALS WITH FIRST PSYCHOSIS

Alexandra Oliveira*, Valmira Toledo, Graça Oliveira, Danielle Bio, Martinus Van De Bilt, Wagner Gattaz, Paulo Sallet

M86. THE COURSE OF NEUROCOGNITIVE CHANGES IN ACUTE PSYCHOSIS: RELATION TO SYMPTOMATIC CHANGE

Liss Anda*, Kolbjørn Brønnick, Erik Johnsen, Rune Kroken, Else-Marie Løberg

M87. THE ROLE OF DISORGANIZATION SYMPTOMS IN THE RELATIONSHIP BETWEEN EXECUTIVE FUNCTIONS AND WHITE MATTER IN SCHIZOPHRENIA

Ainara Gómez-Gastiasoro, Leire Zubiaurre-Elorza, Javier Peña, Naroa Ibarretxe-Bilbao, Oiane Rilo, David Schretlen, Natalia Ojeda*

M88. IT'S ALL IN THE WORDS: LEXICAL PROCESSING IS IMPAIRED IN SCHIZOPHRENIA AND BIPOLAR MANIA

Susan Rossell*, Tamsyn Van Rheenen

(M89) THE PERCEPTION OF INTENTIONALITY IN EARLY PSYCHOSIS

Anne-Kathrin Fett*, Clara Isabel Gonzales-Berdugo, Esther Hanssen, Imke Lemmers-Jansen, Sukhi Shergill, Lydia Krabbendam



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

M90. AUTOBIOGRAPHICAL MEMORY IMPAIRMENT IN CHRONIC SCHIZOPHRENIA

Marc Montgomery Lässer*, Christina J. Herold, Lena A. Schmid, Li Kong, Ulrich Seidl, Johannes Schröder

M91. TAKING IT AT 'FACE VALUE': THE USE OF FACE PROCESSING STRATEGIES IN SCHIZOPHRENIA AND BIPOLAR DISORDER

Tamsyn Van Rheenen*, Nicole Joshua, David Castle, Susan Rossell

M92. VERBAL MEMORY IN FIRST EPISODE PSYCHOSIS PATIENTS: IS THE HIPPOCAMPUS RESPONSIBLE FOR THE DEFICIT?

Rosa Ayasa-Arriola*, Diana Tordesillas-Gutiérrez, Esther Setién Suero, Benedicto Crespo-Facorro

M93. SCHIZOPHRENIA & MUSIC SYNTACTIC PROCESSING- AN EEG STUDY

Christian Mikutta*, Stefan Koelsch, Werner Strik, Andreas Altorfer, Daniel Mathalon

M94. PRELIMINARY EVIDENCE FOR THE INFLUENCE OF WORKING MEMORY LOAD ON THE LEARNED PREDICTIVENESS EFFECT IN SCHIZOPHRENIA PATIENTS

Daniel Núñez*, Vogel Edgar, Pinto Jorge, Calvo Jorge, Yupanqui José

M95. WHAT DOES 2D:4D TELL US ABOUT SOCIAL COGNITION?

Ozge Akgul, Onur Kucukcoban*, İ. Tolga Binbay, Koksall Alptekin, Berna Binnur Akdede

M96. THE EFFECT OF THE MUSCARINIC M1 RECEPTOR ANTAGONIST BIPERIDEN ON COGNITION IN PATIENTS WITH A PSYCHOTIC DISORDER AND HEALTHY CONTROLS

Claudia Vingerhoets*, Geor Bakker, Oswald Bloemen, Matthan Caan, Jan Booij, Therese van Amelsvoort

M97. COOPERATION AND THE EFFECT OF SOCIAL FEEDBACK IN A PUBLIC GOODS PARADIGM IN SCHIZOPHRENIA

Esther Hanssen*, Thomas White, Anne-Kathrin Fett, Caroline Caddy, Sukhi Shergill

M98. ASSESSING CHANGE IN NEUROCOGNITION: RELIABLE CHANGE INDICES FOR NEUROCOGNITIVE ASSESSMENT IN SCHIZOPHRENIA

Anzalee Khan*, Jean-Pierre Lindenmayer, Isidora Ljuri, Veronica Ozog, Samantha Fregenti, Abraham Goldring

M99. THE EXPERIENCE OF SELF-AGENCY IN CHILDREN WITH AND WITHOUT FAMILIAL RISK FOR SCHIZOPHRENIA OR BIPOLAR DISORDER.

Merel Prikken*, Matthijs Vink, Anouk Van Der Weiden, Martijn Koevoets, René Kahn, Manon Hillegers, Neeltje Van Haren

M100. INTRA-INDIVIDUAL VARIABILITY ACROSS COGNITIVE FUNCTIONS IN FIRST-EPISODE SCHIZOPHRENIA-SPECTRUM DISORDER

TT Lui, Wing Chung Chang*, FC Lau, LM Hui, KW Chan, HM Lee, EYH Chen



M101. HYPERVULNERABILITY OF THE ADOLESCENT PERIOD TOWARDS THE PREFRONTAL NEURONAL CONSEQUENCES OF OBESITY ARE MEDIATED BY REELIN, AN EXTRACELLULAR MATRIX PROTEIN LINKED TO EARLY ONSET PSYCHIATRIC DISEASES

Marie Labouesse*, Olivier Lassalle, Juliet Richetto, Ulrike Weber-Stadlbauer, Tina Notter, Lluís Pujadas, Eduardo Soriano, Wolfgang Langhans, Pascale Chavis, Urs Meyer

M102. LOWER FREQUENCY OF METABOLIC SYNDROME PREDICTED BY SCHIZOTYPAL TRAITS IN DISCORDANT SIBLINGS OF PATIENTS WITH SCHIZOPHRENIA

Cem Atbasoglu*, Guvem Gumus Akay, Meram Can Saka, Sinan Guloksuz, Alp Ucoğ, Koksall Alptekin, Sevim Gullu, Jim Van Os

M103. INTERVENTION STUDY: THE EFFECT OF AN LIFESTYLE INTERVENTION IN INPATIENTS WITH SEVERE MENTAL ILLNESS (SMI)

Jeroen Deenik*, Diederik Tenback, Ingrid Hendriksen, Erwin Tak, Peter Van Harten

M104. COMORBID OBSESSIVE COMPULSIVE DISORDER AND SOCIAL FUNCTION IN PATIENTS WITH CHRONIC SCHIZOPHRENIA

Tae Yong Kim*, Hae Gyung Chung, Jin Hee Choi, Hyung Seok So, Suk Hoon Kang, Tai Kiu Choi

M105. THE COURSE OF DIABETES IN SCHIZOPHRENIA AND BIPOLAR DISORDERS: AN EPIDEMIOLOGICAL STUDY

Arad Kodesh*, Stephen Levine, Liora Valinsky, Fabienne Hershkowitz Sikron

M106. NEUROANATOMICAL IMPLICATIONS OF CONCOMITANT MOOD DISORDERS IN SUBJECTS AT CLINICAL HIGH RISK FOR PSYCHOSIS

Yoo Bin Kwak*, TAE YOUNG LEE, Kang Ik Cho, MINAH KIM, SUNG NYUN KIM, JUN SOO KWON

M107. A NETWORK ANALYSIS ON TRAUMA, DISSOCIATION AND SCHIZOPHRENIC SYMPTOMS IN SCHIZOPHRENIA SPECTRUM DISORDERS

Selwyn Renard*, Marieke (Gerdina) Pijnenborg, Paul Lysaker, Rafaele Huntjens, Andre Aleman

M108. PHARMACOLOGIC MANAGEMENT IN CASES OF DUAL DIAGNOSIS- SCHIZOPHRENIA AND ALCOHOL USE DISORDER

Daniel Vasile*, Octavian Vasiliu, Diana Gabriela Vasiliu, Florin Vasile

M109. THE ADVERSE EFFECT OF NICOTINE DEPENDENCE AND CANNABIS USE ON OUTCOME OF FIRST EPISODE PSYCHOSIS IS MEDIATED BY POOR MEDICATION ADHERENCE

Marco Colizzi*, Elena Carra, Sara Fraietta, John Lally, Diego Quattrone, Olesya Ajnakina, Paola Dazzan, Antonella Trotta, Anna Kolliakou, Fiona Gaughran, Mizanur Khondoker, Anthony David, Robin Murray, James MacCabe, Marta Di Forti

M110. 36 MONTH RESULTS OF A SMOKING AND HEALTHY LIFESTYLES INTERVENTION AMONG PEOPLE WITH A PSYCHOTIC DISORDER

Amanda Baker*, Robyn Richmond, Frances Kay-Lambkin, Sacha Filia, David Castle, Robin Callister, Jill Williams, Vanessa Clark, Terry Lewin, Kerrin Palazzi



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

**M111. IMPACT OF CANNABIS USE ON CLINICAL OUTCOMES AND TREATMENT FAILURE IN
FIRST EPISODE PSYCHOSIS**

Rashmi Patel*, Robin Wilson, Richard Jackson, Michael Ball, Hitesh Shetty, Matthew Broadbent, Robert Stewart, Philip McGuire, Sagnik Bhattacharyya

**M112. BETTER SOCIAL BUT WORSE ACADEMIC PREMORBID ADJUSTMENT IN CANNABIS-USERS
PSYCHOTIC PATIENTS ACROSS EUROPE**

Laura Ferraro, Capuccio Veronica, Caterina La Cascia, Lucia Sideli, Alice Mulè, Fabio Seminerio*, Crocettarachele Sartorio, Giada Tripoli, Robin Murray, Daniele La Barbera, Marta Di Forti

**M113. COMPARISON OF CHR RISK SYMPTOMS IN THE PRONIA POPULATION - FIRST RESULTS
FROM THE PRONIA STUDY**

Theresa Haidl*, Kaiser Nathalie, Marlene Rosen, Frauke Schultze-Lutter, Stefan Borgwardt, Paolo Brambilla, Christos Pantelis, Raimo K. R. Salokangas, Stephen Wood, Nikolaos Koutsouleris, Stephan Ruhrmann, and the PRONIA Group

**M114. ADDRESSING THE RISKS OF BEING 'AT RISK': THE EFFECTS OF LABELING VERSUS
SYMPTOM SEVERITY ON PUBLIC ATTITUDES TOWARD INDIVIDUALS AT RISK FOR PSYCHOSIS.**

Dan Koren*, Shulamit Gilboa-Radin, Yulia Libas

**M115. AT RISK FOR PSYCHOSIS OR BIPOLAR DISORDER? EVALUATION OF BIPOLAR AT-RISK
(BAR) CRITERIA IN A UK SAMPLE**

Irina Falkenberg*, Ceri Jones, Lida Xenaki, Philip McGuire, Lucia Valmaggia, Paolo Fusar-poli

M116. EFFECTIVITY OF A DIGITAL PANSS-TRAINING

Nicky Klaasen*, Leonie van Asperen, Claire Kos, Pieter-Jan Mulder, Henderikus Knegtering, André Aleman, Kristy Wolanski, Christian Yavorski, Richard Bruggeman

**M117. VENOUS COMPARED TO CAPILLARY BLOOD SAMPLING WITH A POINT-OF-CARE DEVICE
IN CLOZAPINE TREATMENT: PATIENTS' PREFERENCES**

Jan Bogers*, Dan Cohen

M118. INSIGHT AND SUICIDALITY IN PSYCHOSIS: A CROSS-SECTIONAL STUDY

Carmina Massons*, Javier-David Lopez-Morinigo, Jesús Cobo, Esther Pousa, Anthony David, Rina Dutta

**M119. ASSOCIATIONS BETWEEN PARANOIA AND LEVELS OF DEPRESSION AND ANXIETY IN
THE GENERAL POPULATION: TWO META-ANALYSES**

Yeuk Lai Law*, Suzanne So

**M120. THE SCHIZOTYPY FACTORS ARE A SUITABLE MODEL FOR THE SYMPTOMS OF
SCHIZOPHRENIA**

Elizabeth Thomas*, Kiymet Bozaoglu, Erica Neill, Tamsyn Van Rheenen, Stephanie Louise, Eric Tan, Susan Rossell, Caroline Gurvich

FINAL PROGRAM

FLORENCE, ITALY

2 – 6 APRIL 2016



M121. CLINICAL INSIGHT IN NON-AFFECTIVE PSYCHOSIS AND PSYCHIATRIC HOSPITAL READMISSION: A SYSTEMATIC REVIEW

Ewa Klamerus*, Marianna Antoniadou, Enrico Foglia, Kevin Morgan, Sagnik Bhattacharyya

M122. REPORTED CHILDHOOD ABUSE AND STRESS REACTIVITY IN PSYCHOSIS: A REPLICATION ATTEMPT

Jonas Weijers*, Wolfgang Viechtbauer, Fabian Termorshuizen, Jean-Paul Selten

M123. IS SIMPLE SCHIZOPHRENIA THAT SIMPLE? AN OBSERVATIONAL STUDY

Adriana Fortea*, Daniel Ilzarbe, Laura Espinosa, Laura Nuño, Maria Emilia Chavez, Eduard Parellada

M124. COMPARISON OF FACTOR STRUCTURE OF THE POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS) IN PATIENTS WITH REFRACTORY VERSUS AND NON-REFRACTORY SCHIZOPHRENIA IN A LARGE BRAZILIAN SAMPLE

Rosana Freitas, Cinthia Higushi, Bernardo dos Santos, Adriana Vizzotto, Belquiz Avrichir, Silvia Scemes, Antônio de Sá Júnior, Mario Rodrigues Louzã Neto, Rodrigo Bressan, Ary Gadelha, Helio Elkis*

M125. A SYSTEMATIC REVIEW EXPLORING NEGATIVE SYMPTOMS AND DEPRESSION IN SCHIZOPHRENIA – AN UPDATE OF THE LITERATURE

Carl Krynicki*, John Deakin, Thomas Barnes, Rachel Upthegrove

M126. DEVELOPMENT AND PSYCHOMETRIC VALIDATION OF THE QUESTIONNAIRE OF STRESSFUL LIFE EVENTS (QSLE). SPANISH VERSION.

Anna Butjosa*, Juana Gómez-Benito, Inez Myin-Germeys, Elena Huerta-Ramos, Núria Del Cacho, Montserrat Dolz, Andrea Estela, GENIPE group, Susana Ochoa

M127. PSYCHOMETRIC SCHIZOTYPY PREDICTS PRODROMAL AND SCHIZOPHRENIA-SPECTRUM SYMPTOMS, PSYCHOLOGICAL MEASURES, AND FUNCTIONAL ADAPTATION: A 4-YEAR LONGITUDINAL STUDY

Anna Racioppi*, Tamara Sheinbaum, Sergi Ballespí, Mercè Mitjavila, Georgina M. Gross, Thomas R. Kwapil, Neus Barrantes-Vidal

M128. AUTISM TRAITS AND POSITIVE PSYCHOTIC EXPERIENCES IN ADOLESCENTS FROM THE GENERAL POPULATION: ASSOCIATIONS WITH THEORY OF MIND

Ashleigh Lin*, Ahmad Abu-Akel, Renate Reniers, Katharine Chisholm, Elsa Walsh, Zoe Spruce, Rachel Royston, Stephen Wood

M129. THEORY OF MIND AND ATTEMPTS OF SUICIDE AFTER FIRST EPISODE OF PSYCHOSIS

Manuel Canal-Rivero*, Maria Isabel Calvo-Rubiales, Jordi E. Obiols Llandrich, Miguel Ruiz Veguilla

M130. INSIGHT AND THEORY OF MIND

Manuel Canal-Rivero*, Maria Isabel Calvo-Rubiales, Jordi E. Obiols Llandrich, Miguel Ruiz-Veguilla

M131. PARENTAL PSYCHOSIS AND EARLY DEVELOPMENTAL VULNERABILITY IN OFFSPRING

Kimberlie Dean, Maina Kariuki, Alessandra Raudino, Melissa Green, Stacy Tzoumakis, Titia Sprague, Rhoshel Lenroot, Kristin Laurens, Vaughan Carr*



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

M132. ANTIPSYCHOTIC MEDICATION AND REMISSION OF PSYCHOTIC SYMPTOMS 10 YEARS AFTER A FIRST-EPISODE PSYCHOSIS

Merete Nordentoft*, Regitze Wills, Ditte Resendal Gotfredsen, Carsten Hjorthøj, Ole Mors, Stephen Austin, Nikolai Albert, Gry Secher, Anne Thorup

M133. ASSOCIATION OF WHITE BLOOD CELL COUNT AND C-REACTIVE PROTEIN LEVEL WITH SYMPTOMS OF PSYCHOTIC DISORDERS: FINDINGS FROM A LARGE COHORT

Edith Liemburg*, Ilja Nolte, Hans Klein, Henderikus Knegtering

M134. SYMPTOMATIC, FUNCTIONAL AND PERSONAL REMISSION IN SCHIZOPHRENIA AND RELATED PSYCHOTIC DISORDERS: PERSISTENT PATTERNS IN A LARGE NATURALISTIC COHORT STUDY

Stynke Castelein*, Edith Liemburg, Richard Bruggeman, Ellen Visser

M135. ASSOCIATION BETWEEN SCHIZOPHRENIA AND DEMENTIA: DOES SCHIZOPHRENIA IN OFFSPRING INCREASE THE RISK OF DEVELOPING DEMENTIA? A DANISH POPULATION-BASED STUDY.

Christopher Rohde*, Philip Finn Rising Nielsen, Esben Agerbo

M136. GENERAL FERTILITY RATE IN NON-AFFECTIVE PSYCHOSIS: ROUTINE DATA-LINKAGE USING MATERNITY AND PSYCHIATRIC DATA

Angus MacBeth*, Sarah Barry, Paula McSkimming, John Park, Sohinee Bhattacharya, Roch Cantwell, David St Clair, Andrew Gumley

M137. PROSPECTIVE AND CROSS-SECTIONAL ASSOCIATIONS BETWEEN THEORY OF MIND, SOCIAL FUNCTIONING, AND PSYCHOTIC EXPERIENCES IN ADOLESCENTS IN THE GENERAL POPULATION.

Laura Steenhuis*, Marieke (Gerdina) Pijnenborg, Maaïke Nauta, Andre Aleman, Annegien Bartels-Velthuis

M138. COMPULSORY ADMISSION DURING FIRST EPISODE OF PSYCHOSIS: DOES ETHNICITY STILL MATTER?

Sheri Oduola*, Tom Craig, Dinesh Bhugra, Francois Bourque, Jason Tsang, Charlotte Gayer-Anderson, Craig Morgan

M139. PREVALENCE OF DEFICIT SYNDROME IN SCHIZOPHRENIA: AN UPDATED META-ANALYSIS
Álvaro López-Díaz*, José Luis Fernández-González, Pablo Lorenzo-Herrero

M140. ASSOCIATION BETWEEN POLYGENIC RISK SCORES AND TREATMENT RESISTANCE IN SCHIZOPHRENIA: RESULTS FROM THE CRESTAR COLLABORATION

Theresa Wimberley*, Sandra Meier, Christiane Gasse, Esben Agerbo, James MacCabe, Henriette Horsdal

M141. PARENTAL SOMATIC ILLNESS' EFFECT ON PRODROMAL SYMPTOMS OF CHILDREN – NORTHERN FINLAND BIRTH COHORT 1986 STUDY

Lotta Kinnunen*, Tanja Nordström, Mika Niemelä, Sami Räsänen, Juha Veijola, Jouko Miettunen



M142. MONITORING OF RISK OF VIOLENCE AND PATIENTS' CLINICAL CHARACTERISTICS: A PROSPECTIVE COHORT STUDY

Giovanni de Girolamo*, Viola Bulgari, Valentina Candini, Laura Iozzino, Beatrice Segalini

M143. NEIGHBOURHOOD CHARACTERISTICS AND THE INCIDENCE OF FIRST EPISODE PSYCHOSIS (FEP) AND DURATION OF UNTREATED PSYCHOSIS (DUP)

Brian O'Donoghue*, John Lyne, Laoise Renwick, Abbie Lane, Kevin Madigan, Anthony Staines, Mary Clarke

M144. SERUM C-REACTIVE PROTEIN IN ADOLESCENCE AND SUBSEQUENT SCHIZOPHRENIA IN ADULTHOOD: A POPULATION-BASED PROSPECTIVE BIRTH COHORT STUDY

Stephen Metcalf, Peter Jones, Tanja Nordstrom, Markku Timonen, Pirjo Maki, Jouko Miettunen, Erika Jääskeläinen, Marjo-Riitta Järvelin, Graham Murray, Jan Stochl, Juha Veijola, Golam Khandaker*

M145. HIGH PREVALENCE RATE OF AGITATION IN THE CHINESE POPULATION WITH NEWLY HOSPITALIZED PATIENTS SUFFERING FROM SCHIZOPHRENIA: RESULTS FROM AN OBSERVATIONAL SURVEY IN CHINA

Hongyan Zhang*, Suzhen Zhang, Wifeng MI, Qi Liu, Lingzhi Li

M146. EFFECT OF WIDER SOCIAL ENVIRONMENT ON RELAPSES IN SCHIZOPHRENIA: A SIX-YEAR FOLLOW-UP STUDY

Burcu Ünal, Tolga Binbay*, Mehtap Az, Halis Ulaş, Köksal Alptekin, Berna Akdede

M147. SUB-CLINICAL PSYCHOTIC EXPERIENCES INCREASE RATE OF CONTACT WITH MENTAL HEALTH SERVICES

Vishal Bhavsar*, Matthew Hotopf, Stephani Hatch, Philip McGuire, Victoria Harris, Jane Boydell

M148. PSYCHOTIC-LIKE EXPERIENCES AND VIOLENCE AMONG YOUNG CHINESE MEN

Simone Ullrich*

(M149) PREVALENCE OF NON-RESPONSE AND NON-REMISSION IN SCHIZOPHRENIA

Myrto Samara*, Adriani Nikolakopoulou, Georgia Salanti, Stefan Leucht

M150. SHIFT IN POSITIVE AND NEGATIVE PSYCHOTIC SYMPTOMS AND VIOLENCE

Jeremy Coid*

M151. METABOLIC SCREENING AND STATUS AMONG NEWLY DIAGNOSED PATIENTS WITH SCHIZOPHRENIA: A POPULATION-BASED CROSS-SECTIONAL STUDY.

Henriette Horsdal, Michael Benros, Ole Köhler*, Jesper Krogh, Christiane Gasse

M152. LONGITUDINAL EPIGENETIC ANALYSIS OF CLOZAPINE USE IN TREATMENT-RESISTANT SCHIZOPHRENIA: DATA FROM THE CRESTAR CONSORTIUM

Amy Gillespie*, Eilis Hannon, Emma Dempster, Grant McQueen, Alessia Avila, John Lally, David Collier, Alice Egerton, Jonathan Mill, James MacCabe

M153. STIMULUS REPETITION EFFECTS ON NEUROPHYSIOLOGICAL CORRELATES OF MENTAL WORKLOAD IN PSYCHOTIC PATIENTS

Gregoire Favre*, Sibylle Horat, Pascal Missonnier, François Herrmann, Damien Debatisse, Marco Merlo



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

M154. SEPARATION OF RECENT-ONSET PSYCHOSIS PATIENTS FROM HEALTHY CONTROLS BASED ON RESTING-STATE FUNCTIONAL CONNECTIVITY PATTERN CLASSIFICATION

Shalaila Haas*, Carlos Cabral, Maria Urquijo, Sebastian Von Saldern, Joseph Kambeitz, Nikolaos Koutsouleris, Lana Kambeitz-Ilankovic

M155. LOWER HIPPOCAMPAL MUSCARINIC M1 RECEPTOR EXPRESSION IS RELATED TO VISUAL SPATIAL LEARNING AND MEMORY DEFICITS IN FIRST EPISODE PSYCHOSIS PATIENTS.

Geor (IM) Bakker*, Wilhelmina Vingerhoets, Daphne Boucherie, Matthan Caan, Oswald Bloemen, Jan Booij, Therese van Amelsvoort

M156. CORTICAL HIERARCHY UNDERLIES PREFERENTIAL CONNECTIVITY DISTURBANCES IN SCHIZOPHRENIA

Genevieve Yang, John Murray, Grega Repovs, Michael Cole, Xiao-Jing Wang, David Glahn, Godfrey Pearlson, John Krystal, Alan Anticevic*

M157. ABNORMAL BRAIN ACTIVITY IN THE LEFT PREFRONTAL CORTEX IS RELATED TO DEFICIT IN USING SEMANTIC ENCODING STRATEGIES IN SCHIZOPHRENIA

Synthia Guimond*, Colin Hawco, Martin Lepage

M158. ALTERED CORTICO-LIMBIC CONNECTIVITY DURING THE FACIAL PERCEPTION IN INDIVIDUALS WITH SOCIAL ANHEDONIA

Yi Wang*, Zhi Li, Wen-hua Liu, Xin-hua Wei, Xin-qing Jiang, Raymond C.K. Chan

M159. FUNCTIONAL CONNECTIVITY AND STRIATAL DOPAMINE SYNTHESIS IN SCHIZOPHRENIA TREATED WITH ANTIPSYCHOTIC DRUGS: MULTIMODAL IMAGING STUDY USING [18F]DOPA PET AND RESTING MRI

Euitae Kim*, Young Woo Yoon, Wi Hoon Jung, Mattia Veronese, Oliver Howes, Federico Turkheimer, Jun Soo Kwon

M160. ADJUNCTIVE SELECTIVE ESTROGEN RECEPTOR MODULATOR INCREASES NEURAL ACTIVITY IN THE HIPPOCAMPUS AND INFERIOR FRONTAL GYRUS DURING EMOTIONAL FACE RECOGNITION IN SCHIZOPHRENIA

Ellen Ji*, Cynthia Shannon Weickert, Rhoshel Lenroot, Jochen Kindler, Ashley Skilleter, Ans Vercammen, Christopher White, Raquel Gur, Thomas Weickert

M161. BRAIN ACTIVATION FINDINGS FROM A FAMILY STUDY OF EMOTIONAL AND NON-EMOTIONAL FACE RECOGNITION IN SCHIZOPHRENIA

Michael Spilka*, Vina Goghari

M162. BRAINS OF FIRST-EPISODE PSYCHOSIS PATIENTS DO NOT SYNCHRONIZE WITH OTHERS DURING MOVIE VIEWING CONDITIONS

Teemu Mantyla*, Eva Rikandi, Tuula Kieseppä, Riitta Hari, Lauri Nummenmaa, Jaana Suvisaari, Tuukka Raij



M163. ASSOCIATION OF GENETIC VARIANTS WITH THE BRAIN ACTIVITY DURING EMOTIONAL PROCESSING: A MULTIVARIATE STUDY

Daniela Marvulli*, Tiziana Quarto, Pasquale Di Carlo, Raffaella Romano, Paolo Taurisano, Leonardo Fazio, Antonio Rampino, Alessandro Bertolino, Giulio Pergola, Giuseppe Blasi

M164. HYPERACTIVATION OF SALIENCE NETWORK DURING EYE GAZE PERCEPTION IN SCHIZOPHRENIA

Ivy Tso*, Beier Yao, Stephan Taylor

M165. NEUROIMAGING OF APPRAISALS OF PSYCHOTIC EXPERIENCES: AN EXPERIMENTAL INVESTIGATION OF SYMPTOMATIC AND NON-NEED-FOR-CARE INDIVIDUALS

Raphael Underwood*, Emmanuelle Peters, Veena Kumari

M166. THALAMIC MEDIO-DORSAL CONNECTIVITY DURING ATTENTIONAL CONTROL MEASURED WITH INDEPENDENT COMPONENT ANALYSIS IS ASSOCIATED WITH FAMILIAR RISK FOR SCHIZOPHRENIA AND WITH A POLYGENIC RISK SCORE

Linda A. Antonucci*, Paolo Taurisano, Leonardo Fazio, Raffaella Romano, Giulio Pergola, Roberta Passiatore, Pasquale Di Carlo, Barbara Gelao, Alessandro Bertolino, Giuseppe Blasi

M167. ASSOCIATION OF THE BDNF VAL66MET POLYMORPHISM WITH NEGATIVE SYMPTOMS SEVERITY, BUT NOT COGNITIVE FUNCTION, IN FIRST-EPISODE SCHIZOPHRENIA SPECTRUM DISORDERS

Gisela Mezquida*, Rafael Penades, Bibiana Cabrera Llorca, George Savulich, Antonio Lobo, Ana Gonzalez-Pinto, Maria Jose Penzol, Iluminada Corripio, Emilio Fernandez-Egea, Patricia Gassó, Manuel J. Cuesta, Miguel Bernardo, PEPs Group

M168. DIFFERENTIAL CONSISTENCY OF SUBCORTICO-CORTICAL INTRINSIC CONNECTIVITY PATTERNS IN SCHIZOPHRENIA

Henning Peters*

M169. DEFICITS IN CONTEXT-DEPENDENT ADAPTIVE CODING OF REWARD IN SCHIZOPHRENIA

Matthias Kirschner*, Oliver Hager, Martin Bischof, Matthias Hartmann, Agne Kluge, Erich Seifritz, Philippe Tobler, Stefan Kaiser

M170. VENTRAL STRIATAL ACTIVATION DURING REWARD PROCESSING IN PSYCHOSIS: A NEUROFUNCTIONAL META-ANALYSIS

André Schmidt*, Joaquim Radua, Stefan Borgwardt, Andreas Heinz, Florian Schlagenhauf, Philip McGuire, Paolo Fusar-poli

M171. NEURAL CORRELATES OF TRUST IN HEALTH, PSYCHOSIS AND IN PATIENTS AT ULTRA-HIGH RISK FOR PSYCHOSIS.

Imke Lemmers-Jansen*, Anne-Kathrin Fett, Esther Hanssen, Dick Veltman, Lydia Krabbendam

M172. SUICIDE ATTEMPT IN SCHIZOPHRENIA AND FIRST-EPISODE PSYCHOSIS: CLINICAL AND BIOLOGICAL ASSOCIATIONS.

Ahmed Mhalla*, Rim Mensi, Amel Messaoud, Badii Amamou, Wahiba Douki, Lotfi Gaha



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

M173. CHILDHOOD TRAUMA MODERATES THE EFFECTS OF COMMON VARIANTS OF THE FK506 BINDING PROTEIN 5 (FKBP5) GENE ON RIGHT HIPPOCAMPAL VOLUME IN SCHIZOPHRENIA

Nina Teroganova*, Yann Quidé, Joshua Atkins, Murray Cairns, Natalie Matosin, Vaughan Carr, Melissa Green

M174. CONNECTOMICS IN SCHIZOPHRENIA: FROM EARLY PIONEERS TO RECENT BRAIN NETWORK FINDINGS

Guusje Collin*, Elise Turk, Martijn Van Den Heuvel

M175. CHILDHOOD TRAUMA IN YOUNG ADULTS AT ULTRA HIGH RISK FOR PSYCHOSIS IS ASSOCIATED TO LOWER FRACTIONAL ANISOTROPY IN THE LEFT UNCINATE FASCICULUS AND PARAHIPPOCAMPAL CINGULUM.

Attilio Rapisarda*, Chenhao Wang, Jimmy Lee, Juan Zhou

M176. KETAMINE INDUCED NMDA-RECEPTOR BLOCKADE AND HIPPOCAMPAL GLUTAMATE IN HEALTHY VOLUNTEERS

Nina Kraguljac*, Michael Froelich, Steve Tran, David White, Nona Nichols, Meredith Reid, Adrienne Lahti

M177. A TSPO BLOCKING STUDY TO DETERMINE THE SPECIFIC BINDING OF [11C]-PBR28 IN PATIENTS WITH SCHIZOPHRENIA

Tiago Reis Marques*, Peter Bloomfield, David Owen, Mattia Veronese, Federico Turkheimer, Oliver Howes

M178. WHITE MATTER INTEGRITY IN TREATMENT-REFRACTORY SCHIZOPHRENIA: A DIFFUSION TENSOR IMAGING STUDY

Joseph Rodrigues, Tiago Reis Marques, Marco Picchioni, Christian Ferragamo, Stephen Lawrie, Kyra-Verena Sendt*, Richard A. Kanaan, Sukhi Shergill

M179. INCREASED GLUTAMATE IN PREFRONTAL CORTEX OF PATIENTS WITH PSYCHOTIC DISORDERS AND AUDITORY VERBAL HALLUCINATIONS

Branislava Curcic-Blake*, Leonie Bais, Marieke Pijnenborg, Edith Liemburg, Andre Aleman

M180. THE EFFECT OF CIGARETTE SMOKING ON BRAIN STRUCTURE IN PATIENTS WITH SCHIZOPHRENIA AND HEALTHY SUBJECTS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Elisabetta Miglietta*, Annalisa Giordano, Joaquim Radua, Kempton Matthew, Dazzan Paola

M181. THE EFFECT OF MANUAL EDITING IN FREESURFER

Kasper Jessen*, Kristine Krakauer, Rene Mandl, Egill Rostrup

M182. GREY MATTER VOLUME PATTERNS IN THALAMIC NUCLEI PREDICT GENETIC RISK FOR SCHIZOPHRENIA AND SYMPTOMS SEVERITY

Giulio Pergola*, Silvestro Trizio, Pasquale Di Carlo, Paolo Taurisano, Marina Mancini, Maria Antonietta Nettis, Grazia Caforio, Annabella Di Giorgio, Alessandro Bertolino, Giuseppe Blasi



M183. WHITE MATTER MICROSTRUCTURE AND PHOSPHOLIPASE A2 ACTIVITY IN DRUG-NAÏVE PATIENTS WITH FIRST-EPISEODE PSYCHOSIS: A STATE-DEPENDENT STUDY

Mauricio Serpa*, Jimit Doshi, Tiffany Chaim, Martinus Van De Bilt, Paulo Sallet, Helena Passarelli Giroud Joaquim, Leda Leme Talib, Wagner Gattaz, Geraldo Busatto, Davatzikos Christos, Marcus Zanetti

M184. A COMPREHENSIVE AND SYSTEMATIC REVIEW OF THE STRUCTURAL NEUROIMAGING UNDERPINNINGS OF THOUGHT DISORDER IN SCHIZOPHRENIA

Philip Sumner*, Imogen Bell, Susan Rossell

M185. BRAIN SUBTYPING ENHANCES NEUROIMAGING PREDICTIONS OF SCHIZOPHRENIA GROUP MEMBERSHIP

Dominic B. Dwyer*, Carlos Cabral, Lana Kambeitz-Ilankovic, Joseph Kambeitz, Peter Falkai, Nikolaos Koutsouleris

M186. IDENTIFICATION OF TWO CLUSTERS WITHIN SCHIZOPHRENIA DIAGNOSIS WITH DIFFERENT STRUCTURAL, FUNCTIONAL AND CLINICAL CHARACTERISTICS.

Alba Lubeiro Juárez*, Cristina Rueda, Juan Antonio Hernandez, Javier Sanz, Fernando Sarraimea, Vicente Molina Rodriguez

M187. ABNORMALITIES OF LANGUAGE PATHWAYS IN PATIENTS WITH SCHIZOPHRENIA WITH AND WITHOUT AUDITORY HALLUCINATIONS: A DTI-BASED TRACTOGRAPHY STUDY

Leroux Elise*, Delcroix Nicolas, Sonia Dollfus

M188. SCHIZOPHRENIA AND PSYCHOTIC BIPOLAR I DISORDER: CORTICAL GYRIFICATION AND BRAINAGE SCORES DIFFERENCES

Igor Nenadic*, Raka Maitra, Kerstin Langbein, Maren Dietzek, Heinrich Sauer, Christian Gaser

M189. HETEROGENEITY OF BRAIN STRUCTURAL ENDOPHENOTYPES OF SCHIZOPHRENIA

Igor Nenadic*, Heinrich Sauer, Christian Gaser

M190. THE INFLUENCE OF AHI1 VARIANTS ON THE DIAGNOSIS AND TREATMENT OUTCOME IN SCHIZOPHRENIA

Jung Jin Kim*, Seung Hyun Kim, Jung-Seo Yi, Chi-Un Pae

M191. WHITE MATTER RELATED GENES:ASSOCIATION STUDY IN BOTH SCHIZOPHRENIA AND AUTISM SPECTRUM DISORDERS

Mar Fatjo-Vilas*, Claudia Prats, Maria Jose Penzol, Kebir Ossama, Laura Pina, Gilles Martinez, Fayçal Mouffak, Carmen Moreno, Nemat Jaafari, Edith Pomarol-Clotet, Salvador Miret, Ana Gonzalez-Pinto, Víctor Peralta, Mara Parededa, Marie-Odile Krebs, Lourdes Fañanas

M192. EXPRESSION OF GRM3 AND OF THE SPLICING ISOFORM GRM3Δ4 IN HUMAN POST-MORTEM HIPPOCAMPAL TISSUE ACROSS THE LIFESPAN: RELEVANCE TO SCHIZOPHRENIA

Elisabetta F. Buonaguro*, Gianluca Ursini, Joo Heon Shin, Andrew E. Jaffe, Thomas M. Hyde, Joel E. Kleinmann, Andrea de Bartolomeis, Daniel R. Weinberger



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

M193. DIFFERENT MULTILEVEL PHENOTYPES FOR SCHIZOPHRENIA BASED ON DISRUPTED SIGNALING GENES

Dolores Malaspina*, Thorsten Kranz, Karen Rothman, Adam Berns, Jerry Shields, Raymond Goetz, Moses Chao

M194. GENOME-WIDE EXPRESSION AND DNA METHYLATION ANALYSIS IN A BRAZILIAN COHORT OF ANTIPSYCHOTIC-NAIVE FIRST EPISODE OF PSYCHOSIS PATIENTS

Marcos Leite Santoro*, Simone De Jong, Vanessa Ota, Patricia Moretti, Eduardo Gouvea, Cristiano Noto, Ary Gadelha, Quirino Cordeiro, Rodrigo Bressan, Gerome Breen, Belangero Sinta

M195. BRAIN ASYMMETRY AND SCHIZOPHRENIA IN THE POSTGENOMIC AGE – HOW A SYMPTOM-BASED APPROACH MIGHT HELP UNCOVERING THE GENETIC LINK

Marco Hirnstein*, Onur Güntürkün, Kenneth Hugdahl, Sebastian Ocklenburg

M196. LACK OF ASSOCIATION AND LINKAGE OF SCHIZOPHRENIA TO CHROMOSOME 22Q11 IN KOREAN POPULATION

Yu Sang Lee*, Kyung Sue Hong, Se-Chang Yoon, Eunsoog An

M197. DISTURBANCE OF METABOTROPIC GLUTAMATE RECEPTOR-MEDIATED LONG-TERM DEPRESSION (MGLU-LTD) OF EXCITATORY SYNAPTIC TRANSMISSION IN THE RAT HIPPOCAMPUS AFTER PRENATAL IMMUNE CHALLENGE

Mélanie Cavalier, Azza Ben Sedrine, Léa Thevenet, Nadine Crouzin, Janique Guiramand, Marie-Céleste de Jésus Ferreira, Catherine Cohen-Solal, Gérard Barbanel, Michael Vignes*

M198. ERBB SIGNALING INHIBITION AMELIORATE BEHAVIORAL DEFICIT INDUCED BY PHENCYCLIDINE (PCP) IN MICE

Alon Shamir*

M199. GLUTAMATE DEHYDROGENASE-DEFICIENT MICE: A NOVEL MOUSE MODEL OF SCHIZOPHRENIA-LIKE PHENOTYPES

Sharon S. Lander*, Reut Donner, Nicole Lewandowski, Susana Mingote, Pierre Maechler, Stephen Rayport, Scott S. Small, Inna Gaisler-Salomon

M200. DEFICITS IN NEURONAL AND GABAERGIC MARKERS IN THE FRONTAL CORTEX FOLLOWING SUB-CHRONIC PHENCYCLIDINE TREATMENT IN THE RAT – CORRELATES WITH SCHIZOPHRENIA

Daniela Cadinu*, Samuel Marsh, Stephen Williams, Giovanni Podda, Charles Large, Joanna Neill, Michael Harte

M201. CONSTITUTIVE LOSS OF ERBB4 SIGNALING DOES NOT AFFECT ATTENTION AND INHIBITORY CONTROL IN MICE

Elena Marchisella*, Ruud Wijnands, August B. Smit, Sabine Spijker, Maarten Loos

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



M202. MULTIMODAL BRAIN ANALYSIS IN PSYCHOSIS RISK – THE OULU BRAIN AND MIND STUDY

Juha Veijola*, Vesa Kiviniemi, Tuomas Jukuri, Jenni Koivukangas, Johannes Pulkkinen, Sari Mikkala, Pirjo Mäki, Jennifer Barnett, Peter Jones, Graham Murray

M203. THE EFFECT OF DEVIANCE PREDICTABILITY ON MISMATCH NEGATIVITY IN SCHIZOPHRENIA PATIENTS

Bernhard Müller*, Magdalena Horacek, Christian Kärger, Norbert Scherbaum

M204. DEVELOPMENTAL MOLECULAR PROFILES OF HUMAN CHOROID PLEXUS EPITHELIAL CELLS DETERMINED BY WHOLE TRANSCRIPTOME RNA SEQUENCING

Katina Athanas*, Emily Kohlbrenner, Stephen Jackson, Kamini Varma, Sarah Mauney, Sabina Baretta, Kai Sonntag, Tsung-Ung Wilson Woo

M205. AUGMENTATION OF HUMAN NEOCORTICAL GAMMA OSCILLATIONS WITH A NOVEL KV3 POSITIVE MODULATOR IN VITRO.

Claire Gillougley, Tamara Modebadze, Damian Holliman, Otto Major, Claire Nicholson, Guiseppe Alvaro, Charles Large, Fiona LeBeau, Mark Cunningham*

M206. FRAGMENTATION OF THE PRESYNAPTIC PROTEIN SNAP-25 IS REDUCED IN THE ORBITOFRONTAL CORTEX OF SUBJECTS WITH SCHIZOPHRENIA: A POSSIBLE MECHANISM ENHANCING SNARE FUNCTION

Alfredo Ramos-Miguel*, Alasdair Barr, Andrew Dwork, Gozard Rosoklija, John Mann, William Honer

M207. GLUTAMATE DECARBOXYLASE, SOMATOSTATIN AND PARVALBUMIN EXPRESSION IN THE THALAMIC RETICULAR NUCLEUS IN PATIENTS WITH SCHIZOPHRENIA AND MOOD DISORDERS.

Martin Burgess*, Debora Rothmond, Maree Webster, Cyndi Shannon Weickert

M208. OBSTETRIC COMPLICATIONS AND NEUROCOGNITION IN EARLY-ONSET SCHIZOPHRENIA

Bjorn Rund*, Charlotte Teigset, Christine Mohn

M209. N-ACETYLCYSTEINE PREVENTS THE EMERGENCE OF SCHIZOPHRENIA-LIKE BEHAVIORS IN AN ENVIRONMENTAL TWO-HIT MOUSE MODEL

Ana Herrmann*, Sandra Giovanoli, Urs Meyer, Elaine Elisabetsky

M210. RISK FACTORS MODERATING THE RELATIONSHIP BETWEEN CHILDHOOD TRAUMA AND PREMORBID ADJUSTMENT IN FIRST-EPISODE SCHIZOPHRENIA (FES) PATIENTS.

Sanja Kilian*, Jonathan Burns, Soraya Seedat, Laila Asmal, Bonginkosi Chiliza, Robin Emsley

M211. AUTISM – SCHIZOPHRENIA CONTINUUM HYPOTHESIS IN THE LIGHT OF SOCIAL COGNITION

Gilles Martinez*, Célia Mam-Lam-Fook, Charlotte Alexandre, Narjes Bendjemaa, Raphaël Gaillard, Marie-Odile Krebs, Isabelle Amado



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

M212. ACUTE OR CHRONIC TREATMENT WITH THE ANTIOXIDANT N-ACETYL-CYSTEINE (NAC) RESTORES BEHAVIOR DEFICITS IN MALE RATS OF AN ANIMAL MODEL OF SCHIZOPHRENIA BASED ON NEURODEVELOPMENT

Cristiane Salum*, Inda Lages Nascimento, Angela Rodrigues, Erickson Alves da Silva Souza

M213. FUNCTIONAL ANALYSIS OF SCHIZOPHRENIA-ASSOCIATED GENES DURING ZEBRAFISH DEVELOPMENT

Summer Thyme*, Eric Li, Carrie Sha, Owen Randlett, Steven Zimmerman, Lindsey Pieper, Elizabeth Hubbard, Alix Lacoste, Steven McCarroll, Alexander Schier

M214. COMBINATION OF MAINTENANCE ELECTROCONVULSIVE THERAPY (ECT) AND CLOZAPINE IN PATIENT WITH REFRACTORY SCHIZOPHRENIA : A CASE REPORT

Chul Eung Kim*, Seri Maeng, Jun Hwan Shin

M215. GROUP COGNITIVE-BEHAVIORAL THERAPY FOR KOREAN PATIENTS WITH EARLY PSYCHOSIS

Sung-Wan Kim*, Ga-Young Lee, Hye-Young Yu, Jin-Hee Hong, Jae-Kyeong Kim, Eun-I Jung, Ji-Hyun Park, Cheol Park, Ji-Eun Jang, Jin-Sang Yoon

M216. PEER SUPPORT GROUPS IN THE COMMUNITY AS AN EVOLUTION FROM A PSYCHOEDUCATION PROGRAM: THE EXPERIENCE FROM RIO DE JANEIRO

Leonardo Palmeira*, Olga Leão, Elías Carim Neto, Alexandre Keusen

M217. BASELINE TONE MATCHING ABILITY FACILITATES PERSONALIZATION OF COGNITIVE REMEDIATION APPROACH

Alice Medalia*, Alice Saperstein, Daniel Javitt, Seonjoo Lee

M218. ENVIRONMENTAL ENRICHMENT PREVENTS THE CONTEXTUAL FEAR CONDITIONING DEFICIT IN AN ANIMAL MODEL OF SCHIZOPHRENIA: POSSIBLE ROLE OF BDNF

Camila Santos, Agustin Anastasia, Fernanda Peres, Mariana Diana, Douglas Gouvêa, Vanessa Abilio*

M219. COGNITIVE BEHAVIOURAL THERAPY FOCUSING ON SOCIAL FUNCTIONING IN ADOLESCENTS WITH RECENT ONSET SCHIZOPHRENIA

Carin Meijer*, Eva Velthorst, Frederike Schirmbeck, Nathalie Franke, Elles Messchaert, Lieuwe De Haan

M220. A SMARTPHONE APPLICATION APPROACH TO SUPPORT TREATMENT OF (ATTENUATED) PSYCHOTIC SYMPTOMS IN ADOLESCENTS

Nina Traber-Walker*, Stephan Philipp, Miriam Gerstenberg, Maria Raquel Joris, Susanne Walitz, Maurizia Francini

M221. TRANSCRANIAL MAGNETIC STIMULATION, TRANSCRANIAL DIRECT CURRENT STIMULATION AND ELECTROCONVULSIVE THERAPY FOR MEDICATION-RESISTENT PSYCHOSIS OF SCHIZOPHRENIA

Sanne Koops*, Wendy Nieuwdorp, Metten Somers, Iris Sommer

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



M222. STEM CELL DERIVED INTERNEURON TRANSPLANTS AS A TREATMENT FOR SCHIZOPHRENIA: PRECLINICAL VALIDATION IN A RODENT MODEL.

Jennifer Donegan*, Jennifer Tyson, Sarah Branch, Michael Beckstead, Stewart Anderson, Daniel Lodge

M223. CAPTURING THE INDIVIDUAL ENVIRONMENT OF PATIENTS. BASIS FOR TARGETED PSYCHOTHERAPY.

Inez Myin-Germeys*, Dina Collip, Margreet Oorschot, Johan Lataster, Nicole Geschwind, Marieke Wichers, Tineke Lataster

M224. CLIMB: A MOBILE APP INTERVENTION TO TREAT SOCIAL COGNITION IMPAIRMENTS AND IMPROVE SOCIAL FUNCTIONING IN CHRONIC PSYCHOSIS

Bruno Biagiatti*, Danielle Schlosser, Josh Woolley, Mor Nahum, Sophia Vinogradov

M225. HARNESSING THE POWER OF LATENT PROFILE ANALYSIS TO CLASSIFY NONCLINICAL ADOLESCENTS USING PSYCHOMETRIC INDICATORS OF RISK

Diane Carol Gooding*, Eduardo Fonseca-Pedrero, Javier Ortuño-Sierra, Madeline Pflum, Mercedes Paino, José Muñiz

M226. LONGITUDINAL CHANGES IN AUDITORY VERBAL HALLUCINATIONS IN SCHIZOPHRENIA

Samuel Hwang*, Yong Sik Kim, Hee-Yeon Jung

M227. COGNITIVE BIASES MODERATE PARANOIA AND SUBJECTIVE DISTRESS IN RESPONSE TO SOCIAL STRESS

Wim Veling*, Roos Pot-Kolder, Jacqueline Counotte, Jim Van Os, Mark van der Gaag

M228. ASSOCIATIONS BETWEEN ACOUSTICALLY MEASURED TONGUE AND JAW MOVEMENTS AND NEGATIVE SYMPTOM SEVERITY IN PATIENTS WITH SCHIZOPHRENIA IN ITALY AND THE UNITED STATES

Francesco Bernardini*, Anya Lunden, Michael Covington, Beth Broussard, Brooke Halpern, Yazeed Alolayan, Anthony Crisafio, Luca Pauselli, Leslie Capulong, Roberto Quartesan, Michael Compton

M229. THE CHICKEN OR THE EGG? WHETHER RESILIENCE PRECEDE OR FOLLOW RECOVERY IN SCHIZOPHRENIA.

Anne-Kari Torgalsboen*, Susie Fu, Nikolai Czajkowski

M230. COMPARING THE LIVED-EXPERIENCES OF FIRST-EPIISODE PSYCHOSIS SERVICE-USERS WITH DIFFERING EARLY NEGATIVE SYMPTOM TRAJECTORIES: A MIXED METHODS STUDY

Brioney Gee*, Jo Hodgkins, David Fowler, Caitlin Notley, Anna Lavis

M231. THE CASCADE OF STRESS: A NETWORK APPROACH TO EXPLORE DIFFERENTIAL DYNAMICS IN POPULATIONS VARYING IN FAMILIAL RISK FOR PSYCHOSIS

Annelie Klippel*, Wolfgang Viechtbauer, Ulrich Reininghaus, Johanna Wigman, Claudia Van Borkulo, Inez Myin-Germeys, Marieke Wichers



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

M232. A PROVISIONAL QUALITATIVE ANALYSIS OF THE MEANING OF AND INFLUENCES ON RECOVERY ACCORDING TO PEOPLE DIAGNOSED WITH A FIRST EPISODE PSYCHOSIS 20 YEARS AGO AND THEIR FAMILY MEMBERS/PARTNERS

Donal O'Keeffe*, Ann Sheridan, Aine Kelly, Roisin Doyle, Kevin Madigan, Elizabeth Lawlor, Mary Clarke

M233. A SYSTEMATIC REVIEW AND META-SYNTHESIS OF SERVICE USERS' PERCEPTIONS OF THE MEANING OF AND INFLUENCES ON RECOVERY IN PSYCHOSIS

Donal O'Keeffe*, Brian Keogh, Angela Kearney, Carla Senf, Mary Clarke, Agnes Higgins

M234. CLOZAPINE THERAPEUTIC DRUG MONITORING FROM CAPILLARY BLOOD USING THE DRIED BLOOD SPOTS TECHNIQUE.

Dan Cohen*, Lisanne Geers, Daan Touw, Anton Loonen

M235. FIRST INTERVENTION PHARMACOLOGICAL TREATMENT OF INVOLUNTARILY COMMITTED PATIENTS WITH SCHIZOPHRENIA, SCHIZOTYPAL OR DELUSIONAL DISORDER OVER A 16 YEAR OBSERVATION PERIOD

Monika Edlinger*, Anna-Sophia Welte, Georg Kemmler, Nursen Yalcin-Siedentopf, Wolfgang Fleischhacker, Alex Hofer

M236. ANTIPSYCHOTIC-RELATED FATAL POISONING (ENGLAND AND WALES, 1993-2013)

Simon Handley, Maxine Patel*, Robert Flanagan

M237. CORRELATES OF CLOZAPINE USE AFTER A FIRST EPISODE OF SCHIZOPHRENIA COMPARED TO PATIENTS NOT PRESCRIBED CLOZAPINE: RESULTS FROM A LONG-TERM, PROSPECTIVE STUDY OF 105 FIRST-EPISODE PATIENTS

Alp Uçok*, Uğur Çıkrıklılı, Sercan Karabulut, Öznur Tabak, Ada Salaj, Ceylan Ergül, Christoph Correll

M238. ASSOCIATION BETWEEN WEIGHT GAIN AND REMISSION STATUS IN FIRST-EPISODE PSYCHOSIS

Nicholas Oh, Yuen Mei See, Gary Remington, Jimmy Lee*

M239. ADJUNCTIVE LURASIDONE SUPPRESSES FOOD INTAKE AND WEIGHT GAIN ASSOCIATED WITH OLANZAPINE ADMINISTRATION IN RATS

Gavin Reynolds*, Caroline Dalton, William Watremez, Joshua Jackson, Michael Harte

M240. MULTIDRUG RESISTANCE 1 C3435T AND CYP3A4*1B POLYMORPHISMS MAY DETERMINE ANTIPSYCHOTIC RESPONSE BASED ON THE FIVE SYMPTOMATIC DOMAINS OF SCHIZOPHRENIA AND RELATED DISORDERS

Rosa Catalán*, Alexandre González-Rodríguez, Rafael Penadés, María Jesús Arranz, Blanca Gutiérrez, Fina Pérez-Blanco, Victoria Ruiz, Mercè Torra, Miquel Bernard

M241. THE IMPACT OF MENOPAUSE IN TREATMENT OUTCOMES IN WOMEN WITH SCHIZOPHRENIA

Diego Novick*, William Montgomery, Maria Victoria Moneta, Ahmed El-Shafei, Yan Cheng, Josep Maria Haro



M242. MORTALITY AND CUMULATIVE EXPOSURE TO ANTIPSYCHOTICS, ANTIDEPRESSANTS AND BENZODIAZEPINES

Jari Tiihonen*, Ellenor Mittendorfer-Rutz, Minna Torniainen, Kristina Alexanderson, Antti Tanskanen

M243. THE INFLUENCE OF ANTIPSYCHOTIC TREATMENT ON PERIPHERAL CYTOKINES

Rune A Kroken*, Øystein Bruserud, Farivar Fathian, W. Wolfgang Fleischhacker, Else-Marie Løberg, Solveig Klæbo Reitan, Maria Rettenbacher, Vidar Steen, Silje Skrede, Erik Johnsen

M244. RATE AND PREDICTORS OF NON-RESPONSE TO FIRST-LINE TREATMENT IN FIRST-EPIISODE SCHIZOPHRENIA

Bonginkosi Chiliza*, Laila Asmal, Sanja Kilian, Lebogang Phahladira, Robin Emsley

M245. MODAFINIL COMBINED WITH COGNITIVE TRAINING IMPROVES NEURAL EFFICIENCY DURING WORKING MEMORY RELATIVE TO PLACEBO COMBINED WITH COGNITIVE TRAINING IN HEALTHY VOLUNTEERS: A RANDOMISED-CONTROLLED TRIAL WITH FMRI.

James Gilleen*, Panagiota Michalopoulou, Sukhi Shergill, James Gilleen

M246. GWAS ANALYSIS OF TREATMENT SCHIZOPHRENIA: INTERACTION EFFECT OF CHILDHOOD TRAUMA

Vincenzo De Luca*, Arthur Koga, Philip Gerretsen, Ariel Graff, Ali Bani Fatemi, Nuwan Hettige, John Strauss, Clement Zai, Gary Remington, Carol Borlido

M247. CLOZAPINE IS PRESCRIBED ONCE DAILY IN A MAJORITY OF PATIENTS IN NORTH AMERICA: FINDINGS FROM TWO PSYCHIATRIC INSTITUTES IN UNITED STATES AND CANADA
Hiroyoshi Takeuchi*, Valerie Powell, Stephen Geisler, Michelle DeSanti, Gagan Fervaha, Ofer Agid, John Kane, Gary Remington

M248. ANTIPSYCHOTIC DOSE REDUCTION IN SCHIZOPHRENIA: A SYSTEMATIC REVIEW
Hideaki Tani*, Hiroyuki Uchida, Takefumi Suzuki, Nobuhiro Nagai, Masaru Mimura, Hiroyoshi Takeuchi

M249. LONG-ACTING INJECTABLE ANTIPSYCHOTICS IN FIRST EPISODE PSYCHOSIS-PERSPECTIVES OF FAMILIES

Nishardi Wijeratne*, Ranjith Chandrasena

M250. EARLY SCHIZOPHRENIA PATIENTS TREATED WITH ONCE-MONTHLY PALIPERIDONE PALMITATE OVER A 12-MONTH PERIOD - A RETROSPECTIVE OBSERVATIONAL STUDY

Ludger Hargarter*, Paul Bergmans, Pierre Cherubin, Andreas Schreiner

M251. ASSOCIATION OF BIRTH WEIGHT AND THE DEVELOPMENT OF ANTIPSYCHOTIC INDUCED ADIPOSITY IN INDIVIDUALS WITH SCHIZOPHRENIA

Emilio Fernandez-Egea*, Hisham Ziauddeen, Clemente Garcia-Rizo, Yulia Worbe, Miquel Bernardo, Brian Kirkpatrick, Sue Ozanne, Peter Jones



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

M252. ANTIPSYCHOTIC RESPONSE RATES AND CORRELATIONS WITH THE FIVE SYMPTOMATIC DOMAINS IN SCHIZOPHRENIA AND DELUSIONAL DISORDER: A CASE-CONTROL STUDY

Alexandre González-Rodríguez*, Rafael Penadés, Victoria Ruiz, Mercè Torra, Miquel Bernardo, Rosa Catalán

M253. CLINICAL PREDICTORS OF TREATMENT RESISTANCE IN FIRST EPISODE SCHIZOPHRENIA; A 5 YEAR FOLLOW UP STUDY

John Lally*, Olesya Ajnakina, Arsime Demjaha, Anna Kolliakou, Antonella Trotta, Valeria Mondelli, Tiago Reis Marques, Carmine Pariante, Dazzan Paola, Sukhi Shergill, Oliver Howes, Anthony David, James H MacCabe, Fiona Gaughran, Robin Murray

M254. PHARMACOLOGICAL CHARACTERIZATION OF THE NOVEL GLYCINE TRANSPORTER-1 INHIBITOR BI 425809 ON TARGET ENGAGEMENT IN-VIVO AND IN ANIMAL MODELS RELATED TO COGNITIVE SYMPTOMS OF SCHIZOPHRENIA

Holger Rosenbrock*, Riccardo Giovannini, Bernhard Schmid, Gert Kramer, Roberto Arban, Cornelia Dorner-Ciossek

M255. EXAMINING THE ASSOCIATION BETWEEN SOCIAL COGNITION AND FUNCTIONING IN INDIVIDUALS AT ULTRA-HIGH RISK FOR PSYCHOSIS

Jack Cotter*, Cali Bartholomeusz, Alicia Papas, Kelly Allott, Barnaby Nelson, Alison Yung, Andrew Thompson

M256. ONSET AGE AS A PREDICTOR FOR CLINICAL OUTCOME IN SCHIZOPHRENIA – A SYSTEMATIC REVIEW AND META-ANALYSIS

Johanna Immonen*, Jouko Miettunen, Erika Jääskeläinen

M257. LEVELS OF STRESS, TOLERANCE TO STRESS, AND THE RELATIONSHIP BETWEEN STRESS AND DISTRESS ASSOCIATED WITH ATTENUATED POSITIVE SYMPTOMS IN PEOPLE AT ULTRA-HIGH RISK FOR PSYCHOSIS.

Hannah Ball*, Kinza Janjua, Renate Reniers, Stephen Wood

M258. BEYOND A SINGULAR APPROACH: EXPLORING THE MULTIPLE FACETS OF MOTIVATION IN SCHIZOPHRENIA

Susana Da Silva*, Sarah Saperia, Gagan Fervaha, Ishraq Siddiqui, Ofer Agid, Arun Ravindran, Konstantine Zakzanis, Gary Remington, George Foussias

M259. CLINICAL AND SOCIAL TRAJECTORIES OF FIRST EPISODE PSYCHOSIS PATIENTS OVER FIVE YEARS: THE ROLE OF GENDER DIFFERENCES

Carla Comacchio*, Antonio Lasalvia, Doriana Cristofalo, Chiara Bonetto, Sarah Tosato, Gioia Zanatta, Elisabetta Miglietta, Silvia Zoppi, Sara Petterlini, Katia De Santi, Stylianos Nicolaou, Rossana Riolo, Mirella Ruggeri

M260. INSIGHT AND ADHERENCE IN PRIMARY AND SECONDARY PERSISTENT NEGATIVE SYMPTOMS: A LONGITUDINAL INVESTIGATION OF FIRST-EPISODE SCHIZOPHRENIA.

Michael Bodnar*, Ashok Malla, Ridha Joobar, Martin Lepage

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



M261. ARE SELF-REPORT MEASURES OF SOCIAL FUNCTIONING ASSOCIATED WITH REAL-LIFE SOCIAL FUNCTIONING? AN ESM STUDY IN PATIENTS WITH SCHIZOPHRENIA AND HEALTHY CONTROL INDIVIDUALS

Maude Schneider*, Ulrich Reininghaus, Martine Van Nierop, Mayke Janssens, Inez Myin-Germeys, on behalf of GROUP

M262. A 6-YEAR FOLLOW-UP OF PATIENTS WITH SEVERE SCHIZOPHRENIA UNDERGOING INTENSIVE AND COMPREHENSIVE TREATMENT: CLINICAL AND FUNCTIONAL OUTCOMES

Juan J. Fernandez-Miranda*, Silvia Diaz-Fernandez

M263. ACTIVE RECOVERY TRIAD. A NEW INITIATIVE TO PROVIDE HOPE AND PERSPECTIVE FOR PATIENTS WITH SEVERE MENTAL ILLNESS IN NEED OF LONG-TERM CLINICAL CARE

Lisette Van der Meer*, Tom van Mierlo, Bram Berkvens, Bert Stavenuiter, Yolande Voskes, Jaap van Weeghel

M264. INTERPERSONAL CONSEQUENCES OF SUBCLINICALLY REDUCED EXPRESSIVENESS - AN EMG STUDY OF FACIAL EXPRESSIONS

Marcel Riehle*, Tania M. Lincoln

M265. LANGUAGE DISTURBANCE AND FUNCTIONAL OUTCOME FOLLOWING FIRST EPISODE PSYCHOSIS

Eric Roche*, Ricardo Segurado, Brian O'Donoghue, Felicity Fanning, Laoise Renwick, Caragh Behan, Kevin Madigan, John Lyne, Mary Clarke

M266. LONG TERM TRAJECTORIES OF POSITIVE AND NEGATIVE SYMPTOMS IN FIRST EPISODE PSYCHOSIS: A 10 YEAR FOLLOW-UP STUDY IN THE OPUS COHORT.

Stephen Austin*, Esben Budtz-Jørgensen, Ole Mors, Rikke Gry Secher, Carsten Hjorthøj, Mette Bertelsen, Pia Jeppesen, Lone Petersen, Anne Thorup, Merete Nordentoft

M267. VALIDATION OF A GERMAN VERSION OF THE RESILIENCE SCALE FOR ADULTS (RSA)

Nathalie Kaiser*, Mauro Seves, Stephan Ruhrmann

M268. PSYCHOPATHOLOGY AND FUNCTIONING IN PATIENTS WITH A RECENT ONSET PSYCHOSIS (ROP) - FIRST RESULTS FROM THE PRONIA STUDY

Marlene Rosen*, Nathalie Kaiser, Theresa Haidl, Frauke Schultze-Lutter, Stefan Borgwardt, Paolo Brambilla, Christos Pantelis, Raimo K. R. Salokangas, Stephen Wood, Nikolaos Koutsouleris, Stephan Ruhrmann, and the PRONIA Group .

M269. ATTITUDE TOWARD MEDICATION, SUBJECTIVE WELL-BEING, AND PSYCHOPATHOLOGY IN THE EARLY TREATMENT OF SCHIZOPHRENIA PATIENTS.

Christian Widschwendter*, Susanne Baumgartner, Georg Kemmler, Maria Rettenbacher, Nursen Yalcin-Siedentopf, Wolfgang Fleischhacker, Alex Hofer



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

M270. CHARACTERIZING OUTCOME PREFERENCES IN PATIENTS WITH PSYCHOTIC DISORDERS:
A DISCRETE CHOICE CONJOINT EXPERIMENT

Robert Zipursky*, Charles Cunningham, Bailey Stewart, Heather Rimas, Emily Cole, Stephanie McDermaid Vaz

M271. "I'M OUT OF SYNCH AND ON MY OWN. I AM A SCHIZOPHRENIC." A MINI ETHNOGRAPHY
OF PATIENTS DIAGNOSED WITH SCHIZOPHRENIA IN POLAND.

Karolina Bryl*

M272. INSTRUMENTS TO MEASURE PUBLIC STIGMA AND SELF STIGMA – A REVIEW

Bouwina Sportel*, Marieke (Gerdina) Pijnenborg, Slynke Castelein

M273. IMPAIRED CARDIORESPIRATORY FITNESS (CRF) IN SCHIZOPHRENIA

Richard Hodgson*, Hiram Wildgust

M274. DEVELOPMENT OF THE SUBJECTIVE RECOVERY SCALE FOR THE PATIENTS WITH
SCHIZOPHRENIA (SRS)

Mustafa Yıldız*, Rahsan Erim, Haldun Soygür, Ümit Tural

M275. ASSESSING THE RELEVANCE OF THE QUALITY OF LIFE SCALE IN SCHIZOPHRENIA:
PATIENT AND CAREGIVER PERSPECTIVES

Dieter Naber*, Maud Beillat, Dana B. DiBenedetti, T. Michelle Brown

M276. ON THE RELATIONSHIP BETWEEN DELUSIONS AND QUALITY OF LIFE IN
SCHIZOPHRENIA

Eric Tan*, Susan Rossell

M277. FIRST EPISODE PSYCHOSIS FIDELITY SCALE

Donald Addington*, Ross Norman, Gary Bond, Tamara Sales, Ryan Melton, Emily McKenzie, JianLi Wang

M278. DISCONTENTED RESIDENTS OF SHELTERED HOMES: BETTER FUNCTIONING AND WORSE
QUALITY OF LIFE

Satu Viertio*, Eila Sailas

M279. DEVOLVEMENT OF THE DANISH OPUS-FIDELITY-SCALE FOR SPECIALIZED EARLY
INTERVENTION TEAMS

Marianne Melau*, Merete Nordentoft

M280. ANALYZING THE IMPACT OF EARLY DETECTION ON DURATION OF UNTREATED
PSYCHOSIS: QUANTILE REGRESSION

Sinan Guloksuz, Fangyong Li, Cenk Tek, Scott Woods, Thomas McGlashan, Svein Friis, Vinod Srihari*

M281. OUTCOME EVALUATION OF A CANADIAN FIRST EPISODE PSYCHOSIS PROGRAM.

Sharman Robertson*, Paul Roy, Gretchen Conrad, Angela Stevens



M282. IMPACT OF THE “UNLOCKING AND TREATMENT” INTERVENTION ON FAMILY BURDEN: A FOLLOW-UP STUDY FOR THE FAMILIES WHERE LOCKING OF PATIENTS WITH SMI WERE PRACTICED

Lili Guan*, Jin Liu, Xiamin Wu, Dafang Chen, Xun Wang, Ning Ma, Yan Wang, Byron Good, Xin Yu, Mary-Jo Good, Hong Ma

M283. EXTENT OF MONITORING AND INTERVENTION FOR PHYSICAL HEALTH ISSUES IN THE SINGAPORE EARLY PSYCHOSIS INTERVENTION PROGRAMME (EPIP)

Charmaine Tang*, Swapna Verma

M284. DEVIATION FROM THE 12-HOUR STANDARD SAMPLING TIME DURING THERAPEUTIC DRUG MONITORING OF CLOZAPINE – DOES IT MATTER?

Michelle Jakobsen*, Julie Larsen, Camilla Svensson, Sys Johansen, Kristian Linnet, Jimmy Nielsen, Anders Fink-Jensen

M285. CARDIAC AND CARDIOMETABOLIC ADVERSE EFFECTS IN CHILDREN AND ADOLESCENTS DURING TREATMENT WITH ARIPIRAZOLE OR QUETIAPINE ER – 12-WEEK RESULTS FROM THE TEA STUDY

Karsten Gjessing Jensen*, Christoph Correll, Stefan Gärtner, Ditte Rudå, Dea Gowers Klauber, Marie Stentebjerg-Olesen, Birgitte Fagerlund, Jens Richardt Jepsen, Anders Fink-Jensen, Anne Katrine Pagsberg

M286. DIFFERENCES IN EMOTION RECOGNITION AND ATTRIBUTIONAL STYLE BETWEEN PATIENTS WITH SCHIZOPHRENIA AND HEALTHY CONTROLS

Ingrid Tortadès*, Susana Ochoa, Emma Casas-Anguera, Mar Garcia-Franco, Maria José Escandell, José Ramón Martín, Sònia Vilamala, Gemma Prat, Pablo Gonzalez, Joaquin Fernandez

M287. NEUROLOGICAL SOFT SIGNS AS PREDICTORS OF CLINICAL OUTCOME FOR A MULTI-ELEMENT PSYCHOSOCIAL INTERVENTION ON FEP PATIENTS AND THEIR FAMILIES IN THE CLUSTER-RANDOMIZED CONTROLLED GET UP PIANO TRIAL

Sarah Tosato, Chiara Bonetto, Antonio Lasalvia, Angelo Fioritti, Giovanni de Girolamo, Paolo Santonastaso, Simona Tomassi, Silvio Scarone, Maurizio Miceli, Anna Meneghelli, Katia De Santi, Fausto Mazzi, Emanuela Pileggi, Doriana Cristofalo, Mirella Ruggeri*, The GET UP Group

M288. INTRA-ABDOMINAL FAT GAIN IN PATIENTS INITIATING TREATMENT WITH CLOZAPINE. Marina Garriga, Lourdes Serrano, Andrea Mallorquí, Anxela Torras, Cristina Oliveira, Miguel Bernardo Arroyo, Clemente Garcia-Rizo*

M289. GLUCOSE DISTURBANCES AT THE ONSET OF SERIOUS MENTAL ILLNESSES

Clemente Garcia-Rizo*, Brian Kirkpatrick, Cristina Oliveira, Emilio Fernandez-Egea, Miguel Bernardo

M290. RESTING STATE NETWORKS ALTERATION IN SCHIZOPHRENIA

Gianluca Mingoia*, Igor Nenadic



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

M291. EFFICACY AND SIDE EFFECTS OF ANTIPSYCHOTIC POLIPHARMACY IN A REAL CLINICAL SETTING

Jose Maria Pelayo-Teran*, Yolanda Zapico-Merayo, Jovita Martínez-Díez, Nicolás Martín-Navarro

M292. NEUROPHYSIOLOGICAL MARKERS OF PARANOID SCHIZOPHRENIA.

Andrei Arkhipov*

M293. THE STAR STATUS OF CLOZAPINE IN THE TREATMENT OF POSITIVE SYMPTOMS IN SCHIZOPHRENIA IS LESS VIGOROUS: AN UMBRELLA REVIEW

Ellen Letsoin, Peter F.J. Schulte, Jim Van Os, P. Roberto Bakker*

M294. REWARD LEARNING IN ADULTS WITH 22Q11DS.

Esther van Duin*, Zuzana Kasanova, meritt beck, Dennis Hernaus, Inez Myin-Germeys, Therese van Amelsvoort

M295. CROSS-COUNTRY VARIATIONS IN THE EFFECTS OF CHILDHOOD ABUSE ON PSYCHOSIS: INITIAL RESULTS FOR THE EU-GEI STUDY

Charlotte Gayer-Anderson, Kathryn Hubbard, Stephanie Beards, Bart Rutten, Jim van Os, Marta Di Forti, Robin Murray, Craig Morgan*

M296. INTERPLAY BETWEEN LIFE EVENTS AND FAMILIAL RISK IN THE ONSET OF PSYCHOSIS

Stephanie Beards, Charlotte Gayer-Anderson, Kathryn Hubbard, Valeria Mondelli, Paola Dazzan, Carmine Pariante, Robin Murray, Craig Morgan*

FINAL PROGRAM

FLORENCE, ITALY

2 – 6 APRIL 2016



POSTERS, TUESDAY 5 APRIL

11:00 AM - 1:00 PM

Location: Cavaniglia

Travel Awardee Posters are Circled

T1 USING A STRATIFIED APPROACH IN PSYCHIATRY – IMPLICATIONS FOR TREATMENT AND THE SEARCH FOR UNDERLYING MECHANISMS OF MENTAL ILLNESS

Martine Van Nierop*, Ruud van Winkel, Inez Myin-Germeys, Jim Van Os, Ron de Graaf, Margreet ten Have

T2. RELATIONSHIP BETWEEN CLOZAPINE INDUCED EEG ABNORMALITIES AND THE SERUM CONCENTRATION OF CLOZAPINE IN JAPANESE PATIENTS WITH SCHIZOPHRENIA

Yuka Kikuchi*, Wataru Sato, Yumiko Akamine, Takashi Kanbayashi, Tetsuo Shimizu

T3. EXTRAPYRAMIDAL SYMPTOMS DURING RISPERIDONE MAINTENANCE TREATMENT IN SCHIZOPHRENIA: A PROSPECTIVE, MULTICENTER STUDY

Qi-Jing Bo*, Xian-Bin Li, An-Ning Li, Zhi-Min Wang, Xin Ma, Chuan-Yue Wang

T4. THRESHOLD OF DOPAMINE D2/3 RECEPTOR OCCUPANCY FOR HYPERPROLACTINEMIA IN OLDER PATIENTS WITH SCHIZOPHRENIA

Yusuke Iwata*, Shinichiro Nakajima, Fernando Caravaggio, Takefumi Suzuki, Hiroyuki Uchida, Eric Plitman, Jun Ku Chung, Wanna Mar, Philip Gerretsen, Bruce Pollock, Benoit Mulsant, David Mamo, Ariel Graff-Guerrero

T5. CHILDHOOD NEGLECT DIFFERENTIALLY AFFECTS PSYCHOTIC PATIENTS IN COMPARISON TO HEALTHY SIBLINGS AND CONTROLS

Nadja Maric*, Marina Mihaljevic, Sanja Andric, Tijana Mirjanic

T6. IMMIGRATION AND COMMUNITY MENTAL HEALTH SERVICES: AN EXAMPLE OF AN EFFECTIVE OUTREACH DRUG TREATMENT PROGRAM.

Fran Calvo-García*, Cristina Giralt-Vázquez

T7. RISK OF SUICIDE AMONG HOMELESS WOMEN: GENDER DIFFERENCES IN THE STREETS OF GIRONA (CATALONIA).

Fran Calvo-García*, Cristina Giralt-Vázquez

T8. EFFECT OF BREXPIPIRAZOLE ON WEIGHT AND METABOLIC PARAMETERS: AN ANALYSIS OF SHORT- AND LONG-TERM TRIALS IN SCHIZOPHRENIA

Hans Eriksson*, Catherine Weiss, Mary Hobart, John Ouyang, Emmanuelle Weiller

T9. THE INTERACTION BETWEEN BULLYING AND FKBP5 HAPLOTYPE ON PSYCHOTIC-LIKE EXPERIENCES AND REACTIVITY TO STRESS: DOES IT MATTER IN REAL LIFE?

Paula Cristóbal-Narváez*, Tamara Sheinbaum, Araceli Rosa, Sergi Ballespí, Mercè Mitjavila, Marta de Castro-Català, Elionora Peña, Thomas R. Kwapił, Neus Barrantes-Vidal



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

T10. MISMATCH NEGATIVITY AND P3A AMPLITUDE IN YOUNG ADOLESCENTS WITH FIRST EPISODE PSYCHOSIS: A COMPARISON WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER

Jacob Rydkjaer, Jens Richardt Jepsen, Anne Katrine Pagsberg, Birgitte Fagerlund, Birte Glenthøj, Bob Oranje*

T11. THE FECAL MICROBIOTA OF PATIENTS WITH FIRST EPISODE PSYCHOSIS AND HEALTHY CONTROLS

Jaana Suvisaari*, Emanuel Schwarz, Tuula Kiesepää, Matej Oresic, Sarven Sabuncian, Outi Mantere, Maria Saarela, Robert Yolken, Johanna Maukonen

T12. ASSOCIATIONS OF NEONATAL MARKERS OF INFLAMMATION AND RISK OF AUTISM SPECTRUM DISORDERS

Christina Dalman*, Brian K Lee, Renee Gardner, Håkan Karlsson

T13. EPISODIC MEMORY IMPAIRMENTS ARE ASSOCIATED WITH FUNCTIONAL ALTERATIONS WITHIN THE MEMORY NETWORK IN SCHIZOPHRENIA

Viola Oertel*, Michael Stäblein, Denisa Ghinea, Helena Storchak, Dominik Kraft, Christian Knöchel, Andreas Reif

T14. CORPUS CALLOSUM INTEGRITY DISRUPTION IN TREATMENT RESISTANT SCHIZOPHRENIA

Idaiane Assunção*, Luciana Monteiro de Moura, André Zugman, João Ricardo Sato, Deyvis Rocha, Bruno Bertolucci Ortiz, Cristiano Noto, Rodrigo Bressan, Andrea Andrea Parolin Jackowski, Ary Gadelha

T15. POST-MORTEM EVIDENCE FOR INCREASED MICROGLIA ACTIVITY IN SCHIZOPHRENIA

Iris Sommer*, Charissa Van Kesteren, Rene Kahn

T16. A SYSTEMATIC REVIEW ON THE NEURAL CORRELATES OF APATHY WITHIN MULTIPLE PATIENT POPULATIONS, INCLUDING SCHIZOPHRENIA

Claire Kos*, Marie-Jose Van Tol, Jan Bernard Marsman, Henderikus Knegtering, Andre Aleman

T17. COGNITION AND PSYCHOPATHOLOGY IN FIRST EPISODE OF PSYCHOSIS: ARE THEY RELATED TO INFLAMMATION?

Bibiana Cabrera Llorca*, Miquel Bioque, Rafael Penades, Ana Gonzalez-Pinto, Mara Parellada, Julio Bobes, Antonio Lobo, Borja García-Bueno, Juan Carlos Leza, Miquel Bernardo

T18. RESPONSE TO CLOZAPINE TREATMENT AND NEUROTROPHIC FACTORS LEVEL AMONG SCHIZOPHRENIA PATIENTS

Amir Krivoy*, Eldar Hochman, Hollander Sarah, Weizman Abraham, Michal Taler

T19. IMPAIRMENTS IN PRE-ATTENTIVE AUDITORY PROCESSING AND THE CORTICAL THICKNESS OF ITS STRUCTURAL CORRELATES IN SCHIZOPHRENIA

Jiyeon Seol*, Minah Kim, Kang Ik Cho, June Sic Kim, Tae Young Lee, Jun Soo Kwon

FINAL PROGRAM

FLORENCE, ITALY

2 – 6 APRIL 2016



T20. GLUTAMATE-RELATED AMINOACIDS BEFORE AND AFTER 10 WEEKS OF ANTIPSYCHOTIC TREATMENT IN DRUG NAÏVE FIRST-EPISODE PSYCHOSIS

Beyazit Garip*, Hakan Kayir

T21. ABERRANT TYROSINE TRANSPORT ACROSS PLASMA MEMBRANE - AN ENDOPHENOTYPE MARKER IN SCHIZOPHRENIA

Lena Flyckt*, Nikolaos Venizelos

T22. STRUCTURAL BRAIN CORRELATES OF STRESS REACTIVITY IN THE AT-RISK MENTAL STATE

Maria Calem*, Ulrich Reininghaus, Lucia Valmaggia, Barnaby Nelson, Eva Velthorst, Inez Myin-Germeys, Craig Morgan, Philip McGuire, Matthew Kempton, . EU-GEI At Risk Study

T23. LOW SERUM NOGO-A, UCH-L1 AND α -SYNUCLEIN LEVELS IN PATIENTS WITH SCHIZOPHRENIA COMPARED TO HEALTHY CONTROLS

Ömer Faruk Demirel*, İhsan Çetin, Tarık Sağlam, Nazım Yıldız, Alaattin Duran

T24. MISMATCH NEGATIVITY: ALTERATIONS IN NONCLINICAL ADULTS FROM THE GENERAL POPULATION WHO REPORT SUBCLINICAL PSYCHOTIC SYMPTOMS

Christian Döring*, Mario Müller, Florence Hagenmuller, Vladeta Ajdacic-Gross, Helene Haker, Wolfram Kawohl, Wulf Rössler, Karsten Heekeren

T25. CLINICAL AND COGNITIVE PERFORMANCE AND THE RS53576 SNP OF OXITOCINE RECEPTOR GENE (OXTR) IN RECENT ONSET PSYCHOSIS AND AT RISK MENTAL STATE (ARMS) SUBJECTS

Vanessa Sanchez-Gistau*, Sara Arranz, Montserrat Sole, Angel Cabezas, MJose Algora, Javier Labad, Elisabet Vilella

T26. DYSREGULATED 14-3-3 FAMILY IN SCHIZOPHRENIA

Ying Qing*, Liya Sun, Chao Yang, Jie Jiang, Xuhan Yang, Xiaowen Hu, Donghong Cui, Yifeng Xu, Lin He, Dongmei Han, Chunling Wan

T27. AEROBIC EXERCISE INCREASES BDNF AND PREDICTS ENHANCED COGNITIVE AND GLOBAL FUNCTIONING IN FIRST EPISODE SCHIZOPHRENIA: A UCLA PILOT RCT

Sarah McEwen*, Joseph Ventura, Kenneth Subotnik, Keith Nuechterlein

T28. CORRELATION BETWEEN BDNF SERUM LEVELS AND BASAL CLINICAL CHARACTERISTICS IN FIRST EPISODE PSYCHOSIS

Alba Toll*, Anna Mané, Daniel Berge, Víctor Pérez-Solà

T29. PLATELET SEROTONIN CONCENTRATIONS AND DEPRESSIVE SYMPTOMS OF SCHIZOPHRENIA

Vjekoslav Peitl*, Ante Silić, Draženka Ostojić, Ana Kovak Mufić, Danijel Crnković, Dalibor Karlović



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

T30. IS P300 AN ENDOPHENOTYPE FOR SCHIZOPHRENIA OR A STATE MARKER OF NEUROCOGNITIVE DEFICIT?: EVIDENCE FROM INTER-TRIAL VARIABILITY ANALYSIS
Minah Kim*, Hanwoom Hong, Ji-Hun Kim, Tak Hyung Lee, Tae Young Lee, Sung Nyun Kim, Youngjo Lee, Jun Soo Kwon

(T31) EXAMINING THE RELATIONSHIP BETWEEN GLUTAMATE AND AUDITORY MISMATCH NEGATIVITY (MMN) IN ANTIPSYCHOTIC-NAïVE/FREE PATIENTS WITH SCHIZOPHRENIA: PRELIMINARY FINDINGS FROM AN (1)H-MRS-EEG STUDY

Sri Mahavir Agarwal*, Anushree Bose, Hema Nawani, Venkataram Shivakumar, Anekal Amaresha, Boban Joseph, Janardhanan Narayanaswamy, Ganesan Venkatasubramanian

T32. INTERPERSONAL SENSITIVITY, BULLYING AND PARANOID IDEATION AMONG HELP-SEEKING ADOLESCENTS AND YOUNG ADULTS.

Alice Masillo*, Lucia Valmaggia, Riccardo Saba, Martina Brandizzi, Nella Lo Cascio, Juliana Fortes Lindau, Ludovica Telesforo, Paola Venturini, Valentino Righetti, Marco D'Alema, Paolo Girardi, Paolo Fiori Nastro

T33. MANAGEMENT OF PSYCHIATRIC SYMPTOMS IN PEDIATRIC ANTI-NMDA RECEPTOR ENCEPHALITIS: CASE REPORT AND SYSTEMATIC REVIEW

Sunny Tang*, Orna Alpert

T34. PREDICTING THE NEXT THREE YEARS: TESTING MULTIVARIATE PSYCHOSIS-RISK OUTCOME ALGORITHMS IN AN UNSELECTED ADOLESCENT PSYCHIATRIC SAMPLE

Sebastian Therman*, Maija Lindgren, Jaana Suvisaari, Tyrone Cannon

T35. SCHIZOTYPY IN THE EARLY- TO MID-TEENS PREDICTS PASSIVE SUICIDAL IDEATION TWO YEARS LATER

Richard Linscott*

T36. THE DISCRIMINATIVE VALUE OF THE STRAUSS AND CARPENTER PROGNOSTIC SCALE FOR PREDICTION OF CLINICAL DIAGNOSIS IN EARLY ONSET PSYCHOSIS

Raquel Vicente, Pilar Baos, Celso Arango*, Beatriz Paya, Angel del Rey-Mejias, Josefina Castro-Fornieles, Ana Gonzalez-Pinto, Montse Graell, Dolores Moreno, Marta Rapado-Castro

T37. BASELINE CHARACTERISTICS OF CHILDREN AND ADOLESCENTS WITH PSYCHOSIS RISK SYNDROME: A COMPARISON STUDY VERSUS HEALTHY CONTROLS

Inmaculada Baeza Pertegaz*, Elena De la Serna, Gisela Sugranyes, Olga Puig-Navarro, Clara Espelt, Marta Pardo, Daniel Muñoz, Jordina Tor, Ana Sintés, Montserrat Dolz

T38. TRANSITION TO PSYCHOSIS IN CHILDREN AND ADOLESCENTS AT ULTRA HIGH RISK IN ITALIAN NEUROPSYCHIATRY SERVICES: A FOLLOW-UP STUDY

Giulia Spada*, Silvia Molteni, Michela Tantardini, Federica Ferro, Matteo Chiappedi, Paolo Fusar-Poli, Umberto Balottin

FINAL PROGRAM

FLORENCE, ITALY

2 – 6 APRIL 2016



T39. PSYCHOSOCIAL CHARACTERISTICS OF VOICE HEARING IN NORWEGIAN ADOLESCENTS: A POPULATION-BASED STUDY

Else-Marie Løberg*, Rolf Gjestad, Maj-Britt Posserud, Kristiina Kompus, Astri Johansen Lundervold

T40. PREVALENCE, CLINICAL DIFFERENCES AND IMPACT OF ANXIETY DISORDERS ON CONVERSION TO PSYCHOSIS IN YOUTH AT HIGH RISK OF DEVELOPING PSYCHOSIS

Espadas Marta, Jordina Tor, Marta Carulla, Inmaculada Baeza, Montserrat Dolz*, Elena De la Serna

T41. ADOLESCENT TRAJECTORIES OF COGNITION AND RISK FOR PSYCHOSIS

Hannah Dickson*, Alexis Cullen, Rebecca Jones, Abraham Reichenberg, Ruth Roberts, Sheilagh Hodgins, Robin Morris, Kristin Laurens

T42. THE PRESENCE OF COMORBID MOOD DISORDER IN PSYCHOSIS RISK SYNDROME IN A CHILD AND ADOLESCENT SAMPLE HAS NO INFLUENCE IN TRANSITION RATES TO PSYCHOSIS

Marta Rodríguez, Xavier Álvarez, Álvaro Armendáriz, Jordina Tor, Marta Carulla, Marta Pardo, Daniel Muñoz, Elena De la Serna, Inma Baeza, Montse Dolz*

T43. NEURODEVELOPMENTAL DISORDERS AND THEIR IMPACT ON INITIAL TREATMENT FAILURE IN EARLY ONSET PSYCHOSIS: A HISTORICAL COHORT STUDY USING ELECTRONIC PATIENT RECORDS

Johnny Downs*, Suzannah Lechler, Harry Dean, Nicola Sears, Rashmi Patel, Hitesh Shetty, matthew Hotopf, Tamsin Ford, Celso Arango, James MacCabe, Richard Hayes, Laura Pina-Camacho

T44. PREDICTION OF FUNCTIONAL OUTCOME IN YOUNG PATIENTS WITH A RECENT-ONSET PSYCHIATRIC DISORDER: BEYOND THE TRADITIONAL DIAGNOSTIC CLASSIFICATION SYSTEM.

Amedeo Minichino*, Francesconi Marta, Ricardo Carrion, Kristin Cadenhead, Francesco Saverio Bersani, Maurizio Parisi, Santo Rullo, Massimo Biondi, Arturo Bevilacqua, Roberto Delle Chiaie

T45. PSYCHOSIS PREDICTION IN SECONDARY MENTAL HEALTH SERVICES. A BROAD, COMPREHENSIVE APPROACH TO THE “AT RISK MENTAL STATE” SYNDROME.

Marta Francesconi*, Amedeo Minichino, Kristin Cadenhead, Ricardo Carrion, Arturo Bevilacqua, Santo Rullo, Maurizio Parisi, Francesco Saverio Bersani, Massimo Biondi, Roberto Delle Chiaie

T46. THE BDNF VAL66MET GENOTYPE REGULATES PREPULSE INHIBITION OF ACOUSTIC STARTLE, AN ENDOPHENOTYPE OF SCHIZOPHRENIA: SENSITIVITY TO GLUCOCORTICOID STRESS HORMONE

Michael Notaras, Rachel Hill, Joseph Gogos, Maarten van den Buuse*

T47. ARC/ARG3.1 GENETIC DISRUPTION IN MICE CAUSES DOPAMINE SYSTEM ALTERATIONS AND NEUROBEHAVIORAL PHENOTYPES RELATED TO SCHIZOPHRENIA

Francesco Papaleo*, Francesca Managò, Kuan Wang

T48. PHASE II, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED STUDY OF ADJUNCTIVE TAURINE IN FIRST-EPIISODE PSYCHOSIS

Colin O'Donnell, Kelly Allott, Hok Pan Yuen, Patrick D. McGorry*



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

T49. THE EFFECT OF VIRTUAL REALITY EXPOSURE THERAPY ON SOCIAL PARTICIPATION IN PEOPLE WITH A PSYCHOTIC DISORDER: A MULTI-SITE RANDOMIZED CONTROLLED TRIAL

Roos Pot-Kolder*, Wim Veling, Mark Van der Gaag

T50. CORRELATION BETWEEN FUNCTIONALITY AND SYMPTOM CONTROL IN ACUTE SCHIZOPHRENIA PATIENTS

Tian mei Si*, Hua Fei Lu, Li Li Zhang, Yu Feng, Jian Min Zhuo, Shangli Cai

T51. ASSOCIATIONS OF NEGATIVE SYMPTOMS AND PSYCHOSOCIAL FUNCTIONING IN PATIENTS AT RISK FOR PSYCHOSIS

Katharina Beck*, Christina Andreou, Erich Studerus, Ulrike Heitz, Stephanie Menghini-Müller, Laura Egloff, Anita Riecher-Rössler

T52. EVALUATING THE VERBAL EPISODIC MEMORY DEFICITS IN EMERGING PSYCHOSIS USING STRUCTURAL EQUATION MODELING

Laura Egloff*, Erich Studerus, Ulrike Heitz, Stephanie Menghini-Müller, Sarah Ittig, Stefan Borgwardt, Anita Riecher-Rössler

T53. GENDER DIFFERENCES IN THE SYMPTOMATOLOGY OF PATIENTS AT-RISK FOR PSYCHOSIS - RESULTS FROM THE EU-GEI STUDY

Stephanie Menghini-Müller*, Erich Studerus, Ulrike Heitz, Laura Egloff, Sarah Ittig, EU-GEI Work Package 5, Anita Riecher-Rössler

T54. BEAT VICTIMIZATION! A PSYCHOMOTOR RESILIENCE TRAINING WITH ELEMENTS OF KICKBOXING FOR INDIVIDUALS WITH A PSYCHOTIC DISORDER: RESULTS OF A FEASIBILITY STUDY.

Elisabeth van der Stouwe*, Bertine de Vries, André Aleman, Jooske van Busschbach, Marieke Pijnenborg

T55. SUBJECTIVE EXPERIENCES IN PSYCHOSIS EARLY DETECTION – FACTOR STRUCTURE OF THE FRANKFURT COMPLAINT QUESTIONNAIRE

Martina Uttinger*, Erich Studerus, Sarah Ittig, Ulrike Heitz, Frauke Schultze-Lutter, Anita Riecher-Rössler

T56. PLASMA AND SERUM BRAIN DERIVED NEUROTROPHIC FACTOR LEVELS AND THEIR ASSOCIATION WITH NEUROCOGNITION IN AT-RISK MENTAL STATE, FIRST EPISODE AND CHRONIC SCHIZOPHRENIA PATIENTS

Ulrike Heitz*, Martina Pappmeyer, Erich Studerus, Tobias Vogel, Konstanze Römer, Sarah Ittig, Stefan Borgwardt, Marc Graf, Anne Eckert, Anita Riecher-Rössler

T57. LONG-TERM TOLERABILITY OF ARIPIRAZOLE ONCE-MONTHLY IN PATIENTS WITH SCHIZOPHRENIA FOLLOWING TREATMENT OF AN ACUTE EXACERBATION

John Kane, Timothy Peters-Strickland, Na Jin, Pamela Perry, Michelle Gara, Peter Hertel, Phyllis Salzman*, Anna Eramo, Raymond Sanchez, Robert D. McQuade

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



T58. RESULTS OF AN FDA DEVICE CLEARANCE TRIAL FOR PLASTICITY-BASED ADAPTIVE COGNITIVE REMEDIATION (PACR)

Henry Mahncke*, Sarah-Jane Kim, Catherine Stasio, Trina Walker, Peter Buckley, Stanley Caroff, Erica Duncan, Philip D. Harvey, L. Fredrik Jarskog, Steven Lamberti, Keith Neuchterlein, Martin Strassnig, Dawn Velligan, Joseph Ventura, Sarah Yasmin, Richard Keefe

T59. LONG-TERM SAFETY AND DURABILITY OF EFFECT OF ARIPIRAZOLE LAUROXIL IN A ONE YEAR SCHIZOPHRENIA EXTENSION STUDY

Robert Risinger*, Arielle Stanford, Yangchun Du, Jacqueline Zummo, Hassan Jamal, Chih-Chin Liu, Amy Claxton

T60. THE IMPORTANCE OF VULNERABILITY FACTORS IN AT-RISK MENTAL STATE OF PSYCHOSIS INDIVIDUALS

Martina Papmeyer*, Irène Würsch, Erich Studerus, Rolf-Dieter Stieglitz, Anita Riecher-Rössler

T61. THE INFLUENCE OF A MUSCARINIC M1 RECEPTOR ANTAGONIST ON BRAIN CHOLINE LEVELS IN PATIENTS WITH A PSYCHOTIC DISORDER AND HEALTHY CONTROLS.

Claudia Vingerhoets*, Geor Bakker, Oswald Bloemen, Jan Booij, Matthan Caan, Therese van Amelsvoort

T62. ALKS 3831 DEMONSTRATED EQUIVALENT ANTIPSYCHOTIC EFFICACY WHILE ADDRESSING WEIGHT GAIN: RESULTS FROM A PHASE 2, RANDOMIZED, OLANZAPINE-CONTROLLED STUDY

Bernard Silverman*, Christoph Correll, Peter Weiden, Ying Jiang, Sanjeev Pathak, Lauren DiPetrillo, William Martin, Anjana Bose, Srdjan Stankovic, Elliot Ehrlich

T63. A PHASE 3 STUDY TO EVALUATE WEIGHT GAIN OF ALKS 3831 COMPARED TO OLANZAPINE IN ADULTS WITH SCHIZOPHRENIA

David McDonnell*, Sanjeev Pathak, Lauren DiPetrillo, Adam Simmons, Ying Jiang, Jacqueline Zummo, Hassan Jamal, Bernard Silverman

T64. SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE RISING DOSES OF BI 425809 GIVEN ORALLY TO HEALTHY MALE VOLUNTEERS: A PARTIALLY RANDOMISED (WITHIN DOSE GROUPS), SINGLE-BLIND, PLACEBO-CONTROLLED, PHASE I STUDY

Viktoria Moschetti, Michael Desch, Sophia Goetz, Karl-Heinz Liesenfeld, Sven Wind, Glen Wunderlich, Sun-Young A. Yum*

T65. SAFETY OF LURASIDONE IN OLDER ADULTS WITH SCHIZOPHRENIA: A POOLED ANALYSIS OF SHORT-TERM PLACEBO-CONTROLLED STUDIES

Steven G. Potkin, Michael Tocco*, Andrei Pikalov, Jay Hsu, Josephine Cucchiari, Antony Loebel

T66. POSITIVE PHASE 3 CLINICAL TRIAL OF ITI-007 FOR THE TREATMENT OF SCHIZOPHRENIA: SAFETY RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Cedric O'Gorman, Kimberly Vanover*, Robert Davis, Jelena Saillard, Michal Weingart, Sharon Mates



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

T67. YOGA REDUCES THE BRAIN'S AMPLITUDE OF LOW-FREQUENCY FLUCTUATIONS IN PATIENTS WITH EARLY PSYCHOSIS

Jingxia Jessie Lin*, Xiujuan Geng, Edwin HM Lee, Sherry KW Chan, Wing Chung Chang, Christy LM Hui, Michael Tse, Cecilia LW Chan, PL Khong, William G Honer, Eric YH Chen

T68. CAN RESTING-STATE PATTERNS PREDICT ABERRANT SALIENCE IN EARLY PSYCHOSIS SPECTRUM?

Johanna Weiske*, Carlos Cabral, Sabastian Von Saldern, Maria Urquijo, Joseph Kambeitz, Nikolaos Koutsouleris, Lana Kambeitz-Ilankovic

T69. THE ASSOCIATION BETWEEN COGNITION AND SUB-DOMAINS OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA

Zixu Yang*, Madeline Lim, Bhing-Leet Tan, Jimmy Lee

T70. BELIEF FLEXIBILITY AND DELUSIONS IN PSYCHOSIS: A SYSTEMATIC REVIEW

Chen Zhu*, Xiaoqi Sun, Suzanne So

T71. LONGITUDINAL CHANGE IN NEUROCOGNITION AND ITS RELATION TO SYMPTOMATIC AND FUNCTIONAL CHANGES OVER 2 YEARS IN INDIVIDUALS AT CLINICAL HIGH-RISK FOR PSYCHOSIS

Ye Seul Shin*, So-Yeon Kim, Tae Young Lee, Ji-Won Hur, Na Young Shin, Sung Nyun Kim, Min-Sup Shin, Jun Soo Kwon

T72. PROSPECTIVE MEMORY REMAINS IMPAIRED TWO YEARS AFTER ONSET OF SCHIZOPHRENIA

Eric Cheung*, Simon S Y Lui, Ya Wang, Amy C Y Liu, Raymond C K Chan

T73. TRAJECTORIES OF SOCIAL COGNITION IN SCHIZOPHRENIA AND SCHIZOPHRENIA SPECTRUM DISORDERS

Oleg Papsuev*, Maria Minyaycheva, Larisa Movina, Isaac Gurovich

T74. THEORY OF MIND IMPAIRMENT AS A VULNERABILITY MARKER FOR SCHIZOPHRENIA AND ITS RELATION WITH SCHIZOTYPAL TRAITS: A FAMILY BASED STUDY.

Maria Giralt, Helena Palma-Gudiel*, Salvador Miret, Jordi Soler, Claudia Prats, Lourdes Fañanás, Mar Fatjó-Vilas

T75. UNCOVERING THE COMPUTATIONAL PROCESSES UNDERLYING MOTIVATIONAL DEFICITS IN EARLY SCHIZOPHRENIA

Gagan Fervaha*, Ofer Agid, George Foussias, Hiroyoshi Takeuchi, Ariel Graff-Guerrero, Konstantine Zakzanis, Gary Remington

T76. ENCENICLINE INCREASES THE MATRICS CONSENSUS COGNITIVE BATTERY NEUROCOGNITIVE COMPOSITE SCORE IN PATIENTS WITH SCHIZOPHRENIA

Andrew Ho, Keith Neuchterlein, Richard Keefe, Nancy Dgetluck, Vicki Davis, Ji Yu, Dana Hilt*

FINAL PROGRAM

FLORENCE, ITALY

2 – 6 APRIL 2016



T77. THE GOALS FOR BETTER WORK OUTCOME IN JAPANESE PATIENTS WITH SCHIZOPHRENIA: CUT-OFF PERFORMANCES ON MEASURES OF FUNCTIONAL OUTCOMES

Chika Sumiyoshi*, Philip D. Harvey, Manabu Takaki, Yuko Okahisa, Taku Sato, Ichiro Sora, Keith H. Nuechterlein, Kenneth L. Subotnik, Tomiki Sumiyoshi

T78. IMPACT OF THE FEATURAL/CONFIGURAL PROCESSING OF FACES TO THE FEELING OF FAMILIARITY IN SCHIZOPHRENIA

Delphine Pins*, Alexandra Colin, Sébastien Szaffarczyk, Guillaume Vaiva, Pierre Thomas

T79. MODELLING DIFFICULTIES IN ABSTRACT THINKING IN PSYCHOSIS; THE IMPORTANCE OF SOCIO-DEVELOPMENTAL BACKGROUND

Akiah Berg*, Ingrid Melle, Verena Zuber, Carmen Simonsen, Mari Nerhus, Torill Ueland, Ole A. Andreassen, Kjetil Sundet, Anja Vaskinn

T80. IS CUMULATIVE LIFE TIME DEPRESSION POSITIVELY LINKED TO BETTER COGNITION IN SCHIZOPHRENIA?

Felicitas Meier*, Jennifer Engelen, Bröhl Henrike, Heinen Jessica, Dietsche Bruno, Dannlowski Udo, Kircher Tilo, Krug Axel

T81. DEVELOPMENT OF A PLATFORM AGNOSTIC SOFTWARE ENGINE TO FACILITATE WIDESPREAD ADOPTION OF COGNITIVE REMEDIATION THERAPY IN SCHIZOPHRENIA

Brent Nelson, Elias Boroda, Suzanne Geier Jasberg*, Jazmin Camchong, Kelvin Lim

T82. THE EFFECT AND MECHANISMS OF IMPLEMENTATION INTENTION IN IMPROVING PROSPECTIVE MEMORY PERFORMANCE IN SCHIZOPHRENIA SPECTRUM DISORDERS

Ya Wang*, Xing-jie Chen, Lu-lu Liu, Simon S.Y. Lui, Eric F.C. Cheung, David Shum, Raymond C.K. Chan

T83. PUPIL DILATION RESPONSE TO IMAGINED EMOTIONAL FUTURE EVENTS: RELATIONS TO HIGH AND LOW LEVELS OF APATHY IN A NON-CLINICAL SAMPLE

Marie-Jose Van Tol*, Jan Bernard Marsman, Nora Parigi, Sander Martens, Andre Aleman

T84. ONE YEAR DURABILITY OF THE COMPUTER-ASSISTED COGNITIVE REMEDIATION THERAPY: NEUROCOGNITION, SELF-ESTEEM, QUALITY OF LIFE AND USE OF PSYCHIATRIC EMERGENCY SERVICES

Gemma Garrido*, Maite Barrios, Rafael Penadés, Ana Costas-Carrera, Josep M^a Vendrell, Roser Guillamat, Vicenç Vallès

T85. NEUROCOGNITION IN HELP-SEEKING INDIVIDUALS AT RISK OF PSYCHOSIS AND BIPOLAR DISORDER: OUTCOME AFTER 24 MONTHS

Sibylle Metzler*, Diane Dvorsky, Christine Wyss, Susanne Walitza, Karsten Heekeren, Wulf Rössler, Anastasia Theodoridou

T86. SMOKING IN PREGNANCY, ADOLESCENT MENTAL HEALTH AND COGNITIVE PERFORMANCE IN YOUNG ADULT OFFSPRING IN A FINNISH COHORT SAMPLE

Hugh Ramsay*, Jennifer Barnett, Graham Murray, Pirjo Mäki, Tuula Hurtig, Tanja Nordström, Jouko Miettunen, Vesa Kiviniemi, Zdenka Pausova, Tomas Paus, Juha Veijola



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

T87. COGNITIVE PROFILES IN FIRST EPISODE SCHIZOPHRENIA SPECTRUM DISORDERS

Mabel Rodriguez*, Zuzana Kratochvilova, Iveta Fajnerova, Veronika Vorackova, Aneta Dorazilova, Katerina Sedlakova, Jitka Prajsova, Martin Pastrnak, Juraj Jonas, Filip Spaniel

T88. THE VALUE OF NOVELTY IN SCHIZOPHRENIA

Cristina Martinelli*, Francesco Rigoli, Sukhi Shergill

T89. PERCEPTUAL METACOGNITIVE ACCURACY AND GREY MATTER VOLUME IN FIRST-EPISODE PSYCHOSIS

Geoff Davies*, Charlotte Rae, Sarah Garfinkel, Anil Seth, Medford Nick, Hugo Critchley, Kathy Greenwood

T90. VISUAL VERSUS AUDITORY COGNITIVE TRAINING FOR PEOPLE WITH SCHIZOPHRENIA

Linda Scoriels*, Larissa Genaro, André Poletto, Stella Keffer, Paulo Santos, Luana Gonçalves, Walter Sena, Melissa Fisher, Sophia Vinogradov, Rogério Panizzutti

T91. REDUCED SUSCEPTIBILITY TO THE SOUND-INDUCED FLASH FUSION ILLUSION IN SCHIZOPHRENIA

Lucy Vanes*, Rebekah Wigton, thomas white, daniel joyce, Sukhi Shergill

T92. THE EFFECT OF CHILDHOOD TRAUMA ON COGNITIVE FUNCTION IN A SAMPLE OF CHINESE PATIENTS WITH SCHIZOPHRENIA

Chuan-Yue Wang

T93. COUNTERFACTUAL REASONING DEFICITS ARE RELATED WITH ACUTE NEGATIVE SYMPTOMS IN SCHIZOPHRENIA

Auria Albacete*, Fernando Contreras, José Manuel Menchón

T94. INITIAL PSYCHOMETRIC EVALUATION OF SOCIAL COGNITIVE MEASURES IN SINGAPORE

Sara-Ann Lee*, Keane Lim, Amy Pinkham, Max Lam, Junghee Lee, Jimmy Lee

T95. PERCEPTUAL INFERENCES IN SCHIZOPHRENIA: A PRELIMINARY STUDY IN HEALTHY PARTICIPANTS

Pantelis Leptourgos*, Charles - Edouard Notredame, Renaud Jardri, Sophie Denève

T96. TOWARDS A CORE DYSFUNCTIONAL TIMING NETWORK IN SCHIZOPHRENIA: A META-ANALYSIS

Irene Alústiza*, Joaquim Radua, Antón Albajes-Eizagirre, Manuel Domínguez, Felipe Ortuño

T97. DOES SCHIZOPHRENIA IMPAIR THE ABILITY TO SUSTAIN ATTENTION? INVESTIGATION OF THE PROACTIVE AND REACTIVE MODES OF CONTROL BY EXPLORING THE UNDERPINNING OSCILLATORY ACTIVITY.

Marc Hoonakker*, Nadege Doignon-Camus, Anne Bonnefond

T98. ORTHOGRAPHIC PROCESSING AND LEXICAL ACCESS IN PATIENTS WITH SCHIZOPHRENIA: ANALYSIS OF THE N170 COMPONENT

Maxime Curzietti*, Anne Bonnefond, Pierre Vidailhet, Nadege Doignon-Camus

FINAL PROGRAM

FLORENCE, ITALY

2 – 6 APRIL 2016



T99. EFFECTS OF TRANSCRANIAL DIRECT CURRENT STIMULATION (TDCS) ON COGNITION, BRAIN CONNECTIVITY AND SYMPTOMS IN SCHIZOPHRENIA

Robert C. Smith*, Stanley Colcombe, Sylvia Boules, Mary Youssef, Karen Nolan, Russel H. Tobe, Mohammed Sharifi, Revital Amiaz, Sanela Mattiuz, John M Davis

T100. AGE-SPECIFIC ABNORMALITIES IN WORKING MEMORY IN EARLY ONSET PSYCHOSIS

Maria Isabel Calvo-Rubiales*, Manuel Canal-Rivero, Andrea Morina, Miguel Ruiz Veguilla

T101. THE RELATION OF SCHIZOTYPY AND COGNITION WITH THEORY OF MIND IN FIRST-DEGREE RELATIVES OF PATIENTS WITH DIAGNOSIS OF SCHIZOPHRENIA

Onur Kucukcoban*, Damla Güneyer, Aylin Yurdakul, Özge Akgül, Meliha Diriöz, İ. Tolga Binbay, Koksall Alptekin, Berna Binnur Akdede

T102. SOCIAL COGNITION IMPAIRMENT PROFILES IN TREATMENT-RESISTANT SCHIZOPHRENIA

Anzaalee Khan*, Jean-Pierre Lindenmayer, Isidora Ljuri, Abraham Goldring, Samantha Fregenti, Veronica Ozog, Luka Lucic

T103. METABOLIC SYNDROME, ABDOMINAL OBESITY AND HYPERURICEMIA IN SCHIZOPHRENIA: RESULTS FROM THE FACE-SZ COHORT

Ophelia Godin, Pierre-Michel Llorca, Nicolas Gired, Marion Leboyer, Guillaume Fong*

T104. SOMATIC DISEASES INCREASE THE RISK OF EARLY RE-HOSPITALIZATION AMONG 6,987 INCIDENT PATIENTS WITH SCHIZOPHRENIA

Ole Köhler*, Holger Jelling Sørensen, Michael Eriksen Benros, Christiane Gasse

T105. BODY WEIGHT AND CLINICAL OUTCOMES IN FIRST EPISODE PSYCHOSIS PATIENTS: A 1-YEAR FOLLOW-UP STUDY.

Priyanthi Borgen Gjerde*, Carmen Simonsen, Tatiana Polushina, Ingrid Dieset, Ole Andreas Andressen, Vidar Martin Steen, Ingrid Melle

T106. PROLACTIN CONCENTRATIONS IN ANTIPSYCHOTIC-NAÏVE PATIENTS WITH SCHIZOPHRENIA AND RELATED DISORDERS: A META-ANALYSIS

Leticia Gonzalez-Blanco*, Anne Marie Greenhalgh, Clemente Garcia-Rizo, Emilio Fernandez-Egea, Brian Miller, Brian Kirkpatrick

T107. LIPID PROFILE IN SCHIZOPHRENIA: TUNISIAN STUDY ABOUT 78 PATIENTS WITH SCHIZOPHRENIA AND 68 CONTROLS

Ahmed Mhalla*, Rim Mensi, Amel Messaoud, Walid Bel Hadj Salah, Wahiba Douki, Lotfi Gaha

T108. BLOOD METABOLITE SIGNATURE OF THE DEVELOPMENT OF METABOLIC SYNDROME IN FIRST-EPISODE PSYCHOSIS

Tommi Suvitaival*, Jaana Suvisaari, Outi Mantere, Tuula Kiesepä, Tuulia Hyötyläinen, Matej Oresic

T109. SCHIZOPHRENIA AND METABOLIC SYNDROME: FOLLOW-UP STUDY

Gokhan Yoca*, Mumin Kazim Yazici, A. Elif Anil Yagcioglu, Nurhayat Eni, Sevilay Karahan, Inci Turkoglu, Emine Akal Yildiz



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

T110. CLINICAL FEATURES OF SCHIZOPHRENIA PATIENTS WITH VIOLENT BEHAVIOURS: THE NEED TO CONSIDER DISTINCT SUBTYPES

Mathilde Horn*, Laura Gangloff, Axelle Gharib, Pierre Thomas, Delphine Pins

T111. RELIABILITY AND VALIDITY OF LOW SCORES ON THE POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS) AND THE INFLUENCE OF PRIOR INFORMATION

Steven De Jong*, Selwyn Renard, Wilko Bodde, Pieter-Jan Mulder, Paul Lysaker

T112. DEMOGRAPHIC, CLINICAL, FUNCTIONAL AND COGNITIVE PROFILES OF INDIVIDUALS PRESENTING WITH AT-RISK MENTAL STATE (ARMS) FOR PSYCHOSIS TO ARMS SCREENING PROGRAM IN HONG KONG

HC Lee, Wing Chung Chang*, SI Chan, SY Chiu, LM Hui, KW Chan, HM Lee, EYH Chen

T113. EARLY PSYCHOSIS PATIENTS' AND RELATIVES' ATTACHMENT STYLE: ASSOCIATION WITH CLINICAL AND FUNCTIONAL PRESENTATION

Lidia Hinojosa-Marqués*, Tamara Sheinbaum, Paula Cristóbal-Narváez, Manel Monsonet, Thomas R. Kwapił, Tecelli Domínguez-Martínez, Neus Barrantes-Vidal

T114. AFFECTIVE SYMPTOMS IN FIRST EPISODE PSYCHOSIS: A DIMENSIONAL APPROACH

Diego Quattrone*, Olesya Ajnakina, Marco Colizzi, Elena Carra, Sara Fraietta, Fiona Gaughran, Marta Di Forti, Robin Murray

T115. A MULTIDIMENSIONAL EXAMINATION OF DELUSIONALITY AND INSIGHT IN BODY DYSMORPHIC DISORDER VERSUS PSYCHOTIC DISORDERS

Wei Lin Toh*, David Castle, Rachael Mountjoy, Ben Buchanan, Susan Rossell

T116. AUDITORY VERBAL HALLUCINATIONS IN BIPOLAR DISORDER (BD) AND MAJOR DEPRESSIVE DISORDER (MDD): A SYSTEMATIC REVIEW

Wei Lin Toh*, Neil Thomas, Susan Rossell

T117. DOMAINS OF PSYCHOSIS IN SCHIZOPHRENIA SPECTRUM DISORDERS

Kristan Armstrong*, Stephan Heckers

T118. LOW VITAMIN D ASSOCIATED WITH NEGATIVE AND DEPRESSIVE SYMPTOMS IN PSYCHOTIC DISORDERS, BUT NOT WITH PRO- INFLAMMATORY IMMUNE MARKERS

Mari Nerhus*, Akiah Berg, Ingrid Melle

T119. EFFECT OF STRESSFUL LIFE EVENTS ON SCHIZOTYPAL SYMPTOMS IN SIBLINGS OF PATIENTS WITH FIRST-EPISODE PSYCHOSIS AND HEALTHY CONTROLS.

Anna Butjosa*, Ulrich Reininghaus, Juana Gómez-Benito, Susana Ochoa, GROUP investigators

T120. POSITIVE AND NEGATIVE SCHIZOTYPY PREDICTION OF PRODROMAL SYMPTOMS AND SCHIZOPHRENIA-SPECTRUM PERSONALITY DISORDER TRAITS: A 3-YEAR PROSPECTIVE STUDY

Anna Racioppi*, Tamara Sheinbaum, Sergi Ballespí, Mercè Mitjavila, Georgina M. Gross, Thomas R. Kwapił, Neus Barrantes-Vidal



T121. AGE AT FIRST-CONTACT AND 9-MONTH OUTCOME IN PATIENTS WITH FIRST-EPIISODE SCHIZOPHRENIA SPECTRUM DISORDERS

Giovanni de Girolamo for the GET-UP Group*

T122. TEMPERAMENT IN INDIVIDUALS WITH PSYCHOTIC DISORDERS BEFORE AND AFTER THE ONSET OF ILLNESS

Jouko Miettunen*, Nina Rautio, Matti Penttilä, Eka Roivainen, Juha Veijola, Matti Isohanni, Erika Jääskeläinen

T123. NEIGHBOURHOOD CHARACTERISTICS AND THE RATE OF IDENTIFICATION OF YOUNG PEOPLE AT ULTRA-HIGH RISK FOR PSYCHOSIS AND RISK OF TRANSITION

Brian O'Donoghue*, Alison Yung, Stephen Wood, Abbie Lane, Andrew Thompson, Ashleigh Lin, Patrick D McGorry, Barnaby Nelson

T124. A POPULATION-BASED LONGITUDINAL STUDY OF MATERNAL PRENATAL DEPRESSION AND RISKS OF PSYCHOSIS AND DEPRESSION IN ADULT OFFSPRING: ROLE OF CHILDHOOD SERUM INTERLEUKIN 6

Golam Khandaker*, Sarah Rabhi, Jan Stochl, Rebecca Pearson, Jonathan Evans, Stan Zammit, Glyn Lewis, Peter Jones

T125. CHILDHOOD TRAUMAS IN YOUNG ADULTS WITH CLINICAL AND FAMILIAL RISK FOR PSYCHOSIS - THE NORTHERN FINLAND 1986 BIRTH COHORT

Pirjo Mäki*, Tuija Mähönen, Tanja Nordström, Juha Veijola

T126. TOBACCO SMOKING AND RISK OF FIRST EPISODE PSYCHOSIS: A CASE-CONTROL STUDY IN SAO PAULO, BRAZIL

Paulo Menezes*, Geraldo Busatto, Philip McGuire, Robin Murray, Marcia Scazufca

T127. THE INFLUENCE OF POLYGENIC RISK SCORES ON THE ASSOCIATION BETWEEN INFECTIONS AND SCHIZOPHRENIA

Michael Benros*, Betina Trabjerg, Sandra Melanie Meier, Manuel Mattheisen, Preben Mortensen, Ole Mors, Anders Børglum, David Hougaard, Bent Nørgaard-Pedersen, Merete Nordentoft, Esben Agerbo

T128. INADEQUATE CANCER DIAGNOSTICS AMONG PERSONS WITH SEVERE MENTAL ILLNESS: A POPULATION-BASED COHORT STUDY

Anita Tønder Nielsen*, Trine Munk-Olsen, Mogens Vestergaard, Janne Tidselbak Larsen, Nis Palm Suppli, Susanne Oksbjerg Dalton, Peter Vedsted, Merete Nordentoft, Thomas Munk Laursen

T129. PATHWAY FROM PERINATAL CIRCUMSTANCES TO MORTALITY AT MIDLIFE IN PSYCHOSES: A 45-YEAR FOLLOW-UP STUDY OF THE NORTHERN FINLAND BIRTH COHORT 1966

Nina Rautio*, Erika Jääskeläinen, Tanja Nordström, Jouko Miettunen, Matti Isohanni, Jussi Seppälä

T130. JOINT EFFECTS OF PRENATAL EXPOSURE TO INFECTION AND PERIPUBERTAL ADVERSITY IN SCHIZOPHRENIA

Jean-Christophe Debost*, Janne Tidselbak Larsen, Liselotte Petersen, Trine Munk-Olsen, Preben Bo Mortensen



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

T131. CANNABIS USE AND ADHERENCE TO ANTIPSYCHOTICS: A SYSTEMATIC REVIEW AND META-ANALYSIS.

Enrico Foglia*, Tabea Schoeler, Ewa Klamerus, Kevin Morgan, Sagnik Bhattacharyya

T132. IS HYPER-THEORY-OF-MIND SPECIFICALLY AND INDEPENDENTLY ASSOCIATED TO PSYCHOTIC EXPERIENCES IN PREADOLESCENCE?

Lars Clemmensen*, Jim van Os, Marjan Drukker, Anja Munkholm, Martin K. Rimvall, Mette Væver, Charlotte Ulrikka Rask, Agna Bartels-Velthuis, Anne Mette Skovgaard, Pia Jeppesen

T133. USING HOME-RECRUITMENT TO INCREASE PARTICIPATION AND REPRESENTATIVENESS OF RESEARCH AMONG INDIVIDUALS WITH PSYCHOSIS

Marianne Haapea*, Matti Isohanni, Erika Jääskeläinen, Juha Veijola, Jouko Miettunen

T134. EXPLORING RISK FACTORS IN EARLY AND LATE ONSET SCHIZOPHRENIA

Ajit Selvendra*, Laura Chen, Anne Stewart, David Castle

T135. ESTIMATION OF INCIDENCE RATE OF FIRST EPISODE PSYCHOSIS IN A BRAZILIAN LARGE CATCHMENT AREA

Rosana Shuhama*, Camila Loureiro, Taciana Ragazzi, Craig Morgan, Jim van Os, Antonio Santos, Paulo Louzada-Junior, Cristina Del-Ben

T136. RESILIENCE IN SCHIZOPHRENIA: A COMPARATIVE STUDY BETWEEN A REMOTE ISLAND AND AN URBAN AREA IN JAPAN

Kazunari Yoshida*, Takefumi Suzuki, Yasushi Imasaka, Ken-ichiro Kubo, Yuya Mizuno, Juri Saruta, Keiichi Tsukinoki, Masaru Mimura, Hiroyuki Uchida

T137. SOCIO DEMOGRAPHIC AND CLINICAL CHARACTERISTICS IN FIRST EPISODE PSYCHOSIS

Ahmet Ayer*, Esra Aydinli, Koksai Alptekin

T138. SCHIZOPHRENIA-SPECTRUM DISORDERS AND VIOLENT REOFFENDING: A NATIONAL COHORT STUDY OF CONVICTED PRISONERS

Seena Fazel*, Zheng Chang, Henrik Larsson, Paul Lichtenstein

T139. PREDICTING CLINICAL OUTCOMES IN PSYCHOTIC DISORDERS USING ELECTRONIC CASE REGISTERS AND NATURAL LANGUAGE PROCESSING

Rashmi Patel*, Robert Stewart, Philip McGuire

T140. A COMPARATIVE STUDY ON THE PREVALENCE RATE AND TREATMENT OF AGITATION AMONG CHINESE NEWLY HOSPITALIZED SCHIZOPHRENICS BETWEEN PSYCHIATRIC HOSPITALS AND GENERAL HOSPITALS

Hongyan Zhang*, Suzhen Zhang, Wifeng MI, Qi Liu, Lingzhi Li

T141. THE GOTHENBURG RESEARCH AND INVESTIGATION ON PSYCHOSIS - GRIP: OUTCOMES FROM A STANDARDIZED CLINICAL PROTOCOL FOR PSYCHOTIC PATIENTS

Anneli Goulding*, Kristina Annerbrink, David Berg, Mikael Landén



T142. EXPLORING THE EFFECT OF COMT AND BDNF POLYMORPHISMS ON ASSOCIATION BETWEEN PSYCHOTIC EXPERIENCES AND DEPRESSION-SUICIDAL IDEATION IN A SIX-YEAR FOLLOW-UP OF GENERAL POPULATION BASED SAMPLE

Tolga Binbay*, Umut Kırılı, Hayriye Elbi, Bülent Kayahan, Hüseyin Onay, Ferda Özkinay, Jim van Os, Koksal Alptekin

T143. EVIDENCE FOR NEIGHBOURHOOD EFFECTS ON SUB-CLINICAL PSYCHOTIC EXPERIENCES: PRELIMINARY RESULTS FROM THE SOUTH EAST LONDON COMMUNITY HEALTH STUDY

Vishal Bhavsar*, Philip McGuire, Matthew Hotopf, Victoria Harris, Stephani Hatch, Jane Boydell

T144. DETERMINANTS OF OUTCOME IN FIRST-EPISODE PSYCHOSIS: RE-ADMISSIONS TO PSYCHIATRIC INPATIENT CARE

Simone Ullrich*

T145. DOES A SYNDOMIC OR ETHNICITY EXPLAIN DISPARITIES IN PSYCHOSIS IN THE UK?

Jeremy Coid*

T146. ACADEMIC PERFORMANCE IN CHILDREN OF MOTHERS WITH SCHIZOPHRENIA AND OTHER SEVERE MENTAL ILLNESS, AND RISK FOR THE DEVELOPMENT OF PSYCHOSIS: A POPULATION-BASED STUDY

Ashleigh Lin*, Patricia DiPrinzio, Deidra Young, Peter Jacoby, Andrew Whitehouse, Flavie Waters, Assen Jablensky, Vera Morgan

T147. HIGHER COMPLEXITY OF EEG SIGNAL AS A STATE MARKER IN FIRST EPISODE PSYCHOSIS COMPARED TO INDIVIDUALS WITH AT RISK MENTAL STATE FOR PSYCHOSIS AND HEALTHY CONTROLS.

Vincent Laprevote*, Avinash Ramyeed, Julien Krieg, Erich Studerus, Christina Andreou, Raymund Schwan, Anita Riecher-Rössler

T148. MISMATCH NEGATIVITY (MMN) IN PSYCHOSIS FOLLOWING TRAUMATIC BRAIN INJURY (PFTBI)

Rachel Batty*, Philip Makarios, Susan Rossell

T149. C9ORF72 REPEAT EXPANSIONS THAT CAUSE FRONTOTEMPORAL DEMENTIA ARE DETECTABLE AMONG PATIENTS WITH PSYCHOSIS.

Annie Watson, Mochtar Pribadi, Kodavali Chowdari, Sue Clifton, Joel Wood, Bruce L Miller, Giovanni Coppola, Vishwajit Nimgaonkar*

T150. NEUROTROPHIN SIGNALING IN FIRST EPISODE PSYCHOSIS: RELATION TO RESPONSE TO ANTIPSYCHOTICS AFTER 1 YEAR OF FOLLOW-UP

Monica Martinez-Cengotitabengoa*, Karina MacDowell, Susana Alberich, Mara Parellada, Pilar Saíz, Roberto Rodriguez, Esther Berrocoso, Miguel Bernardo, Ana Gonzalez-Pinto, Juan Carlos Leza



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

T151. MINOR NEUROLOGICAL SIGNS AND CLINICAL COURSE IN FIRST-EPISODE PSYCHOSIS: A TEN-YEAR FOLLOW-UP STUDY

Naika Ferruccio*, Julia Lappin, Margaret Heslin, Kevin Morgan, Adanna Onyejiaka, Tim Croudace, Peter B. Jones, Robin Murray, Paul Fearon, Gillian Doody, Craig Morgan, Paola Dazzan

T152. PSYCHOSIS-RISK IS ASSOCIATED WITH INCREASED CEREBRAL BLOOD FLOW IN THE STRIATUM: RESULTS OF AN ARTERIAL SPIN LABELING MR-STUDY

Jochen Kindler*, Frauke Schultze-Lutter, Martinus Hauf, Chantal Michel, Thomas Dierks, Benno G. Schimmelmann, Daniela Hubl

T153. VISUAL HABITUATION IS IMPAIRED IN UNAFFECTED SIBLINGS OF SUBJECTS AFFECTED BY SCHIZOPHRENIA: A PATTERN-REVERSAL VEP STUDY

Giorgio Di Lorenzo*, Fabio Ciabattini, Emanuela Bianciardi, Fabiola Ferrentino, Cherubino Di Lorenzo, Gianluca Coppola, Michele Ribolsi, Cinzia Niolu, Francesco Pierelli, Alberto Siracusano, Stefano Seri

T154. THE EFFECTS OF TAK-063 ON COGNITION IN A MULTIPLE DOSE, PHASE 1 STUDY IN HEALTHY JAPANESE SUBJECTS AND SUBJECTS WITH SCHIZOPHRENIA ARE CONSISTENT WITH ITS SOMNOLENT EFFECTS

Tom Macek*, Maggie McCue, Jinhui Xie, Keith Wesnes

T155. TAK-063 INCREASES GAMMA SYNCHRONY IN SUBJECTS WITH SCHIZOPHRENIA

Tom Macek*, Maggie McCue, Jinhui Xie, Jack Johnstone, Peter Boeijinga

T156. THE PDE-10A INHIBITOR TAK-063 REVERSES KETAMINE-INDUCED CHANGES IN FMRI BOLD SIGNAL

Deborah Yurgelun-Todd, Perry Renshaw, Paul Goldsmith, Jinhui Xie, Tolga Uz, Tom Macek*

T157. ALTERED RIGHT ANTERIOR INSULA ACTIVITY DURING ANTICIPATION OF FOOD AND SOCIAL REWARDS IN SCHIZOPHRENIA: AN FMRI STUDY

Chao Yan*, Zheng-hui Yi, Qin-yu Lv, Xu Li, Raymond C K Chan

T158. PET IMAGING EVIDENCE OF ALTERED DOPAMINERGIC MODULATION OF REWARD RESPONSES IN VENTRAL STRIATUM IN FAMILIAL RISK TO PSYCHOSIS

Zuzana Kasanova*, Jenny Ceccarini, Therese van Amelsvoort, Michael Frank, Jan Booij, Alexander Heinzl, Ye Rong, Oliver Winz, Felix Mottaghy, Inez Myin-Germeys

T159. NEURAL CORRELATES OF THE NEGATIVE PRIOR EXPECTANCY BIAS IN SCHIZOPHRENIA: AN FMRI MULTIVARIATE ANALYSIS.

Ilvana Dzafo, Andrew Martin*, Hana Burianová, Bryan Mowry

T160. ABERRANT SHIFT OF NEURAL ACTIVITY DURING HAND GESTURE PERFORMANCE IN SCHIZOPHRENIA: LESS MOTOR BUT MORE LIMBIC ACTIVITY

Katharina Stegmayer*, Stephan Bohlhalter, Tim Vanbellinghen, Andrea Federspiel, Roland Wiest, René Müri, Werner Strik, Sebastian Walther



T161. THE EFFECT OF ARIPIPRAZOL VERSUS RISPERIDONE ON PLANNING-RELATED BRAIN ACTIVATION

Edith Liemburg*, Frank Van Es, Henderikus Knegtering, Andre Aleman

T162. ARE EMOTION PROCESSING DEFICITS IN SCHIZOPHRENIA AND MAJOR DEPRESSION MOOD-RELATED SYMPTOMS?

Jennifer Engelen*, Felicitas Meier, Bröhl Henrike, Heinen Jessica, Dietsche Bruno, Krug Axel, Kircher Tilo, Dannowski Udo

T163. NEUROBIOLOGY OF INSIGHT IN SCHIZOPHRENIA: FINDINGS FROM A SYSTEMATIC REVIEW

Rose Mary Xavier*, Allison Vorderstrasse

T164. STRESS AND EMOTION PROCESSING IN SIBLINGS OF SCHIZOPHRENIA PATIENTS: PRELIMINARY RESULTS

Judith M.C. van Leeuwen*, Matthijs Vink, Sebastiaan F. W. Neggers, Marian Joëls, René S. Kahn, Christiaan H. Vinkers

T165. EMOTION REGULATION AND INSIGHT IN SCHIZOPHRENIA: AN FMRI TASK STUDY

Daouia Larabi*, Lisette van der Meer, Branislava Cur ic-Blake, André Aleman

T166. THE EFFECT OF MENTALIZATION-BASED TREATMENT IN PATIENTS WITH FIRST EPISODE SCHIZOPHRENIA – A FMRI STUDY

Gabriele Sachs*, Helga Felsberger, Julia Furtner, Andreas Erfurth

T167. FRONTO-SUBCORTICAL FUNCTIONAL CONNECTIVITY IN PATIENTS WITH SCHIZOPHRENIA AND BIPOLAR DISORDER DURING A VERBAL FLUENCY TASK.

Leroux Elise*, Vandeveld Anais, Delcroix Nicolas, Sonia Dollfus

T168. BRAIN PDE10A OCCUPANCY MEASURED BY PET AFTER ORAL ADMINISTRATION OF TAK-063, A NEWLY DEVELOPED PDE10A INHIBITOR, IN HUMAN VOLUNTEERS

Akihiro Takano, Per Stenkrona, Vladimir Stepanov, Nahid Amini, Stefan Martinsson, Max Tsai, Paul Goldsmith*, Jingtao Wu, Jinhui Xie, Tolga Uz, Tom Macek, Christer Halldin

T169. CHOOSING WITH OTHERS IN MIND: NEURAL MECHANISMS OF SOCIAL MINDFULNESS IN HEALTH AND PSYCHOSIS.

Imke Lemmers-Jansen*, Anne-Kathrin Fett, Dick Veltman, Lydia Krabbendam

T170. NEURAL CORRELATES OF REWARD PROCESSING IN HEALTHY SIBLINGS OF PATIENTS WITH SCHIZOPHRENIA

Esther Hanssen*, Jorien Van Der Velde, Paula Gromann, Sukhi Shergill, Lieuwe De Haan, Richard Bruggeman, Lydia Krabbendam, Andre Aleman, Nienke van Atteveldt

T171. PREVALENCE OF METABOLIC SYNDROME IN PATIENTS WITH SCHIZOPHRENIA IN KOREA: A MULTICENTER NATIONWIDE CROSS-SECTIONAL STUDY

JungSun Lee, Yeon Ho Joo*, Korean Society for Schizophrenia Research Group



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

T172. METABOLIC RISK FACTORS IN FIRST EPISODES OF PSYCHOSIS: FINDINGS FROM THE PEPS STUDY

Miquel Bioque*, Clemente Garcia-Rizo, M Paz Garcia-Portilla, Bibiana Cabrera Llorca, Antonio Lobo, Ana González-Pinto, Mara Parellada, Iluminada Corripio, Adrián Llerena, Amalia Lafuente, Jerónimo Saiz, Miquel Bernardo

T173. STUDYING CORTICAL THINNING IN SCHIZOPHRENIA WITH ULTRA HIGH-FIELD MRI

Bart Ferguson*, Natalia Petridou, Hilleke E. Hulshoff Pol, Wiepke Cahn, René S. Kahn, Rene C. W. Mandl

T174. NEUROANATOMICAL MARKERS OF AUTISTIC TRAITS IN FIRST EPISODE PSYCHOSIS

Renate Reniers, Katharine Chisholm, Ashleigh Lin, Rachel Upthegrove, Stephen Wood*

T175. HPA AXIS FUNCTION AND GREY MATTER VOLUME REDUCTIONS: IMAGING THE DIATHESIS-STRESS MODEL IN INDIVIDUALS AT ULTRA HIGH-RISK OF PSYCHOSIS

Isabel Valli*, Nicolas Crossley, Fern Day, James Stone, Stefania Tognin, Valeria Mondelli, Lucia Valmaggia, Carmine Pariante, Philip McGuire

T176. INDIVIDUAL PREDICTION OF LONG-TERM OUTCOME IN ADOLESCENTS AT ULTRA-HIGH RISK FOR PSYCHOSIS FROM BASELINE MRI BRAIN SCANS

Hugo Schnack*, Sanne de Wit, Tim Ziermans, Mireille Nieuwenhuis, Patricia Schothorst, Herman van Engeland, René Kahn, Sarah Durston

T177. INTRINSIC CONNECTIVITY OF FRONTO-TEMPORAL NETWORKS IN ADOLESCENTS AT ULTRAHIGH RISK FOR PSYCHOSIS: COMPARISON WITH FIRST EPISODE PSYCHOSIS PATIENTS AND CONTROLS

Gisela Sugranyes*, Cristina Sole-Padullés, Elena De la Serna, vanessa Sanchez-gistau, Olga Puig-Navarro, Clara Espelt, Mireia Rosa, Josefina Castro-Fornieles, Inmaculada Baeza

T178. HIPPOCAMPAL GLUTAMATE AND HIPPOCAMPAL FUNCTIONAL CONNECTIVITY IN SCHIZOPHRENIA

Adrienne Lahti*, Nina Kraguljac, David White

T179. COGNITIVE CORRELATES OF FUNCTIONAL CONNECTIVITY IN SCHIZOPHRENIA: A RESTING-STATE FMRI STUDY

Dominik Kraft*, Viola Oertel-Knöchel, Michael Stäblein, Claudia Schmied

T180. RELATIONSHIP BETWEEN ABNORMAL GYRIFICATION AND CLINICAL VARIABLES IN FIRST-EPISODE SCHIZOPHRENIA

Daiki Sasabayashi*, Yoichiro Takayanagi, Shimako Nishiyama, Tsutomu Takahashi, Atsushi Furuichi, Mikio Kido, Yumiko Nishikawa, Mihoko Nakamura, Kyo Noguchi, Michio Suzuki

T181. INFORMATION PROCESSING SPEED MEDIATES THE RELATIONSHIP BETWEEN WHITE MATTER AND GENERAL INTELLIGENCE IN SCHIZOPHRENIA

Clara Alloza*

FINAL PROGRAM

FLORENCE, ITALY

2 – 6 APRIL 2016



T182. WHITE MATTER CORRELATES OF IMPAIRED GESTURE PERFORMANCE AND RECOGNITION IN SCHIZOPHRENIA

Petra Viher*, Katharina Stegmayer, Stéphanie Giezendanner, Andrea Federspiel, Stephan Bohlhalter, Tim Vanbellingem, René Müri, Roland Wiest, Werner Strik, Sebastian Walther

T183. PREVENTING PSYCHOSIS: IMPROVING BRAIN NETWORKS IN ULTRA HIGH RISK PATIENTS BY MEANS OF PSYCHOLOGICAL INTERVENTIONS.

Tina Kristensen*

T184. SCHIZOTYPY AND PSYCHOSIS PRONENESS EFFECTS IN A WORKING MEMORY FMRI PARADIGM

Igor Nenadic*, Kerstin Langbein, Maren Dietzek, Gerd Wagner, Ralf Schlösser, Heinrich Sauer

T185. BRAIN STRUCTURAL CORRELATES OF SCHIZOTYPY IN HEALTHY SUBJECTS: CORTICAL THICKNESS AND FOLDING

Igor Nenadic*, Alexander Rapp, Kerstin Langbein, Maren Dietzek, Amelie Schreier, Heinrich Sauer, C. Christoph Schultz

T186. STRUCTURAL PLASTICITY OF WHOLE BRAIN NETWORKS FOLLOWING AEROBIC ENDURANCE TRAINING IN MULTI-EPIISODE SCHIZOPHRENIA PATIENTS AND HEALTHY CONTROLS

Joseph Kambeitz*, Daniel Keeser, Katriona Keller-Varady, Peter Falkai, Berend Malchow

T187. SUBCORTICAL SHAPE DIFFERENCES IN REGIONS SUPPORTING WORKING MEMORY IN HIGH AND LOW FUNCTIONING SCHIZOPHRENIA

Eva Alden*, Derin Cobia, James Reilly, Matthew Smith

T188. EXTRACELLULAR AND BRAIN TISSUE RELATED ABNORMALITIES IN SUBJECTS AT CLINICAL HIGH RISK FOR PSYCHOSIS IN SHANGHAI

Yingying Tang, Ofer Pasternak, Marek Kubicki, Yogesh Rath, TianHong Zhang*, Junjie Wang, HuiJun Li, LiHua Xu, Zhenying Qian, Katharine O'Neal, Anni Zhu, Robert W. McCarley, Martha E. Shenton, Jijun Wang, Larry J. Seidman

T189. THE EFFECTS OF GENETIC AND ENVIRONMENTAL RISK FACTORS FOR SCHIZOPHRENIA ON CORTICAL THICKNESS

Emma Neilson*, Catherine Bois, Jude Gibson, Lynsey Hall, Heather Whalley, Andrew McIntosh, Stephen Lawrie

T190. DECREASED EEG SPECTRAL ENTROPY MODULATION ASSOCIATED WITH COGNITIVE IMPAIRMENT IN SCHIZOPHRENIA.

Alba Lubeiro Juárez*, Javier Gómez Pilar, Vicente Molina Rodríguez

T191. HIPPOCAMPAL-STRIATAL-MIDBRAIN CONNECTIVITY DURING REWARD PREDICTION IN HIGH-RISK SUBJECTS FOR PSYCHOSIS: CORRELATIONS WITH ABNORMAL BELIEF FORMATION AND DOPAMINE

André Schmidt*, Toby Winton-Brown, Anthony Grace, Paolo Fusar-poli, Philip McGuire



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

T192. CONTRIBUTION OF OXYTOCIN PATHWAY GENES TO AMYGDALA ACTIVITY IN SCHIZOPHRENIA, BIPOLAR DISORDER AND HEALTHY CONTROLS

Marit Haram*, Lars Tjelta Westlye, Ole A. Andreassen, Ingrid Melle, Martin Tesli

T193. EFFECTS OF MUSCARINIC M1 RECEPTOR SEQUENCE VARIATION ON EXECUTIVE FUNCTION IN SCHIZOPHRENIA AND HEALTHY CONTROLS

Sean Carruthers*, Susan Rossell, Caroline Gurvich

T194. A STUDY OF GENE-GENE INTERACTIONS BETWEEN GENES ON CHROMOSOME 22Q11 IN SCHIZOPHRENIA IN KOREA

Yu Sang Lee*, Kyung Sue Hong, Eunsoog An

T195. GENDER-SPECIFIC ASSOCIATIONS OF THE BRAIN-DERIVED NEUROTROPHIC FACTOR VAL66MET POLYMORPHISM WITH NEUROCOGNITIVE FUNCTIONING AND CLINICAL FEATURES IN PATIENTS WITH SCHIZOPHRENIA

Sung-Wan Kim*, Yo-Han Lee, Min Jhon, Ju-Yeon Lee, Hee-Ju Kang, Seon-Young Kim, Kyung-Yeol Bae, Jae-Min Kim, Il-Seon Shin, Jin-Sang Yoon

T196. ASSOCIATION BETWEEN ZNF804A AND THE RISK OF SCHIZOPHRENIA AND BIPOLAR DISORDERS ACROSS DIAGNOSTIC BOUNDARIES

So Yung Yang*, Ji Hyun Baek, Youngah Cho, Ik Soo Huh, Eun-Young Cho, Taesung Park, Kyooseob Ha, Kyung Sue Hong

T197. EXOME SEQUENCING IN PATIENTS WITH SCHIZOPHRENIA

Anna Koller, Frederick Neukirch, Lisa Winkler, Kerstin Ludwig, Julian Hecker, Jana Strohmaier, Holger Thiele, Marcella Rietschel, Markus M Nöthen, Franziska Degenhardt*

T198. VITAMIN D TREATMENT DURING PREGNANCY PREVENTS SCHIZOPHRENIA-RELATED PHENOTYPES IN A MATERNAL IMMUNE ACTIVATION ANIMAL MODEL

Darryl Eyles*, Stephanie Vulliamot, Leon Luan, Urs Meyer

T199. IL-6 IS A CRITICAL FACTOR IN THE HIPPOCAMPUS-MEDIATED NEURAL CIRCUIT ALTERATION UNDERLYING PSYCHOSIS-ASSOCIATED PHENOTYPES

Daisuke Fukudome*, Mari Kondo, Tomoaki Tezuka, Catherine Foss, Martin Pomper, Atsushi Kamiya, Akira Sawa

T200. PERINATAL ASPHYXIA AND CESAREAN SECTION CHANGES THE EXPRESSION OF NOVEL SCHIZOPHRENIA RISK GENES IN RAT

Keiko Iwata*, Alessandra Paparelli, Tomoyasu Wakuda, Conrad Iyegbe, Robin Murray, Nori Takei

T201. OVEREXPRESSION OF G-PROTEIN COUPLED RECEPTOR 85 (GPR85) IN THE RAT HIPPOCAMPUS INDUCES DEFICITS IN SPATIAL SHORT-TERM MEMORY

Eliza Koros*, Birgit Stierstorfer, Roberto Arban, Thorsten Lamla



T202. AGE-DEPENDENT ALTERATIONS IN GABAERGIC SIGNALING, MEDIATORS OF INFLAMMATORY PATHWAYS AND REDOX HOMOEOSTASIS IN FRONTAL CORTEX OF THE MAM RAT MODEL

Thomas Lanz*, Nathaniel Hodgson, Gabriel Sholder, Simon Xi, William Howe, Rouba Kozak, Takao Hensch, Patricio O'Donnell

T203. TRANSGENERATIONAL TRANSMISSION AND MODIFICATION OF BEHAVIORAL DEFICITS INDUCED BY PRENATAL IMMUNE ACTIVATION

Ulrike Weber-Stadlbauer*, Juliet Richetto, Marie Labouesse, Urs Meyer

T204. ROLE OF AMPA RECEPTOR DEFICIENCY IN THE ONSET OF SCHIZOPHRENIA IN AN INDUCIBLE GENETIC MOUSE MODEL

Dragos Inta*, Miriam Vogt, Hasan Elkin, Peter Gass

T205. UBE3B EXPRESSION IN THE PREFRONTAL CORTEX DURING DEVELOPMENT AND IN SCHIZOPHRENIA

Emily Kohlbrenner*, Tsung-Ung Wilson Woo

T206. THE DOPAMINERGIC RESPONSE TO ACUTE STRESS IN HEALTH AND PSYCHOPATHOLOGY: A SYSTEMATIC REVIEW

Thomas Vaessen*, Dennis Hernaus, Inez Myin-Germeys, Thérèse van Amelsvoort

T207. NO LINK BETWEEN DURATION OF PRODROMAL AND PSYCHOTIC SYMPTOMS AND BRAIN STRUCTURAL VOLUMES IN EMERGING PSYCHOSIS

Charlotte Rapp*, Carlos Canela, Erich Studerus, Anna Liisa Walter, Jacqueline Aston, Stefan Borgwardt, Anita Riecher-Rössler

T208. INCREASED EXPRESSION OF ALPHA-2,8-SIALYLTRANSFERASE 8 (ST8SIA2) IN SUPERIOR TEMPORAL GYRUS OF ELDERLY PATIENTS WITH SCHIZOPHRENIA

Toni Mueller*, Stefani Yates, Vahram Haroutunian, James Meador-Woodruff

T209. UNRAVELLING THE ROLE OF SCHIZOPHRENIA RISK GENES IN MICROGLIA: SPECIFIC FUNCTIONS IN THE ANTI-INFLAMMATORY PHENOTYPE?

Lot de Witte, Lynn van Olst, Manja Litjens, Elly Hol, Christiaan Vinkers, René Kahn, Marjolein Sneeboer*

T210. EFFECT OF CLOZAPINE AND HALOPERIDOL IN THE MORPHOLOGY AND NEURODEVELOPMENT OF ZEBRAFISH EMBRYO.

Carles Garcia-Ribera*, Gretsén Velezmoro, Javier Terriente, Javier Joya, Oriol Vall, Cristina Pujades

T211. PREFRONTAL GRAY MATTER VOLUME LOSS IS ASSOCIATED WITH DECREASED WORKING MEMORY PERFORMANCE IN ADOLESCENTS WITH A FIRST EPISODE OF PSYCHOSIS

Marta Rapado-Castro*, Mara V. Arenzana, Joost Janssen, David Fraguas, Josefina Castro-Fornieles, Ana González-Pinto, Montse Graell, Soraya Otero, Manuel Desco, Christos Pantelis, Celso Arango



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

T212. WHY IS EXOTROPIA (ONE SPECIFIC TYPE OF STRABISMUS) A SIGNIFICANT RISK FACTOR FOR SCHIZOPHRENIA?

Christopher von Bartheld, Andrea Agarwal, Cheng-yuan Feng, Austin Christensen, Dan Wen, Kellie Cassinelli, L. Alan Johnson, Brian Kirkpatrick*

T213. VERY PRETERM BORN ADULTS EXPERIENCE ELEVATED LEVELS OF PSYCHOPATHOLOGY THAT ARE ASSOCIATED WITH THE VOLUMES OF CORTICOSTRIATAL WHITE MATTER TRACTS
Jasmin Kroll*, Sean Froudust-Walsh, Jane Tseng, Philip Brittain, Slava Karolis, Chiara Nosarti

T214. UNCOVERING COMPONENTS OF COGNITIVE BEHAVIOURAL CASE MANAGEMENT (CBCM) IN UHR INDIVIDUALS: WHAT IS IMPLEMENTED AND WHAT IS EFFECTIVE?

Jessica A Hartmann*, Patrick D McGorry, G Paul Amminger, Hok Pan Yuen, Connie Markulev, Lavoie Suzie, Miriam R Schäfer, Meredith McHugh, Barnaby Nelson

T215. INDIVIDUALIZED METACOGNITIVE THERAPY FOR DELUSIONS: EFFECTIVENESS IN A PRAGMATIC CONTROLLED TRIAL

Christina Andreou*, Martina Fieker, Charlotte Wittekind, Brooke Schneider, Steffen Moritz

T216. EXERCISE IMPROVES CLINICAL SYMPTOMS, QUALITY OF LIFE, GLOBAL FUNCTIONING AND DEPRESSION IN SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS

Meenakshi Dauwan*, Marieke Begemann, Sophie Heringa, Iris Sommer

T217. THETA BURST TRANSCRANIAL MAGNETIC STIMULATION FOR AUDITORY VERBAL HALLUCINATIONS

Margot Slot*, Sanne Koops, Edwin van Dellen, Maya Schutte, Wendy Nieuwdorp, Sebastiaan F. W. Neggers, Iris Sommer

T218. COGNITIVE REMEDIATION GROUP THERAPY REDUCES PERSISTENT NEGATIVE SYMPTOMS IN SCHIZOPHRENIA OUTPATIENTS: RCT RESULTS

Daniel Mueller*, Volker Roder

T219. COGNITIVE THERAPY AND MOTIVATIONAL INTERVIEWING: REDUCING CANNABIS CONSUMPTION IN INDIVIDUALS WITH PSYCHOSIS

Henrietta Steinhart*, Ulrich Reininghaus, Cecile Henquet, Tineke Lataster, Maurice Smits, Christine Barrowclough, Inez Myin-Germeyns

T220. AN EVENT-RELATED POTENTIAL EEG-NEUROFEEDBACK TRAINING TO TREAT AUDITORY VERBAL HALLUCINATIONS IN SCHIZOPHRENIA PATIENTS

Kathryn Heri*, Laura Diaz Hernandez, Daniela Hubl, Thomas Dierks, Thomas Koenig

T221. IMPACT OF PSYCHOSOCIAL INTERVENTIONS ON CAREGIVER BURDEN OF SCHIZOPHRENIC OUTPATIENTS. A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS

Elaine Di Sarno*, Mario Rodrigues Louzã Neto

FINAL PROGRAM

FLORENCE, ITALY

2 – 6 APRIL 2016



T222. COMPARING THE EFFICACY OF TWO TYPES OF COGNITIVE REMEDIATION IN SCHIZOPHRENIA: RESULTS FROM A TWO-SITE RETROSPECTIVE COHORT STUDY.

Bruno Biagianti*, Matteo Cella, Clare Reeder, Sophia Vinogradov, Til Wykes

T223. PRELIMINARY EVIDENCE FOR IMPAIRED OBJECT RECOGNITION AS A NEURAL CORRELATE OF VISUAL DEREALISATION PHENOMENA IN FIRST EPISODE SCHIZOPHRENIA PATIENTS

Daniel Nuñez*, Rieke Oelkers-Ax, André Rupp, Heribert Sattel, Franz Resch, Matthias Weisbrod, Thomas Fuchs

T224. DIFFERENCES BETWEEN PATIENTS WITH SCHIZOPHRENIA AND UNAFFECTED CONTROLS IN COMPUTATIONALLY DERIVED ACOUSTIC PHONETIC PARAMETERS AND MEASURES OF LEXICAL VARIATION AND IDEA DENSITY

Luca Pauselli*, Michael Compton, Anya Lunden, Sean Cleary, Yazeed Alolayan, Brooke Halpern, Beth Broussard, Anthony Crisafio, Leslie Capulong, Benson Ku, Pierfrancesco Balducci, Francesco Bernardini, Bill Hollingsworth, Michael Covington

T225. UNAWARENESS AND MISATTRIBUTION OF SYMPTOMS IN SCHIZOPHRENIA: RELATIONSHIP WITH SYMPTOM CLUSTERS AND SOCIO-DEMOGRAPHIC VARIABLES

Ada Ruiz*, Esther Pousa, Carles Garcia-Ribera, Carmina Massons, Susana Ochoa, Judith Usall, Jesús Cobo

T226. STRESS IN THOSE AT RISK FOR PSYCHOTIC DISORDER: A POSSIBLE ROLE FOR MOMENTARY STRESS IN THE EXACERBATION OF AFFECTIVE AND PSYCHOTIC SYMPTOMS.

Yori van der Steen*, Judith Gimpel-Drees, Inez Myin-Germeys, Wolfgang Viechtbauer, Claudia Simons, Mariëlle Lardinois, Tanja Michel, Birgit Janssen, Andreas Bechdolf, Michael Wagner, Tineke Lataster

T227. RELIABILITY AND VALIDITY OF THE KOREAN VERSION OF THE MOTIVATION AND PLEASURE SCALE-SELF REPORT (MAP-SR), A SELF-REPORT MEASURE OF NEGATIVE SYMPTOMS

Ji Sun Kim*, Seon-Kyeong Jang, Seon-Cheol Park, Joong-Kyu Park, Jung Suk Lee, Kee-Hong Choi, Jung-Seo Yi, Seung-Hwan Lee

T228. EXPERIENCES OF ANTIPSYCHOTIC TREATMENT IN CLINICAL RECOVERY FROM FIRST EPISODE PSYCHOSIS

Jone Bjørnstad*, Larry Davidson, Inge Joa, Tor Ketil Larsen, Wenche ten Velden Hegelstad, Johannes Langeveld, Marius Veseth, Ingrid Melle, Jan Olav Johannessen, Kolbjørn Brønnick

T229. PARANOIA AND FACETS OF SELF-ESTEEM IN EARLY PSYCHOSIS: ASSOCIATIONS ACROSS PSYCHOMETRIC AND REAL-LIFE ASSESSMENT METHODS

Manel Monsonet*, Paula Cristóbal-Narváez, Tamara Sheinbaum, Tecelli Domínguez-Martínez, Thomas R. Kwapil, Neus Barrantes-Vidal

T230. AN EMBEDDED, EMBODIED, ENACTIVE ACCOUNT TO PSYCHOSIS

Inez Myin-Germeys*



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

T231. THE DIFFERENCES BETWEEN INDIVIDUALS WITH PERSISTENT AND NON-PERSISTENT PSYCHOTIC-LIKE EXPERIENCES: A FOLLOW-UP STUDY IN THE GENERAL POPULATION OF HONG KONG

Kit Wai Lee*, Kit Wa Chan, Wing Chung Chang, Edwin Ho Ming Lee, Christy Lai Ming Hui, Jingxia Lin, Eric Yu Hai Chen

T232. THE COURSE OF ACOUSTIC VERBAL CHARACTERISTICS OVER TIME

Jack J.A. Jenner, L.B. Luteijn*

T233. QUETIAPINE ER VERSUS ARIPIPRAZOLE IN CHILDREN AND ADOLESCENTS WITH PSYCHOSIS—THE RANDOMISED, BLINDED CLINICAL TOLERABILITY AND EFFICACY OF ANTIPSYCHOTICS (TEA) TRIAL.

Anne Katrine Pagsberg*, Pia Jeppesen, Dea Klauber, Karsten Gjessing Jensen, Ditte Rudå, Marie Stentebjerg-Olesen, Eva Ann-Sofie Saldeen, Niels Bilenberg, Anne Dorte Stenstrøm, Jesper Pedersen, Jens Richardt Jepsen, Birgitte Fagerlund, Christian Gluud, Maria Skoog, Per Winkel, Christoph U. Correll, Anders Fink-Jensen

T234. ADOLESCENT CANNABINOID EXPOSURE INCREASES THE SUSCEPTIBILITY FOR A SCHIZOPHRENIA-LIKE PHENOTYPE IN A NOVEL RODENT MODEL

David Aguilar*, Stephanie Perez, Andrea Guffrida, Daniel Lodge

T235. POTENTIAL DRUG-DRUG INTERACTIONS IN MEXICAN PATIENTS WITH SCHIZOPHRENIA.

María Conchita Ocaña Zurita*, Alma Genis, Isela Juárez-Rojop, Carlos Alfonso Tovilla-Zárate, Thelma Beatriz González-Castro, María Lilia López Narváez, Humberto Nicolini

T236. THE EFFECTS OF POSITIVE ALLOSTERIC MODULATOR OF $\alpha 7$ NICOTINIC RECEPTORS ON COGNITIVE AND SENSORIMOTOR GATING DEFICITS IN A SCHIZOPHRENIA-LIKE MODEL IN RATS.

Agnieszka Potasiewicz*, Agnieszka Nikiforuk, Małgorzata Hołuj, Piotr Popik

T237. DRD2 CO-EXPRESSION NETWORK AND A RELATED POLYGENIC SCORE PREDICT BRAIN ACTIVITY, BEHAVIORAL PHENOTYPES AND TREATMENT RESPONSE LINKED TO SCHIZOPHRENIA.

Pasquale Di Carlo*, Giulio Pergola, Enrico D'ambrosio, Jose A. Apud, Antonio Rampino, Grazia Caforio, Venkata S. Mattay, Daniel R. Weinberger, Giuseppe Blasi, Alessandro Bertolino

T238. THE EFFECT OF ANTIPSYCHOTIC TYPE AND DOSE CHANGES ON DYSKINESIA AND PARKINSONISM IN PATIENTS WITH A SERIOUS MENTAL ILLNESS (SMI)

Charlotte Mentzel*, P. Roberto Bakker, Glen Matroos, Hans Hoek, Marjan Drukker, Marina Tijssen, Peter Van Harten

T239. TREATMENT WITH ANTIPSYCHOTICS IN LATE-LIFE SCHIZOPHRENIA

Rob Kok*, Shenara Sheikkariem, Nicolien Kist, Julia Van Den Berg



T240. CLINICAL AND FUNCTIONAL RESPONSE TO PALIPERIDONE PALMITATE IN EARLY SCHIZOPHRENIA – A RETROSPECTIVE OBSERVATIONAL STUDY IN NEWLY DIAGNOSED PATIENTS TREATED OVER A 12-MONTH PERIOD

Ludger Hargarter*, Paul Bergmans, Pierre Cherubin, Andreas Schreiner

T241. EFFECTIVENESS OF ANTIPSYCHOTICS USED IN FIRST EPISODE PSYCHOSIS: A NATURALISTIC COHORT STUDY

Andrew Thompson*, Michael Harris, Gail Kavanagh, Steven Marwaha, Vijitha Wickramasinghe, Ketan Jethwa, Nirmalan Ayadurai, Richard Whale

T242. A SYSTEMATIC REVIEW AND META-ANALYSIS OF TREATMENTS FOR CLOZAPINE-INDUCED OBESITY AND METABOLIC SYNDROME: EVIDENCE FROM RANDOMISED-CONTROLLED TRIALS

Jorge Zimbron, Golam Khandaker, Chiara Toschi, Peter Jones, Emilio Fernandez-Egea*

T243. A NOVEL KV3 POSITIVE MODULATOR AUGMENTS RODENT PREFRONTAL FAST NETWORK OSCILLATIONS IN VITRO FOLLOWING SUB-CHRONIC PCP TREATMENT.

Tamara Modebadze, Claire Gillougley, Guiseppe Alvaro, Charles Large, Fiona LeBeau, Mark Cunningham*

T244. THE EFFECT OF CUMULATED ESTROGEN EXPOSURE AND OTHER FEMALE HORMONAL EVENTS ON CLINICAL TRAJECTORIES AND ANTIPSYCHOTIC RESPONSE IN POSTMENOPAUSAL SCHIZOPHRENIA WOMEN

Alexandre González-Rodríguez*, Rosa Catalán, Rafael Penadés, Victoria Ruiz, Mercè Torra, Miquel Bernardo

T245. CLINICAL RISK FACTORS ASSOCIATED WITH CLOZAPINE INDUCED NEUTROPENIA

John Lally*, Steffi Malik, Megan Pritchard, Johnny Downs, James MacCabe

T246. SCREENING FOR ANTIPSYCHOTIC DRUGS WHICH DO NOT INTERACT WITH MONOAMINE RECEPTORS

Eric Prinssen*, Jean-Luc Moreau, Thomas Mueggler, Lucinda Steward, Taleen Hanania, Dani Brunner, Vadim Alexandrov, Emer Leahy, Sabine Kolczewski

T247. INHIBITION OF PDE1 LEADS TO MEMORY IMPROVEMENT IN ANIMAL MODELS RELATED TO COGNITIVE SYMPTOMS OF SCHIZOPHRENIA VIA ENHANCEMENT OF DOPAMINE D1 RECEPTOR SIGNALING

Holger Rosenbrock*, Niklas Schülert, Riccardo Giovannini, Roland Pfau, Birgit Stierstorfer, Scott Hobson, Anton Pekcec

T248. INFORMING CLINICIANS, PATIENTS AND GUIDELINES. NETWORK META-ANALYSIS ON 24 ANTIPSYCHOTIC DRUGS AND A BROAD RANGE OF IMPORTANT OUTCOMES FOR SCHIZOPHRENIA - A PROTOCOL

Maximilian Huhn*, Myrto SamaraDepartment of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universität München, Germany, Yikang Zhu, Johannes Schneider, Philipp Rothe, Matteo Rabaioli-Fischer, Susanne Bächer, Stefan Leucht



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

T249. EFFECTS OF N-ACETYLCYSTEINE IN SCHIZOPHRENIA-LIKE BEHAVIORS INDUCED BY A PROGRESSIVE REGIMEN OF AMPHETAMINE SENSITIZATION IN MICE

Ana Herrmann*, Roberta Andrejew, Radharani Benvenuti, Elaine Elisabetsky

T250. PATTERN OF ANTIPSYCHOTIC PRESCRIPTION AMONG PATIENTS WITH SCHIZOPHRENIA AT A NIGERIAN NEUROPSYCHIATRIC HOSPITAL

Babatunde Fadipe*, Timothy Adebowale, Yetunde Fadipe, Andrew Olagunju

T251. TREATMENT-RESISTANT SCHIZOPHRENIA: SIMPLE PAIRWISE AND NETWORK META-ANALYSIS OF ALL ANTIPSYCHOTICS

Myrto Samara*, Adriani Nikolakopoulou, Georgia Salanti, Stefan Leucht

T252. TREATMENT STRATEGIES IN CASE OF NON-RESPONSE IN SCHIZOPHRENIA: META-ANALYTICAL ASSESSMENTS OF INCREASING THE ANTIPSYCHOTIC DOSE AND SWITCHING THE ANTIPSYCHOTIC DRUG VERSUS CONTINUATION OF THE SAME ANTIPSYCHOTIC DOSE AND DRUG.

Myrto Samara*, Stefan Leucht

T253. A MOLECULAR IMAGING STUDY OF POSTSYNAPTIC DENSITY TRANSCRIPTS IN ANTIPSYCHOTIC-NAÏVE VS. ANTIPSYCHOTIC-EXPOSED ANIMALS. A MOLECULAR EXPLANATION FOR DISCREPANCY IN TREATMENT RESPONSES DEPENDING ON TREATMENT HISTORY

Felice Iasevoli, Federica Marmo, Elisabetta F. Buonaguro*, Gianmarco Latte, Rodolfo Rossi, Carmine Tomasetti, Andrea de Bartolomeis

T254. DIFFERENT RECEPTOR PROFILE AND DOSE OF ANTIPSYCHOTICS INDUCE DIFFERENTIAL CHANGES IN LEVEL AND TOPOGRAPHY OF POSTSYNAPTIC DENSITY TRANSCRIPTS ASSOCIATED TO PSYCHOSIS PATHOPHYSIOLOGY.

Andrea de Bartolomeis, Felice Iasevoli, Federica Marmo, Anna Eramo, Gianmarco Latte, Camilla Avagliano, Carmine Tomasetti, Elisabetta F. Buonaguro*

T255. PREVENTION OF DISABILITY IN TREATMENT RESISTANT SCHIZOPHRENIA (TRS) NEEDS INDIVIDUATION OF FACTORS CONTRIBUTING TO SOCIAL IMPAIRMENT. RESULTS FROM A PILOT STUDY USING A STRINGENT OPERATIVE PROCEDURE TO CATEGORIZE TRS PATIENTS.

Felice Iasevoli, Maria Vittoria Formato, Raffaele Balletta, Sara Giordano, Emiliano Prinzivalli, Gianmarco Latte, Rodolfo Rossi, Elisabetta F. Buonaguro*, Andrea de Bartolomeis

T256. SYMPTOMATIC REMISSION STATUS IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH PALIPERIDONE PALMITATE (1-MONTH AND 3-MONTH FORMULATIONS)

Adam Savitz*, Haiyan Xu, Srihari Gopal, Isaac Nuamah, David Hough, Maju Mathews

T257. RESILIENCE IN INDIVIDUALS CLINICALLY AT HIGH RISK FOR PSYCHOSIS - FIRST RESULTS FROM THE PRONIA STUDY

Nathalie Kaiser*, Theresa Haidl, Marlene Rosen, Frauke Schultze-Lutter, Stefan Borgwardt, Paolo Brambilla, Christos Pantelis, Raimo K.R. Salokangas, Stephen Wood, Nikolaos Koutsouleris, Stephan Ruhrmann, and the PRONIA Group .

FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016



T258. PEER PROBLEMS AND LOW SELF-ESTEEM MEDIATES THE SCHIZOTYPY – REACTIVE AGGRESSION RELATIONSHIP IN ADOLESCENTS

Keri Wong*, Adrian Raine

T259. SOCIAL AND ROLE FUNCTIONING IN A HIGH RISK CHILD AND ADOLESCENT SAMPLE

Montserrat Dolz*, Jordina Tor, Marta Pardo, Daniel Muñoz, Marta Carulla, Xavier Álvarez, Elena De la Serna, Gisela Sugranyes, Inmaculada Baeza

T260. COMPARING DOMAINS OF FUNCTIONING IN CLINICAL HIGH RISK SUBJECTS, RECENT ONSET PSYCHOSIS AND RECENT ONSET DEPRESSION PATIENTS - FIRST RESULTS FROM THE PRONIA STUDY

Marlene Rosen*, Theresa Haidl, Nathalie Kaiser, Frauke Schultze-Lutter, Stefan Borgwardt, Paolo Brambilla, Christos Pantelis, Raimo K. R. Salokangas, Stephen Wood, Nikolaos Koutsouleris, Stephan Ruhrmann, and the PRONIA Group

T261. THE BULLYING SCALE - FIRST RESULTS FROM THE PRONIA STUDY

Theresa Haidl*, Marlene Rosen, Nathalie Kaiser, Frauke Schultze-Lutter, Stefan Borgwardt, Paolo Brambilla, Christos Pantelis, Raimo K. R. Salokangas, Stephen Wood, Nikolaos Koutsouleris, Stephan Ruhrmann, and the PRONIA Group

T262. SELF-STIGMA AND ITS RELATIONSHIP WITH VICTIMIZATION, PSYCHOTIC SYMPTOMS AND SELF-ESTEEM AMONG PEOPLE WITH SCHIZOPHRENIA SPECTRUM DISORDERS.

Ellen Horselsenberg*, Joeske van Busschbach, Marieke Pijnenborg, Andre Aleman

T263. MENTALIZING ABILITY AS A MEDIATOR BETWEEN REPORTED CHILDHOOD ABUSE AND NON-AFFECTIVE PSYCHOTIC DISORDER.

Jonas Weijers*, Liesbeth Eurelings-Bontekoe, Jean-Paul Selten

T264. LANGUAGE DISTURBANCE AND FUNCTIONAL CAPACITY IN EARLY PSYCHOSIS

Eric Roche*, Ricardo Segurado, Aisling McClenaghan, Maurice Bonar, Mary Clarke

T265. PREDICTING PSYCHOSOCIAL FUNCTIONING IN SCHIZOPHRENIA: THE ROLE OF CLINICAL SYMPTOMS AND THE AWARENESS OF ILLNESS

Álvaro López-Díaz*, Fermín González-Higueras, Pedro Torres-Hernández

T266. RECOVERY IN SCHIZOPHRENIA: A NATURAL 5-YEAR FOLLOW-UP STUDY IN A PRIVATE PRACTICE

Mustafa Yıldız*

T267. ATTEMPTS OF SUICIDE IN FIRST EPISODE OF PSYCHOSIS AND PSYCHOSOCIAL FUNCTIONING

Manuel Canal-Rivero*, Jorge Garcia Egea, Jordi E. Obiols Llandrich, Miguel Ruiz Veguilla

T268. CANNABIS USE AND ATTEMPTS OF SUICIDE IN FIRST EPISODE OF PSYCHOSIS

Manuel Canal-Rivero*, Gloria Benítez, Alba Yañez Castro, Jorge Garcia Egea, Jordi E. Obiols Llandrich, Miguel Ruiz Veguilla



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

T269. VALIDATION AND IMPLEMENTATION OF THE INDIVIDUAL RECOVERY OUTCOMES COUNTER (I.ROC) IN AN SMI POPULATION IN THE NETHERLANDS – RESEARCH PLAN

Bouwina Sportel*, Hettie Aardema, Nynke Boonstra, Stynke Castelein, Marieke (Gerdina) Pijnenborg

T270. HEALTH RELATED QUALITY OF LIFE IN SCHIZOPHRENIA AND OTHER PSYCHOSES: AQOL-4D FINDINGS FROM THE SECOND AUSTRALIAN NATIONAL SURVEY OF PSYCHOSIS

Amanda Neil, Vaughan Carr*, Andrew Mackinnon, Anna Waterreus, Helen Stain, Mary-Claire Hanlon, Sam Korn, Vera Morgan

T271. RELIABILITY AND VALIDITY OF THE SPECIFIC LEVELS OF FUNCTION SCALE - JAPANESE VERSION; RELATION TO COGNITIVE INSIGHT

Tomiki Sumiyoshi*, Keiichiro Nishida, Hidehito Niimura, Atsuhito Toyomaki, Tsubasa Morimoto, Masayuki Tani, Ken Inada, Taiga Ninomiya, Hikaru Hori, Yosuke Koshikawa, Toshihiko Kinoshita, Ichiro Kusumi, Akira Iwanami, Takefumi Ueno, Takeshi Terao, Kazuyuki Nakagome

T272. WHAT DO SERVICE USERS WANT FROM A SMARTPHONE APP FOR PSYCHOSIS?

Sandra Bucci*

T273. QUALITY OF LIFE ASSESSMENT IN SCHIZOPHRENIA DIAGNOSED PATIENTS WITH PREDOMINANT NEGATIVE SYMPTOMS

Daniel Vasile*, Octavian Vasiliu, Diana Gabriela Vasiliu, Florin Vasile

T274. ASSESSING THE RELEVANCE OF THE SUBJECTIVE WELL-BEING UNDER NEUROLEPTICS–SHORT FORM IN SCHIZOPHRENIA: PATIENT AND CAREGIVER PERSPECTIVES

Dieter Naber*, Maud Beillat, Dana B. DiBenedetti, T. Michelle Brown

T275. MEASURING WELL-BEING IN CHRONIC SCHIZOPHRENIA: THE SIGNIFICANCE OF POSITIVE SYMPTOMS

Julia Brown*, Gisela Mezquida, Emilio Fernandez-Egea

T276. DOES FUNCTIONING AND LIFE SATISFACTION DIFFER FOR SCHIZOPHRENIA PATIENTS WITH CO-MORBID DEPRESSION?

Eric Tan*, Susan Rossell

T277. ASSOCIATION OF KNOWLEDGE AND CAUSAL EXPLANATION OF SCHIZOPHRENIA STUDENTS' ATTITUDE TOWARDS SERVICE USERS: A COMPARISON BETWEEN NURSING AND MEDICAL UNDERGRADUATES

Lucia Sideli, Caterina La Cascia, Fabio Seminerio*, Valentina Barone, Crocettarachele Sartorio, Roberta D'agostino, Alice Mulè, Laura Ferraro, Giada Tripoli, Michel Inguglia, Antonio Francomano, Daniele La Barbera, Marta Di Forti, Robin Murray

T278. AN AUDIT OF CLOZAPINE USE IN FIRST EPISODE PSYCHOSIS

Roisin Doyle, Donal O'Keeffe*, Caragh Behan, Sarah Masterson, Aine Kelly, Ann Sheridan, Dolores Keating, Caroline Hynes, Kevin Madigan, Elizabeth Lawlor, Mary Clarke



T279. DOES LONG ACTING ARIPIRAZOLE IMPROVE OUTCOMES IN ROUTINE CLINICAL PRACTICE?

Richard Hodgson*, Chandan Aladakatti, Brittany Davenport

T280. FIVE-YEAR OUTCOMES OF FEP PATIENTS RECEIVING INTEGRATED VS. FUNCTIONAL MENTAL HEALTH CARE. A PILOT STUDY FROM THE PICOS

Elisabetta Miglietta*, Antonio Lasalvia, Doriana Cristofalo, Sarah Tosato, Chiara Bonetto, Gioia Zanatta, Silvia Zoppei, Sara Petterlini, Carla Comacchio, Giorgia Dimitri, Dario Lamonaca, Francesco Gardellin, Mirella Ruggeri

T281. FREE ASSOCIATIONS AS BOTH A VERBAL AND NONVERBAL PHENOMENON IN DANCE/ MOVEMENT THERAPY - A CASE STUDY WITH PATIENTS DIAGNOSED WITH SCHIZOPHRENIA AND VARYING DEGREES OF RELATED FORMS OF PSYCHIATRIC DIAGNOSES.

Karolina Bryl*

T282. THE MORAY PSYCHOSIS SURVEY: PREVALENCE, DEMOGRAPHICS AND TREATMENT CHARACTERISTICS IN A RURAL COHORT OF PATIENTS DIAGNOSED WITH SCHIZOPHRENIA
 Angus MacBeth*, Hannah Greaves

T283. META-ANALYSIS OF OXYTOCIN IN SCHIZOPHRENIA: EFFECTS ON SOCIAL COGNITION
 Angus MacBeth*, Andrew Gumley

T284. PREDICTORS OF PRE-DIABETES IN OVERWEIGHT OR OBESE SCHIZOPHRENIA PATIENTS TREATED WITH CLOZAPINE OR OLANZAPINE: BASELINE RESULTS FROM AN ONGOING RANDOMISED CONTROLLED TRIAL

Julie Larsen*, Louise Vedtofte, Kamuran Koyuncu, Mathilde Jakobsen, Hans Jespersen, Michelle Jakobsen, Camilla Svensson, Christoph Correll, Tina Villsbøll, Anders Fink-Jensen

T285. CATATONIA IN FIRST EPISODE OF PSYCHOSIS: CORRELATIONS WITH HYPERPROLACTINEMIA AND DUP

Jorge Cuevas-Esteban*, Anna Butjosa, Núria Del Cacho, Regina Vila-Badia, Elena Rubio-Abadal, Maria Jose Rodriguez, Montserrat Dolz, GRUP PEP-PROLACTINA, Judith Usall

T286. PRELIMINAR RESULTS OF THE EFFECTIVENESS OF THE MCT GROUP IN PEOPLE WITH PSYCHOSIS IN REHABILITATION SERVICES

Mar Garcia-Franco*, Gemma Prat, Sonia Vilamala-Anton, Maria José Escandell-Morcillo, Jose Ramón Martin-Martinez, Ingrid Tortades-Arumi, J. Gonzalez, R. Monreal, Susana Ochoa

T287. RISK OF PSYCHOSIS AND INTERNAL MIGRATION: RESULTS FROM THE BOLOGNA FIRST EPISODE PSYCHOSIS STUDY

Ilaria Tarricone, Jane Boydell, Armisa Kokona, Federico Triolo, Lisa Gamberini, Enrico Sutti, Michela Marchetta, Marco Menchetti, Marta Di Forti*, Robin Murray, Craig Morgan, Domencio Berardi



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

T288. ANTHROPOMETRIC VALUES IN NAÏVE FIRST EPISODE OF NON AFFECTIVE PSYCHOSIS:
THE ROLE OF WEIGHT AT BIRTH

Clemente Garcia-Rizo*, Fernandez-Egea Emilio, Cristina Oliveira, Brian Kirkpatrick, Miguel Bernardo Arroyo

T289. METABOLIC SYNDROME OR GLUCOSE ABNORMALITIES IN FIRST EPISODE OF PSYCHOSIS?

Clemente Garcia-Rizo*, Emilio Fernandez-Egea, Cristina Oliveira, Ana Meseguer, Bibiana Cabrera, Gisela Mezquida, Miquel Bioque, Rafael Penades, Eduard Parellada, Miguel Bernardo Arroyo, Brian Kirkpatrick

T290. BONE MINERAL DENSITY AS A MARKER OF CUMULATIVE ESTROGEN EXPOSURE IN
PSYCHOTIC DISORDER: A 3 YEAR FOLLOW-UP STUDY

Christine van der Leeuw, Sanne Peeters, Patrick Domen, Marinus van Kroonenburgh, Jim Van Os, Machteld Marcelis*

T291. PREVENTING FIRST AND SUBSEQUENT RELAPSES IN FIRST EPISODE OF NON-AFFECTIVE
PSYCHOSIS IN A THREE YEAR LONGITUDINAL FOLLOW-UP: THE ROLE OF ADHERENCE

Jose Maria Pelayo-Teran*, Gajardo Galán Virginia, García de la Foz Víctor, Martínez-García Obdulia, Ayesa-Arriola Rosa, Crespo-Facorro Benedicto, Tabares-Seisdedos Rafael

T291. THE OPEN TRANSLATIONAL SCIENCE IN SCHIZOPHRENIA PROJECT: JANSSEN CLINICAL
TRIAL AND NIH DATA TOGETHER IN AN OPEN-SCIENCE COLLABORATION

Marsha Wilcox

T293. SPATIAL DISTRIBUTION OF PSYCHOTIC DISORDERS IN AN URBAN AREA OF FRANCE

Baptiste Pignon*, Franck SCHURHOFF, Grégoire Baudin, Aziz Ferchiou, Jean-Romain Richard, Ghassen Saba, Marion Leboyer, James Kirkbride, Andrei Szoke

T294. GENETIC POLYMORPHISM OF THE INFLAMMATORY C-REACTIVE PROTEIN (CRP) AND
SCHIZOPHRENIA

Ayari Fayza*, Ben Chaaben Arij, Ben Ammar Hanen, Aissa Amina, Abaza Hajer, Douik Hayet, Ouni Nesrine, Arfaoui Abir, Zid Zaineb, Harzallah Latifa, Boughzou Sabrine, Selmi Mouhamed Anis, Leboyer Marion, Tamouza Ryad, El hehmi Zouhaier, Guemira Fethi

FINAL PROGRAM

FLORENCE, ITALY

2 – 6 APRIL 2016



INDEX OF PRESENTERS AND AUTHORS*

Abi-Dargham, Anissa	3, 29, 38	Bais, Leonie	84
Abilio, Vanessa	118	Bajouco, Miguel	93
Aboraya, Ahmed	101	Bak, Maarten	79
Abram, Samantha	55	Baker, Amanda	107
Abu-Akel, Ahmad	78	Bakker, Geor (IM)	112
Addington, Donald	124	Bakker, P. Roberto	126
Addington, Jean	4	Balado, Claudia Prats	76
Agarwal, Sri Mahavir	14, 130	Ball, Hannah	122
Agid, Ofer	60	Bang, Minji	79
Aguilar, David	150	Barch, Deanna	4
Akdede, Berna	96	Barron, David	80
Albacete, Auria	136	Bartels-Velthuis, Annegien	32
Albergo, Dalila	99	Bartholomeusz, Cali	84
Albert, Nikolai	40, 93	Barzilay, Ran	14, 71
Alden, Eva	145	Basu, Sutapa	80
Allen, Paul	26	Batty, Rachel	77, 141
Alloza, Clara	144	Baudin, Grégoire	97
Alonso, Sergio Sánchez	91	Beck, Katharina	132
Alphs, Larry	5	Begemann, Marieke	76
Alptekin, Koksul	92	Benes, Francine	47
Alústiza, Irene	136	Benros, Michael	14, 139
Alvarez, Maria-José	95	Ben-Zeev, Dror	28
Amminger, G. Paul	61	Berg, Akiah	135
Anand, Ravi	37	Bernardini, Francesco	119
Anda, Liss	105	Bernardo, Miquel	72
Andreou, Christina	148	Berretta, Sabina	41
Andric, Sanja	14, 81	Bertolino, Alessandro	4
Anticevic, Alan	12, 112	Bervoets, Chris	79
Antoniades, Mathilde	56	Bhattacharyya, Sagnik	56
Antonucci, Linda A.	113	Bhavsar, Vishal	111, 141
Arango, Celso	3, 16, 38, 41, 55, 130	Biaggi, Alessandra	98
Arias, Barbara	75	Biagianti, Bruno	119, 149
Arkhipov, Andrei	126	Bilenberg, Niels	83
Armando, Marco	71	Binbay, Tolga	111, 141
Armstrong, Kristan	138	Bioque, Miquel	144
Asmal, Laila	14, 86	Birchwood, Max	40
Assunção, Idaiane	128	Bittner, Robert	84
Atbasoglu, Cem	107	Bjornestad, Jone	149
Athanas, Katina	117	Bloemen, Oswald	86
Austin, Stephen	61, 123	Blokland, Gabriëlla	14, 52
Ayer, Ahmet	80, 140	Bloomfield, Michael	29
Ayesa-Arriola, Rosa	77, 106	Bo, Qi-Jing	127
Back, Dayae	91	Bodnar, Michael	122
		Bogers, Jan	70, 108

* The Index of Authors and Presenters includes only First Authors of Posters, Speakers of Plenary Sessions, Symposia, and Workshops.



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

Bohlken, Marc	14, 52	Chawner, Samuel	100
Bojesen, Kirsten Borup	70	Chen, Eric	3, 4, 40
Boonstra, Nynke	95	Cheung, Eric	134
Bortolato, Marco	29	Chiliza, Bonginkosi	121
Bossong, Matthijs	26	Chong, Siow Ann	4
Bourget, Dominique	92	Chung, Young Chul	73
Bourque, Josiane	53	Cieslik, Paulina	72
Bowie, Christopher	48	Ciufolini, Simone	14, 58
Bralet, Marie-Cécile	89	Clementz, Brett	42
Brandizzi, Martina	94	Clemmensen, Lars	140
Brannan, Stephen	37	Coenen, Michaela	31
Brouwer, Rachel	86	Cohen, Dan	120
Brown, Julia	154	Coid, Jeremy	111, 141
Bruggeman, Richard	78	Colizzi, Marco	107
Bryl, Karolina	124, 155	Collin, Guusje	114
Bucci, Sandra	79, 103, 154	Comacchio, Carla	122
Buchanan, Robert	4, 5, 38	Conn, Jeff	15, 25
Büki, Alexandra	88	Cornblatt, Barbara	5
Bull, Helen	93	Coromina, Marta	85
Buonaguro, Elisabetta F.	87, 115, 152	Correll, Christoph	4, 28, 38
Burdick, Katherine	42	Cortes-Briones, Jose	14, 70
Burgess, Martin	117	Cosgrove, Donna	14, 51
Busatto, Geraldo	3	Cotter, David	64
Butjosa, Anna	109, 138	Cotter, Jack	122
Cabral, Carlos	70	Crespo-Facorro, Benedicto	96
Cadinu, Daniela	116	Cristóbal-Narváez, Paula	127
Cahalan, Susannah	14, 23	Cropley, Vanessa	50
Calem, Maria	129	Crossley, Nicolas	14, 85
Calvo, Ana	66	Cuevas-Esteban, Jorge	155
Calvo-García, Fran	127	Cullen, Alexis	69
Calvo-Rubiales, Maria Isabel	101, 137	Cunningham, Mark	117, 151
Canal-Rivero, Manuel	69, 109, 153	Curcic-Blake, Branislava	114
Cannon, Mary	4, 39, 66	Curzietti, Maxime	136
Cannon, Tyrone	3	Dalman, Christina	4, 128
Capdevielle, Delphine	90	Daniel, David	92
Caron, Marc	52	Da Silva, Susana	122
Carpenter, William	31, 65	Dauwan, Meenakshi	14, 148
Carruthers, Sean	146	David, Anthony	4, 13, 66
Carr, Vaughan	60, 109, 154	Davidson, Michael	73
Castelein, Stynke	110	Davies, Daniel	104
Castle, David	4	Davies, Geoff	61, 136
Catalán, Rosa	120	Dazzan, Paola	3, 4, 5, 13, 17, 38, 56
Cella, Matteo	48, 61	Deakin, John F.	4, 5, 16, 58
Chang, Wing Chung	74, 106, 138	de Boer, Janna	90
Chang, Xiao	86	Debost, Jean-Christophe	139
Chan, Kit Wa Sherry	60	Deenik, Jeroen	107
Chan, Raymond	5, 83	Degenhardt, Franziska	146
Chaumette, Boris	69		

FINAL PROGRAM

FLORENCE, ITALY

2 – 6 APRIL 2016



de Girolamo, Giovanni	111, 139	Fayza, Ayari	156
De Jong, Steven	74, 138	Fazel, Seena	68, 140
De la Serna, Elena	75	Ferguson, Bart	144
DeLisi, Lynn	3, 4	Fernandez-Egea, Emilio	121, 151
De Luca, Vincenzo	121	Fernandez-Miranda, Juan J.	123
Demartinis, Nicholas	37	Ferruccio, Naika	142
Demers, Marie-France	97	Fervaha, Gagan	134
Demirel, Ömer Faruk	129	Fett, Anne-Kathrin	14, 49, 77, 105
de Zwart, Sonja	14, 50	Finke, Carsten	39
Di Carlo, Pasquale	150	Firth, Joseph	89
Dickerson, Faith	31, 78	Fischer, Elena	86
Dickson, Hannah	101, 131	Fisher, Helen	27, 39
Di Forti, Marta	29, 155	Fleischhacker, Wolfgang	4, 5, 51, 59, 92
Di Lorenzo, Giorgio	102, 142	Flores, Cecilia	29
Di Prinzio, Patricia	14, 82	Flyckt, Lena	75, 129
Dollfus, Sonia	48, 79	Foecking, Melanie	64
Dollfus, Sophia	5	Foglia, Enrico	140
Dolz, Montserrat	71, 131, 153	Fond, Guillaume	69, 98
Domen, Patrick	56	Fong, Guillaume	137
Donegan, Jennifer	14, 119	Forsyth, Jen	92
Döring, Christian	129	Fortea, Adriana	109
Downs, Johnny	101, 131	Foussias, George	41
Doyle, Roisin	81	Frajo-Apor, Beatrice	76
Drake, Richard	75	Francesconi, Marta	101, 131
D'Souza, Deepak	29, 57, 98	Fukudome, Daisuke	146
Du, Xin	88	Galderisi, Silvana	41, 49
Dwork, Andrew	30	Gallego, Juan	98
Dwyer, Dominic	61, 115	Galletly, Cherrie	31, 78
Edlinger, Monika	120	Gama, Maiara Zeni Graif	99
Edye, Michelle	88	Ganella, Eleni	85
Egloff, Laura	132	Garcia-Franco, Mar	155
Ehlers, Cornelius	94	Garcia, Jordi Soler	88
Elboukhari, Hasna	88	Garcia-Ribera, Carles	147
Elena, Huerta-Ramos	88	Garcia-Rizo, Clemente	125, 156
Elise, Leroux	115, 143	Gardner, Renee	69
Elkis, Helio	76, 93, 109	Garip, Beyazit	129
Emsley, Robin	4, 5	Gariup, Maria	71, 101
Engelen, Jennifer	143	Garrido, Gemma	135
Englund, Amir	29	Gattaz, Wagner	4
Eriksson, Hans	127	Gee, Brioney	119
Evans-Lacko, Sara	65	Geerts, Hugo	73
Eyles, Darryl	64, 146	Gerstenberg, Miriam	38
Fadipe, Babatunde	14, 93, 152	Gevonden, Martin	68
Falkai, Peter	5, 49, 66	Gilbert, Elsa	51
Falkenberg, Irina	108	Gilleen, James	51, 121
Falkenberg, Liv E.	86	Gillespie, Amy	111
Fatjo-Vilas, Mar	115	Gjerde, Priyanthi Borgen	137
Favre, Gregoire	111	Goldsmith, Paul	102, 143



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

Gonzalez-Blanco, Leticia	99, 137	Hodgson, Richard	124, 155
González-Rodríguez, Alexandre	122, 151	Honer, William	66
Gooding, Diane Carol	119	Hong, Kyung Sue	4, 90
Gopal, Srihari	94	Hoonakker, Marc	136
Goulding, Anneli	95, 140	Horn, Mathilde	138
Grace, Anthony	10, 26	Horselsenberg, Ellen	78, 153
Grazioplene, Rachael	56	Horton, Leslie	14, 100
Green, Melissa	42	Howes, Oliver	5, 40, 64
Green, Michael	3	Howe, William	101
Grent-'t-Jong, Tineke	85	Hoy, Kate	60
Groc, Laurent	39	Huang, Eric	37
Gruber, Oliver	83	Huhn, Maximilian	68, 103, 104, 151
Guan, Lili	125	Huhtaniska, Sanna	91
Guilera, Georgina	31	Husain-Krautter, Sehba	70
Guimond, Synthia	112	Huttunen, Matti	4
Gur, Raquel	15, 27, 36	Hwang, Samuel	119
Haapea, Marianne	140	Hwang, Tzung-Jeng	83
Haas, Shalaila	112	Iizuka, Kunio	104
Hahn, Chang-Gyu	64	Ilzarbe, Daniel	100
Haidl, Theresa	108, 153	Immonen, Johanna	122
Hanina, Adam	96	Inta, Dragos	53, 147
Hanssen, Esther	106, 143	Ishizuka, Koko	15, 63
Haram, Marit	146	Isohanni, Matti	49
Hargarter, Ludger	121, 151	Iwata, Keiko	146
Hartmann, Jessica	14, 148	Iwata, Yusuke	127
Harvey, Phil	5	Iyegbe, Conrad	69
Harvey, Philip	16, 51, 75	Jakobsen, Ane	89
Hasan, Alkomiet	59	Jakobsen, Michelle	125
Hasson-Ohayon, Ilanit	94	Jang, Seon-Kyeong	102
Hazelgrove, Katie	53	Janowska, Sylwia	92
He, Yujie	88	Janssen, Joost	37
Heckers, Stephan	3, 48	Jardri, Renaud	32
Heitz, Ulrike	132	Jasberg, Suzanne Geier	135
Helldin, Lars	105	Jauhar, Sameer	56
Hensch, Takao	15, 46	Jensen, Karsten Gjessing	125
Heres, Stephen	59	Jeppesen, Pia	32, 58
Heri, Kathryn	148	Jessen, Kasper	114
Heringa, Sophie	59	Jhon, Min	99
Herrmann, Ana	117, 152	Ji, Ellen	112
Hickling, Lauren	102	Jingxia, Lin	65
Higuchi, Cinthia	80	Joe, Soohyun	92
Hilker, Rikke	81	Johnstone, Eve	65
Hillegers, Manon	47, 100	Jones, Andrea	14, 82
Hilt, Dana	134	Jongsma, Hannah	14, 54
Hinojosa-Marqués, Lidia	138	Joo, Sung Woo	89
Hirnststein, Marco	116	Joo, Yeon Ho	143
Hjorthøj, Carsten	31	Juárez, Alba Lubeiro	115, 145
Ho, Newfei	70	Jung, Myung Hun	95

FINAL PROGRAM

FLORENCE, ITALY

2 – 6 APRIL 2016



Just, David	99	Klippel, Annelie	119
Kahn, René	3, 64	Kodesh, Arad	107
Kaiser, Nathalie	123, 152	Koevoets, Godefridus	14, 85
Kaiser, Stefan	41	Kohlbrenner, Emily	147
Kakela, Juha	93	Köhler, Ole	54, 82, 111, 137
Kambeitz-Ilankovic, Lana	99	Kok, Rob	150
Kambeitz, Joseph	87, 145	Koops, Sanne	118
Kane, John	28	Koponen, Hannu	49
Kapur, Shitij	3, 5, 13, 38	Koren, Dan	108
Karlsson, Håkan	57	Koros, Eliza	146
Kasanova, Zuzana	142	Korth, Carsten	58
Katsel, Pavel	30	Kos, Claire	128
Katthagen, Teresa	56	Koutsouleris, Nikolaos	15, 35, 37, 49
Kaya, Yunus	94	Kraan, Tamar	97
Keefe, Richard	75	Kraft, Dominik	144
Kegeles, Lawrence	47	Kraguljac, Nina	114
Kelleher, Ian	32, 39	Krakowski, Menahem	57
Kelley, Megan	94	Kraus, Michael	75
Kennedy, James	4, 5, 16, 52	Kristensen, Tina	145
Kent, Jerillyn	42, 84	Krivoy, Amir	128
Khan, Anzalee	106, 137	Kroken, Rune A.	121
Khandaker, Golam	111, 139	Kroll, Jasmin	88, 148
Kikuchi, Yuka	127	Krynicky, Carl	109
Kilian, Sanja	117	Kucukcuban, Onur	14, 106, 137
Killackey, Eoin	93	Kwak, Yoo Bin	107
Kim, Chul Eung	118	Labouesse, Marie	14, 107
Kim, Euitae	112	Lahti, Adrienne	144
Kim, Ji Sun	149	Lally, John	58, 122, 151
Kim, Jung Jin	115	Laloyaux, Julien	76
Kim, Minah	130	Lam, Max	76
Kim, Pitna	88	Lancaster, Sarah	86
Kim, Seung Hyun	93	Lander, Sharon S.	116
Kim, Sung-Wan	118, 146	Langbein, Kerstin	100
Kim, Tae Yong	107	Lanz, Thomas	147
Kim, Yong Sik	68	Laprevote, Vincent	100, 141
Kimura, Haruhide	58	Larabi, Daouia	143
Kindler, Jochen	71, 142	Larsen, Julie	155
Kinnunen, Lotta	110	Lasalvia, Antonio	65, 79
Kircher, Tilo	28, 48	Lässer, Marc Montgomery	77, 106
Kirkbride, James	54, 83	Laursen, Thomas	52
Kirkpatrick, Brian	148	Law, Yeuk Lai	108
Kirli, Umut	55	Lawrie, Stephen	38
Kirschner, Matthias	113	Lee, Jimmy	120
Kjelby, Eirik	80	Lee, Junghee	31, 49
Klaasen, Nicky	108	Lee, Kit Wai	81, 150
Klamerus, Ewa	109	Lee, Kyuyoung	93
Klauber, Dea Gowers	94	Lee, Rico Sze Chun	80
Kline, Emily	14, 78	Lee, Sara-Ann	136



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

Lee, Sze Chun	14	Mark, Winifred	71
Lee, Yu Sang	70, 116, 146	Marotta, Roberta	100
Leirer, Daniel	52	Marques, Tiago Reis	114
Lemmers-Jansen, Imke	113, 143	Martin, Andrew	77, 142
Lennox, Belinda	39	Martinelli, Cristina	136
Lepage, Martin	41	Martinez, Gilles	117
Leptourgos, Pantelis	136	Martinez-Cengotitabengoa, M.	141
Levi, Linda	81	Martin, Joaquín Carlos	68
Levine, Stephen	73, 102	Martins-De-Souza, Daniel	30, 64
Lewis, Shon	4, 60	Marvulli, Daniela	113
Liemburg, Edith	110, 143	Masdeu, Joseph	39
Lin, Ashleigh	55, 72, 109, 141	Masillo, Alice	130
Lin, Jingxia Jessie	134	Massons, Carmina	108
Lindenmayer, Jean-Pierre	74, 104	Mathews, Maju	69, 102
Lindgren, Maija	97	Maziade, Michel	47
Linscott, Richard	130	McDonnell, David	103, 133
Linszen, Mascha	55	McEvoy, Joseph	4
Lizano, Paulo	14, 99	McEwen, Sarah	14, 129
Llorca, Bibiana Cabrera	128	McGorry, Patrick	3, 5, 17, 47, 59, 60, 131
Løberg, Else-Marie	131	McGrath, John	4, 5, 13, 15, 31, 42, 45
López-Díaz, Álvaro	90, 110, 153	McGuire, Philip	5, 26, 59
Lopez, Lorna	4, 69	Meador-Woodruff, James	64
Loureiro, Camila	70	Medalia, Alice	118
Lu, Yun	90	Meier, Felicitas	135
Lui, Simon S. Y.	105	Meijer, Carin	118
Luteijn, Bert L.B.	78, 150	Melau, Marianne	124
Lyall, Amanda	50	Meltzer, Herbert	3, 9
Lystad, June	76	Menezes, Paulo	4, 139
MacBeth, Angus	72, 110, 155	Menghini-Müller, Stephanie	132
MacCabe, James	16, 54	Mentzel, Charlotte	97, 150
Macek, Tom	37, 74, 142	Mentzel, Thierry	97
Mahncke, Henry	133	Merritt, Kate	50
Maj, Mario	4	Metzler, Sibylle	135
Mäki, Pirjo	53, 139	Meyer, Urs	64
Makowski, Carolina	50	Meyer-Lindenberg, Andreas	66
Malaspina, Dolores	116	Mezquida, Gisela	113
Malavia, Tulsi	52	Mhalla, Ahmed	14, 77, 113, 137
Malchow, Berend	66	Mierlo, Hans van	58
Malda, Aaltsje	85	Miettunen, Jouko	139
Malenfant, Esthel	97	Miglietta, Elisabetta	82, 114, 155
Malhotra, Anil	38	Mihaljevic, Marina	87
Malla, Ashok	40	Mikutta, Christian	77, 106
Mansueto, Giovanni	14, 68	Mingoia, Gianluca	125
Mantyla, Teemu	112	Minichino, Amedeo	101, 131
Marcelis, Machteld	156	Minor, Kyle	14, 61
Marchisella, Elena	116	Mittal, Vijay	42, 66
Marder, Steve	5		
Maric, Nadja	127		

FINAL PROGRAM

FLORENCE, ITALY

2 – 6 APRIL 2016



Miyata, Jun	84	Oertel, Viola	128
Mizrahi, Romina	29	O'Gorman, Aoife	14, 70
Modinos, Gemma	26	O'Hanlon, Erik	66
Moghaddam, Bitá	29	Oh, Hyerim	86
Mollon, Josephine	53	Øie, Merete	40
Monsonet, Manel	149	Ojeda, Natalia	30, 48, 76, 105
Moore, James	28	Okahisa, Yuko	69
Moreines, Jared	72	O'Keeffe, Donal	120, 154
Morgan, Craig	54, 96, 126	Oliveira, Alexandra	105
Morkved, Nina	60	Onwumere, Juliana	89
Mortensen, Preben	4	Oranje, Bob	128
Mothet, Jean-Pierre	41	O'Reilly, Richard	60
Mouchlianitis, Elias	57	Ormel, Paul R.	88
Mucci, Armida	41	Ortiz, Bruno	79
Mueller, Daniel	148	Østefjells, Tiril	82
Mueller, Toni	147	Ostergaard, Soren Dinesen	102
Müller, Bernhard	117	Overjero, Santiago	91
Müller, Daniel	87	Paccalet, Thomas	53
Murray, Robin	27, 65	Pagsberg, Anne Katrine	38, 150
Myers, Neely	94	Pain, Oliver	87
Myin-Germeys, Inez	119, 149	Palma-Gudiel, Helena	134
Naber, Dieter	74, 124, 154	Palmeira, Leonardo	118
Nahar, Abhinav	86	Pantelis, Christos	5, 17, 57, 64
Nakajima, Shinichiro	14, 91	Paolini, Enrico	81
Neilson, Emma	14, 145	Papaleo, Francesco	131
Nelson, Barnaby	28, 39, 57	Papmeyer, Martina	103, 133
Nenadic, Igor	5, 16, 50, 115, 145	Papsuev, Oleg	14, 134
Nerhus, Mari	138	Pardeller, Silvia	104
Newbury, Joanne	14, 82	Park, Il Ho	84
Nielsen, Anita Tønder	139	Pasternak, Ofer	50
Nielsen, Mette	97	Patel, Maxine	5, 120
Nieman, Dorien	57	Patel, Rashmi	14, 108, 140
Nijman, Saskia	30	Pauselli, Luca	82, 149
Nikiforuk, Agnieszka	90	Peitl, Vjekoslav	129
Nilsson, Peter	70	Pelayo-Teran, Jose Maria	126, 156
Nilsson, Sandra Feodor	31	Penades, Rafael	74
Nimgaonkar, Vishwajit	141	Peralta, Tania Gómez	87
Noordsy, Douglas	4	Pergola, Giulio	114
Nordentoft, Merete	17, 40, 61, 110	Pertegaz, Inmaculada Baeza	130
Noto, Cristiano	57	Peters, Emmanuelle	4
Notter, Tina	87	Peters, Henning	113
Novick, Diego	120	Pientka, Laura	89
Nuechterlein, Keith	40, 60	Pignon, Baptiste	156
Nuñez, Daniel	106, 149	Pijnenborg, Marieke (Gerdina)	30
Nuss, Philippe	69	Pino, Oscar	31
O'Donnell, Patricio	4, 47	Pins, Delphine	135
O'Donoghue, Brian	111, 139	Piskulic, Danijela	75
Oduola, Sheri	110	Pletnikov, Mikhail	41



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

Pocklington, Andrew	47	Robertson, Sharman	124
Pol, Hilleke Hulshoff	5, 16, 59, 66	Roche, Eric	55, 81, 123, 153
Porcelli, Annamaria	104	Rodriguez, Mabel	136
Pos, Karin	97	Rodriguez, Victoria	104
Potasiewicz, Agnieszka	14, 150	Rohde, Christopher	110
Pot-Kolder, Roos	132	Roos, Johannes	86
Pousa, Esther	104	Rosenbrock, Holger	122, 151
Prat, Gemma	94	Rosen, Marlene	123, 153
Pratt, Judith	58	Rösler, Lara	56
Preisig, Martin	47	Rossell, Susan	77, 105
Prikken, Merel	106	Rotharmel, Maud	92
Prinssen, Eric	101, 151	Rudå, Ditte	68
Puig-Navarro, Olga	71	Ruggeri, Mirella	125
Purcell, Shaun	42	Ruiz, Ada	79, 149
Purves-Tyson, Tertia	29	Rund, Bjorn	40, 117
Qing, Ying	129	Rüsch, Nicolas	65
Quattrone, Diego	138	Rutigliano, Grazia	61
Rabinowitz, Jonathan	73	Sachs, Gabriele	77, 143
Racioppi, Anna	109, 138	Sailas, Eila	93
Ragland, J. Daniel	51	Salum, Cristiane	118
Raij, Tuukka	90	Salzman, Phyllis	132
Ramos-Miguel, Alfredo	117	Samara, Myrto	14, 111, 152
Ramsay, Hugh	14, 135	Sanada, Kenji	89
Ranning, Anne	54	Sanchez-Gistau, Vanessa	129
Rapado-Castro, Marta	14, 88, 89, 147	Sand, Michael	73
Rapisarda, Attilio	114	Santoro, Marcos Leite	14, 116
Rapp, Alexander	95	Saperia, Sarah	94
Rapp, Charlotte	147	Sarno, Elaine Di	148
Rautio, Nina	139	Sasabayashi, Daiki	144
Reeder, Clare	30	Savitz, Adam	73, 152
Reichenberg, Abraham	40	Sawa, Akira	5, 13, 37, 41
Reichenberg, Avi	49	Sawada, Ken	86
Renard, Selwyn	78, 107	Schäppi, Lea	96
Rendal, Yolanda	79	Schijven, Dick	87
Revell, Emily	105	Schiltz, Kolja	30
Revuelta, José Pérez	95	Schmidt, André	14, 113, 145
Reynolds, Gavin	120	Schnack, Hugo	37, 144
Rey, Romain	79	Schneider, Maude	123
Richetto, Juliet	72	Schultz, C. Christoph	95
Riecher-Rössler, Anita	4, 73	Schulz, Charles	5
Riehle, Marcel	123	Schutte, Maya	80
Rikandi, Eva	85	Schwab, Sibylle	4
Rimvall, Martin	32	Scoriels, Linda	14, 136
Risinger, Robert	103, 133	Scott, Madeline	88
Riva, Marco Andrea	90	Seidman, Larry	40, 72, 104
Rivollier, Fabrice	87	Seitz, Johanna	14, 56
Rizk, Dalia Nagui	89	Selvaggi, Pierluigi	90
Rizvi, Asra	80	Selvendra, Ajit	140

FINAL PROGRAM

FLORENCE, ITALY

2 – 6 APRIL 2016



Seminerio, Fabio	78, 95, 108, 154	Sullivan, Sarah	82
Sendt, Kyra-Verena	114	Sumiyoshi, Chika	135
Seol, Jiyeon	128	Sumiyoshi, Tomiki	154
Seppälä, Jussi	49	Sumner, Philip	115
Serpa, Mauricio	115	Supanya, Suttha	81
Shamir, Alon	116	Suvisaari, Jaana	128
Shannon-Weickert, Cynthia	3	Suvitaival, Tommi	137
Shapiro, Daniel	14, 76	Suzuki, Kazunori	91
Sheinbaum, Tamara	97	Swaminathan, Vaidy	83
Shin, Ye Seul	134	Takeuchi, Hiroyoshi	121
Shuhama, Rosana	140	Tan, Eric	77, 124, 154
Siddiqui, Ishraq	50	Tandon, Rajiv	5
Siedman, Larry	11	Tang, Charmaine	125
Sigvard, Anne	85	Tang, Sunny	130
Silverman, Bernard	103, 133	Tani, Hideaki	14, 121
Sinkevičiute, Ignė	91	Tarland, Emilia	91
Si, Tian mei	132	Tasma, Magda	95
Skene, Nathan	64	Tatar, Zeynep Baran	79
Slot, Margot	148	Termorshuizen, Fabian	51
Smeland, Olav	52	Teroganova, Nina	114
Smesny, Stefan	70, 100	Therman, Sebastian	130
Smith, Geoffrey	100	Thomas, Elizabeth	108
Smith, Matthew	84	Thompson, Andrew	39, 73, 151
Smith, Robert C.	99, 137	Thorup, Anne	53, 71
Sneeboer, Marjolein	147	Thyme, Summer	118
Somers, Julian	59	Tianmei, Si	4
Sommer, Iris	4, 27, 48, 128	Tiihonen, Jari	5, 121
Sonnenschein, Susan	91	Tocco, Michael	103, 133
Sormunen, Elina	53	Todorov, Louise	80
Spada, Giulia	130	Toh, Wei Lin	138
Spedding, Michael	5	Tol, Marie-Jose Van	135
Spilka, Michael	112	Toll, Alba	129
Sportel, Bouwina	124, 154	Torgalsboen, Anne-Kari	119
Srihari, Vinod	28, 124	Torrey, E. Fuller	65
Stäblein, Michael	84	Tortadès, Ingrid	125
Stain, Helen	72	Tortelli, Andrea	83
Steenhuis, Laura	110	Traber-Walker, Nina	118
Stegmayer, Katharina	142	Tréhout, Maxime	86
Steiner, Johann	30	Trotta, Antonella	68
Steinhart, Henrietta	148	Tseng, Huai-Hsuan	50
Stiekema, Annemarie	93	Tso, Ivy	113
Stilo, Simona	54	Tsujino, Naohisa	102
Strik, Werner	48	Turner, Jessica	38
Studerus, Erich	74, 102	Ucok, Alp	120
Subramaniam, Karuna	84	Ueland, Torill	30
Suetani, Shuichi	81	Uher, Rudolf	47
Sugranyes, Gisela	144	Uhlhaas, Peter	47
Suk, Kyounggho	41	Ullrich, Simone	111, 141



5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia Towards Targeted Treatment

Underwood, Raphael	113	Wang, Yi	112
Upthegrove, Rachel	39	Wartelsteiner, Fabienne	94
Urquijo, Maria F.	105	Weber-Stadlbauer, Ulrike	147
Uttinger, Martina	132	Weickert, Cynthia Shannon	27, 64
Uzbekov, Marat	98, 99	Weickert, Thomas	5, 27, 72
Vaessen, Thomas	147	Weijers, Jonas	109, 153
Valiente, Alba	83	Weiser, Mark	4, 49, 65
Valli, Isabel	144	Weiske, Johanna	134
van Dellen, Edwin	86	Wende, Kim	84
van den Buuse, Maarten	27, 131	Werbeloff, Nomi	80
Van der Gaag, Mark	27	Whitford, Thomas	98
Van der Meer, Lisette	123	Widschwendter, Christian	123
van der Steen, Yori	149	Wigman, Johanna	55, 81
van der Stouwe, Elisabeth	132	Wijeratne, Nishardi	121
van der Zalm, Yvonne	83	Wilcox, Marsha	37, 156
van Duin, Esther	126	Wimberley, Maria Theresa	54
Vanes, Lucy	70, 136	Wimberley, Theresa	110
Van Haren, Neeltje	5, 28, 75	Winton-Brown, Toby	26
Van Harten, Peter	42	Wolf, Daniel	66
van Leeuwen, Judith M.C.	143	Wong, Keri	71, 153
Van Nierop, Martine	14, 27, 127	Woodberry, Kristen	51
Van Os, Jim	42	Wood, Stephen	144
Vanover, Kimberly	59, 74, 103, 133	Wozniak, Monika	101
Van Rheenens, Tamsyn	55, 77, 106	Wykes, Til	3, 15, 26, 48
Van Winkel, Ruud	27	Xavier, Rose Mary	143
Varese, Filippo	27	Yan, Chao	142
Vasile, Daniel	72, 107, 154	Yang, Lawrence	65
Veijola, Juha	117	Yang, So Yung	146
Veling, Wim	55, 119	Yang, Szu-Nian	82
Velligan, Dawn	4, 61	Yang, Zixu	134
Velthorst, Eva	49	Yildiz, Mustafa	124, 153
Ventura, Joseph	48, 73	Yoca, Gokhan	137
Vernal, Ditte Lammers	38	Yoon, Jong	85
Vernon, Anthony	78	Yoshida, Kazunari	140
Vidal, Grisel Orellana	75	Yum, Sun-Young A.	103, 133
Viertio, Satu	124	Zammit, Stanley	52
Vignes, Michael	116	Zaytseva, Yulia	76
Viher, Petra	145	Zhang, Hongyan	111, 140
Vincent, Angela	39	Zhang, Jian	87, 92
Vincent, Philippe	92	Zhang, TianHong	14, 75, 145
Vingerhoets, Claudia	106, 133	Zhou, Fu-Chun	105
Vinogradov, Sophia	3	Zhu, Chen	134
Vogel, Jelle Sjoerd	89	Zhu, Yikang	91
Voineskos, Aristotle	5, 13, 16, 38, 53	Ziermans, Tim	105
Voisey, Joanne	83	Zimmerman, Eric	101
Voss, Martin	28	Zipursky, Robert	28, 124
Walther, Sebastian	42	Zumárraga, Mercedes	68, 98
Wang, Chuan-Yue	136	Zurita, María Conchita Ocaña	150
Wang, Ya	135	Zuschlag, Zachary	58

NOTES

[illegible]



NOTES

168